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Summary 
Death receptor 3 (DR3) is a member of the TNFRSF and has one confirmed TNFSF ligand - 
TNF-like protein 1A (TL1A).  Recent studies have suggested a role for DR3/TL1A in 
osteoclast (OC) and osteoblast (OB) biology.  However, the mechanism through which 
they acted and the consequences in diseases characterised by adverse bone pathology 
were not investigated.  This thesis investigated the role of DR3/TL1A in OC formation and 
resorptive function (murine and human), diseases characterised by OC hyper-activity and 
homeostatic OB differentiation and function (murine) using cell culture and molecular 
biology techniques. 
DR3/TL1A were demonstrated for the first time to have a direct effect on in vitro OC 
formation and resorptive function in both murine and human models.  DR3 was revealed 
to be critical for OC resorptive function (murine) while TL1A dose-dependently increased 
osteoclastogenesis and resorptive function in the human system.  Studies into the 
mechanism identified that DR3/TL1A regulated expression of the chemokines CCL2 and 
CCL3 as well as the activation of MMP-9.  In rheumatoid arthritis patient serum TL1A was 
significantly increased, with levels linked to the presence of rheumatoid factor and erosive 
disease. Intriguingly, DR3/TL1A were shown to have no direct significant role in the 
increased OC activity associated with post-menopausal osteoporosis; DR3 was not 
detected on patient-derived OC precursors and serum levels of TL1A were not elevated.  
Analysis of murine osteoprogenitors and OB revealed expression of DR3 and TL1A and 
suggested a novel autocrine role in OB differentiation. This was supported by the OB 
mineralisation assay results which demonstrated reduced differentiation, MMP-2 and 
MMP-9 activation and mineral deposition in DR3ko cultures. 
The results presented in this thesis identify a novel, complex and multi-factorial role for 
DR3/TL1A in controlling OC and OB differentiation and function; imbalances in which can 
lead to the pathogenesis of adverse bone pathology.  
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1 Introduction 
1.1 Bone 
The adult human skeleton is comprised of 206 bones.  Depending on its location each 
bone has one or more specific functions including structural support and movement, 
protection of vital organs and maintenance of mineral homeostasis.  Bone is split into two 
main types: flat bone, such as the skull and scapula, and long bone such as the femur and 
tibia.  Long bone (Fig 1.1) consists of a hollow diaphysis which flairs at the end to form the 
metaphysis, the region below the growth plate, and the epiphyses, the region above the 
growth plate.  The shaft is mainly composed of dense, solid bone known as cortical bone, 
whereas, the metaphysis and epiphysis contain a honeycomb-like network of 
interconnected trabecular plates surrounding bone marrow known as cancellous bone. 
Bones are surrounded by an outer fibrous sheath known as the periosteum.  This is an 
envelope of fibrous connective tissue that covers all bone surfaces, except at joints.  The 
periosteum provides nourishment to the bone via blood vessels as well as containing 
nerve endings and the bone cells – the osteoclast and the osteoblast.  The inner surface 
of bone, which is in contact with the marrow, is known as the endosteum.  This is a 
membranous sheath that contains blood vessels, osteoclasts and osteoblasts (1).  Rather 
than being solid and inanimate, bones are dynamic organs that are continuously changing 
via a process known as bone remodelling. 
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1.2 Bone Remodelling 
Throughout a lifetime the skeleton is subjected to a variety of stresses and strains leading 
to the formation of cracks and micro-damage.  To maintain the integrity of the skeleton it 
is continuously remodelled; in the adult human skeleton, approx. 5 – 10% of the existing 
bone is replaced every year (2).  Remodelling is accomplished by the coupled activities of 
a group of cells collectively termed the bone remodelling unit (BRU) or basic multicelluar 
unit (BMU).  The cells that constitute the BMU are the osteoblast (OB), a cell that 
produces the organic bone matrix and aids in its mineralisation (3); the osteoclast (OC), a 
cell responsible for the degradation of bone and extracellular matrix (ECM) (4); the 
osteocyte, an osteoblast-derived cell that lies within the bone matrix which acts as a 
mechanosensor and an endocrine cell (5); and the bone lining cell, a cell that helps couple 
bone formation to resorption (6).  There are four distinct phases in the bone remodelling 
cycle (7): i) initiation, ii) resorption, iii) reversal and iv) formation (Fig 1.2). 
1.2.1 Initiation 
The initiation phase of bone remodelling is induced by mechanical strain, damage or by 
signals from cytokines or systemic factors.  This generates local signals that lead to the 
digestion of the thin layer of non-mineralised matrix under the lining cells, exposing the 
mineralised matrix to which the OC can attach (8-10).  OC and their precursors are 
recruited to the site of bone remodelling from the circulatory system and the ‘osteoclast 
niche’; an area on the bone surface near osteoblasts that contains cell-cycle-arrested 
quiescent osteoclast precursors (QuOPs) (11, 12).  Initiation of resorption is induced 
through osteoclast-osteoblast communication within the BMU; with osteoblast-lineage 
produced receptor activator of NF-κB ligand (RANKL) and macrophage colony stimulating 
factor (MCSF) driving the differentiation and survival of the OC and their precursors (13-
16). 
1.2.2 Resorption 
Once the remodelling process is initiated resorption of the bone occurs.  OC attach to the 
exposed surface of the mineralised matrix where they polarise and form a sealed 
microenvironment.  This sealed microenvironment is acidified to breakdown the inorganic 
component of bone followed by release of the enzymes cathepsin K, matrix 
metalloproteinase-9 (MMP-9) and tartrate resistant acid phosphatase (TRAP) to 
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breakdown the organic component (4, 17).  Following resorption of the old damaged 
bone the process undergoes reversal. 
1.2.3 Reversal 
Toward the end of the resorption phase of the bone remodelling cycle mononuclear cells 
of OB-lineage move into the resorption pit.  These mononuclear cells remove the old 
demineralised collagen while laying down a new thin layer (18-20).  During this phase 
EphB4-receptor expressing OB interact with ephrinB2-expressing OC in a process known 
as ‘coupling’.  Apoptosis of the OC subsequently follows while the OB-lineage cells are 
stimulated to differentiate and form new bone.  
1.2.4 Formation 
Bone formation is a two-step process and proceeds slowly, taking approximately 3 
months (compared to resorption which typically takes 3 weeks).  The OB first secretes the 
unmineralised osteoid.  This is composed of 90% type I collagen, the remaining 10% being 
made up of some minor types of collagen, proteoglycans and specific bone proteins such 
as osteopontin, bone sialoprotein and osteocalcin.  Once the osteoid is secreted the OB 
triggers mineralisation by releasing matrix vesicles.  These establish suitable conditions 
for initial mineral deposition by concentrating phosphate and calcium ions.  When the OB 
has completed the matrix formation they undergo a number of possible fates.   
The majority of OBs become apoptotic; however, some undergo further differentiation.  
The terminal differentiation stage of the OB is the osteocyte.  Osteocytes are encased in 
bone and support its structure and viability, while also acting as mechanosensors.  
Through the production of sclerostin (SOST), an inhibitor of Wnt signalling, the osteocyte 
regulates the amount of new bone formation that takes place.  The remaining OBs that 
haven’t undergone apoptosis or differentiation into osteocytes form the bone lining cells.  
The differentiation and function of the OC and the OB are covered in more detail in 
sections 1.3 and 1.4. 
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1.3 The Osteoclast 
The OC is a terminally differentiated, highly motile, multinucleated cell; they can contain 
between 3 – 100 nuclei but typically contain 10 – 20 nuclei (21).  They come from an 
haematopoietic origin (22, 23) and are formed by the fusion of monocyte / macrophage 
precursors.  Mature osteoclasts have several features that distinguish them from other 
macrophage polykaryons (large multinucleated macrophages such as Langhans’ giant cells 
(24)) that are also useful in their identification (Table 1.1); however, the most commonly 
employed are their multinuclear appearance and the expression of tartrate resistant acid 
phosphatase (TRAP) (25, 26).   
Although OC are derived from the monocyte / macrophage lineage their precise origin 
remains unclear.  Monocytes develop from haematopoietic stem cells in the bone 
marrow that go through a series of intermediate multipotential stages; the common 
myeloid progenitor (CMP), the granulocyte/macrophage progenitor (GMP) and the 
macrophage/dendritic cell progenitor (MDP) stages (27).  There is some uncertainty, 
however, about what constitutes the point of divergence of the OC lineage from the 
macrophage lineage.  The phenotype of murine and human OC precursors is explored in 
more detail below. 
1.3.1 Murine Osteoclast Precursors 
Early in vitro work by Kurihara et al (28), used isolated spleen cells and identified the 
colony-forming unit (CFU)-blast as the earliest identifiable hematopoietic precursor that 
could form OC.  This was built upon by Arai et al (29) who revealed by flow cytometry that 
c-Kit+ CD11bdull cells in the BM contained the OC progenitors; compared to the c-Kit+ 
CD11bhi population which contained macrophages and granulocytes.  The c-Kit+ CD11bdull 
cells could be further divided into c-FMS+ and c-FMS- subsets with the c-FMS- cells 
demonstrating a higher degree of immaturity and multipotency, taking longer to 
differentiate into OC.  This was supported by Jacquin et al (30) who showed that CD3- 
CD45R- CD11b-/lo c-FMS+ c-Kithi cells rapidly formed OC when cultured in the presence of 
MCSF and RANKL.  In recent studies by de Vries et al (31), CD31+ Ly6C+ myeloid blasts 
were demonstrated to respond quickly to MCSF and RANKL, when compared to CD31hi 
Ly6C- early blasts and CD31- Ly6Chi monocytes.  In a study by Geissmann et al (32), murine 
blood monocytes were divided into two functional subsets; short lived CX3CR1lo Gr1+ 
inflammatory monocytes and CX3CR1hi Gr1- long-lived resident macrophages that gave 
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rise to OC.  A summary of the current paradigm for murine OC precursors is shown in Fig 
1.3. 
1.3.2 Human Osteoclast Precursors 
The phenotypic identification of the human OC precursor in the bone marrow is less 
defined compared to the murine OC precursor.  In vitro co-culture assays by Mbalaviele et 
al (33) demonstrated that isolated CD34+ haematopoietic stem cells could be 
differentiated into OC.  Further work by Koizumi et al (34) identified OC precursors and 
immature OC (1-3 nuclei) to be positive for CX3CR1, while mature multinucleated OC 
were CX3CR1-negative.  Human peripheral blood monocytes are a readily accessible 
alternative source of OC precursors (12, 35, 36).  Initial studies by Fujikawa et al (26), 
Quinn et al (37) and Massey, Flanagan et al (38) identified that CD14+ monocytes isolated 
from peripheral blood could readily differentiate into bone resorbing OC.  Further studies 
have added to the clarification of the circulating OC precursor phenotype.  Human 
peripheral monocytes consist of two major subsets CD16+ and CD16-.  These cells 
additionally differ in their expression of CX3CR1 (32) and CD33 (39); with CX3CR1lo CD16- 
CD14hi CD33hi monocytes readily differentiating into OC and CX3CR1hi CD16+ CD14lo CD33lo 
monocytes forming few OC.  These results demonstrate that the human and murine OC 
precursors differ in their phenotypic receptor expression.  A summary of the human OC 
precursor phenotype is depicted in Fig 1.3.   
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Feature Function Ligand Role 
c-Fms Receptor MCSF 
Proliferation and 
survival 
RANK Receptor RANKL Differentiation 
Calcitonin 
Receptor 
Receptor Calcitonin 
Inhibits osteoclast 
activity 
αvβ3 integrin Receptor 
arginine-glycine-
aspartic acid 
(RGD) motif 
Mediates cell – 
substrate attachment 
OSCAR Receptor - Differentiation 
CCR1 
Chemokine 
Receptor 
CCL3, CCL5, CCL7, 
CCL9 
OC migration / 
differentiation 
CCR2 
Chemokine 
Receptor 
CCL2 
OC migration / 
differentiation 
CCR4 
Chemokine 
Receptor 
CCL2, CCL5 
OC migration / 
differentiation 
CCR5 
Chemokine 
Receptor 
CCL3, CCL5 
OC migration / 
differentiation 
V-ATPase 
(ATP6i complex) 
Proton pump - 
Acidification of 
resorption lacunae 
Carbonic 
Anhydrase II (CAII) 
Proton pump - Generation of H+ ions 
MMP-9 Gelatinase - 
OC migration and bone 
resorption 
Cathepsin K Protease - Bone resorption 
TRAP Enzyme - Bone resorption 
ADAM8 
A Disintegrin And 
Metalloproteinase 
- Differentiation 
c-src Tyrosine Kinase - 
Formation of ruffled 
border 
Actin Ring Structure - Bone resorption 
Table 1.1.  Osteoclast Features for use in Identification (adapted from (4, 17, 40-42)) 
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1.3.3 Osteoclast Differentiation 
While differences are observed in human and murine OC precursor phenotype, the 
differentiation pathways are comparable.  Osteoclast differentiation is the process by 
which mononuclear cells undergo fusion into the multinucleated OC.  The process 
involves a number of cytokines and hormones, from different cellular sources, that 
stimulate or inhibit differentiation (Table 1.2).  The two critical cytokines required for OC 
differentiation have been identified as MCSF and RANKL.  These are discussed in further 
detail in sections 1.3.3.1 and 1.3.3.2.  The current model for OC differentiation is depicted 
graphically in Fig 1.4.  Osteoclasts precursors are recruited to sites of bone remodelling 
from the circulation following chemokine gradients.  At these sites the precursor cells 
proliferate in response to MCSF.  The precursor cells then undergo differentiation 
following interaction between receptor activator of nuclear factor κB (RANK), expressed 
on the precursor cell and its ligand RANKL, which is primarily expressed on the surface of 
osteoblasts but can also be cleaved into a soluble form by metalloprotease.  The 
precursor cells fuse together following chemokine gradients forming the multinucleated 
OC.  Chemokines involved in OC differentiation are discussed in section 1.3.5.  Control of 
OC differentiation is via the soluble receptor osteoprotegerin (OPG) which is produced by 
T cells and osteoblasts (43). This competes with RANK for RANKL binding, inhibiting OC 
differentiation. 
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Cytokines Main Source 
Effect on OC 
Formation 
Direct / 
Indirect 
Macrophage Colony 
Stimulating Factor (MCSF) 
Osteoblasts, 
activated T cells 
↑ Direct 
Receptor Activator of Nuclear 
Factor-κB (RANKL) 
Osteoblasts, T cells ↑ Direct 
Osteoprotegerin (OPG) Osteoblasts ↓ Direct 
Tumour Necrosis Factor (TNF) 
Macrophages, TH1 
cells 
↑ 
Direct and 
indirect 
Interferon-gamma (IFNγ) TH1 cells, NK cells ↓ Direct 
    
Interleukins  
(IL-) 
Main Source 
Effect on OC 
Formation 
Direct / 
Indirect 
IL-1 
Monocytes, 
Fibroblasts 
↑ 
Direct and 
indirect 
IL-3 Activated T cells ↑ Direct 
IL-4 TH2 cells, NKT cells ↓ Direct 
IL-6 
TH2 cells, Dendritic 
cells, Osteoblasts 
↑ 
Direct and 
Indirect 
IL-10 TH2 cells ↓ Direct 
IL-11 
Haematopoietic 
tissue 
↑ Indirect 
IL-17 
TH17, memory T 
cells 
↑ Indirect 
IL-18 
Macrophages, 
Dendritic cells 
↓ Indirect 
    
Hormones and 
Prostaglandins 
Main Source 
Effect on OC 
Formation 
Direct / 
Indirect 
1,25-dihydroxy-vitamin D Kidneys ↑ Indirect 
Parathyroid Hormone (PTH) Parathyroid glands ↑ Indirect 
Prostaglandin E2 (PGE2) 
Most nucleated 
cells 
↑ Direct 
Oestrogen Ovaries, fat cells ↓ 
Direct and 
indirect 
Table 1.2.  Factors that directly or indirectly affect OC formation (adapted from (2, 12, 44, 
45)).  
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1.3.3.1 MCSF / c-Fms 
Early in vitro systems of OC formation from marrow and circulating mononuclear 
precursors established the necessity for contact with an osteoblast / bone stromal cell 
population (46, 47).  Studies with the osteopetrotic op/op mouse identified osteoblast / 
stromal cell-derived MCSF as an absolute requirement for the differentiation and 
proliferation of OC precursors with op/op mice unable to form multinucleated OC (48).  
The importance of MCSF signalling in OC formation was further supported by Dai et al 
(49).  In their study, the targeted disruption of c-Fms, the MCSF receptor, resulted in a 
more extreme osteopetrotic phenotype than the op/op mice. 
1.3.3.2 OPG / RANKL / RANK 
Direct cell-cell contact was demonstrated to be essential for osteoclastogenesis in early in 
vitro studies (46, 47).  This led to attempts to discover the membrane-bound factor on 
stromal cells.  Initial attempts were unsuccessful; however, in 1997 two groups 
discovered a protein that blocked osteoclast formation in vitro and in vivo.  This protein 
was subsequently termed OPG (50, 51).  OPG was determined to be a soluble decoy 
receptor belonging to the TNF receptor super family (TNFRSF) (50).  Studies using 
transgenic mice expressing rat OPG showed a systemic osteopetrotic phenotype, while in 
vitro addition of OPG to osteoclast cultures inhibited OC formation.  Ovariectomised rats 
treated with recombinant OPG were observed to exhibit an increase in bone volume and 
a decrease in OC numbers relative to controls (50); while OPG deficient mice exhibited 
severe osteoporosis resulting from excessive osteoclast differentiation and activity (52, 
53).  From these studies it was speculated that OPG was a receptor for an unidentified 
TNF-related protein that normally acts as an osteoclast maturation factor. 
The major breakthrough in OC biology was the discovery by Lacey et al (54) in 1998 of a 
membrane-bound and soluble ligand for OPG that was capable of directly affecting 
osteoclastogenesis.  Named OPGL, it was subsequently identified as the previously 
characterised tumour necrosis factor super family (TNFSF) member TNF related 
activation-inducing cytokine (TRANCE; TNFSF11) (55).  In addition to OPG, the ligand was 
also demonstrated to activate the TNFRSF member RANK (TNFRSF11A).  TNFSF11 is now 
generally named after its receptor, RANK-ligand or RANKL (56, 57).  The initial study by 
Lacey et al (54) demonstrated that stimulation of in vitro co-cultures and OC precursors 
with RANKL and MCSF stimulated the development of numerous large, functionally active 
osteoclasts.  Administration of RANKL to mice also resulted in the significant increase in 
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blood-ionised calcium (hypercalcaemia), while co-administration of OPG significantly 
reduced the effects of RANKL.  Histomorphometric and radiographic analysis of the tibia 
from the RANKL-treated mice revealed reduced bone volume.  However, no change in the 
number of OC was observed between the control and treated animals, though a 
significant increase in the size and nuclearity of OC in the RANKL-treated group was seen 
(54). Further evidence for the importance of RANKL in OC formation was provided by 
Kong et al. (58).  In their studies RANKL knockout mice were observed to exhibit 
osteopetrosis and defects in tooth eruption that were associated with an absence / 
deficiency of osteoclasts (58).  
RANK, the receptor for RANKL, was originally described in dendritic cells by Anderson et al 
(56).  It was subsequently identified on the surface of OC precursors and mature OC in 
vivo by Hsu et al (59).  Recombinant RANK-Fc was observed to bind with high affinity to 
RANKL and inhibit OC differentiation and activity in vitro and in vivo (59).  Furthermore, in 
a study by Dougall et al (60), RANK-/- mice were demonstrated to exhibit severe 
osteopetrosis, highlighting the importance of this receptor in OC formation and bone 
remodelling.  OC precursor survival and differentiation induced by c-Fms / MCSF, and 
RANK / RANKL signalling, is via the activation of a number of signalling pathways.  This 
results in the transcription and activation of numerous OC specific genes.  These 
pathways are outlined below. 
1.3.4 MCSF and RANKL Signalling Pathways 
Phosphorylation of the receptor c-FMS by MCSF activates two main signalling pathways 
(Fig 1.5): i) the extracellular-signal-regulated kinase (ERK) pathway via growth-factor-
receptor-bound protein 2 (GRB 2) and ii) the protein kinase B (PKB, also known as Akt) 
pathway via phosphoinositide 3-kinase (P13K) (61).  Prolonged activation of ERK by MCSF 
also promotes its nuclear translocation where it induces c-FOS and nuclear factor of 
activated T cells, cytoplasmic 1 (NFATc1) expression (62).  Activation of these pathways 
promotes osteoclast precursor proliferation and stimulates the expression of the receptor 
RANK (2). 
Binding of RANKL to RANK induces the trimerisation of RANK and the adaptor molecule 
TRAF-6, activating a number of downstream signalling cascades (Fig 1.5).  NFATc1 is 
activated via the NF-κB and c-FOS pathways (63, 64) while activator protein-1 (AP-1) is 
induced through the action of mitogen-activated kinases (MAPKS); including Jun-N-
terminal kinase (JNK), p38 (63) and its component c-FOS (65).  Robust induction of 
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NFATc1 during osteoclastogenesis is driven by auto regulation of its promoter (66), along 
with continued activation of calcium signalling and AP-1 (64).  NFATc1 is subsequently 
translocated to the nucleus, in a process mediated by calcineurin, where in co-operation 
with other transcription factors such as AP-1, PU.1 and microphthalmia-associated 
transcription factor (MITF), it regulates a number of osteoclastogenic specific genes; CatK, 
TRAP, calcitonin receptor and B3 integrin (64, 67, 68). 
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1.3.5 Osteoclast Chemokines 
OC precursor migration involves at least two major steps: i) release of the cells from the 
bone marrow into the circulation and ii) homing from the peripheral blood to sites of 
bone resorption.  This mobilisation of the precursor cells is a complex process involving 
proteolytic enzymes, stromal cells, cytokines and chemokines (69).  Chemokines are small 
chemotactic cytokines that function as key mediators in the migration of cells.  They can 
be divided into four branches, depending on the spacing and sequence motifs of their first 
cysteine (C) residues; these are C, CC, CXC and CX3C, where X is another amino acid. 
OC precursors are retained in the BM through the interaction of CXCL12 (stromal cell-
derived factor-1, SDF-1) and its receptor CXCR4, expressed on OC precursors (70).  
Reduction of CXCL12 concentration or CXCR4 expression in the bone marrow leads to the 
release of OC precursors into the peripheral blood (71).  In the peripheral blood stream 
the precursors are directed to sites of bone resorption via chemokine gradients.  
Chemokine signalling via their respective receptors (Table 1.3) is also required for the 
induction of fusion, differentiation and maturation of the mononuclear precursor cells 
into the multinucleated OC.  The effect of the chemokines CXCL8, CXCL1, CCL2 and CCL3 
on OC precursor migration and differentiation are explored in more detail below. 
1.3.5.1 CXCL8 / Interleukin-8 (IL-8) 
CXCL8 is a chemokine produced at high basal levels by osteoclasts (72).  It exerts its 
effects through the receptors CXCR1 and CXCR2.  Studies into the effects of CXCL8 on OC 
migration and function have yielded contrasting results.  Addition of exogenous CXCL8 to 
rat OC cultures was demonstrated to stimulate cell spread and motility while suppressing 
resorption (73).  In a human model, however, studies by Bendre et al (74, 75) 
demonstrated that exogenous CXCL8 stimulated osteoclastogenesis and bone resorption; 
by mechanisms dependent and independent of the RANKL pathway. 
1.3.5.2 CXCL1 / Mouse Keratinocyte-derived cytokine (KC) 
CXCL1 has been proposed as a murine functional homologue of human CXCL8, and it 
functions as the major pro-inflammatory alpha chemokine in mice.  The receptor for 
CXCL1, CXCR2 is highly expressed in osteoclast precursors (76).  CXCL1 is a 
chemoattractant for macrophages (77), suggesting that it may act as a chemoattractant 
for murine osteoclast precursors. 
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1.3.5.3 CCL2 
CCL2 (monocyte chemoattractant protein-1, MCP-1) is a potent chemokine for 
monocytes, with high levels of its receptor CCR2 expressed on the cells (78, 79).  Initial 
indications for a role of CCL2 in OC precursor recruitment were provided by observations 
from Wise et al (80).  They demonstrated that dental follicle cells, at the site of tooth 
eruption, express CCL2 prior to the influx of monocytes and formation of OC (81).  Studies 
by Kim et al (82, 83) demonstrated that CCL2 is induced by RANKL in mononuclear cells, 
and enhances OC-like cell formation.  However, cells induced by treatment of cultures 
with CCL2 alone, while multinucleated and calcitonin receptor positive, could not resorb 
bone unless stimulated by RANKL (83).  Additional support for the role of CCL2 in 
osteoclastogenesis, acting in an autocrine / paracrine manner, was provided by Miyamoto 
et al (84).  In their studies OC formation was significantly reduced in CCL2-deficient mice, 
with DC-STAMP, NFATc1, and CatK down-regulated in the OC that did form. 
1.3.5.4 CCL3 
CCL3 (macrophage inflammatory protein-1α, MIP-1α) and its receptors CCR1 and CCR5 
are expressed by OC and their precursors (85, 86).  CCL3 is a direct stimulator of RANKL-
induced osteoclastogenesis in bone and bone marrow cells, acting in a dose dependent 
manner (85, 87-89).  Blockage of CCL3 (90, 91) or its receptors (86) has been shown to  
inhibit OC formation.  Serum levels of CCL3 have also been demonstrated to correlate 
with the level of bone destruction in multiple myeloma patients (92) and are significantly 
elevated in synovial fluid from rheumatoid arthritis patients (93). 
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Chemokine 
Alternative 
Nomenclature 
Receptor(s) Action 
CXCL12 
Stromal cell-derived 
factor-1 (SDF-1) 
CXCR4 
Recruitment of pre-
cursors from bone 
marrow to peripheral 
blood 
CX3CL1 Fractalkine CX3CR1 
OC migration and 
attachment 
sphingosine-1-
phosphate 
S1P 
 
S1P receptors 
Recruitment of 
precursors  from 
peripheral blood to bone 
CXCL8 Interleukin-8 (IL-8) CXCR1, CXCR2 
OC differentiation and / 
or motility 
CXCL2 
Macrophage 
Inflammatory Protein-2α 
(MIP-2α) 
CXCR2 OC maturation 
CXCL10 
Interferon-γ-inducible 
10kDa protein (IP-10) 
CXCR3 OC maturation 
CCL2 
Macrophage 
chemoattractant 
protein-1 (MCP-1) 
CCR2 OC differentiation 
CCL3 
Macrophage 
Inflammatory Protein-1α 
(MIP-1α) 
CCR1, CCR5 OC differentiation 
CCL9 
Macrophage 
Inflammatory Protein-1γ 
(MIP-1γ) 
CCR1 
OC differentiation and 
survival 
CCL5 RANTES CCR1, CCR5 OC migration 
Table 1.3.  Chemokines involved in Osteoclast / OC precursor Migration and 
Differentiation (adapted from (27, 94)). 
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1.3.6 Osteoclast Bone Resorption 
The main function of the OC is the degradation and resorption of bone.  Bone 
degradation requires physical contact between the osteoclast and the bone matrix.  It is 
now clear that the principal integrin mediating osteoclast attachment to the bone matrix 
is the αvβ3 integrin.  This was demonstrated in β3 deficient mice who displayed 
osteopetrosis due to dysfunctional osteoclasts (95).  The αvβ3 heterodimer recognises the 
amino acid motif Arg-Gly-Asp (RGD) which is present in bone residing proteins such as 
osteopontin and sialoprotein (61), allowing the osteoclast to attach and spread on the 
bone substrates in an RGD-dependent manner.  Osteoclasts that lack the αvβ3 integrin are 
still able to attach to bone, however, they are unable to organise their cytoskeleton into a 
sealing zone and have abnormal ruffled membranes (95).  Attachment of the OC to bone 
causes it to undergo a number of intracellular changes, generating two polarised 
structures; the ruffled membrane and the actin ring.  Formation of these structures 
enables the OC to initiate bone resorption. 
In the generation of the first polarised structure, the ruffled membrane, acidified vesicles 
containing CatK and MMPs are transported to the bone-apposed plasma membrane (96, 
97).  These vesicles fuse to the membrane, in a manner regulated by the small GTPase 
Rab 3D (98).  This fusion results in the formation of the ruffled membrane, an organelle 
unique to the osteoclast.  Experiments have shown that the non-receptor tyrosine kinase 
(NRTK) c-Src is also critical for the formation of the ruffled membrane (99, 100).  A high 
level of c-Src expression in osteoclasts is consistent with the importance of this kinase.  In 
addition to the formation of the ruffled membrane, contact with bone prompts the 
osteoclast to polarise its filamentous actin (F-actin) into a circular structure known as the 
actin ring (101).  This creates a sealed zone around the ruffled border (102).  
The sealed compartment under the OC formed by the generation of the sealing zone is 
known as the resorption pit or Howship’s lacunae.  This pit is acidified to a pH of ~4.5 by 
the fusion of acidic vesicles to the ruffled border and an electrogenic proton pump 
(H+ATPase); generated by the ATP6i complex (103) coupled to a Cl- channel.  The 
formation of HCl in the sealed microenvironment dissolves the inorganic solid 
hydroxyapatite, exposing the organic matrix beneath.  Further secretion from the 
osteoclasts ruffled membrane continues with the export of lytic enzymes such as CatK 
and MMP-9 into the resorption pit to digest the organic matrix (104-106).  The enzymes 
involved in OC resorption are covered in section 1.3.7. Efficient osteoclast activity 
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requires the transport and removal of the degraded ions and collagen fragments from the 
resorption pit into the extracellular fluid. 
A specific plasma membrane domain located in the upper part of the cell, called the 
functional secretary domain (FSD) is the area of the cell where degradation products are 
targeted (101).  Degradation products are endocytosed in to the osteoclast through a 
specific section of the ruffled membrane.  They are transcytosed through the cell and 
finally secreted into the extracellular fluid through the FSD.  This transcytotic pathway is 
supported with thick bundles of microtubules, which originate from the ruffled 
membrane and continue towards the FSD (107, 108).  The extent to which the 
degradation of collagen and other matrix components is extracellular and the extent to 
which this takes place in intracellular transcytotic vesicles is not completely known.  
Results suggest that TRAP is localised in the transcytotic vesicles of resorbing osteoclasts 
and that it can generate highly destructive reactive oxygen species able to destroy 
collagen (109).  This activity together with the co-localisation of TRAP and collagen 
fragments in the transcytotic vesicles suggest TRAP functions in the destruction of matrix-
degradation products in these vesicles (110). 
Although the events involved in the initiation of bone resorption (Fig 1.6) are relatively 
well understood the signals that arrest the process are less well known.  Recent 
developments in the field suggest that the osteoblast and osteoclast are ‘coupled’, with 
reverse signalling through OC ephrinB2 by OB EphB4 suppressing OC function and 
initiating OB differentiation and bone formation (111, 112). 
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1.3.7 Osteoclast Bone Degradation Enzymes 
Degradation of bone by the OC involves a number of enzymes that are responsible for the 
processing of the organic matrix (Table 1.4).  These include members of the matrix 
metalloproteinase (MMP) family, cysteine proteinases (Cathepsin K) and metalloenzymes 
(TRAP). 
Cathepsins 
Alternative 
Nomenclature 
Latent / Active 
(kDa) 
Substrate 
Cathepsin K CatK 43 / 29 
Type I collagen, 
Osteopontin, 
Osteonectin 
    
Metalloenzymes 
Alternative 
Nomenclature 
kDa Substrate 
Tartrate Resistant 
Acid phosphatase 
TRAP 35 Degradation products 
    
MMP Designation 
Alternative 
Nomenclature 
Latent / Active 
(kDa) 
Collagen Substrate 
MMP-9 
Gelatinase B 
92 kDa gelatinase 
92 kDa type IV 
collagenase 
92 / 86 IV, V, VII, X, XIV 
MMP-14 
MT1-MMP 
Membrane Type 1 – 
MMP 
66 / 56 I, II, III 
MMP-1 
Collagenase-1 
Fibroblast collagenase 
Interstitial 
collagenase 
55 / 45 I, II, III, VI, VII, X 
MMP-3 
Stromelysin-1 
Transin-1 
57 / 45 III, IV, IX, X, XI 
MMP-2 
Gelatinase A 
72 kDA gelatinase 
72 kDa type IV 
collagenase 
72 / 66 
I, III, IV, V, VII, X, XI, 
XIV 
MMP-10 
Stromelysin-2 
Transin-2 
57 / 44 III, IV, V,IX, X 
Table 1.4. Principal enzymes and MMPs involved in OC bone degradation (adapted from 
(113-115)). 
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1.3.7.1 Osteoclast derived MMP’s and MMP-9 
Matrix metalloproteinase’s (MMPs), also known as matrixins, are a class of extracellular 
and membrane-bound proteases.  They play a central role in the breakdown of 
extracellular matrix (ECM) in embryonic development, morphogenesis, reproduction, and 
tissue resorption and remodelling (113).   All members of the MMPs are synthesised as 
prepro-enzymes and, in the majority of cases, secreted as inactive pro-MMPs.  OC MMPs 
have the ability to process both helical and denatured type I collagen; the most well 
characterised being the gelatinase matrix metalloproteinase-9 (MMP-9; (114, 116, 117). 
MMP-9 is predominantly expressed by OC and OC precursors in adult bone.  The 
contribution that MMP-9 activity plays in OC biology is only just being understood, with 
dual roles in bone resorption and cell migration.  Evidence for the classical role of MMP-9 
in bone resorption was provided by Everts et al (118, 119) and Tezuka et al (106).  In these 
studies high levels of expression of MMP-9 mRNA in OC were shown along with secretion 
of the enzyme into the resorption lacuna, demonstrating a role in bone resorption.  MMP-
9, however, wasn’t found to be rate limiting, as the resorptive activity of OC in MMP-9 
null mice compares to that of wild type mice (120).  This revealed that MMP-9 is not the 
principal enzyme involved in matrix solubilisation (121). 
The additional role for MMP-9 in OC migration has evolved from a number of studies.  In 
experiments by Vu et al (121) using MMP-9 null mice, the invasion of OC into the growth 
plate was delayed, resulting in the formation of lengthened growth plates. This 
observation that MMP-9 is involved in OC migration was supported in a study by 
Cackowski et al (122) who demonstrated that OC formation in MMP-9 null mice was due 
to reduced OC migration.  Evidence that the MMPs involved in OC invasion were 
osteoclastic in origin came from work performed by Sato et al (123).  Their experiments 
showed that OCs were able to migrate through collagen in the absence of other cells and 
that osteoclastic MMPs appear, therefore, unique amongst the OC proteinases for 
migration of OCs through collagen.  A role for the involvement of MMP-9 in the migration 
and invasion of OC is also consistent with the early expression of the gelatinase during OC 
differentiation (117, 121, 124, 125).   While the studies into MMP-9 have demonstrated 
that it is not the principal enzyme involved in bone degradation, the proteinase Cathepsin 
K is critical.  
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1.3.7.2 Cathepsin K 
Cathepsin K (CatK) is a cysteine protease active at low pH that plays a key role in the 
degradation of bone.  It is highly expressed in OCs compared to the other cathepsins (105, 
126).  It is largely responsible for cleaving and removing the organic matrix during OC 
resorption (104, 127).  The importance of CatK in bone remodelling can be seen in the 
rare human disease pycnodysostosis and CatK-deficient mice. Pycnodysostosis results 
from mutations in the Ctsk gene, leading to decreased CatK enzymatic activity.  Bones in 
these patients are characterised by defective remodelling and poor structure.  High levels 
of collagen fibres are found to remain in the resorption pit as well as accumulation of 
non-digested collagen fibrils in vesicles inside the OC (128).  CatK-deficient mice also 
demonstrate a mild osteopetrotic phenotype due to a high number of OC with impaired 
function (104, 129). 
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1.4 The Osteoblast 
The osteoblast is the principal cell involved in the formation of new bone (130). They arise 
from pluripotent stem cells found in the BM.  These stem cells have the proliferative 
potential to form single colonies (CFU-Fs) with the capacity to form bone, cartilage and 
fibrous tissue (131, 132).  The CFU-Fs are commonly referred to as mesenchymal stem 
cells (MSC) and are separate from the haematopoietic stem cell lineage.  Enrichment of 
the MSCs from BM preparations takes advantage of the adherent nature of the stem 
cells.  Analysis of these cells demonstrated that the STRO-1+ fraction contained the 
osteogenic precursors in human and rat, however, this lineage marker is not expressed in 
mouse marrow (133, 134).  In a murine system the markers Sca1 and CD34 have been 
successfully used to identify the BM MSCs (134).  Differentiation of the stem cells into 
mature bone forming OB is controlled under a spectrum of signalling proteins, hormones, 
cytokines, growth factors and transcription factors (Table 1.5).  OB differentiation is 
discussed in further detail in section 1.4.1. 
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Determinant Effect 
Adrenomedullin  Mitogenic effects on OB 
Androgen 
Increases differentiation of post-proliferative OB and 
mineralisation 
Activating transcription factor 4 
(ATF4) 
Required for bone formation 
β-Catenin High levels stimulate OB differentiation 
Bone morphogenetic Proteins 
(BMPs) 
Support OB differentiation 
CXCL12  
(Stromal-derived factor-1, SDF-1) 
Promotes growth and survival of marrow stromal 
cells 
Epidermal Growth Factor (EGF)  Stimulates MSCs to differentiate 
Oestrogen  
Increases IGF-1; stimulates osteoprogenitor 
proliferation and collagen synthesis 
Glucocorticoid  
Promotes OPC differentiation, increases apoptosis of 
mature OB 
Insulin-like growth-factor 
(IGF-1/IGF-2)  
Anabolic regulators; IGF-1 required for anabolic 
effects of PTH 
Immobilisation Inhibits bone formation 
Mechanical load Stimulates bone formation 
Oncostatin M  
Increases IGF-1 and alkaline phosphatase, promoting 
OPC differentiation 
Osterix (OSX) Required for OB differentiation and bone formation 
Parathyroid hormone (PTH)  Numerous anabolic effects via regulation of OB genes 
Peroxisome proliferator-
activated receptor  gamma 
(PPARγ2) 
Inhibits OB differentiation, promotes adipocyte 
differentiation 
Prostaglandin E2 (PGE2) Increases BMP2 expression 
Runx2 Required for OB differentiation and bone formation 
Sclerostin (SOST) 
BMP antagonist secreted by osteocytes, inhibits OB 
differentiation and activity, suppressed by 
intermittent PTH 
Thyroid stimulating hormone  
Decreases Wnt/LRP5 signalling, inhibits OB 
differentiation and collagen synthesis 
1,25(OH)2D3  
Upregulates OB genes that are components of the 
ECM 
Table 1.5.  Factors regulating OB differentiation and function (Adapted from (135, 136)) 
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1.4.1 Osteoblast Differentiation 
The initial stage of OB differentiation is the generation of the osteoprogenitor cell (OPC) 
from the MSCs.  OPCs are multi-potential and are directed to specific cell fates by 
transcriptional regulators.  At an early stage of differentiation members of the canonical 
Wnt / β-catenin pathway and bone morphogenetic proteins (BMPs) shift the cell fate of 
the MSC towards the osteoblast lineage, suppressing adipogenic transcription factors 
while inducing the osteogenic transcription factors.  Expression of the transcription factor 
Runx2, also known as core-binding factor subunit alpha-1 (cbfa 1), is essential for MSC 
differentiation into the OPC (137).  Still under the influence of the Wnt pathway and 
BMPs a second transcription factor, osterix (OSX), is induced.  Induction of OSX drives the 
differentiation of the OPC towards the pre-osteoblast (or immature OB) (138).  The pre-
OB still has the potential to divide and expresses low levels of alkaline phosphatase (ALP) 
activity, an early marker of the OB phenotype.  The final stages of OB differentiation and 
mineralisation are dependent on the transcription factors OSX and activating 
transcription factor 4 (ATF4) (139).  Induction of these transcription factors leads to the 
generation of the non-proliferating mature cuboidal OB that actively synthesises bone 
matrix. The role and function of key pathways and transcription factors involved in OB 
differentiation are explored further in sections 1.4.1.1, 1.4.1.2 and 1.4.1.3.  At the end of 
mineralisation the mature OBs are subjected to a number of different outcomes.  The 
majority undergo apoptosis while the remainder become trapped in the matrix and 
become osteocytes or remain on the surface and become bone-lining cells (Fig 1.7).  
While the processes involved in OB differentiation and function in vivo are complex, MSCs 
can be persuaded to undergo osteogenesis in vitro.    
In vitro osteogenic differentiation of marrow derived MSCs from the mouse was 
demonstrated by Schoeters et al (140).  In this set of experiments they demonstrated that 
MSC differentiation and OB mineralisation could be induced in the presence of foetal calf 
serum, β-glycerophosphate and ascorbic acid.  The ascorbic acid initiates the formation of 
the collagenous extracellular matrix and the synthesis of several OB-related proteins 
(141).  β-glycerophosphate provides an exogenous phosphate source, required for 
induction of mineralisation.  Addition of the synthetic glucocorticoid dexamethasone 
(Dex) is also added to in vitro cultures as it has been demonstrated to stimulate OB 
differentiation and function in mouse (142),  rat (143) and human (144) MSCs.  
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1.4.1.1 The Canonical Wnt / β-Catenin Pathway 
The first stage in MSC differentiation towards the mature OB is dependent on the 
canonical Wnt / β-Catenin pathway.  Canonical Wnt signalling is a key event in normal 
bone development and the regulation of bone mass in adults.  Wnt ligands transduce 
their signal through cell surface frizzled receptor interactions, which are regulated by the 
transmembrane LRP co-receptors. The binding of Wnt ligands triggers a chain of events, 
which leads to the dephosphorylation of β-catenin.  The freed β-catenin then enters the 
nucleus where it forms a complex with transcriptional regulators.  The discovery of the 
importance of the canonical Wnt / β-catenin pathway came from studies by Boyden et al 
(145) and Little et al (146).  They demonstrated that a high bone mass phenotype human 
genetic disorder was due to an activating mutation in the canonical Wnt ligand co-
receptor LRP5.  This role of Wnt signalling in bone formation was further supported by 
the observation that inactivating mutations of the LRP5 gene resulted in osteoporosis 
pseudoglioma syndrome (147).  Additional support for the importance of the canonical 
Wnt / β-catenin pathway in OB development has come from a number of genetic mouse 
models.  Work by Hill et al (148) and Day et al (149) demonstrated that a high level of β-
catenin differentiates mesenchymal cells towards the OB lineage while low / moderate 
levels promotes chondrogenesis.  Activity of canonical Wnt signalling is controlled by a 
number of extracellular and intracellular inhibitors.  The association of Dickkopf-related 
protein 1 (DKK1) with LRP5, sclerostin with LRP5/6 and secreted frizzled related proteins 
(SFRPs) with Wnt ligands, inhibit the signalling process by stopping the formation of the 
receptor complex (150).    
1.4.1.2 Bone Morphogenetic Proteins 
BMPs are members of the transforming growth factor-beta (TGF-β) family.  Studies have 
demonstrated that BMP-2, -4 and -7 are potent inducers of osteogenesis in vivo and in 
vitro (151).  BMPs interact with specific BMP receptors (BMPRs) on the cell surface 
mobilising the intracellular receptor signalling mothers against decapentaplegic (R-Smads) 
that heterodimerise with the DNA binding Smad4.  The activated Smad complex enters 
the nucleus where it induces the transcription of key genes involved in the commitment 
to the osteogenic lineage (138).  The activity of the BMPs is regulated by a number of 
inhibitory Smads as well as the secreted factors Chordin and Noggin (152).  Elucidation of 
the precise function of the BMPs in osteoblastogenesis and bone formation has been 
done through the analysis of deficiencies and mutations in the receptors and intracellular 
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Smad signalling components.  BMP-null mice cannot be generated due to early embryonic 
lethality (153, 154).  
1.4.1.3 Transcription Factors – Runx2/Cbfa1, Osterix and ATF4 
Additional to Wnt and BMP signalling, differentiation of OB from the MSCs requires the 
induction of a number of critical transcription factors.  The transcription factors are 
expressed and function at different stages during the differentiation process, defining the 
developmental stages of the OB lineage.  The initial transcription factor identified as 
critical for OB differentiation was Runx2/Cbfa1. 
Induction of Runx2/Cbfa1 is subsequent to Sox9 expression (155); a transcription factor 
marker of MSCs.  The significance of Runx2 was demonstrated in a murine knockout 
model.  Mice deficient in the Runx2 gene were non-viable due to a lack of OB, resulting in 
a complete lack of ossification (156, 157).  In humans, mutations in the Runx2 gene 
results in the disorder cleidocranial dysplasia (158); which is characterised by hypoplasia / 
aplasia of the clavicles, patent fontanelles, supernumerary teeth and short stature.  In 
studies by Ducy et al (159) transgenic mice overexpressing Runx2 DNA-binding domain 
(ΔCbfa1) in postnatal differentiated OB were observed to have a normal skeleton at birth.  
However, these mice later developed osteopenia.  This phenotype was caused by a 
decrease in bone formation while OC number and activity remained at a normal level.  
These studies revealed Runx2 also regulates differentiated OB function as well embryonic 
ossification.  The second transcription factor shown to be critical for OB formation and 
function was the zinc finger protein Osterix. 
Induction of OSX occurs downstream of Runx2.  This was demonstrated in Runx2-
deficient mice, who also exhibited no OSX expression.  The importance of OSX in OB 
development was identified by Nakashima et al (138).  In their study they revealed that 
deletion of OSX resulted in the complete absence of OB in murine embryos, despite 
normal expression of Runx2.  Further studies by Zhou et al (160) using conditional OSX 
knockouts revealed that, like Runx2, OSX was essential for OB differentiation and new 
bone formation in growing and adult bones. The final key transcription factor shown to 
regulate OB function is ATF4. 
The transcription factor ATF4 has been shown to have an important role in mature OB 
lineage cells.  In a study by Yang et al (139) misregulation of ATF4 activity was linked to 
the skeletal abnormalities observed in patients with Coffin-Lowry syndrome.  ATF4-
deficient mice were also observed to have a high perinatal death rate.  Analysis of the 
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mice that survived at multiple timepoints over a year showed a severe reduction in bone 
volume and thickness of trabeculae.  This phenotype was due in part to the OB failing to 
reach terminal differentiation and a defect in OB function (139).  ATF4 functions in OB 
through two mechanisms.  The first is by the direct regulation of the expression of OB-
derived osteocalcin,  the second by promoting efficient amino acid import to ensure 
correct protein synthesis by the OB (139). 
1.4.2 Bone Formation 
Before bone formation starts, OB-lineage cells are recruited to the resorption pit where 
they remove old demineralised collagen left by the OC (18-20).  Removal of the collagen is 
via a number of MMPs secreted by cells of the OB-lineage (Table 1.6).  Bone formation 
can be split into 2 main phases of activity: i) osteoid synthesis and iii) matrix 
mineralisation.  At each step the OB expresses different proteins and enzymes, which 
enable the process to be performed successfully.   
1.4.2.1 Osteoid Synthesis 
Initial steps in bone formation, and also one of the earliest markers of OPCs, is the 
synthesis of type I collagen.  This makes up 90% of the organic component of bone; 
however, trace amounts of type III and type V collagens may be present at certain stages 
of bone formation (161).  Non-collagenous proteins, including proteoglycans, glycosylated 
proteins such as tissue nonspecific alkaline phosphatase, Gla-containing proteins 
(osteocalcin) and lipids compose the remaining organic material, and are synthesised by 
the bone forming cells and are exogenously-derived from the serum (Table 1.7).  
Following osteoid synthesise the OB mineralises the organic matrix. 
1.4.2.2 Mineralisation 
Mineralisation of bone is completed by the incorporation of hydroxyapatite 
(Ca10(PO4)6(OH)2) into the newly deposited osteoid.  The exact mechanism by which 
mineralisation occurs is not fully understood.  Membrane bound extracellular bodies 
(extracellular matrix vesicles) released from OB facilitate initial mineral deposition by 
accumulating calcium and phosphate ions in a protected environment.  Clusters of these 
ions come together to form the first stable crystals.  Addition of ions to these crystals 
follows, resulting in their growth (162).  An important role for the non-collagenous 
proteins in mineralisation has been suggested by a number of groups, with osteonectin 
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linking the bone mineral and collagen phases (163), and ALP-deficient mice showing 
impaired mineralisation (164).  
 
MMP 
Designation 
Alternative 
Nomenclature 
Latent / Active 
(kDa) 
Collagen Substrate 
MMP-2 
Gelatinase A 
72 kDA gelatinase 
72 kDa type IV 
collagenase 
72 / 66 
I, III, IV, V, VII, X, XI, 
XIV 
MMP-8 Collagenase 2 55 / 46 - 42 I, II, II 
MMP-9 
Gelatinase B 
92 kDa gelatinase 
92 kDa type IV 
collagenase 
92 / 86 IV, V, VII, X, XIV 
MMP-13 Collagenase 3 65 – 60 / 55 - 50 II 
MMP-14 
MT1-MMP 
Membrane Type 1 – MMP 
66 / 56 I, II, III 
Table 1.6.  Members of the MMP family produced by osteoblasts (adapted from (19, 113, 
165, 166)). 
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Protein Function 
Aggrecan Storage of water and ions, matrix organisation 
Albumin Inhibits the growth of hydroxyapatite crystals 
Alkaline Phosphatase 
Carries Ca2+ and increases local phosphate concentration by 
hydrolyzing pyrophosphates 
Asporin Regulates collagen structure 
Biglycan Associates with collagen and TGF-β and other growth factors 
Decorin 
Associates with collagen and may regulate TGF-β activity and 
fibril diameter.  Blocks cell attachment to fibronectin 
Fibromodulin 
Associates with collagen and TGF-β, may regulate fibril 
arrangement 
Fibronectin Binds to cells, fibrin, heparin, gelatine and collagen 
Glypican Regulates cell development through BMP-SMAD signalling 
Lumican Associates with collagen may regulate fibril arrangement 
Matrix Gla protein Negative regulator of mineralisation 
Osteoadherin Possible role in cell attachment 
Osteocalcin 
Regulates activity of OC and their pre-cursors, possible role in the 
switch between bone formation and resorption.  Suggested to be 
a hormone. 
Osteonectin 
Positive regulator of bone formation binding growth factors, 
regulating collagen organisation and mediates hydroxyapatite 
deposition 
Osteopontin / Bone 
sialoprotein 
Associates with cells, may regulate mineralisation and cell 
proliferation.  Blocks nitric oxide synthase. 
Perlecan Regulates cell signalling 
Secreted 
Phosphoprotein 
Associates with regulators of mineralisation in the serum 
Tetranectin Possible role in matrix mineralisation 
Type I Collagen 
Serves as scaffolding, binds and orients other proteins that 
nucleate hydroxyapatite deposition 
Type III Collagen Present in trace amounts.  May regulate collagen fibril diameter 
Type V Collagen Present in trace amounts.  May regulate collagen fibril diameter 
Vitronectin A cell attachment protein  
Table 1.7.  Proteins associated with the bone matrix (Adapted from (161)). 
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1.5 Bone Disease 
Like any other organ of the body, bone is susceptible to disease.  Diseases of the bone 
(Table 1.8) are typically characterised by a direct or indirect effect on the balance of 
remodelling, leading to an increase or decrease in bone resorption and bone formation.  
The aetiology of these diseases is varied with nutrition, physical activity, inflammation, 
genetic abnormalities and hormonal changes all playing a role.  The pathogenesis of 
inflammatory arthritides and osteoporosis are explored in more detail next. 
Disease 
Genetic / 
Metabolic 
Symptoms 
Osteoporosis Metabolic 
Reduced bone mineral density leading to 
increased risk of fracture  
Osteopenia Metabolic Reduced bone mineral density 
Osteopetrosis Genetic 
Increase in bone mass due to defective 
bone resorption 
Paget’s Disease Metabolic 
Excessive bone resorption and bone 
formation 
Osteomalcia and 
Rickets 
Metabolic 
Softening of bone due to deficiency or 
impaired metabolism of Vit D, phosphate 
and calcium 
Renal Osteodystrophy Metabolic Bone mineral deficiency 
Osteogenesis 
Imperfecta 
Genetic 
Brittle bone due to deficiency in Type I 
collagen 
Osteitis Fibrosa Cystica Metabolic 
Increased osteoclast activity caused by 
hyperparathyroidism leading to bone pain 
and fractures  
Inflammatory 
Arthritides 
Metabolic 
Increased bone destruction and bone 
formation 
Non-union Fracture Metabolic 
Fracture does not heal due to movement, 
poor blood supply, OB mal-regulation and 
low OPCs. 
Osteochondroma Genetic Benign bone tumour 
Osteosarcoma Genetic Malignant bone tumour 
Table 1.8.  Overview of diseases of the bone.  (Adapted from (167)) 
37 
 
1.5.1 Inflammatory Arthritis 
Inflammatory joint diseases are a group of diverse rheumatic disorders, which have 
inflammation and adverse destructive structural and functional changes of the bone 
tissue in common.  Inflammatory joint diseases can be broadly split into two categories; i) 
those that are seropositive for rheumatoid factor (RF) e.g. rheumatoid arthritis (RA) and 
ii) those that are seronegative for RF e.g. the spondyloarthropathies (SpAs) which include, 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) (168). 
1.5.1.1 Spondyloarthropathies 
Joint inflammation in the SpAs affects the axial skeleton in addition to the diarthrodial 
joints.   Characteristically the joint inflammation is asymmetrical with proximal and distal 
joints affected (27).  The SpAs share a number of common features including 
inflammatory back pain, peripheral arthritis, enthesitis, dactylitis, and uveitis.  In contrast 
to RA the SpAs are also characterised by increased bone formation; with delicate marginal 
syndesmophytes common in AS, and bulky, non-marginal syndesmophytes more common 
in reactive arthritis and psoriatic arthritis (169).  The exact aetiology of the SpAs is 
unknown though characteristics include increased T cell and macrophage numbers,  as 
well as greater expression of pro-inflammatory cytokines, IL-1, TNF and IFNγ, at sites of 
inflammation (169). 
1.5.1.2 Rheumatoid Arthritis 
Rheumatoid arthritis is a common systemic chronic inflammatory disease that affects 
approximately 1% of the global population, and is associated with significant morbidity 
and increased mortality (170).  RA is characterised by persistent inflammation of multiple 
joints and the infiltration of immune cells (Fig 1.8 (a)); mainly macrophages, T cells and 
plasma cells (171). These cells initiate structural changes within the joint; hyperplasia of 
the synovial lining and eventual cartilage and bone damage that cause loss of mobility at 
later stages of the disease.  Diagnosis of RA is performed according to the criteria jointly 
published by the American College of Rheumatology (ACR) and the European League 
Against Rheumatism (EULAR) as shown in Table 1.9 (172).  A score of >6/10 is required for 
classification of a patient as having definite RA. 
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Section A Joint Involvement Score 
 1 large joint 0 
 2 – 10 large joints 1 
 
1 – 3 small joints (with or without involvement of large 
joints) 
2 
 
4 – 10 small joints (with or without involvement of large 
joints) 
3 
 10 joints (at least 1 small joint) 5 
Section B Serology (at least 1 test required)  
 Negative RF and negative ACPA 0 
 Low-positive RF or low-positive ACPA 2 
 High-positive RF or high-positive ACPA 3 
Section C Acute-phase Reactants (at least 1 test required)  
 Normal CRP and normal ESR 0 
 Abnormal CRP or abnormal ESR 1 
Section D Duration of Symptoms  
 < 6 weeks 0 
 > 6 weeks 1 
Table 1.9.  ACR/EULAR Rheumatoid Arthritis Classification Criteria.  RF = rheumatoid 
factor.  ACPA = anti-citrullinated protein antibody.  CRP = C-reactive protein.  ESR = 
erythrocyte sedimentation rate.  (Reproduced from (172)). 
The exact aetiology of RA is unknown, however, in the last 30 years giant strides have 
been made in the characterisation of the intracellular mediators, or cytokines, that drive 
this disease (170, 171, 173, 174).  Initial cytokine analysis of RA verified that a large 
number of pro-inflammatory cytokines such as; IL-1, TNF, IL-6 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) were produced by the rheumatoid 
synovial membrane (173, 175, 176).   The significance of TNF in RA was identified by 
Brennan et al (177).  In their study they showed that culturing RA synovium cells in the 
presence of TNF specific antibodies abrogated IL-1 production.  This work was further 
supported through subsequent experiments that showed use of anti-TNF antibodies also 
downregulated the expression of other pro-inflammatory cytokines, such as IL-6, GM-CSF 
and IL-8 (178, 179) indicating that TNF may be at the top of a pro-inflammatory cascade.  
This increase in pro-inflammatory cytokines associated with RA has a knock on effect on 
OC formation and activity leading to increased bone destruction.  Levels of the TNFSF 
members RANKL (TNFSF11) (180), TNF (TNFSF2) (181) and homologous to lymphotoxins 
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exhibiting inducible expression and competing with herpes simplex virus glycoprotein D 
for herpes-virus entry mediator [HVEM], a receptor expressed by T lymphocytes (LIGHT, 
TNFSF14) (182, 183) are upregulated in the serum and synovial fluid of RA patients.  While 
RANKL induces osteoclast formation directly (15, 16, 60), TNF and LIGHT have been 
shown to synergistically enhance its effects (182, 184, 185).  To abrogate the damage 
caused by the inflammation associated with RA, patients are given a range of treatments. 
Traditionally RA is treated with non-steroidal anti-inflammatory drugs (NSAIDs), 
glucocorticoids and disease-modifying anti-rheumatic drugs (DMARDs).  Only the 
DMARDs can impede or halt the destructive disease processes, while NSAIDs are used for 
the daily control of pain.  Development of anti-TNF therapies has made significant 
improvements in the treatment of RA.  Anti-TNF treatments such as adalimumab (human 
monoclonal antibody), etanercept (TNF receptor-IgG fusion protein) and infliximab 
(mouse-human chimera antibody) work by blocking TNF signalling via its receptor TNFR1 
preventing the negative effects of TNF in RA patients (186).   However, there are some 
patients who do not respond to the treatment.  Reasons for a lack of response are 
generally unknown, due to RA being such a complex and heterogeneous disease, but 
targets must include inflammatory cell types and other as of yet uncharacterised 
cytokines.   
1.5.2 Osteoporosis 
Osteoporosis (OP) is a well established medical and socioeconomic problem characterised 
by a low bone mineral density (BMD), deteriorated bone microarchitecture (Fig 1.8 (b)) 
and an increased risk of fracture (187).  It is considered a silent disease because bone loss 
occurs without symptoms and approximately two thirds of vertebral fractures are 
asymptomatic (188).  Approximately 40% of white, postmenopausal women and 13% of 
men are affected by OP, and with an aging population in western society this number is 
expected to increase over the coming years (189-191).  Fractures most commonly occur in 
the spine, hip or wrist but other bones can be affected, such as the humerus or ribs.  
Osteoporotic fracture leads to a loss of mobility and subsequent decrease in quality of 
life.  More worrisome, however, osteoporotic fractures of the spine or hip lead to an 
increase in mortality; due to hospitalisation and the enhanced risk of other complications 
such as pneumonia or thromboembolic disease (192).  Due to OP being a silent disease 
diagnosis can be problematic. 
40 
 
Historically diagnosis of OP was through the presence of non-traumatic fractures on a 
setting of low bone mass, detected through radiographic examination (193).  While 
clinically useful in the past this method had low sensitivity and was based on 
complications of the disorder rather than the underlying pathology; the imbalance in 
osteoclast and osteoblast activity.  Development of dual x-ray absorptiometry (DXA) 
allowed the measurement of bone mass at any site in the skeleton with a high level of 
precision (2% - 4%) (194). The technique provided a clearer clinical definition of OP (Table 
1.10).  Even though methods for the detection and diagnosis of OP have improved it is 
still often only diagnosed after the first clinical fracture (195, 196). 
Level Definition 
Normal 
Bone density is within 1 standard deviation (SD) (+1 or -
1) of the young adult mean. 
Low Bone Mass 
Bone density is between 1 and 2.5 SD below the young 
adult mean (-1 to -2.5 SD). 
Osteoporosis 
Bone density is 2.5 SD or more below the young adult 
mean (12.5 SD or lower) 
Severe (Established) 
Osteoporosis 
Bone density is more than 2.5 SD below the young 
adult mean, and there have been one or more 
osteoporotic fractures 
Table 1.10.  World Health Organisation (WHO) Definitions Based on Bone Density 
The aetiology and pathogenesis of OP are not fully defined.  A major cause is an 
imbalance in the bone remodelling process, where increased OC activity leads to 
excessive bone resorption compared to bone formation (52, 197).  A number of studies 
have also suggested that decreased bone formation plays a significant role (198, 199).  In 
the female population, onset of menopause is the major factor that contributes to the 
development of post-menopausal OP with the associated oestrogen deficiency linked to a 
subtle increase in expression of the cytokines RANKL, TNF, IL-1 and IL-6 in ex vivo cultures 
(197, 200-204).  The significance of these increases in the pathogenesis of the disease in 
vivo, however, is less clear.  Low body-mass index, a family history of fractures, smoking, 
low dietary calcium intake, vitamin D deficiency and the use of glucocorticoids also have a 
role in the pathogenesis of the disease (205).  A variety of treatments can be prescribed 
for OP, with the aim of increasing bone density and correcting the imbalance in 
remodelling.  
Current baseline therapies for the treatment of OP include lifestyle modifications 
(increased physical activity and cessation of smoking), and vitamin D and calcium 
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supplementation (206, 207).  In higher risk groups, pharmacological interventions are 
employed.  These fall into two classes: i) those that inhibit bone resorption 
(antiresorptive) and ii) those that stimulate bone formation (anabolic).  The main group of 
antiresorptive drugs is the bisphosphonates.  Bisphosphonates have a long half-life in the 
skeleton meaning treatment can be daily, weekly, monthly or yearly, depending on the 
drug and the route of administration (intravenous versus oral).  They act upon the OC 
inhibiting their activity either by a direct toxic effect or by altering their cytoskeleton 
(208).  More recently drugs that stimulate bone formation have been approved for 
treatment.  Anabolic drugs such as intact PTH (1-84) and teriparatide exert their effect by 
directly increasing bone formation by the OB (209).  The mechanism of action of 
Strontium ranelate is unclear though it most likely acts via a combination of 
physiochemical effects and modest effects of increased bone formation and decreased 
bone resorption (210).  In recent years the first monoclonal antibody (mAb) for the 
treatment of OP has been developed and approved for use.  Denosumab is a fully 
humanised mAb directed against RANKL (211).  Denosumab works by inhibiting the 
differentiation of osteoclasts, mimicking the natural action of OPG and leads to a 
progressive rise in bone strength (212). 
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1.6 The Tumour Necrosis Factor Superfamily 
The cytokines RANKL and OPG and their receptor RANK are members of the tumour 
necrosis factor superfamily (TNFSF).  As discussed in section 1.3, these TNFSF members 
play a critical role in bone homeostasis and as such have been targeted for therapy; 
Denosumab is a monoclonal antibody against RANKL used in the treatment of OP.  The 
impact of some, but not all of the TNFSF members on bone homeostasis has been 
described in the literature.  In the following sections the close structural homology and 
signalling events related to function in the TNFSF are discussed, with focus on death 
receptor 3 (DR3) and its ligand TNF-like protein 1A (TL1A). 
The origins of the TNFSF date back to 1962 with the discovery by O’Malley et al (213) of 
an LPS induced factor in serum that was capable of tumour regression; named tumour-
necrotising factor (213).  This was subsequently re-named in 1975 by Carswell et al (214) 
to tumour necrosis factor (TNF).  In 1968 lympohtoxin (LT) was first described by Williams, 
Granger et al (215) as a protein produced by lymphocytes that could kill tumour cells.  
Characterisation of the two proteins by Aggarwal et al (216, 217), in 1984 / 1985, 
revealed that they were homologous and shared common cell-surface receptors.  This 
finding indicated the possibility of a TNF superfamily.  To date the TNF superfamily 
consists of 29 receptors and 18 ligands, all with similar structures (Table 1.11).   
TNFSF ligands are type II trans-membrane proteins characterised by a conserved C-
terminal domain known as the ‘TNF homology domain’ (THD).  This trimeric domain is 
responsible for receptor binding and its sequence identity between family members is 
between 20 – 30% (218).  Although most of the ligands are synthesised as membrane-
bound proteins, they may also be cleaved and released as soluble proteins to exert their 
effect (218, 219).  Like the TNFSF, members of the TNF receptor superfamily (TNFRSF) also 
share a high degree of homology. 
Members of the TNF receptor superfamily (TNFRSF) are characterised by their repeated 
cysteine-rich extracellular sequence homology (218, 220).  They are type I trans-
membrane proteins, though there are some exceptions. BCMA, TACI, BAFFR and XEDAR 
are type III trans-membrane proteins while DcR1, DcR2, DcR3 and OPG are secreted 
proteins (219, 221).  Receptors of the TNFSF can be split into 3 groups based upon their 
cytoplasmic sequence and signalling properties: i) Receptors containing one or more TRAF 
Interacting Motifs (TIMs), ii) receptors containing a death domain (DD) in the cytoplasmic 
44 
 
tail – death receptors and iii) receptors that do not contain a functional intracellular 
signalling domain or motif – decoy receptors (222).  The structure and function of the 
TNFRSF death receptors are detailed below. 
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Receptor 
TNFRSF 
Designation 
Expression Ligand 
TNFSF 
Designation 
Expression Effect 
CD27 TNFRSF7 T Cells CD27L TNFSF7 T Cells, B Cells, NK Cells Activation of T cells 
TNFR2 TNFRSF1B Immune Cells, Endothelial Cells TNF / LT TNFSF2 / TNFSF1 Immune Cells Immune Defence 
LTβR TNFRSF3 T Cells, NK Cells LT TNFSF1 Immune Cells Immune Defence 
FN14 TNFRSF12A Endothelial Cells, Fibroblasts TWEAK TNFSF12 Monocytes Inflammation, Proliferation 
HVEM TNFRSF14 T Cells LIGHT TNFSF14 Immune Cells Viral Entry 
CD30 TNFRSF8 Reed-Sternberg Cells CD30L TNFSF8 T Cells, Monocytes Th2 Cell Function 
CD40 TNFRSF5 Reed-Sternberg Cells CD40L TNFSF5 T Cells, B Cells Immune Cell Homeostasis 
4-1BB TNFRSF9 Activated T Cells, Monocytes, NK Cells 4-1BBL TNFSF9 B Cells, DCs, Macrophages T Cell, B Cell Activation 
OX40 TNFRSF4 T Cells OX40L TNFSF4 T Cells, B Cells T Cell, B Cell Homeostasis 
GITR TNFRSF18 CD4
+
CD25
+
 T Cells GITRL TNFSF18 ? T Cell Homeostasis 
RANK TNFRSF11A Osteoclasts RANKL TNFSF11 
Activated T Cells and 
Osteoblasts 
Osteoclastogenesis 
BCMA TNFRSF17 Immune Cells APRIL / BAFF TNFSF13 / TNFSF13B Immune Cells B Cell Homeostasis 
TACI TNFRSF13B Immune Cells APRIL / BAFF TNFSF13 / TNFSF13B Immune Cells B Cell Homeostasis 
BAFFR TNFRSF13C Immune Cells BAFF TNFSF13B Immune Cells B Cell Homeostasis 
XEDAR TNFRSF27 Ectodermal derivative EDA2 ? Skin Hair / Teeth morphogenesis 
TROY TNFRSF19 
Embryo Skin, Epithelium, Hair follicles, 
Brain 
? ? ? Embryonic Development 
RELT TNFRSF19L Lymphoid Tissues ? ? ? T Cell Homeostasis 
Table 1.11.  Members of the TNF receptor super family, their ligands and function.  (Adapted from (219, 220, 223, 224)).  
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Death 
Receptors 
TNFRSF 
Designation 
Expression Ligand 
TNFSF 
Designation 
Expression Effect 
CD95 TNFRSF6 Most Normal Cells CD95L TNFSF6 Splenocytes, Thymocytes Immune Defence 
TNFR1 TNFRSF1A Most Normal Cells TNF / LT TNFSF2 / TNFSF1 Immune Cells 
Immune Defence, 
Inflammation 
DR3 TNFRSF25 Activated T Cells, Osteoblasts, Macrophages TL1A TNFSF15 
Endothelial Cells, T Cells, 
Macrophages 
T Cell Homeostasis and 
Activation, Inflammation 
DR4 TNFRSF10A Most Normal Cells TRAIL TNFSF10 NK Cells, T Cells, DCs Immune Defence 
DR5 TNFRSF10B Most Normal Cells TRAIL TNFSF10 NK Cells, T Cells, DCs Immune Defence 
DR6 TNFRSF21 Resting T Cells ? ? ? ? 
EDAR TNFRSFEDAR Ectodermal derivative EDA1 ? Skin Hair, Teeth Morphogenesis 
NGFR TNFRSF16 Nervous System ? ? ? CNS Development 
       
       
Decoy 
Receptors 
TNFRSF 
Designation 
Expression Ligand 
TNFSF 
Designation 
Expression Effect 
OPG TNFRSF11B Osteoblasts, Most Normal Cells RANKL / TRAIL TNFSF11 / TNFSF10 
Activated T Cells and 
Osteoblasts 
Decoy Receptor 
DcR1 TNFRSF10C Most Normal Cells TRAIL TNFSF10 NK Cells, T Cells, DCs Decoy Receptor 
DcR2 TNFRSF10D Most Normal Cells TRAIL TNFSF10 NK Cells, T Cells, DCs Decoy Receptor 
DcR3 TNFRSF6B T Cells TL1A TNFSF15 
Endothelial Cells, T Cells, 
Macrophages 
Decoy Receptor 
Table 1.11 (Cont.).  Members of the TNF receptor super family, their ligands and function.  (Adapted from (219, 220, 223, 224)). 
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1.7 Death Receptors 
The death receptor (DR) group of the TNFRSF are so called due to the presence of a 
cytoplasmic region of approximately 80 residues termed the death domain.  When this is 
triggered it results in the transduction of either apoptotic or survival signals (223).  Death 
receptors can be further split based upon their signalling complex.  The first group 
comprises the death-inducing signalling complexes (DISCs; CD95, DR4 and DR5), which 
results in the activation of caspase-8 and the transduction of the apoptotic signal.  The 
second group of receptors (TNFR1, DR3, DR6 and EDAR) recruit a different set of 
molecules which can transduce both apoptotic and survival signals (219, 223). 
Transduction of signal via the DR requires the recruitment of a number of intracellular 
adaptor molecules (Fig 1.9).  Generation of the DISC consists of an oligomerised receptor, 
which recruits the adaptor molecule Fas-associated death domain (FADD) and isoforms of 
procaspase 8.  The interaction between these molecules results in caspase 8 being 
released into the cytosol to propagate the apoptotic signal.  Signalling via TNFR1 differs 
from above in that it can form two signalling complexes.  The first complex, formed at the 
membrane, comprises the adaptor molecules TNFR-associated death domain protein 
(TRADD), receptor-interacting protein (RIP) and TNF-associated factor (TRAF).  This 
triggers the nuclear factor-κB (NF-κB) pathway, promoting cell survival.  The second 
signalling complex works in a manner similar to the DISC using FADD and caspase 8 to 
induce apoptosis (223, 225-228).  Death receptor 3 (DR3) is a member of the TNFRSF that 
has a high degree of homology to TNFR1.  The role and function of DR3 and its ligand TL1A 
in inflammation, immunity and bone is only just starting to be discovered.  The remainder 
of this introduction will focus on what is currently known about DR3 and TL1A. 
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1.8 Death Receptor 3 
Death Receptor 3 (also known as wsl-1, APO-3, TNF related-receptor apoptosis-mediating 
protein (TRAMP), lymphocyte associated receptor of death (LARD), TNF receptor-like 3 
(TR3), TNF receptor superfamily member 25 (TNFRSF25)) was identified in 1996 / 1997 by 
a number of groups (229-233); Kitson et al (229), Screaton et al (230), Marsters et al (231), 
Chinnaiyan et al (232) and Bodmer et al (233).  With the exception of Kitson et al (229), 
who used a yeast two-hybrid system utilising the death domain of TNFR1 as a binding 
target and PCR,  the discovery of DR3 was based on searching expressed sequence tag 
(EST) databases.  Genes that had extracellular cysteine-rich domains and intracellular 
death domains with a homology to TNFR1, CD95 and FAS (230-233) were screened for.  
The DR3 gene was mapped to human chromosome 1p36.3 by Bodmer et al (233) using 
fluorescence in situ hybridisation (FISH) analysis.  DR3 was found to be overall highly 
homologous to TNFR1, CD95 and FAS, with sequence identity reported as 26% - 29%, 22% 
- 23% and 27% respectively (229-232).  The homology to TNFR1 increased to 40% - 48% in 
the death domain (230-233).  The structure of DR3 was determined to have a signal 
sequence followed by an extracellular region, making up the extracellular domain (ECD), a 
transmembrane domain and an intracellular domain (ICD), with two N-linked glycosylation 
sites at amino acid positions 67 and 106.  The ECD contains four cysteine-rich 
pseudorepeats, while the ICD contained a sequence, which resembled the death domains 
found in the ICD of TNFR1 and CD95.  Notably, four out of the six amino acid residues in 
the death domain of TNFR1 that are essential for signalling are identical in DR3 with the 
remaining two semi-conserved (231). 
The murine DR3 gene was identified in 2001 by Wang et al (234) through probing genomic 
mouse DNA with full-length human DR3 gene cDNA.  Murine DR3 was found to be overall 
63% homologous to human DR3; 94% in the death domain and 53% in the ECD.  Murine 
DR3 was found to contain two putative N-linked glycosylation sites in the ECD, which were 
conserved in human DR3.  25 of the 28 ECD cysteines found in human DR3 were also 
conserved.  However, a 9 amino acid deletion in the second half of the third cysteine rich 
domain (CRD) of murine DR3 was found, resulting in the absence of two conserved 
cysteine residues.  In addition two significant amino acid substitutions were found within 
the 3rd CRD of murine DR3; with the sixth conserved cysteine replaced by threonine and 
phenylalanine replaced by a cysteine.  Despite these differences the binding properties of 
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murine DR3 were predicted to be the same as human DR3 (234).  Having identified DR3 as 
a new member of the TNFRSF the authors went on to detail its expression. 
 
1.8.1 DR3 Expression 
Initial northern blot analysis identified human DR3 expression to be mainly restricted to 
lymphoid organs; with 3.5 – 4kb mRNA transcripts detected in the adult spleen, thymus 
and peripheral blood lymphocytes (229-233).  Additional studies, however, identified low 
levels of DR3 gene expression in the small intestine, lung, colon and foetal kidney (231).  
Gene expression was also identified in activated T cells, primary monocytes and early 
myeloid cell lines (235).  While not as ubiquitously expressed as other members of the 
TNFRSF, recent studies have shown that expression of DR3 is not as restricted as 
previously thought.  Cell surface receptor expression has been detected on CD4+ T cells 
(236), CD8+ T Cells (237), NK cells (238),  NKT Cells (237), monocytes / macrophages (OC 
precursors; (239, 240)) and osteoblasts (241).  Murine DR3 was demonstrated to have a 
similar expression pattern to human DR3.  Murine DR3 mRNA has been detected in the 
heart, kidney, spleen, liver, thymus, brain (234) and bone marrow macrophages (242).  
Cell surface receptor has also been shown on NKT cells, CD4+ T Cells and CD8+ T cells 
(243).   In describing DR3 expression a number of splice variants were identified. 
The initial studies into human DR3 by Screaton et al (230) identified 12 splice variants.  
The isoform missing exon 3 was shown to include the trans-membrane and death 
domains, whereas the remaining isoforms potentially encoded soluble receptors.  In their 
study, it was suggested that all but 3 of the DR3 isoforms were generated by the skipping 
of one or more complete exons, with two variants having a 101- and 200-bp insert.  The 
remaining DR3 isoform was found to contain three additional nucleotides.  The isoform 
detected by Warzocha et al (244), termed DR3β, differed from the full length receptor by 
a 20- and a 7-bp insert.  The predicted translated products showed that DR3 and DR3β 
have identical intracytoplasmic and trans-membrane domains but differed in their extra-
cellular domains.  In the murine system, 3 DR3 splice variants were described by Wang et 
al (234).  Variant 1 was observed to be the largest isoform and encoded a protein 55kDa in 
size.  Variant 2 was described as a soluble form of the receptor with a missing exon 6, 
resulting in an early stop site before the transmembrane domain.  The third variant 
consisted of variant 1 lacking exons 5 and 6 resulting in a protein with both a 
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transmembrane and cytoplasmic domain, but without the fourth cysteine rich domain.  
The effect that this has on its capacity for ligand binding and signalling has yet to be 
determined.   
 
1.8.2 The DR3 Signalling Pathway 
The conservation in structure between DR3 and TNFR1 suggested that they must have 
similar signalling pathways.  This hypothesis was confirmed in a study by Chinnaiyan et al 
(232) using glutathione-S-transferase (GST) fusion protein binding studies.  DR3 associated 
specifically with TRADD but not with FADD or RIP in vitro; a truncated death domain 
mutant of DR3 did not demonstrate any interaction with TRADD.  When DR3 was 
expressed in 293 human embryonic kidney cells in the presence of TRADD, however, 
enhanced binding of RIP, FADD and TRAF2 were detected (232).  Further support for the 
important role of TRADD in the DR3 signalling pathway was published by Pobezinskaya et 
al (245).  Failure of DR3 signalling in TRADD deficient mice was due to lack of recruitment 
of the adaptor proteins TRAF2 and RIP1, leading to a non-functional DR3 signalling 
complex.  Upon formation of the complete signalling complex DR3 can induce both the 
apoptotic pathway and the NF-κB pathway (Fig 1.10).   
Induction of the apoptotic pathway by DR3 signalling has been demonstrated by a number 
of groups.  Overexpression of full length DR3 in 293 cells resulted in morphological 
changes; blebbing, rounding, condensing and detachment from the dish, all indications of 
apoptosis (229-232).  Overexpression of a truncated from of DR3, lacking the cytoplasmic 
domain, was not able to induce cell death (229).  Apoptosis induced by DR3 could be 
blocked by dominant negative versions of FADD or FADD-like interleukin-1β-converting 
enzyme (FLICE), indicating that they are necessary components of the DR3 apoptotic 
pathway (232).  Activation of NF-κB by DR3 was identified with a luciferase reporter gene 
assay (229, 233).  This showed DR3 expression to strongly induce NF-κB in a dose-
dependent fashion, however, truncated forms of DR3 were not able to activate NF-κB 
(232).  Use of dominant negative derivatives of RIP and TRAF2 blocked DR3-induced NF-κB 
activation; it was not affected however, by a dominant negative derivative of FADD (232).   
These initial studies into the DR3 signalling pathway were obtained with transient systems 
where DR3 and / or the signalling molecule were overexpressed. Whether they were 
representative of the natural signalling response remained unknown. 
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To address this Wen et al (246) studied DR3 signalling in TF-1 cells, which naturally express 
the receptor.   Activation of DR3 by TL1A consistently recruited the adaptor molecules 
TRADD, TRAF2 and RIP.  Very little FADD or procaspase-8 was detected in the complex 
(246).  Stimulation of the cells with TL1A, in addition to the NF-κB pathway, also activated 
the JNK, p38 and ERK1,2 MAPK pathways in a dose- and time-dependent manner.  
Induction of apoptosis by DR3 signalling was only observed following treatment of the TF-
1 cells with a NF-κB inhibitor, or a general protein synthesis inhibitor, stopping the 
synthesis of the anti-apoptotic molecule c-IAP2, which was potently induced by TL1A 
signalling (246).  The results demonstrated that while in transient systems DR3 signalling 
can actively induce the apoptotic and NF-κB pathways, in cells expressing natural levels of 
DR3 induction of NF-κB is favoured.  
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1.8.3 The DR3 Ligand 
Following the discovery of DR3, work into the identification of its ligand(s) began.  To date 
three potential ligands for DR3 have been reported; the TNFSF members Apo3L/TWEAK 
(TNFSF12; (247)) and TL1A (TNFSF15; (248)), and the adhesion molecule E-selectin (249).  
This thesis will focus on the TNFSF member ligands of DR3. 
1.8.3.1 The DR3 Ligand – Apo3L / TWEAK 
The first suggested ligand for DR3 was Apo3L (247).  Apo3L was identified following a 
search of an EST database for sequences, which had a similarity to TNF.  It was 
subsequently shown to have a type II trans-membrane protein topology.  Northern blot 
analysis identified a broad range of expression of Apo3L in foetal and adult tissue (247).  
Analysis of the function of Apo3L demonstrated it could induce apoptosis in cells by 
activating caspases through FADD, as well as being able to activate the NF-κB pathway 
using the same cytoplasmic elements as TNF (247).  Apo3L was also identified 
independently by Chicheportiche et al (250) and named TWEAK.  However, in this study it 
did not bind DR3.  Confirmation that TWEAK / Apo3L was not the true ligand for DR3 was 
put forward in a study by Kaptein et al in 2000 (251).  Using an ELISA-based in vitro assay 
no significant binding of TWEAK to DR3 was detected.  Consistent to the ELISA method no 
TWEAK / Apo3L was co-immunoprecipitated using DR3-Fc.  In cell based assays, treatment 
of DR3 transfected cells with TWEAK / Apo3L had no effect on NF-κB or apoptosis 
induction.  Furthermore no significant difference in the ability of TWEAK / Apo3L to bind 
to peripheral blood lymphocytes isolated from DR3wt and DR3ko mice was detected (251).  
Taken together this data strongly suggested that Apo3L / TWEAK was not the true ligand 
for DR3.  Work by Migone et al (248) in 2002 identified the endothelial cell-derived TNF-
like factor, TL1A, as the ligand for DR3. 
1.8.3.2 The DR3 Ligand – TL1A 
TL1A was identified through EST databases and found to be a longer variant of TNF-like 
molecule (TL1), also known as vascular endothelial growth inhibitor (VEGI).  TL1A mRNA 
was found to be expressed predominantly by endothelial cells though low levels were 
detected in the kidney, intestine, lung, spleen and thymus (248).  It was shown to bind 
successfully to a DR3-Fc and DcR3-Fc fusion proteins as well as a membrane bound form 
of DR3, while no association was detected with any other receptors tested (248).  In 
addition to endothelial cells (248, 252) expression of TL1A has been shown on monocytes 
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and dendritic cells following FcγR activation (253), activated CD4+ and CD8+ T cells (237) 
and plasma cells (254).  TL1A is currently the only identified TNFSF ligand for DR3.  
However, it can also bind to the decoy receptor DcR3 (248).  Upon binding DcR3 the 
effects of TL1A are neutralised.  Binding to DR3, however, can initiate a variety of 
responses depending on the cell type.  
 
1.9 Effects of DR3/TL1A Signalling 
Like other members of the TNFSF, TL1A has been shown to enhance T cell proliferation 
and cytokine production by activated T cells.  The proliferative effect of TL1A is enhanced 
in sub-optimally activated cells with a more pronounced effect in memory T cells versus 
naïve T cells (255, 256).  Co-stimulation with TL1A also enhances production of a range of 
cytokines in both naïve and total T cells including IFNγ, IL-2, -4 and -13 (248, 256, 257).  
Early studies demonstrated that TL1A is associated with the expansion of T-helper subsets 
and can synergise with IL-12 and IL-18 to affect development of IFNγ T cells (248, 258).  
More recently in a study by Jones et al (236) TL1A has been shown to differentially 
regulate distinct outcomes in naïve and activated T cells; affecting Th17 generation, 
maintenance and proliferation.  TL1A signalling in naïve and pre-activated effector cells 
was demonstrated to suppress the initial commitment of naïve T cells into Th17 cells.  The 
effector characteristics of pre-conditioned Th17 cells, however, was maintained (236). 
Less is known about the role of TL1A in CD8+ T cells.  In a study by Slebioda et al (259) 
addition of soluble TL1A was shown to co-stimulate CD8+ T cell proliferation and IL-2 
production.  Work by Twohig et al (243) demonstrated that TL1A signalling on CD8+ T cells 
was essential for efficient development of antiviral CD8+ T cell immunity.  Additional to 
any effects on T cells TL1A has been shown to synergise with IL-12 and IL-18 increasing 
IFNγ production and cytotoxicity by natural killer (NK) cells (258, 260).  In NKT cells TL1A 
promotes a more restricted cytokine release compared to T cells, with enhanced 
expression of IL-4 and IL-13 but not IFNγ (237).  The role that DR3 / TL1A play in bone 
biology has only recently come to prominence and has not been fully investigated.  
Currently there are only two papers that directly examine the functional role of DR3/TL1A 
in OB and OC biology. 
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1.9.1 Effects of DR3/TL1A Signalling in Osteoclast Biology 
The role of DR3/TL1A in OC biology was touched upon in a study by Bull, Williams et al 
(242).  In this study, DR3-deficient mice were protected from bone erosion in an antigen 
induced arthritis (AIA) model.  Histological analysis of the arthritic joint demonstrated 
comparable TRAP expression in DR3wt and DR3ko mice in the femoral head and growth 
plate.  However, at sites of bone erosion TRAP staining was significantly greater in DR3wt 
mice.  These data implicated a role for DR3 in in vivo osteoclast formation at sites of bone 
pathology, but not in areas away from the pannus. This hypothesis was supported by their 
in vitro studies.  Addition of TL1A to murine BMM cultures and human PBMC cultures 
significantly enhanced RANKL-induced OC formation.  The mechanism involved, however, 
was not investigated in their study.   While DR3 / TL1A have been shown to have an effect 
on primary OC formation, their role in OB biology is less well defined. 
1.9.2 Effects of DR3/TL1A Signalling in Osteoblast Biology 
Expression of DR3 on the cell surface of primary human OB and the MG63 OB cell line was 
demonstrated by Bu et al (261) and Borysenko et al (241).  The function that DR3 plays in 
OB biology however, is unclear.  In the study by Borysenko et al (241) cross-linking of DR3 
on MG63 cells induced apoptosis, but only at low cell density.  Addition of TL1A to MG63 
cells was also demonstrated to increase levels of apoptosis 4-fold.  However, when TL1A 
was added to primary human OB no difference in apoptosis was observed.  Only after 
sensitisation of primary OB with cycloheximide, an inhibitor of protein bio-synthesis, was 
TL1A observed to have any effect on apoptosis.  The results from the Borysenko et al 
(241) study suggest a role for DR3 / TL1A in the regulation of OB apoptosis.  This 
regulation however, is only present under very specific conditions.  The main focus of this 
thesis will be investigating the functional role of DR3 / TL1A in OC and OB biology. 
 
1.10 DR3 / TL1A and Inflammatory Disease 
Since their initial discovery, DR3 and TL1A have been linked to the pathogenesis of a 
number of inflammatory diseases in clinical studies and experimental models; including 
Crohn’s disease (262), ulcerative colitis (263), irritable bowel disease (IBD) (254, 263), 
rheumatoid arthritis (264-266), ankylosing spondylitis (267, 268), psoriatic skin lesions 
(269), arthrosclerosis (239, 270, 271), allergic lung inflammation (237) and  renal 
inflammation (272).  The majority of these studies have focused on the effects of 
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DR3/TL1A on the T cell response.  Early studies by Bamias et al (254) demonstrated an up-
regulation of TL1A and DR3 in intestinal lamina propria CD4+ and CD8+ T cells isolated 
from patients with IBD.  Addition of TL1A to T cells involved in small intestinal immune 
and inflammatory responses (CCR9+) have also been demonstrated to enhance IL-12/IL-8 
IFNγ production (257, 273), suggesting an important role for DR3/TL1A in the 
pathogenesis of IBD.  This is supported by studies that have identified a strong genetic link 
between TL1A and IBD with a number of TNFSF15 single nucleotide polymorphisms (SNPs) 
that confer significant risk (274-276).  In animal models of IBD DR3/TL1A interactions have 
been shown to exacerbate intestinal inflammation via stimulation of Th1 and Th17 
pathways (277), and by providing co-stimulatory signals to lymphocytes (255).  In an 
animal model of allergic lung inflammation DR3 was identified as the trigger for amplified 
Th2 cytokine production by polarised CD4 cells and for IL-13 production by NKT cells.  
Blockage of DR3 in this model was shown to inhibit the allergic lung inflammation (237).  
While the majority of studies have looked at T cell response to DR3 and TL1A in 
inflammatory disease, studies investigating the effects on other cell types have been 
performed.   
Work by Kim et al (239), demonstrated the presence of DR3 in atherosclerotic plaques.  
This was built upon by Kang et al (278) and Kim et al (271) who showed that foam cells 
within the plaques express both DR3 and TL1A.  The importance of this in the 
pathogenesis of atherosclerosis was identified by McLaren et al (270), who demonstrated 
that TL1A promotes foam cell formation in human macrophages in vitro.  DR3 was also 
revealed to regulate foam cell formation and contributed significantly to the actions of 
TL1A.  In a 2013 study, Bamias et al (279) showed an association between TL1A levels and 
atheromatic plaque formation in RA with dysregulated TL1A-induced signalling potentially 
associated with the risk of accelerated atherosclerosis.  In psoriatic skin lesions up-
regulation of DR3 and TL1A were observed in the cell populations critically involved in the 
pathogenesis of the skin inflammation, such as keratinocytes and macrophages.  The role 
that they played in the initiation of the inflammation was not investigated (269).  Evidence 
for the involvement of DR3/TL1A in the pathogenesis of bone related disease has arisen 
from recent clinical and animal studies. 
The association between DR3/TL1A and the inflammatory arthritides has been reported in 
a number of studies.  Elevated levels of TL1A have been reported in the serum of 
rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients (264, 267).  While in RA 
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patients increased duplication of the DR3 gene has been identified (265).  In an animal 
model of antigen-induced arthritis (AIA) Bull, Williams et al (242) demonstrated that DR3-
deficient mice were protected from bone erosion.  Co-administration of TL1A in AIA (242) 
and collagen induced arthritis (CIA; (266)) was also shown to significantly exacerbate bone 
destruction and deformation.  These data all indicated an important role for DR3 and TL1A 
in the pathogenesis of bone-related disease; however, the mechanisms through which it 
acts are unknown.  The role of DR3/TL1A in the pathogenesis of diseases characterised by 
OC over-activity is explored in more detail in chapter 5.  
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1.11 Aims of the Thesis 
Expression of DR3 has been demonstrated on the surface of osteoclast precursors and 
osteoblasts.  The effect exerted on these cells by DR3/TL1A signalling and their role in 
bone-related disease however, is poorly defined.  While addition of TL1A to murine BMM 
macrophage cultures and human PBMC cultures has been shown to significantly enhance 
osteoclast formation, it is unknown whether this is due to a direct or indirect effect, or the 
mechanisms involved.  The effect of DR3 and TL1A on OB biology is even less well defined. 
The aims of this thesis were three-fold:  Firstly, to determine the direct effect of DR3/TL1A 
on osteoclast formation and function and to elucidate the mechanisms involved.  
Secondly, to assess the role of DR3/TL1A in the pathogenesis of disease characterised by 
OC over-activity; namely rheumatoid arthritis and osteoporosis.  Thirdly, identify the role 
of DR3 in osteoblast formation and function.  The specific objectives of this thesis are: 
 To establish the mechanism by which DR3 / TL1A induces osteoclastogenesis in 
a murine system. 
Osteoclast formation and function will be evaluated in mice genetically deficient 
in DR3 (DR3ko) and wild-type mice (DR3wt).  Markers of osteoclast formation and 
function will be analysed to determine the mechanism through which they act. 
 To establish the mechanism by which DR3 / TL1A induces osteoclastogenesis in 
man. 
Osteoclast formation and function will be evaluated in human CD14+ monocyte 
cultures ± TL1A. Markers of osteoclast formation and function will be analysed to 
determine the effect of TL1A. 
 To determine whether the DR3 / TL1A axis is a central determinant in the 
pathogenesis of disease characterised by increased osteoclast activity. 
Serum from arthritis patients will be analysed to assess whether changes in TL1A 
levels may have a role in the pathogenesis of the disease.  DR3 expression, 
osteoclast formation and function will be evaluated in CD14+ cell cultures ± TL1A 
derived from post-menopausal patients.  Markers of osteoclast formation and 
function will be analysed to determine whether DR3/TL1A have a role in the 
development of osteoporosis and fracture. 
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 To assess the role of DR3 / TL1A in osteoblast differentiation and function. 
Osteoblast formation and function will be evaluated in mice genetically deficient 
in DR3 (DR3ko) and wild-type mice (DR3wt).    
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Chapter 2 
 
Materials and Methods 
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2.1 Materials 
All materials used in this project are listed alphabetically below.  A list of suppliers is 
described in section 2.3. 
 
2.1.1 Antibodies 
Antibodies used throughout this study for flow cytometry, immunohistochemistry and the 
collagenase bio-assay are shown in Table 2.1. 
 
Antibody Clone Supplier Purpose 
Anti-human CD14 - FITC 61D3 eBioscience Flow Cytometry 
Anti-human DR3 - PE JD3 eBioscience Flow Cytometry 
Mouse IgG1 – FITC MOPC-31C BD Biosciences Flow Cytometry 
Mouse IgG1 – PE P3.6.2.8.1 eBioscience Flow Cytometry 
Polyclonal Goat anti-
murine DR3 - 
Biotinylated 
- R&D Systems Flow Cytometry 
Goat IgG - Vector Labs Flow Cytometry 
Rat anti-mouse 
CD16/CD32  
(Fc Block) 
- BD Biosciences Flow Cytometry 
Anti-mouse  CD44 – FITC IM7 eBiosciences Flow Cytometry 
Anti-mouse RANKL – PE IK22/5 Santa Cruz Flow Cytometry 
Streptavidin - APC - 
Life Technologies, 
Invitrogen 
Flow Cytometry 
Alexa Fluor® 594 
Phalloidin 
- 
Life Technologies, 
Invitrogen 
Immunocytochemistry 
Anti-Cathepsin K - Abcam Immunocytochemistry 
Rabbit IgG - DAKO Immunocytochemistry 
Goat anti- Rabbit IgG - 
FITC 
- 
Life Technologies, 
Invitrogen 
Immunocytochemistry 
Rabbit IgG - Sigma-Aldrich Rheumatoid Factor ELISA 
Anti-human IgM 
(F(ab)’2-Peroxidase 
- Sigma-Aldrich Rheumatoid Factor ELISA 
Rheumatoid Factor - DiAgam Rheumatoid Factor ELISA 
Anti-type I collagen - Sigma-Aldrich Collagenase Bio-assay 
Goat anti-mouse IgG - 
Peroxidise 
- Sigma-Aldrich Collagenase Bio-assay 
Table 2.1.  List of antibodies used throughout the study 
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2.1.2 Chemicals 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. 
 
2.1.3 Culture Medium 
Medium used for the culture of murine and human osteoclasts and osteoblasts 
throughout this study are listed below: 
2.1.3.1 Murine Osteoclast Medium  
Heat-inactivated foetal calf serum (FCS) (10%; Biosera) and Penicillin-Streptomycin (50 
units/ml - 50μg/ml; Life Technologies, Invitrogen) were added to Alpha Modification 
Minimum Essential Medium (αMEM; Life Technologies, Invitrogen). 
2.1.3.2 Human Osteoclast Medium 
Heat-inactivated FCS (10%), L-glutamine (20mM; Life Technologies, Invitrogen) and 
Penicillin-Streptomycin (50 units/ml - 50μg/ml) were added to Roswell Park Memorial 
Institute 1640 basal medium (RPMI-1640; Life Technologies, Invitrogen). 
2.1.3.3 Murine Osteoblast Medium 
Heat-inactivated FCS (20%) and Penicillin-Streptomycin (50 units/ml - 50μg/ml) were 
added to αMEM medium. 
2.1.3.4 Murine Osteoblast Mineralising Medium 
Heat-inactivated FCS (10%), Penicillin-Streptomycin (50 units/ml - 50μg/ml), 
dexamethasone (DEX; 10nM), β-glycerophosphate (βGP) stock solution (10mM) and 
ascorbic acid (AA) stock solution (50μg/ml) were added to αMEM medium. 
L-Ascorbic acid (AA) stock solution (12.5mg/ml) – 125mg of AA was dissolved in 10ml of 
sterile PBS. 
Dexamethasone (DEX) stock solution (10mM) – 39.2mg of DEX was dissolved in 10ml of 
absolute ethanol. 
DEX working solution (10μM) – 1ml of 10mM DEX stock was diluted in 999ml of sterile 
PBS. 
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β-Glycerophosphate (βGP) stock solution (1M) – 2.16g of βGP was dissolved in 10ml of 
sterile PBS. 
 
2.1.4 Distilled Water (dH2O) 
dH2O was obtained from a Millipore reverse osmosis system followed by filtration through 
two ion exchange resin columns using a Millipore Milli-Q system.  dH2O was used for the 
preparation of buffers, reagents and stains throughout this study. 
 
2.1.5 DR3 Genotyping Primers 
Three primers (AV1, 2R and 4F) were used to differentiate DR3wt and DR3ko from DR3het 
littermates. The specific sequence for each primer was identified in advance of the studies 
and is previously described (234). The specific primer sequence needed to identify each 
DR3 genotype is provided below (Table 2.2): 
Primer 
Name 
Product Primer Sequence 
Predicted Size 
(bp) 
AV1 KO DR3 gene CAT CGC CTT CTA TCG CCT TC 320 
2R 
WT + KO DR3 
gene 
GAA AGG ATG AAA CTT GCC TGT 
TGG 
280 / 320 
4F WT DR3 gene 
AGA AGG AGA AAG TCA GTA 
GGA CCG 
280 
Table 2.2 Primers used in murine DR3 genotyping 
DR3 genotyping primers were supplied by Life Technologies, Invitrogen.  Primers were 
reconstituted in dH2O at a concentration of 100µm. 
 
2.1.6 Equipment and Software 
Equipment and software used for analysis throughout this study is listed below. 
2.1.6.1 Flow cytometry 
Flow cytometry was performed using the BD AccuriTM C6 flow cytometer and analysed 
using BD CFlow® Plus software (BD Biosciences). 
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2.1.6.2 Pictures and Analysis 
Visualisation of cells, OC and resorption pits in this study was performed with an Olympus 
BX41 Microscope (Olympus UK).  Photographs were taken with an Olympus Camedia C-
3030 Digital Camera (Olympus UK) and analysed with Corel Paint Shop Pro x (Corel UK 
Ltd), Image J (National institute of Health (NIH)) and Carestream Molecular Imaging 
Software (Carestream).  
2.1.7 Gels 
The reagents used for the manufacture of gels used for the separation of DNA and 
proteins throughout this study are listed below: 
2.1.7.1 Agarose Gel (1.6%) 
Agarose gel (1.6%) – 2.4g agarose (1.6%; Life technologies, Invitrogen) was dissolved in 
150ml of 1X TBE by heating in a microwave, at full power.  Ethidium bromide (7.5μl at 
10mg/ml), required for the visualisation of bands, was added to the gel as it cooled.  Gels 
were poured into a mould and allowed to cool until set. 
2.1.7.2 Zymogram Gel (12%) 
Zymogram Gel (12%) – 2.5ml 1.5M Tris pH 8.8 (25% v/v), 4.17ml Acrylamide (41.7% v/v; 
Bio-Rad), 1ml 2% gelatine (10% v/v), 0.1ml 10% SDS (1% v/v), 50µl ammonium persulfate 
(0.5% v/v), 20µl TEMED (0.2% v/v; Bio-Rad) and 2.16ml dH2O (21.6% v/v) were mixed 
together.  Gel mixture was pipette into the mould and allowed to set before use. 
 
2.1.8 General Labware 
2.1.8.1 CD14 Isolation Kit 
All materials used for the isolation of CD14+ cells (CD14 microbeads, MiniMACSTM 
Separator, MS Column, 30μm pre-separation filter) were supplied by Miltenyi Biotec. 
2.1.8.2 ELISA Plates 
All 96 well ELISA plates used for the analysis of soluble mediators in culture supernatants 
were obtained from Nunc International. 
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2.1.8.3 Plastic ware 
All microcentrifuge tubes (0.5ml and 1.5ml) and Petri dishes were supplied by Grenier Bio 
One.  5ml polystyrene round bottom test tubes used for flow cytometry were supplied by 
VWR International. 
2.1.8.4 Surgical Tools 
Stainless steel forceps, scissors and disposable scalpels used to obtain and clean murine 
femora were obtained from Fisher Scientific. 
2.1.8.5 Tissue Culture Flasks 
All tissue culture flasks (T25 and T75) used for the culture of cells were obtained from 
Nunc International.  
2.1.8.6 Tissue Culture Plates 
All tissue culture plates (6 well, 12 well and 48 well) used for the culture of cells were 
obtained from Grenier Bio One. 
 
2.1.9 Mouse Strains 
The mouse strains used for the analysis of DR3 in OC and OB formation and function in 
this study are listed below: 
C57BL/6 - DR3 heterozygous (DR3het), DR3 wildtype (DR3wt) and DR3 knockout (DR3ko) 
DBA/1 - DR3 heterozygous (DR3het), DR3 wildtype (DR3wt) and DR3 knockout (DR3ko) 
 
2.1.10 Recombinant Cytokines and Enzymes 
Recombinant MCSF, RANKL, TL1A and polyHistidine used for the differentiation and 
stimulation of murine and human in vitro osteoclast cultures were supplied by R&D 
Systems Europe.  MMP-9 standard was supplied by R&D Systems Europe.  Recombinant 
human cathepsin K was supplied by Dr Vera Knäuper (School of Dentistry, Cardiff 
University) and Enzo Life Sciences.  Cathepsin K control was supplied by Biomedica 
Gruppe. 
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2.1.11 Solutions and Buffers 
All solutions and buffers used in this project are listed below.   
Phosphate buffered saline (PBS) pH7.2 used throughout this study was supplied by Life 
Technologies, Invitrogen. 
2.1.11.1 Cathepsin K Bio-assay and Zymogram Reagents 
Acetic acid (50mM) - 300μl of acetic acid was diluted in 100ml of dH2O. 
Assay buffer – 1g of bovine serum albumin (BSA; 1%) and 50μl of Tween-20 (0.05%) were 
added to 100ml of PBS. 
Blocking buffer – 1g of BSA (1%) was dissolved in 100ml of PBS. 
Buffer A – 4.1g of sodium acetate (NaOAC; 50mM), 584.5mg of 
Ethylenediaminetetraacetic acid (EDTA; 2mM), 308.5mg of Dithiothreitol (DTT; 2mM), 
20.5g of sodium chloride (NaCl; 350mM) and 1.5ml of Chondroitin 4-Sulfate Sodium Salt 
(0.15%) was dissolved in 1L of dH2O. 
Cathepsin K Development buffer – 141.96g of sodium phosphate dibasic (Na2HPO4; 0.1M), 
292.25mg of EDTA (1mM) and 308.5mg of DTT (2mM) was dissolved in 1L of dH2O. 
Cathepsin K Renaturation buffer – 7.87g of Tris (65mM) and 200ml of glycerol (20%) was 
dissolved in 1L of dH2O.  pH was adjusted to pH7.4 with hydrochloric acid (HCl) solution. 
Cathepsin K Sample buffer – 476mg of leupeptin (0.1mM) was dissolved in 10ml of 
zymogram sample buffer. 
Citrate buffer - 4.2g of citric acid (0.2M) was dissolved in 100ml of dH2O.  The pH of the 
solution was adjusted to 3.95 with potassium hydroxide (KOH) solution. 
Development solution - 10µl of 30% w/v hydrogen peroxide (H2O2; 0.03%) and 100µl 
Tetramethylbenzidine (TMB; 1%) were added to 10ml of citrate buffer. 
TMB - 240mg of TMB (0.1M) was dissolved in 5ml of dimethyl sulphoxide (DMSO; 50%) 
and 5ml of absolute ethanol (50%). 
Type I collagen stock – 2mg of type I collagen (2mg/ml) was dissolved in 1ml of 50mM 
acetic acid. 
Wash buffer - 500μl of Tween-20 (0.05%) was added to 1L of PBS. 
 
68 
 
2.1.11.2 CD14+ Isolation Reagents 
MACS buffer / Murine DR3 flow cytometry buffer – 0.5g of BSA (0.5%) and 58mg of EDTA 
(2mM) was dissolved in 100ml of PBS. 
2.1.11.3 DNA and Protein Gel Reagents 
Ammonium persulfate (10%) – 100mg of ammonium persulfate was dissolved in 1ml of 
dH2O. 
Gelatine (2%) – 2g of gelatine was dissolved in 100ml of dH2O. 
Tris pH8.8 solution (1.5M) – 181.7g of Tris was dissolved in 1L of dH2O.  pH was adjusted 
to 8.8 with HCl. 
2.1.11.4 DR3 Genotyping Buffers and Solutions 
DNA Loading Buffer Orange G - 250mg of Orange G loading dye (2.5mg/ml) and 30ml of 
glycerol (30%) was added to 100ml of 2x TBE. 
DR3 Genotyping Master Mix – All master mix reagents were purchased from Life 
Technologies, Invitrogen.  5µl of 1mM deoxyribonucleotide triphosphates (dNTPs), 4µl of 
10x polymerase chain reaction (PCR) buffer, 1.2µl of 50mM magnesium chloride (MgCl2), 
0.2µl of AV1 primer, 0.4µl of 4F primer, 0.8µl of 2R primer and 0.5µl of Taq DNA 
polymerase were mixed per genotyping sample. 
EDTA (1M) – 292.24g of EDTA was dissolved in 1L of dH2O. 
Ethanol (70%) – 700ml of absolute ethanol (70%) was diluted with 300ml of dH2O (30%). 
Lysis buffer – 2ml of 5M NaCl (2% v/v), 5ml of 1M Tris pH8 (5% v/v), 10ml of 1M EDTA 
(10% v/v), 10ml of 10% Sodium dodecyl sulphate (SDS; 10% v/v) and 1.333ml of 
proteinase k (1.3%v/v; Roche) were made up to 100ml in dH2O. 
NaCl (5M) – 292.2g of NaCl was dissolved in 1L of dH2O. 
SDS (10%) – 100g of SDS was dissolved in 1L of dH2O. 
1x Tris/Borate/EDTA (TBE) – 10ml of 10x TBE (Fisher Scientific) was diluted in 90ml of 
dH2O. 
2x TBE – 20ml of 10x TBE was diluted in 80ml of dH2O. 
1M Tris pH8 – 121.14g of Tris was dissolved in 1L of dH2O, pH was adjusted to pH8 with 
HCl. 
69 
 
2.1.11.5 ELISA Buffers and Solutions 
Coating Buffer (0.1 M Sodium Carbonate, pH 9.5) - 7.13g of Sodium bicarbonate (NaHCO3; 
85mM), 1.59g of sodium carbonate (Na2CO3; 15mM) was dissolved in 1L of dH2O, pH was 
adjusted to 9.5 with sodium hydroxide (NaOH) solution. 
Development solution – made up as section 2.1.11.1. 
Wash buffer – made up as section 2.1.11.1. 
2.1.11.6 Flow Cytometry Reagents 
Flow Cytometry buffer – 100μl of FCS (1%) was added to 10ml of PBS. 
4% Formaldehyde – 10.8ml of 37% formaldehyde was added to 89.2ml of PBS. 
2.1.11.7 MMP-9 Zymogram Reagents 
Development buffer – 2ml of 10x zymogram development buffer (Bio-Rad) was added to 
18ml of dH2O. 
Renaturation buffer – 2ml of 10x zymogram renaturation buffer (Bio-Rad) was added to 
18ml of dH2O. 
2.1.11.8 Murine TL1A RT-PCR Reagents 
TL1A master mix – All master mix reagents were purchased from Life Technologies, 
Invitrogen.  5µl of 1mM dNTPs, 4µl of 10x PCR buffer, 1.2µl of 50mM MgCl2 and 0.5µl of 
Taq DNA polymerase were mixed per sample. 
 
2.1.12 Solvents 
All solvents used in this study (absolute ethanol, glacial acetic acid, dimethylformamide 
(DMF), iso-propanol and methanol) were supplied by Fisher Scientific unless otherwise 
stated. 
70 
 
2.1.13 Stains and Histological Materials 
The reagents and materials used in the manufacture of stains for the visualisation of cells, 
resorption pits and gels throughout this study are listed below: 
2.1.13.1 Actin Immunocytochemistry 
Actin stain - 100µl of Alexa Fluor® 594 Phalloidin (Life Technologies, Invitrogen) at 
200units/ml (0.5units/ml) was diluted in 10ml of PBS. 
Blocking solution – 1g of BSA (1%) was dissolved in 100ml of PBS. 
4', 6-diamidino-2-phenylindole (DAPI) nucleic acid stain - 1.5μl of DAPI stock at 5mg/ml 
(300nM; Life Technologies, Invitrogen) was diluted in 10ml of PBS. 
4% Formaldehyde – made up as section 2.1.11.6. 
Permabilisation solution – 10μl of Triton X-100 (0.1%) was added to 10ml of PBS. 
2.1.13.2 Additional Histological Materials 
Round glass coverslips (5mm diameter) were supplied by Waldemar Knittel 
Glasbearbeitungs- GmbH.  Glass slides were supplied by Fisher Scientific.  Ivory discs 
(6mm diameter) were supplied by Cardiff University.  DPX mountant was supplied by 
Sigma-Aldrich. 
2.1.13.3 Alizarin Red Stain 
Alizarin Red - 1g of alizarin red stain (1%) was dissolved in 100ml of dH2O, pH was adjusted 
to pH4.2 with KOH. 
50% methanol – 50ml methanol (50% v/v) was diluted with 50ml dH2O (50% v/v). 
4% Formaldehyde – made up as section 2.1.11.6. 
2.1.13.4 Alkaline Phosphatase (ALP) Stain 
Alkaline phosphatase (ALP) stain – 33.4μl of BCIP solution (0.334%) and 44μl of NTB 
solution (0.44%) were added to 10ml of Tris buffer. 
5-bromo-4-chloro-3-indolyphosphate (BCIP) solution – 7.5mg of BCIP (0.75mg/µl) was 
dissolved in 100μl of 70% DMF. 
DMF (70%) – 7ml of DMF was diluted in 3ml of dH2O. 
Nitro blue tetrazolium (NBT) solution – 5mg of NBT was dissolved in 100μl of 100% DMF. 
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4% Formaldehyde – made up as section 2.1.11.6. 
Tris buffer – 1.22g of Tris (100mM), 0.58g of NaCl (100mM) and 0.476g of MgCl2 (50mM) 
was dissolved in 100ml of dH2O. 
2.1.13.5 Differential Stain 
Giemsa Stain – 11ml of Giemsa stain (11%) was diluted in 89ml of PBS pH6.8. 
May-Grunwald Stain – 50ml of May-Grunwald stain (50%) was diluted in 50ml of PBS 
pH6.8 (50%). 
PBS pH6.8 – One PBS tablet (VWR) was dissolved per 100ml dH2O. 
2.1.13.6 MMP-9 and Cathepsin K Zymogram Stain 
Coomassie blue stain – 0.25g of Brilliant Blue R Coomassie (0.25%) was dissolved in 100ml 
of destain. 
Destain – 450ml of methanol (45%) and 100ml of acetic acid (10%) were added to 450ml 
of dH2O (45%). 
2.1.13.7 Resorption Pit Staining  
Calcein solution (0.8mM) – 5mg of calcein was dissolved in 10ml of dH2O. 
Hydrogen Peroxide Solution (1%) - 333µl of H2O2 (30% w/v) was added to 10ml of dH2O. 
Toluidine Blue Stain (0.5%) - 0.50g of Toluidine Blue stain was dissolved in 100ml of dH2O. 
2.1.13.8 TRAP Stain 
Acetate Buffer (0.1M) - 3.52ml of 0.2M sodium acetate solution (35.2% v/v) and 1.48ml of 
0.2M acetic acid solution (14.8% v/v) was added to 5ml dH2O (50%v/v). 
Acetic Acid Solution (0.2M) - 0.115ml Acetic Acid was diluted in 9.885ml of dH2O. 
Fixative – 4ml of 25% grade 1 gluteraldehyde (10%) was diluted in 10ml of dH2O. 
Harris’ haematoxylin Stain (VWR) 
Naphthol AS-MX Phosphate Disodium Salt (10mg/ml) - 10mg of Naphthol AS-MX 
Phosphate Disodium Salt was dissolved in 1ml of dH2O. 
1x Scott’s tap water – 1ml of 10x Scott’s tap water was diluted in 9ml of dH2O. 
Sodium Acetate Solution (0.2M) - 0.164g of Sodium Acetate was dissolved in 10ml of 
dH2O. 
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Sodium Tartrate (0.3M) - 0.69g of Sodium Tartrate was dissolved in 10ml of dH2O. 
TRAP Stain - 5ml of 0.1M acetate buffer (50%v/v), 1ml of 0.3M sodium tartrate (10%v/v), 
100µl of 10mg/ml Naphthol AS-MX Phosphate Disodium Salt (1%v/v) and 100µl of Triton 
X-100 (1%v/v) was added to 3.80ml of dH2O (38%v/v).  3mg of Fast red Violet LB salt 
(0.3mg/ml) was dissolved per 10ml. 
 
2.1.14 TL1A RT-PCR Primers 
Four primers were designed for the detection of murine TL1A by RT-PCR.  Primers were 
designed by W. Perks (Dr E. Wang Laboratory).  The primer sequences and predicted 
product size are provided in Table 2.3: 
Primer 
Name 
Product Primer Sequence 
Predicted Size 
(bp) 
P1 TL1A 
F - CCC CGG AAA AGA CTG TAT 
R – GGT GAG TAA ACT TGC TGT 
75 
P2 TL1A 
F – GCT GCC TGT TGT CAT TTC C 
R – TCT GGG AGG TGA GTA AAC TTG 
149 
P3 TL1A 
F – TCA TTT CCC ATC CTC GCA GGA CTT 
R – TAA TTG TCA GGT GTG CTC TCG GCT 
166 
P4 TL1A 
F – CAG CAG AAG GAT GGC AGA 
R – CTC TGG CCT GTG TCT ACA 
91 
β-actin β-actin 
F – CGG CCA GGT CAT CAC TAT TG 
R – CTC AGT AAC CCG CCT AG 
450 
Table 2.3. Primers used in murine TL1A mRNA PCR 
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2.2 Methods 
The methods used throughout this study are outlined below. 
 
2.2.1 Animals 
Animals were housed in the Joint Biological Services Unit (Cardiff University) at constant 
temperature and humidity on a 12 hour light/dark cycle.  All animals were kept in filter 
top containers.  Food and water were available ad libitum.  DR3ko animals were initially 
generated using 129/Sv mouse strain stem cells and backcrossed onto a C57BL/6 
background (280).  The DBA/1 DR3ko mouse strain was generated through backcrossing 
C57BL/6 DR3het mice with DBA/1 wildtype mice for 7 generations, generating a DR3ko 
mouse with less than 1% C57BL/6 DNA.  All C57BL/6 and DBA/1 DR3ko animals were 
generated in house. 
 
2.2.2 Murine DR3 Genotyping 
In order to determine the DR3 genotype of the C57BL/6 and DBA/1 mice used throughout 
this study PCR was performed on ear snips obtained from individual animals on a weekly 
basis. 
Ear snips were taken from individual mice, by trained operators, and placed into labelled 
micro centrifuge tubes.    Lysis buffer (750µl) was added to the microcentrifuge tube 
containing the ear snip and incubated overnight at 56°C in a water bath.  Salt extraction 
was performed by adding 310μl of 5M NaCl to the samples, vortexing and incubating for 
30 minutes at room temperature.  Samples were spun at 13,250g for 25 minutes and 
800μl of the aqueous phase removed and placed into a new labelled tube.  Ice-cold iso-
propanol (500µl) was added and the samples vortexed before being spun for 10 minutes 
at 13,250g.  Supernatant was removed from the samples and 500μl of 70% ethanol added.  
Samples were incubated for 30 minutes at room temperature before being spun for 10 
minutes at 13,250g.  Supernatant was removed from the samples which were placed at 
37°C for an hour until dry.  dH2O (50µl) was added to each sample and placed at 37°C for 
2-3 hours to re-dissolve DNA. 
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For PCR 8μl of DNA was added to a thin walled PCR tube along with 20μl of dH2O.  
Required volume of DR3 genotyping master mix was made up and 12.1μl added to each 
tube.  Tubes were placed into the MyGene™ Series Peltier thermal cycler (LongGene 
Scientific Instruments) and run through the DR3 genotyping program, as defined in Table 
2.4. 
Step Temperature (°C) Time Number of Cycles 
Initial denaturation 94 5 minutes 
1 Annealing 60 45 seconds 
Elongation 72 45 seconds 
Denaturation 94 45 seconds 
33 Annealing 60 45 seconds 
Elongation 72 45 seconds 
Denaturation 94 45 seconds 
1 Annealing 60 45 seconds 
Elongation 72 5 minutes 
Table 2.4. DR3 genotyping PCR settings 
Samples were removed from the PCR thermal cycler and 4μl of DNA loading buffer orange 
G added to each sample.  A 1.6% agarose gel was made up.  The gel was placed into the 
running tank and covered with 1x TBE buffer.  5μl of 1KB DNA ladder (Life Technologies, 
Invitrogen) was added to the first well of the gel followed by 15 - 20μl of sample to 
subsequent wells.  Gels were run at 100V for 90 minutes after which bands present in the 
gel were visualised using a UVP BioDoc It™ imaging system. 
 
2.2.3 Cell Count 
Cell counts on murine bone marrow cells, human cells and osteoblasts were performed 
using a standardised method.  Cell suspension (10µl) was diluted 1:1 with Trypan Blue 
(Sigma-Aldrich) and applied to a haemocytometer.  Viable cells were identified under a 
white light by the exclusion of blue dye. Cells were counted in 4 sections of the 
haemocytometer (Fig 2.1) and the total number of cells present calculated using the 
following equation: 
Total No. cells / ml = (No. cells / No. of sections counted) x 2 (dilution factor) x (1x104) 
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2.2.4 Murine Bone Marrow Cell Isolation 
Murine bone marrow cells were used as a source of precursor cells for the murine 
osteoclast and osteoblast differentiation assays reported in this thesis.  Bone marrow 
(BM) was isolated from C57BL/6 and DBA/1, male and female mice, aged between 8 – 18 
weeks.  Mice were sacrificed by schedule I; an overdose of carbon dioxide (CO2) followed 
by cervical dislocation.  Hind legs were removed.  Cleaned femurs were excised using a 
scalpel and the head (caput femoris) removed.    Bones were placed into a 0.5ml micro 
centrifuge tube, into which a hole had been made in the base.  The 0.5ml micro centrifuge 
tube was placed inside a 1.5ml micro centrifuge (Fig 2.2) and centrifuged at 13,250g for 1 
minute, causing the bone marrow to pellet in the 1.5ml micro centrifuge tube.  Isolated 
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bone marrow was re-suspended in 500μl murine osteoclast medium (for OC assays) or 
500µl murine osteoblast medium (for OB assays). 
 
 
 
 
 
 
 
2.2.5 Murine Bone Marrow Differential Staining 
In advance of performing OC differentiation assays it was important to determine the 
cellular phenotype of DR3wt and DR3ko bone marrow.  Differential cell counts were 
performed using a small proportion of cells (10µl of 6.4x106 cells / ml cell suspension) 
from 5 aged-matched DBA/1 DR3wt and DR3ko mice (10-16 weeks) used in OC assays.  
Sterilised glass coverslips were placed into a Petri dish and 10µl of cell suspension added 
to the surface and incubated for 2 hours at 37°C 5% CO2.  After 2 hours non-adherent cells 
were removed by washing the coverslips twice in PBS pH7.2.  Cells were fixed by 
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immersion in methanol for 15 minutes.  Methanol was removed and discs immersed in 
May-Grunwald stain for 15 minutes then Giemsa stain for 15 minutes.  Stain was removed 
and the cells washed in PBS then dH2O before being allowed to air dry.  Dried coverslips 
were then mounted onto slides using DPX and placed at 60°C overnight to dry. 
Images of the mounted coverslips were taken at 20x magnification and cropped to 
represent a size of 1000µm2.  Cell type was defined by its morphology.  Numbers of 
lymphocytes, monocytes, neutrophils, erythrocytes, myoblasts and megakaryocytes were 
analysed and frequency calculated as a % of all cells. 
 
2.2.6 Murine Osteoclast Differentiation Assay 
Osteoclast differentiation assays were established using bone marrow cells harvested 
from aged matched DBA/1 or C57BL/6 DR3wt and DR3ko mice (10 – 18 weeks).   Initially OC 
assays were set-up on glass coverslips for looking at the relative contribution of DR3 and 
TL1A.  In order to look at the functional role assays were set-up on an ivory substrate.  
Bone marrow was isolated as described in section 2.2.4.  Cells were counted (section 
2.2.3) and re-suspended in murine osteoclast medium at a concentration of 6.4x106 cells / 
ml (glass coverslip assays) or 3.2x106 cells / ml (ivory disc assays), to give a final volume of 
approx. 3ml. 
2.2.6.1 Glass Coverslip Assay 
Bone marrow was isolated from 3 age-matched DR3wt and DR3ko male DBA/1 mice (aged 
10 – 16 weeks).  Cells were adhered onto glass coverslips as above.  Coverslips were 
placed into a 48 well tissue culture plate and 500μl of murine osteoclast medium 
supplemented with one of four conditions (Table 2.5) was added (Fig 2.3); each condition 
was set-up in triplicate: 
 Condition 1 Condition 2 Condition 3 Condition 4 
MCSF 25ng/ml + + + + 
RANKL 2ng/ml - - + + 
TL1A 10ng/ml - + - + 
Table 2.5.  Supplemented murine osteoclast medium conditions 
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Cells were incubated at 37°C 5% CO2.  On day 3 supernatants were removed and 
replenished with fresh media and the experiment run to day 7.  OC were identified by 
TRAP staining (Section 2.2.13) and total cell count and OC size calculated.  A summary of 
the procedure is shown in Fig 2.4. 
2.2.6.2 Ivory Disc Assay 
Before OC assays could be performed on ivory discs development of the method was 
required.  Bone marrow was obtained from the femora of a DBA/1 DR3wt mouse (12 
weeks).  Bone marrow cells were plated onto glass coverslips as above, at the two cell 
concentrations cited in Table 2.6.  Each condition was run in triplicate: 
Volume Cell Concentration 
10µl 6.4x106 cells / ml 
20µl 3.2x106 cells / ml 
Table 2.6.  Volumes and cell concentrations added to coverslips 
Cells were stained and analysed for differential analysis as defined in section 2.2.5 with 
the following modifications; cell number per 1mm2 was calculated for each sample.  
Subsequent experiments, on ivory discs, were set-up using 20µl of cell suspension at 
3.2x106 cells / ml. 
The final protocol used for the culture of murine OC on ivory discs was as follows.  Bone 
marrow was isolated from 6 age-matched DR3wt and DR3ko female DBA/1 mice (aged 10 – 
18 weeks).  Cells were plated onto ivory discs and experiment set-up as glass coverslip 
assay (section 2.2.6.1).  On day 3 and day 7 supernatants were removed, aliquoted and 
stored at -70°C for subsequent analysis by ELISA (CCL2, CXCL1, CCL3 and pro MMP-9).  
Wells were replenished with fresh media and the experiment run to day 10.  All outcome 
measures were as above (section 2.2.6.1) with the addition of resorption pit analysis 
(section 2.2.14.3).  A summary of the procedure is shown in Fig 2.5. 
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2.2.7 Isolation of CD14+ Cells (Osteoclast Precursors) from Peripheral Blood of Healthy 
Females 
In order to perform human osteoclastogenesis assays CD14+ cells were first isolated from 
peripheral blood mononuclear cells (PBMCs).  Ethical approval was obtained from the 
Medical / Dental School Research Ethics Committee (MDSREC Reference Number: 09/21) 
for the collection of venous peripheral blood from healthy female volunteers.  Peripheral 
blood (40ml) was collected and mixed with heparin (Sigma-Aldrich), to stop coagulation.  
A separate 10ml peripheral blood sample was collected and allowed to clot at room 
temperature for 30 minutes before serum was harvested and stored.  
For the isolation of the CD14+ cells from peripheral blood 5ml Histopaque -1077 (Sigma-
Aldrich) was added to a 15ml centrifuge tube and 10ml of blood gently overlaid ensuring 
blood and histopaque did not mix.  Four x 15 ml were used for each blood preparation.  
PBMCs were separated from the red blood cells and the plasma by centrifugation 
(samples were spun at 400g for 30 minutes).  Plasma was removed and discarded.  
PBMCs, located at the interface of the plasma and histopaque, were carefully removed 
and transferred to a clean sterile 15ml centrifuge tube.  PBMCs were washed 3 times by 
adding 10ml Hank’s balanced salt solution (HBSS; Life Technologies, Invitrogen) and 
spinning at 300g for 10 minutes.  HBSS was removed after each spin and replaced with 
fresh HBSS.  After the third wash all HBSS was removed and replaced with 5ml human 
osteoclast medium, cells were kept on ice and a cell count performed (section 2.2.3).  
Approx. 1x105 cells were removed for testing by flow cytometry for CD14 and DR3 
expression (section 2.2.8).  Cells were passed through a pre-separation filter into a new 
15ml centrifuge tube and spun at 300g for 10 minutes.  Medium was removed and 
replaced with 80μl MACS buffer and 20μl CD14 microbeads per 107 cells and incubated on 
ice for 15 minutes.  Cells were passed through the magnetic column according to the 
manufacturer’s protocol.  CD14- cells passed through the column and were discarded.  
CD14+ cells were removed from the column by flushing with MACS buffer and collected in 
a new 15ml centrifuge tube and a cell count performed (section 2.2.3).  Cells were spun at 
300g for 10 minutes and re-suspended in human OC medium to a final concentration of 
3.2x106 / ml for use in ivory disc assays, 6.4x106 / ml for use in glass coverslip assays and 
1x106 / ml for use in plastic tissue culture plate assays.  Approximately 1x105 cells were 
removed for testing by flow cytometry for CD14 and DR3 expression (section 2.2.8). 
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2.2.8 Flow Cytometric Analysis of CD14 and DR3 Expression on Isolated CD14+ Cells 
Cells from two sources were analysed; (i) immediately prior to adherence onto ivory discs 
(section 2.2.7) or (ii) cells removed from the surface of the substrate, after 7 days culture 
in MCSF (section 2.2.9). These cells were rubbed gently with a cell scraper and added, 
along with culture medium, to a 5ml round bottom test tube.  Cells were spun at 800g for 
3 minutes and the medium replaced with 600μl flow cytometry buffer before being split 
equally between 3 round bottom test tubes (200μl per tube / ~30,000 cells).  5μl 
(1μg/test) of anti-human CD14-FITC, 5μl (0.125μg/test) anti-human DR3-PE or 
corresponding isotype antibody was added to the relevant test tube and incubated on ice 
for 30 minutes.  Cells were spun at 800g for 3 minutes and supernatant removed and 
replaced with fresh flow cytometry buffer.  Wash procedure was repeated 3 times.  After 
final wash cells were re-suspended in 200μl flow cytometry buffer and 200μl 4% 
formaldehyde.  Cells were run through the BD AccuriTM C6 Flow Cytometer and data 
analysed using BD CFlow® Plus software.  20,000 events were acquired per sample.  
Forward scatter-area (FSC-A) against forward scatter-height (FSC-H) plots were generated 
and doublets excluded by gating on the single cells.  FSC-A against side scatter-area (SSC-
A) plots were then generated and cell debris excluded by gating.  Monocytes were 
positively selected for by gating, and expression of CD14 and DR3 calculated from scatter 
plots or histograms. 
 
2.2.9 Expansion of CD14+ Cells (OC Precursors) and Induction of DR3 Expression 
In order to determine conditions for CD14+ cell expansion and CD14+ DR3 expression 
isolated CD14+ cells were plated and adhered onto substrates as shown in Table 2.7. 
 
Glass Coverslip 
48 Well Plastic 
Tissue Culture Plate 
Ivory Disc 
Volume of Cell 
Suspension 
10μl 100μl 20µl 
Table 2.7.  Volume of cell suspension added to substrate 
Coverslips and ivory discs were transferred to a 48 well plate.  Human OC medium (500µl) 
supplemented with 5ng/ml MCSF was added to each well.  Cells were incubated at 37°C 
5% CO2.  On day 3 supernatants were removed and replenished with fresh media and 
experiment run to day 7.  Cells were tested for DR3 expression according to section 2.2.8.  
A summary of the procedure is shown in Fig 2.6.  
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2.2.10 Human Osteoclastogenesis Assay 
Initially OC assays were set-up in plastic tissue culture plates for looking at the effect of 
TL1A on OC differentiation.  In order to look at the functional role assays were set-up on 
an ivory substrate.  Human OC differentiation assays were established using CD14+ cells 
isolated from PBMCs, as described in section 2.2.7.  Cell counts were performed (section 
2.2.3) and cells re-suspended in human osteoclast medium at a concentration of 3.2x106 
cells / ml.  
2.2.10.1 Plastic TC Plate Assays 
CD14+ cells were isolated from the peripheral blood (section 2.2.7) of 5 healthy females.  
Cells were adhered to 48 well plates as above.  Human OC medium (500µl) supplemented 
with 5ng/ml MCSF was added per well.  Cells were incubated at 37°C 5% CO2 with medium 
removed and replenished with fresh media on day 3.  DR3 expression was tested for on 
day 7 (referred to as Day 0 of osteoclastogenesis assay; section 2.2.8).  Supernatants were 
removed and replaced with 500μl medium supplemented with one of four conditions 
(Table 2.8); each condition was set-up in duplicate: 
 Condition 
1 
Condition 
2 
Condition 
3 
Condition 
4 
MCSF 5ng/ml + + + + 
RANKL 5ng/ml - - + + 
TL1A 10ng/ml - + - + 
polyHistidine 
2.5µg/ml 
- 
- + + 
Table 2.8. Supplements added to human OC medium in plastic TC plate assays 
Wells were terminated on days 1, 2, 3, 4 and 5 and cells stained for TRAP (section 2.2.13).  
Supernatants were collected, aliquoted and stored at -70°C for subsequent analysis by 
ELISA (CCL2 and CXCL8). 
2.2.10.2 Ivory Assays 
Initial assays were performed to determine the experiment termination time point; 
allowing analysis of OC numbers and function.  CD14+ cells were isolated from the 
peripheral blood of a healthy female (section 2.2.7).  Cells were adhered to ivory discs as 
in section 2.2.9.  Ivory discs were placed into a 48 well tissue culture plate and 500µl 
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supplemented human OC medium (Table 2.9) was added, each condition was set-up in 
duplicate: 
 Condition 1 
MCSF 5ng/ml + 
RANKL 5ng/ml + 
polyHistidine 2.5µg/ml + 
Table 2.9. Supplements added to human OC medium in development of assay 
Cells were incubated at 37°C 5% CO2. On day 3, 7, 10, 14 and 18 supernatants were 
removed and replenished with fresh media and experiment run to day 21.  OC were 
identified by TRAP staining (section 2.2.13) and total cell count calculated.  Resorption pits 
were identified by staining (section 2.2.14.3) and % disc resorbed calculated.  A summary 
of the procedure is shown in Fig 2.8.  Subsequent human osteoclast assays on ivory discs 
were run to day 14 where sufficient OC and resorption pits were detected. 
The final protocol used for the culture of human OC from CD14+ cells was as follows.  
CD14+ cells were isolated from the peripheral blood (section 2.2.7) of 6 healthy females 
(Fig 2.9).  Cells were plated onto ivory discs as above.  Discs were transferred to two 48 
well plates (Fig 2.7) and 500μl human OC medium supplemented with 5ng/ml MCSF 
added.  Cells were incubated at 37°C 5% CO2 with medium removed and replenished with 
fresh media on day 3.  DR3 expression was tested for on day 7 (referred to as Day 0 of 
osteoclastogenesis assay; section 2.2.8).  Supernatants were removed and replaced with 
500μl medium supplemented with one of six conditions (Table 2.10); each condition was 
set-up in duplicate: 
 Condition 
1 
Condition 
2 
Condition 
3 
Condition 
4 
Condition 
5 
Condition 
6 
MCSF 5ng/ml + + + + + + 
RANKL 
5ng/ml 
- 
- - + + + 
TL1A 
10ng/ml 
- 
+ - - + - 
TL1A 
100ng/ml 
- 
- + - - + 
polyHistidine 
2.5µg/ml 
- 
- - + + + 
Table 2.10. Human OC assay conditions 
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On day 3, 7 and 10 supernatants were removed, aliquoted and stored at -70°C for 
subsequent analysis by ELISA (CCL2, CXCL8, CCL3, TL1A, TNF and total MMP-9).  Wells 
were replenished with fresh media and the experiment run to day 14. 
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2.2.11 Isolation of CD14+ Cells (Osteoclast Pre-cursors) from Peripheral Blood of Post-
Menopausal Patient Cohorts 
Ethical approval was required for the acquisition of peripheral blood in patients attending 
fracture clinics to determine the level of TL1A and TNF in the serum.  The application for 
ethical approval was initially submitted to the South East Wales Research Ethics 
Committee and reviewed on 12 May 2010.  Additional amendments to the application 
were requested. The application was resubmitted and a favourable ethical opinion was 
given for the study on the 15 October 2010, 5 months after the initial application (REC 
reference number: 10/WSE02/44).  Post-menopausal patients were to be recruited to one 
of three cohorts:  
 - Osteoporosis, - Fracture (OP-Frac-) 
 - Osteoporosis, + Fracture (OP-Frac+) 
 + Osteoporosis, + Fracture (OP+Frac+) 
Patients were either included or excluded from the study using the criteria below: 
Inclusion criteria 
 Attending for first bone density scan 
 Adult 
 Female  
 Post-Menopausal 
Exclusion criteria 
 Recent fracture (in the past 3 months) 
 History of corticosteroid use (except inhaled or topical) or  
 Anti-TNF therapy. 
 Patients with known seropositive rheumatoid arthritis, inflammatory bowel 
disease 
 Recent history of continuous treatment with bisphosphonate, calcitonin, 
Strontium ranelate or parathyroid hormone (i.e. for more than 3 months). 
 Patients with known primary hyperparathyroidism 
 Currently taking part in another study 
Nurses at the fracture liaison service or the Open Access Primary Care service obtained 
consent from each patient. Peripheral blood (40ml) was collected and mixed with heparin, 
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to stop coagulation. A separate 10ml peripheral blood sample was collected and was 
allowed to clot at room temperature for 30 minutes before serum was harvested and 
stored.  CD14+ cells were isolated as in section 2.2.7. 
 
2.2.12 Post-Menopausal Patient Cohort Osteoclast Assays 
Patient cohort OC assays were performed on ivory discs using CD14+ cells isolated from 
PBMCs.  Assays were performed as in section 2.2.10.2 with the following modifications; 
human OC medium was supplemented with the conditions in Table 2.11. A summary of 
the procedure is outlined in Fig 2.10. 
 Condition 
1 
Condition 
2 
Condition 
3 
Condition 
4 
MCSF 5ng/ml + + + + 
RANKL 5ng/ml - - + + 
TL1A 100ng/ml - + - + 
polyHistidine 
2.5µg/ml 
- 
- + + 
Table 2.11.  Patient cohort OC assay conditions  
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2.2.13 Identification of Mononuclear Cells and Osteoclasts in Culture 
Murine BM cells (section 2.2.6) or human CD14+ cells (section 2.2.10) grown on plastic, 
glass and / or ivory were visualised by staining with haematoxylin.  Osteoclasts were 
identified by their morphology (>3 nuclei) and positive TRAP stain.   Cultures were washed 
twice with PBS and 150µl of fixative added per well.  After 15 minutes incubation fixative 
was removed and the cells were washed a further 2 times with PBS.  TRAP stain (300µl) 
was added per well and incubated for 5 minutes.  TRAP stain was removed and cells 
washed twice with PBS.  After staining for TRAP ivory discs were photographed for 
analysis as below.  Haematoxylin stain (150µl) was added to each coverslip / disc and 
incubated for 1 minute before being removed and cells washed with PBS.  1x Scott’s Tap 
Water (150µl) was added and incubated for 1 min before being removed and cells washed 
twice with PBS.  Glass coverslips were mounted onto slides using DPX and dried overnight 
at 60°C.  Coverslips and discs were photographed for analysis. 
Stained coverslips, plates and ivory discs were visualised at 10x magnification and five 
images per disc (Fig 2.11) taken.  Images were cropped to represent a size of 1000µm2 and 
the number of OC counted.  OC were then outlined in black using the paintbrush tool.  
The brightness and contrast of the image was adjusted to remove all background leaving 
the black outline of the OCs.  Outlined OC were filled in black using the flood fill tool and 
the image saved for the calculation of OC area using Image J.  Images were opened in 
Image J and the scale set at 1440pixels = 1000μm.  The threshold of image was adjusted 
so all OCs were detected.  The area of the OCs was then calculated and the results copied 
into Microsoft Office Excel. 
Total cell count was performed on cropped images, after haematoxylin staining, using 
Carestream Molecular Imaging Software.  Briefly images were loaded and the auto-region 
of interest (ROI) tool selected from the navigation bar.  New ROI set was selected and the 
following parameters set; edge detection, edge gradient = 20%, restrict size – Min=50, 
Max=no restriction.  ROI’s were found by selecting add. 
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2.2.14 Assessing Mediators of Osteoclast Formation and Function 
A variety of methods were used to assess mediators of OC formation and function on 
ivory discs.  They are listed below. 
2.2.14.1 Chemokine Analysis 
A number of chemokines associated with OC differentiation are released as soluble 
mediators.  The chemokines CCL2, CXCL1, CXCL8 and CCL3 were measured in the culture 
supernatants or serum by ELISA (R&D Systems).  A general method is provided, with 
specifc buffers and concentrations outlined in Table 2.12.  
96 well ELISA plates were coated with 100µl of specific capture antibody and incubated 
overnight at room temperature.  Following incubation the capture antibody was discarded 
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and the plate washed 4 times with wash buffer.  The plates were blocked at room 
temperature, with mechanical shaking, with 300µl of blocking buffer.  After 2 hours the 
plates were washed 4 times with wash buffer.  Diluted specific standards (100µl) for the 
ELISA were added, in duplicate.  Samples were either used neat or diluted in dilution 
buffer and 100µl added in duplicate.  Samples were incubated for 2 hours at room 
temperature with mechanical shaking.  After 4 washes with wash buffer 100µl of specific 
detection antibody was added to each well and the plate incubated for 2 hours at room 
temperature with mechanical shaking.  Plates were washed 4 times with wash buffer and 
100µl of streptavidin-HRP added and incubated at room temperature for 20 minutes.  
After 4 final washes, 100µl of development solution was added and the colour developed 
at room temperature.  Reaction was terminated by the addition of 50µl of 12% sulphuric 
acid (H2SO4).  The optical density of the plate was measured as 450nm. 
ELISA 
Coating 
Buffer 
Wash 
Buffer 
Blocking 
Buffer 
Dilution 
Buffer 
Capture 
Antibody 
Detection 
Antibody 
Standard 
Murine 
CCL2 
PBS 
0.05% 
Tween 
in PBS 
1% BSA 
in PBS 
1% BSA in 
PBS 
0.2µg/ml 
in PBS 
50ng/ml 
in 
Dilution 
Buffer 
250pg/ml – 
3.9pg/ml 
Murine 
CXCL1 
2.0µg/ml 
in PBS 
200ng/ml 
in 
Dilution 
Buffer 
1000pg/ml 
– 
15.63pg/ml 
Murine 
CCL3 
0.4µg/ml 
in PBS 
100ng/ml 
in 
Dilution 
Buffer 
500pg/ml – 
7.8pg/ml 
Human 
CCL2 
1.0µg/ml 
in PBS 
100ng/ml 
in 
Dilution 
Buffer 
1000pg/ml 
– 
15.625pg/
ml 
Human 
CXCL8 
4.0µg/ml 
in PBS 
20ng/ml 
in 
Dilution 
Buffer 
2000pg/ml 
– 
31.3pg/ml 
Human 
CCL3 
0.4µg/ml 
in PBS 
200ng/ml 
in 
Dilution 
Buffer 
500pg/ml – 
7.8pg/ml 
Table 2.12.  ELISA buffers and antibody concentrations used in chemokine analysis 
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2.2.14.2 Cytokine Analysis 
Levels of the cytokines TNF (BD Bioscience) and TL1A (Peprotech) were measured in 
culture supernatants and serum by ELISA.  The method is described in section 2.2.14.1.  
Specific buffers and antibody concentrations are outlined in Table 2.13. 
ELISA 
Coating 
Buffer 
Wash 
Buffer 
Blocking 
Buffer 
Dilution 
Buffer 
Capture 
Antibody 
Detection 
Antibody 
Standard 
Human 
TL1A 
PBS 
0.05% 
Tween 
in PBS 
1% BSA 
in PBS 
0.1% 
BSA, 
0.05% 
Tween 
in PBS 
1.0µg/ml 
in PBS 
0.5µg/ml 
in 
Dilution 
Buffer 
4000pg/ml – 
62.5pg/ml 
Human 
TNF 
Coating 
buffer 
0.05% 
Tween 
in PBS 
10% FCS 
in PBS 
10% FCS 
in PBS 
1:250 
dilution in 
coating 
buffer 
1:250 
dilution in 
dilution 
buffer 
500pg/ml – 
7.8pg/ml 
Table 2.13. Buffers and antibody concentrations used in the human TNF and TL1A ELISAs 
 
2.2.14.3 Resorption Pit Analysis 
Two methods were used for the analysis of resorption pits made by murine and human 
OC on ivory discs; they are outlined below. 
2.2.14.3.1 Light Microscope 
Resorption pits made by osteoclasts cultured on ivory discs were visualised by staining 
with toluidine blue.  Discs were individually sonicated for 1 minute at 22Hz, using a 
Soniprep 150 (MSE) to disrupt adherent cells.  Remaining cells were removed from the 
discs by gentle rubbing with a cotton bud.  1% hydrogen peroxide solution (200µl) was 
added to each disc and incubated overnight at room temperature with mechanical 
shaking to remove haematoxylin stain from the disc.  Discs were washed twice with dH2O 
and 200µl 0.5% toluidine blue stain added.  Discs were incubated for 1 minute at room 
temperature before the stain was removed and discs washed twice with dH2O.  Discs were 
photographed and analysed as above for osteoclasts (section 2.2.13). 
2.2.14.3.2 Confocal Microscope 
In order to obtain more detailed analysis of resorption pits a method using confocal 
microscopy was developed.  Cultured cells were removed from the discs as in section 
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2.2.14.3.1.  Initially discs were placed onto a glass slide for visualisation of the resorption 
pits, using a Leica TCS SP2 AOBS spectral confocal microscope (Leica Microsystems Ltd) 
and Leica confocal software (Leica Microsystems Ltd).  Discs were imaged using reflective 
light, at x10 and x40 magnification.  After identification of areas for improvement the 
following modifications were made; following removal of haematoxylin stain discs were 
washed twice in dH2O.  Calcein fluorescent dye solution (200µl) was added to each well 
and incubated at room temperature for 10 minutes.  Discs were washed twice with dH2O 
and mounted onto glass slides with DPX; discs were covered with a coverslip and dried 
overnight at 60°C.  Discs were scanned using a 495nm wavelength laser, exciting the 
calcein dye.  Images were taken at x10 and x40 magnification. To measure the depth of 
resorption pits a ‘z series’ was performed, creating a 3D reconstruction of the pits.   Start 
point of the ‘z series’ was set at the surface of the ivory disc.  Z position was adjusted until 
just the base of the resorption pit was in focus, and set.   ‘z series’ was configured to take 
50 images per scan.  3D reconstruction of the ‘z series’ images were performed using the 
Leica confocal software. 
2.2.14.4 Tissue Degrading Enzymes 
OC utilise enzymes to degrade the organic component of bone.  Levels of MMP-9 and  
cathepsin K were analysed in culture supernatants. 
2.2.14.4.1 MMP-9 
Murine and human pro MMP-9 were measured in culture supernatants by ELISA (R&D 
Systems), following the method outlined in 2.2.14.1.  Specific buffers and antibody 
concentrations can be found in Table 2.14. 
ELISA 
Coating 
Buffer 
Wash 
Buffer 
Blocking 
Buffer 
Dilution 
Buffer 
Capture 
Antibody 
Detection 
Antibody 
Standard 
Murine 
pro 
MMP-9 
PBS 
0.05% 
Tween 
in PBS 
1% BSA 
in PBS 
0.1% 
BSA, 
0.05% 
Tween 
in PBS 
4.0µg/ml 
in PBS 
250ng/ml 
in 
Dilution 
Buffer 
20,000pg/ml 
– 312.5pg/ml 
Human 
Total 
MMP-9 
1% BSA 
in PBS 
1.0µg/ml 
in PBS 
100ng/ml 
in 2% *HI 
NGS in 
Dilution 
Buffer 
2000pg/ml – 
31.3pg/ml 
Table 2.14. Buffers and antibody concentrations used in the MMP-9 ELISAs. 
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Active and inactive MMP-9 present in culture supernatnats was assessed by zymogram 
using the following method.  
A 15 well 10% ‘Ready Gel’ zymogram gel (Bio-Rad) was attached to the gel frame and 
electrode and placed into the gel tank.  The comb was removed from the gel and 
zymogram running buffer (Bio-Rad) pipetted into the wells of the gel and added to the gel 
tank.  Samples were diluted 1:5 with zymogram sample buffer (Bio-Rad) and 15µl added 
to the relevant sample well.  MMP-9 standard (15µl) diluted to 10ng/ml in zymogram 
sample buffer was added to an empty well.  Broad range pre-stained protein ladder (5µl) 
(Bio-Rad) was added to an empty well.  The gel tank was topped up with running buffer 
until the gel was completely covered.  The lid was placed on the gel tank and the gel run 
at a constant 100V for 2 hours.  After completion of running time the gel was removed 
from the gel tank and gel frame and placed into a plastic tray where it was incubated for 
15 minutes in renaturation buffer.  After the incubation period the renaturation buffer 
was discarded and replaced with fresh renaturation buffer for a further 15 minutes.  
Following incubation the renaturation buffer was discarded and the gel placed in 
development buffer and incubated at 37°C for 20 hours.  After 20 hours incubation the 
incubation buffer was discarded and replaced with destain for 10 minutes.  Destain was 
removed and the gel placed in coomassie blue stain for 30 – 60 minutes at room 
temperature with mechanical shaking.  When the gel was sufficiently stained it was placed 
back into destain to allow the visualisation of bands before being placed in dH2O to be 
analysed. 
Visualisation of bands present on MMP-9 zymogram gels was performed with the 
Carestream In Vivo FX Pro (Carestream) and Carestream Molecular Imaging Software.  
Images were taken using the settings outlined in Table 2.15.  Analysis of the images was 
performed using Carestream Molecular Imaging Software. 
Setting Value 
Exposure 4 seconds 
UV Epi Illumination 
f-Stop 2.50 
FoV 120.92 
Focal Plane Tray 
Table 2.15. Carestream In Vivo FX Pro Zymogram Imaging Settings 
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2.2.14.4.2 Cathepsin K 
Measurement and visualisation of cathepsin K in OC cultures supernatants was analysed 
using a number of methods. 
For the Cathepsin K Collagenase Bio-assay, 96 well ELISA plates were coated with 50µl 
type I collagen at a concentration of 10µg/ml (25µl type I collagen stock solution in 5.5ml 
PBS) overnight at 4°C with mechanical shaking.  Following incubation the type I collagen 
was discarded and the plate washed 4 times with wash buffer.  Plates were blocked at 
room temperature, with mechanical shaking, with 300µl of blocking buffer.  After 2 hours 
the plates were washed 4 times with wash buffer.  Bacterial collagenase (100µl; 
Clostridiopeptidase A; Sigma-Aldrich) was used as a standard and added in duplicate 
(sensitivity range: 10,000pg/ml – 3.2pg/ml).  Buffer A (100µl) was added in duplicate as a 
blank.  Recombinant human Cathepsin K (100µl) at 460ng/ml was added in duplicate.  
Samples were diluted 1:10 and 1:100 in buffer A and 100µl added to the plate in 
duplicate.  Samples were incubated at 37°C for 24 hours.  After 4 washes with wash buffer 
100µl of detection antibody (1:15,000 of stock dilution of anti-type I collagen in assay 
buffer) was added to each well and the plate incubated for 1 hour at room temperature 
with mechanical shaking.  Plates were washed 4 times with wash buffer and 100µl of a 
secondary antibody (1:10,000 dilution of anti-mouse IgG peroxidase conjugated in assay 
buffer) was added to each well.  Plates were incubated for 1 hour at room temperature, 
with mechanical shaking, before being washed 4 times with wash buffer.  Development 
solution (100µl) was added and the colour developed at room temperature.  Reaction was 
terminated by the addition of 50µl of 12% sulphuric acid (H2SO4).  The optical density of 
the plate was measured as 450nm. 
Analysis of sample optical density (OD) allowed for the calculation of % collagen left in 
well.  Blanks were taken as having 100% of collagen remaining as no enzymes were 
present for degradation.  % of collagen remaining in each well, compared to the blank was 
calculated as follows: 
ODSample x 100 
ODBlank 
Analysis of the effect of FCS on the collagenase bio-assay was tested following the 
procedure above with the following modifications; buffer A was made up containing a 
range of FCS concentrations: 10%, 5%, 2% and 1%.  Cathepsin K controls were made up 
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using modified buffer A so that they contained the final concentrations of FCS: 10%, 5%, 
2%, 1%, 0.5%, 0.25%, 0.1% and 0.05%.  Two sets of standard were made up as above with 
the second containing 10% FCS.  Blanks were run in duplicate with and without 10% FCS. 
The Cathepsin K zymogram was adapted from work by Li et al (281).  A gel frame was 
constructed and a 12% acrylamide gel made up.  The Cathepsin K was set-up and run as 
per the procedure outlined in section 2.2.14.4.1 with the following modifications; 
Cathepsin K control sample from Biomedica Cathepsin K ELISA was diluted 1:5, with 
Cathepsin K sample buffer, to give a final concentration of 107pmol/L.  Initial sample was 
serial diluted 1:5 to give the final concentrations: 21.4pmol/L, 4.28pmol/L, 0.856pmol/L, 
0.171pmol/L, 0.034pmol/L and 0.007pmol/L.  After completion of running, gels were 
added to Cathepsin K renaturation buffer followed by Cathepsin K development buffer. 
For additional Cathepsin K zymograms the following modifications were made; 
recombinant human Cathepsin K (Enzo Life Sciences) was diluted 1:5 in sample buffer to 
give a concentration of 0.023µg/ml.  Initial sample was serial diluted 1:5 to give the final 
concentrations: 4.6ng/ml, 0.92ng/ml, 184pg/ml, 36.8pg/ml, 7.36pg/ml and 1.472pg/ml.  
Incubation buffer was adjusted to pH 4 and pH 5 with HCl.  Cathepsin K zymograms were 
analysed as in section 2.2.14.4.1. 
Cathepsin K was visualised in situ using immunocytochemistry.  Human osteoclasts were 
cultured in a 48 well plate according to the procedure outlined in section 2.2.10 with the 
following modifications; after adherence 500μl supplemented human OC medium (Table 
2.16) was added to the cells. 
 Condition 1 
MCSF 5ng/ml + 
RANKL 5ng/ml + 
polyHistidine 2.5µg/ml + 
Table 2.16. Medium supplements used in culture of cells for CatK immunocytochemistry  
Cells were incubated at 37°C 5% CO2 with medium replenished every 3 to 4 days.  On day 
14 cultures were terminated and cells stained.  Cells were fixed, permeabilised, blocked 
and stained for actin as in section 2.2.14.5.  Anti-Cathepsin K antibody (200µl) or isotype 
control (Rabbit IgG), at 1µg/ml, 2µg/ml, 3µg/ml and 4µg/ml (diluted in blocking solution), 
was added to each well and incubated for 1 hour at room temperature.  Cells were 
washed twice with PBS and 200µl Goat anti-Rabbit-FITC conjugated (diluted 1:50 in 
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blocking solution) was added to each well, and incubated at room temperature for 30 
minutes. Cells were washed twice with PBS and 200μl DAPI nucleic acid stain was added 
to each well for 3 minutes at room temperature.  Cells were washed twice with PBS.  Cells 
were visualised under a Leica DM IRBE fluorescent microscope with Openlab 3.1.7 
software. 
2.2.14.5 Actin ring Formation 
Formation of the actin ring plays a key role OC resorption.  To determine whether DR3 
affects actin ring formation cells were stained using immunocytochemistry.   Murine 
DR3wt osteoclasts were cultured in a 48 well tissue culture plate as per the procedure 
outlined in section 2.2.6 with the following modifications; 3.2x105 cells were added per 
well.  After 10 days culture cells were washed twice with PBS.  200μl of 4% formaldehyde 
was added per well and incubated at room temperature for 10 minutes.  Cells were 
washed a further 2 times with PBS.  Permabilisation solution (200µl) was added and cells 
incubated for 3-5 minutes at room temperature.  Cells were washed twice with PBS and 
300μl of blocking solution was added and incubated for 30 minutes at room temperature, 
blocking solution was removed and cells washed twice with PBS.  Actin stain (200µl) was 
added to each well and incubated at room temperature for 20 minutes.  Cells were 
washed twice with PBS and 200μl DAPI nucleic acid stain was added to each well for 3 
minutes at room temperature.  Cells were washed twice with PBS.  Cells were visualised 
under a Lecia DM IRBE fluorescent microscope (Lecia Microsystems Ltd) with Openlab 
3.1.7 software (Perkin Elmer). 
 
2.2.15 Assessing TL1A Levels in Serum from Patients with Inflammatory Arthritis 
In order to determine whether DR3 and TL1A have a role in the pathogenesis of 
inflammatory arthritis levels of TL1A and rheumatoid factor (RF) were measured in serum 
from rheumatoid arthritis (RA), osteoarthritis (OA) and psoriatic arthritis (PsA) patients 
and healthy normal serum.  Ethical approval was obtained from the Bro-Taf Health 
Authority (Reference 02/4692-Cardiff, Wales, UK) for the collection of venous peripheral 
blood from consenting RA patients and healthy normal subjects.  Peripheral blood (20ml) 
was collected and allowed to clot at room temperature for 30 minutes before serum was 
harvested and stored.   
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2.2.15.1 Serum TL1A 
Serum TL1A levels were measured by ELISA (section 2.2.14.2).  Grouping of RA patients 
into those displaying erosive or non-erosive disease was carried out by Rheumatology 
doctors at Cardiff and Vale University Health Board, Heath Hospital; based on analysis of 
x-rays taken at time of sample collection. 
2.2.15.2 Rheumatoid Factor 
To analyse serum levels of RF an in-house ELISA was developed.  ELISA was performed 
according to the method in section 2.2.14.1.  Capture antibody used was Rabbit IgG, 
detection antibody was anti-human IgM (F(ab)’2-Peroxidase and standard was 
rheumatoid factor.  Specific buffers and antibody concentrations are found in Table 2.17. 
ELISA 
Coating 
Buffer 
Wash 
Buffer 
Blocking 
Buffer 
Dilution 
Buffer 
Capture 
Antibody 
Detection 
Antibody 
Standard 
Rheumatoid 
Factor 
PBS 
0.05% 
Tween 
in PBS 
1% BSA 
in PBS 
1% BSA, 
0.05% 
Tween 
in PBS 
10µg/ml 
in PBS 
1:5000 
dilution in  
Dilution 
Buffer 
500 – 
15.625 
units 
Table 2.17. Buffers and antibody concentrations used in the RF ELISA 
 
2.2.16 Murine Osteoblast Assays 
Osteoblast assays were established using bone marrow cells harvested from aged 
matched DBA/1 or C57BL/6 DR3wt and DR3ko mice (8 – 12 weeks).  Bone marrow was 
isolated as described in section 2.2.4.  Cells were re-suspended in murine osteoblast 
medium and added to a T75 tissue culture flask.  Medium was removed and replenished 
with fresh media every 3 – 4 days until cells were 90% - 100% confluent. 
2.2.16.1 Osteoblast Mineralisation Assay 
Confluent osteoprogenitors were removed from the culture vessel by gentle scraping with 
a cell scraper.  Cells were added to a 15ml centrifuge tube and spun at 800g for 3 minutes.  
Medium was removed, cells re-suspended in 5ml fresh murine osteoblast media and a cell 
count performed (section 2.2.3).  Cells were re-suspended to a final concentration of 4 x 
105 / ml and 1ml of cell suspension added per well of a 12 well tissue culture plate (Fig 
2.12).  Cells were incubated overnight at 37°C 5% CO2.  Murine osteoblast medium was 
103 
 
removed and replaced with murine osteoblast mineralising medium and cells incubated at 
37°C 5% CO2. On day 3, 7, 10, 14, 17, 20 and 23 supernatants were removed, aliquoted 
and stored at -70°C for subsequent analysis by ELISA (pro MMP-9).  Wells were 
replenished with fresh media and the experiment run to day 26.  Plates were removed at 
day 17, 20, 23 and 26 for staining for mineralisation (section 2.2.19.1) and ALP (section 
2.2.19.2). 
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2.2.17 Flow Cytometric Analysis of DR3, RANKL and CD44 Expression on 
Osteoprogenitors and Mineralising Osteoblasts 
Bone marrow was isolated from two C57BL/6 and 2 DBA/1 age-matched DR3wt and DR3ko 
mice (8-12 weeks).  Osteoprogenitors were cultured in T25 culture flasks according to 
section 2.2.16.  When cells were 70% confluent medium was removed from half of the 
flasks and replaced with murine osteoblast mineralising medium.  Cells were cultured for 
a further 7 days when mineralisation was visible in the flasks containing murine osteoblast 
mineralising medium.  Cells were removed from the surface of the T25 tissue culture 
flasks by gentle scraping and added, along with culture medium, to a 5ml round bottom 
test tube.  Cells were spun at 800g for 3 minutes and the medium replaced with 1.5ml 
murine DR3 flow cytometry buffer before being split equally between 6 round bottom test 
tubes (200μl per tube).  Cells were spun at 800g for 3 minutes, supernatant removed and 
replaced with 200μl PBS containing Fc block (1/500 dilution).  Cells were incubated for 15 
min at 4°C before being spun at 800g for 3 minutes.  Fc block was removed and cells re-
suspended in 200μl murine DR3 flow cytometry buffer containing 2% normal goat serum.  
Cells were incubated for 30 min at 4°C before being spun at 800g for 3 minutes.  
Supernatant was removed and replaced with 200μl murine DR3 flow cytometry buffer 
containing 0.5% normal goat serum and either 2μl Polyclonal Goat anti-murine DR3 
(1/100 dilution), 2μl  anti-murine CD44 (1/100 dilution), 2μl  anti-murine RANKL (1/100 
dilution or isotype control at the same concentration.    Cells were incubated for 30 – 45 
min at 4°C.  Cells were spun at 800g for 3 minutes, supernatant removed and washed 
three times in murine DR3 flow cytometry buffer.  Murine DR3 flow cytometry buffer 
(200µl) containing streptavidin-APC (1/500 dilution) was added to the cells and incubated 
for 30 min at 4°C.  Cells were washed three times before being re-suspended in 200μl 
murine DR3 flow cytometry buffer and fixed with 200μl 4% formaldehyde.  Cells were run 
through the BD AccuriTM C6 Flow Cytometer and data analysed using BD CFlow® Plus 
software.  50,000 events were acquired per sample.  Forward scatter-area (FSC-A) against 
forward scatter-height (FSC-H) plots were generated and doublets excluded by gating on 
the single cells.  FSC-A against side scatter-area (SSC-A) plots were then generated and cell 
debris excluded by gating.  Osteoprogenitors were positively selected for by gating, and 
expression of CD44, RANKL and DR3 calculated from scatter plots or histograms.   
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2.2.18 TL1A RT- PCR 
Reagents for the detection of murine TL1A were not available at the time of this study.  To 
determine whether cells produced TL1A, primers were designed and tested on cDNA 
isolated from immune complex stimulated RAW cells, osteoprogenitors and mineralising 
osteoblasts.   
2.2.18.1 Immune Complex (IC) Stimulated RAW Cells 
RAW cells were added to a T75 tissue culture flask and cultured until confluent in murine 
osteoclast medium.  Plate bound immune complexes were generated by coating a 48 well 
plate with 500µl of mouse IgG (0.1μg/ml) and incubated overnight at 4°C.  Following 
incubation the mouse IgG was discarded and the plate washed twice with PBS.  500µl of 
anti-mouse IgG (0.1μg/ml) was added to each well and incubated overnight at 4°C.  Anti-
mouse IgG was removed and plates washed twice with PBS.  RAW cells were removed 
from the tissue culture flask by gentle scraping and added to a 15 centrifuge tube.  Cells 
were spun at 800g for 3 minutes and re-suspended in 5ml murine osteoclast medium.  A 
cell count was performed (section 2.2.3) and cells re-suspended to a final concentration of 
2x105 / ml.  Cell suspension (500µl; 1x105 cells) was added to each well containing plate 
bound immune complexes and incubated at 37°C 5% CO2 for 3 days.  Medium was 
removed from the wells and cells washed twice with PBS.  mRNA was extracted from the 
cells using a Qiagen RNeasy Mini kit, following the manufacturer’s instructions.  The 
concentration of mRNA was calculated using a NanoDrop 3300 (Thermo Scientific).  For 
conversion of RNA into cDNA by RT-PCR 2μg RNA was added to a thin walled PCR tube 
with 1μl 250ng oligo dT primers and 1μl 10mM dNTPs and the volume made up to 11μl 
with RNase free dH2O.  Samples were incubated at 65°C for 5 minutes then placed on ice 
for 1 minute.  Samples were centrifuged at 12,000g for 1 minute and 4μl 5x 1st strand 
buffer and 2μl 0.1M DTT added.  Reverse transcriptase (1µl) was added to each sample 
and samples placed into the thermal cycler and run through the RT-PCR program as 
defined in Table 2.18.  All reagents used for conversion of RNA into cDNA were supplied 
by Life Technologies, Invitrogen. 
Step Temperature (°C) Time Number of Cycles 
Annealing 25 10 minutes 
1 Elongation 42 50 minutes 
inactivation 70 15 minutes 
Table 2.18. RT-PCR thermal cycler settings for conversion of RNA into cDNA 
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2.2.18.2 TL1A Gradient PCR 
For TL1A gradient PCR 1µl of IC stimulated RAW cell cDNA (section 2.2.18.1) was added to 
a thin walled PCR tube with 8μl of dH2O.  The required volume of TL1A master mix was 
made up and 12.1µl added to each tube along with 1µl of the primer to be tested (P1 – 
P4).  Tubes were placed into the PCR thermal cycler and run through the TL1A gradient 
PCR program, as defined in Table 2.19.  Sample products were run on a 1.6% agarose gel 
and visualised as outlined in section 2.2.2.  Subsequent TL1A RT-PCR was performed using 
primer 4 and an annealing temperature of 59°C. 
Step Temperature (°C) Time Number of Cycles 
Initial denaturation 94 5 minutes 
1 Annealing 53.2 / 55.6 / 58 / 59 / 60 45 seconds 
Elongation 72 45 seconds 
Denaturation 94 45 seconds 
33 Annealing 53.2 / 55.6 / 58 / 59 / 60 45 seconds 
Elongation 72 45 seconds 
Denaturation 94 45 seconds 
1 Annealing 53.2 / 55.6 / 58 / 59 / 60 45 seconds 
Elongation 72 5 minutes 
Table 2.19. TL1A gradient PCR thermal cycler settings 
2.2.18.3 Osteoprogenitor / Mineralising Osteoblast TL1A RT-PCR 
Osteoprogenitors and mineralising osteoblast were cultured according to section 2.2.16 
with the following modifications; mineralisation medium was added to the cells and 
mRNA extracted and converted to cDNA (section 2.2.18.1) on days 0, 5, 10 and 15.  TL1A 
RT-PCR was performed according to section 2.2.18.2. 
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2.2.19 Assessing Murine Osteoblast Function 
A variety of methods were used to assess the function of OB in culture.  These are listed 
below. 
2.2.19.1 Visualisation of Osteoblast Mineralisation 
Mineralisation in murine osteoblasts cultures was visualised by staining with alizarin red 
stain.  Cultures were washed twice with PBS and 300µl of 4% formaldehyde added per 
well.  After 15 minutes incubation fixative was removed and the cells were washed a 
further 2 times with PBS.  Alizarin red stain (300µl) was added per well and incubated for 
30 minutes.  Stain was removed and cells washed 4 times with 50% methanol.  On the 4th 
wash methanol was left in wells for 10 minutes to remove all non-specific staining before 
being removed and cells washed with dH2O and allowed to air-dry. 
Stained plates were scanned using a flatbed scanner at 300dpi.  Corel Paint Shop Pro X 
was used to crop the individual wells for analysis.  Background of the plate was removed 
from each image leaving just the stained area.  Images were opened in image J and the 
scale set to 8.2 pixels = mm.  Pictures were changed to 8-bit colour and the threshold 
adjusted so all mineralisation was detected.  The area of the well that was stained was 
calculated and reported as a percentage of the well. 
2.2.19.2 Visualisation of Alkaline Phosphatase Activity 
Alkaline phosphatase (ALP) activity in osteoblast cultures was visualised by staining with 
the ALP stain.  Cultures were washed and fixed as in section 2.2.19.1.  ALP stain (300µl) 
was added per well and incubated for 30 minutes.  Stain was removed and cells washed 
with dH2O and allowed to air-dry.  Staining was analysed as in section 2.2.19.1. 
2.2.19.3 MMP-2 and MMP-9 
Levels of pro MMP-9 were measured in culture supernatants by ELISA, with active MMP-2 
and MMP-9 detected in culture supernatants by zymography.  The methodology is 
described in section 2.2.14.4.1. 
2.2.19.4 Visualisation of Osteoblast Cell Number 
DBA/1 DR3wt- and DR3ko-derived osteoblasts were cultured to day 26 and cell numbers 
visualised by staining with DAPI as in section 2.2.14.5  
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2.2.20 Analysis of DBA/1 In Vivo Bone Phenotype 
Analysis of DBA/1 in vivo bone phenotype was performed to determine whether there is 
any difference between DR3wt and DR3ko mice. DR3wt and DR3ko, male and female mice (6 
per group) were aged to either 8 or 20 weeks.  At the selected time point mice were 
sacrificed by schedule 1; an overdose of carbon dioxide (CO2) followed by cervical 
dislocation.  Mouse weights were recorded before the lower half of the body was 
removed and stored in 70% alcohol to fix tissues.  Excess flesh was removed from the 
femurs.  X-rays of the femora and spines were taken with the Carestream In Vivo FX Pro 
and Carestream Molecular Imaging Software.  Regions of Interest were selected using the 
Carestream Molecular Imaging Software and femur length and bone density calculated. 
 
2.2.21 Statistical Analysis 
All results were graphically illustrated as the mean ± standard error of the mean (SEM) 
and were statistically analysed using Graphpad Prism v5.  P values of <0.05 were 
considered significant while those of <0.01 were considered highly significant.  The 
statistical tests used in this study were the Mann-Whitney-U test, used for comparing the 
means of two unpaired groups of non-normally distributed data.  Students unpaired T-
test, used for comparing the means of two groups of normally distributed data.  One-way 
and two-way ANOVAs were used when comparing more than two groups or variables 
respectively, followed by a Bonferroni post hoc test.  Graphpad QuickCalcs outlier 
calculator (Grubb’s test) was used to detect significant outliers. 
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Abcam (Cambridge, UK) 
BD Biosciences (Oxford UK) 
Biosera (East Sussex, UK) 
Bio-Rad (Hertfordshire, UK) 
Biomedica Gruppe (Austria) 
Carestream (Hertfordshire, UK) 
Corel UK Ltd (Maidenhead, UK) 
DAKO (Cambridgeshire, UK) 
DiAgam (Ghislenghien, Belgium) 
Enzo Life Sciences (Exeter, UK) 
eBioscience (Hatfield UK) 
Fisher Scientific (Loughborough, UK) 
Graphpad (LaJolla, CA) 
Life Technologies Invitrogen (Paisley, UK) 
Leica Microsystems Ltd (Milton Keynes, UK) 
LongGene Scientific Instruments (China) 
Miltenyi Biotec (Surrey, UK) 
MSE (London, UK) 
Nunc International (New York, USA) 
Olympus UK (Southend-on-sea, UK) 
Perkin Elmer (Buckinghamshire, UK) 
Qiagen (Manchester, UK) 
R&D Systems Europe (Abingdon, UK) 
Roche (Burgess Hill, UK) 
Sigma-Aldrich (Dorset, UK) 
Taicaan Technologies (Southampton, UK) 
UVP (Cambridge, UK) 
VWR (Leicestershire, UK) 
Waldemar Knittel Glasbearbeitungs- Gmb (Braunschweig, Germany) 
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Chapter 3 
 
The Role of Death Receptor 3 and TL1A in 
Murine Osteoclast Differentiation and 
Function 
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3.1 Introduction 
Bone remodelling is a balanced cycle of bone breakdown and bone formation that 
maintains the integrity and strength of the skeleton, throughout a person’s life. The two 
main cell types that regulate this process are; (i) the osteoclast, the cell responsible for 
the degradation and resorption of bone and (ii) the osteoblast, a cell that produces the 
organic bone matrix and aids in its mineralisation.  The process of bone remodelling is 
controlled by a number of different factors.  Key among them are members of the TNFSF, 
both receptors and ligands.  Signalling through the TNFRSF member RANK by its ligand 
RANKL is critical for OC formation (15, 54, 56), and without this trigger OC differentiation 
will not take place.  Other members of the TNFSF have also been shown to act 
synergistically with RANK / RANKL signalling enhancing OC formation and bone turnover; 
such as TNF (TNFSF2) and its receptor tumour necrosis factor receptor 1 (TNFR1) (282, 
283).  Although these receptors and ligands are important, the functionality of all the 
members of the TNFSF in bone is not known.  The primary focus of this chapter is to 
explore the impact of DR3 and its ligand TL1A upon OC formation and function in the 
mouse. 
To date there is only one paper that explores the effect of DR3 and TL1A on OC function.  
Work published by Bull, Williams et al (242) demonstrated that in a C57BL/6 AIA model of 
experimental arthritis, DR3ko mice displayed mild pathological features of arthritis; 
showing general absence of synovial hyperplasia, lack of pannus formation, and no 
evidence of bone erosion when compared to their DR3wt counterparts.  Confirmation that 
this resistance to AIA was DR3 specific was shown through the co-administration of TL1A 
upon the induction of AIA, in DR3het mice.  Co-administration of TL1A resulted in a 
significant dose-dependent exacerbation of disease in DR3het mice.  In contrast, TL1A had 
no significant effect on arthritis progression in DR3ko mice.  To determine whether the 
observed effects were due to DR3/TL1A signalling acting upon OC and their precursors 
they carried out in vitro assays using bone marrow cells (BMCs).  These assays showed 
that DR3wt and DR3ko mice exhibited no significant difference in their ability to generate 
osteoclasts, in the presence of soluble RANKL and MCSF.  However, the addition of TL1A 
to the cultures significantly enhanced the development of osteoclasts in DR3wt but not 
DR3ko BMC cultures.  The data demonstrates a role for TL1A in promoting 
osteoclastogenesis, in the presence of RANKL and MCSF, in a DR3 dependent manner.  
However, the mechanism through which it drives OC formation is unknown. 
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The study by Bull and Williams was the first to demonstrate the impact of DR3 and TL1A 
upon OC formation in vitro.  These studies were conducted using BMCs from the C57BL/6 
strain of mouse.  In this current study the C57BL/6 strain was used as our control, while 
investigating the response of BMCs from the DBA/1 strain.  The DBA/1 strain of mouse 
provides an excellent background to study bone biology, and is the benchmark for the CIA 
model, which shares several pathogenic features with human rheumatoid arthritis.  These 
features include synovial hyperplasia, mononuclear cell infiltration and cartilage and bone 
degradation (284).  In addition a number of groups have demonstrated that aging male 
DBA/1 mice spontaneously developed an ankylosing phenotype (285-287), highlighting 
the strain as a model of the spondyloarthritides.  A major difference between RA and the 
main subtype of spondyloarthritis, ankylosing spondylitis (AS), is the formation of new 
bone in AS.  However, RA and AS share a number of common features.  Both are 
inflammatory diseases, they display focal bone erosions and exhibit reduced bone density 
leading to osteopenia and osteoporosis (288-292).  While the development of osteopenia 
is partly due to a reduction in bone formation, an increase in OC activity is also observed.  
The reasons for the differences between the C57BL/6 and DBA/1 strains of mice, in the 
development of bone / OC-related diseases are unknown.  This chapter will determine 
whether there are any phenotypic differences in DR3 driven bone biology and OC 
response to TL1A. 
Functional analysis of OC formation and activity is traditionally done through analysis of 
OC numbers and resorption pits, though a number of other factors can also be 
investigated to try and determine the mechanism of action.  The chemokines CXCL1 
(mouse kc, which shares many similar functions to human CXCL8) (76), CCL2 (79, 293, 294) 
and CCL3 (85, 90) have been shown to be involved in and enhance OC precursor 
recruitment, migration and fusion.  Analysis of (i) actin ring formation, a marked 
cytoskeletal rearrangement that necessarily precedes bone resorption (295); (ii) MMP-9 
expression, a gelatinase that is found in high levels in the resorption pit (105, 106);  (iii) 
Cathepsin K, the most prominent proteinase in human osteoclasts and the main bone 
degrading enzyme (104), all provide additional information on the mechanisms of OC 
resorptive function.  An effect of TL1A on two of these factors (CXCL8 and MMP-9) has 
already been shown (240, 278).  Work by Kang et al (278) and Su et al (240) demonstrated 
that signalling through DR3 by TL1A, on the THP-1 macrophage cell line, induced CXCL8 
and MMP-9 expression in vitro.  The effect of TL1A on CXCL8 and MMP-9 expression by 
OC however, has currently not been investigated. 
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The aim of this chapter was to explore DR3 biology in the context of OC using BMCs from 
DBA/1 mice.  The ability of BMCs from DR3wt and DR3ko mice to differentiate in to OC and 
resorb a bone substrate, namely ivory discs, was investigated.  To determine the 
mechanism through which DR3/TL1A signalling acts culture supernatnats were analysed.  
Levels of specfic mediators involved in OC differentiation and tissue degrading enzymes 
involved in resorption were measured.   The specific objectives of this chapter are: 
 To undertake phenotypic characterisation of bone marrow cells from DBA/1 DR3wt 
and DR3ko mice. 
 To isolate BMCs from DBA/1 DR3wt and DR3ko mice and develop an in vitro culture 
system for osteoclasts grown on glass coverslips and ivory discs. 
 To assess the impact of DR3 on osteoclast formation on glass coverslips and ivory 
discs 
 To assess the impact of DR3 on osteoclast resorptive function on  ivory disc. 
 To determine if TL1A modulates osteoclast differentiation in a DR3-dependent 
manner and to assess the impact of TL1A upon resorptive function  in vitro. 
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3.2 Results 
3.2.1 Murine DR3 Genotyping 
The colony of DR3wt and DR3ko (C57BL/6 and DBA/1) mice employed for all the studies 
outlined in this thesis were generated from Heterozygous / Heterozygous (DR3het) 
breeding pairs.  For this reason each new litter of mice was screened by PCR to determine 
the genotype of each mouse. The PCR methodology was developed in-house by Dr E 
Wang (Co-supervisor); the methodology is described in section 2.2.2.  One of three PCR 
products were generated, this was dependent upon the genotype of the mouse.   One 
band at a molecular weight (MW) of 280 base pairs (bp) was produced for DR3wt mice, 
corresponding to a section of the coding region of the DR3 gene.  One band at a MW of 
320bp was expected for DR3ko mice, corresponding to the inserted neo portion of the 
vector used to replace the DR3 coding region. Two bands at MWs of 280bp and 320bp 
were used to identify DR3het mice, which possessed both DR3wt and DR3ko alleles.   A 
typical genotyping screen is shown in Fig 3.1.  While the number of mice obtained per 
week was highly variable the genotype was typically split into 25% DR3wt, 25% DR3ko and 
50% DR3het.  For each PCR run 95% of samples yielded a result to determine the genotype 
of the mouse.  In 5% of cases a second PCR run was required for successful determination 
of genotype. 
 
3.2.2 Comparison of DR3wt and DR3ko Bone Marrow Cellular Phenotype 
To ensure that the cell population used at the initiation of the assay was matched 
between DR3wt and DR3ko bone marrow, differential cells counts (Fig 3.2 (b)) were 
performed (section 2.2.5) using male DBA/1 mice (n=5).  Cells were identified by their size, 
granularity and nucleus size and shape.  Data is presented as a percentage of the total 
bone marrow cells (mean±SEM).  Erythrocytes were found to be the most common cell 
type present in DR3wt and DR3ko bone marrow (51.5±2.4% versus 53.5±3.1%).  Leukocytes 
accounted for 48.1±2.69% (DR3wt) and 46.2±4.7% (DR3ko) of the population; of these 
neutrophils were the most common (35.7±2.2% versus 31.6±2.7%) and monocytes the 
least (2.6±0.2% versus 3.0±0.9% - Fig 3.2 (a)).  The data observed for DR3ko mice were 
comparable to DR3wt mice with no significant differences for any of the cell types 
evaluated. 
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3.2.3 Assessing the Impact of DR3 upon the Development of Osteoclasts on Glass 
Coverslips 
A reproducible osteoclastogenesis assay had been established in the laboratory prior to 
the initiation of this project. This method used glass coverslips to support the cells during 
their expansion and differentiation. Bone marrow cells, isolated from the femora of age-
matched male DBA/1 DR3wt and DR3ko mice (n=3) were used as a source of precursor cells. 
The culture methodology is outlined in section 2.2.6.1.   Osteoclasts were successfully 
cultured from both DR3wt and DR3ko BMCs (Fig 3.3).  The numbers of macrophages and 
TRAP+ OC per glass coverslip are expressed as cells/mm2 (mean±SEM) for graphical 
presentation (Fig 3.4 (a)). Comparison between DR3wt and DR3ko cultures demonstrated no 
significant difference at endpoint on day 7 (900±49/mm2 versus 766±47/mm2). 
Differential counts were also performed. When TRAP+ osteoclasts were reported as a 
percentage of total cells (mean±SEM), no significant difference was observed between 
DR3wt and DR3ko (Fig 3.4 (b)). Finally, osteoclast diameter (in μm, mean±SEM) was 
measured. This parameter has previously been reported to be an indirect measure of 
osteoclast resorptive function (296-299). Osteoclast diameter in DR3wt (110±5μm) and 
DR3ko (96±8μm) cultures were not significantly different (Fig 3.4 (c)). These data 
demonstrate that DR3 does not affect osteoclastogenesis when cells are cultured on glass 
coverslips. 
 
3.2.4 Assessing the Impact of TL1A upon the Development of Osteoclasts on Glass 
Coverslips 
TL1A is the only known TNFSF ligand for DR3.  The impact of TL1A upon 
osteoclastogenesis in DR3wt and DR3ko cultures was assessed. At experiment endpoint on 
day 7 TL1A was observed to significantly decrease the total cell number in DR3wt cultures 
(-TL1A=900±49/mm2 versus +TL1A=648±105/mm2, P=<0.05; Fig 3.4 (a)).  Cell numbers in 
DR3ko cultures remained unaffected by TL1A, indicating the specificity of the ligand for 
DR3 in this system.  TL1A was also observed to affect the size of osteoclasts generated in 
culture. In DR3wt cultures mean OC diameter increased from 110±5µm to 135±15µm (-
TL1A versus +TL1A; Fig 3.4 (c)).  When DR3ko cultures were treated with TL1A, osteoclasts 
were larger (109±8μm) than those observed in untreated cultures (96±8μm). The change 
in osteoclast size induced by TL1A, however, was not significantly different in either DR3wt 
or DR3ko cultures.  
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3.2.5 Development of Murine Osteoclast Differentiation Assay on Ivory Discs 
In order to assess the effect of DR3 and TL1A on osteoclast resorptive function it was first 
necessary to establish a reproducible in-house osteoclastogenesis assay on a bone 
substrate (section 2.2.6.2).  The substrate chosen was ivory; it is composed of 
hydroxyapatite, a substance that osteoclasts recognise and can resorb.  In contrast to 
glass, ivory is porous and absorbs a certain volume of liquid when cells are dispensed onto 
its surface. The ivory discs used were slightly larger than the glass coverslips used in 
section 3.2.3 and 3.2.4 (6mm versus 5mm in diameter).  For this reason, addition of 10µl 
of cell suspension to the ivory disc resulted in undesirable, uneven concentration of cells 
in the centre of the disc and excessive dehydration that rendered the cells unviable.  To 
overcome these problems the volume of cell suspension added to the disc was increased 
from 10µl to 20µl.  The concentration of the cells in the suspension was reduced from 
6.4x106 / ml to 3.2x106 / ml to compensate for this increase in volume.  Cell number / 
mm2 was measured.  There was no significant difference in cell density when glass and 
ivory culture conditions were compared (217±36 versus 242±66 cells/mm2; Fig 3.5).  20µl 
of cell suspension (3.2x106 cells/ml) was used in all subsequent osteoclast assays on ivory 
discs. 
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3.2.6 Assessing the Effect of DR3 on Osteoclast Differentiation (Ivory Discs) 
BMCs were isolated from the femora of age-matched female DBA/1 DR3wt and DR3ko mice 
(n=6).  Osteoclastogenesis assays were performed using identical cytokine concentrations 
(MCSF, RANKL and TL1A) as previously described for the glass coverslip assays (section 
2.2.6.2) with MCSF ± TL1A cultures run as controls.  Osteoclasts were successfully cultured 
from both DR3wt and DR3ko BMCs in cultures containing RANKL, with no OC observed in 
the control cultures (Fig 3.6).  The total number of cells (macrophages and TRAP+ OC) per 
ivory disc were visualised by staining with haematoxylin, counted and expressed as 
cells/mm2 (mean±SEM) for graphical presentation.  Comparison between DR3wt and DR3ko 
control cultures (573±46 versus 527±51; Fig 3.7 (a)) and OC cultures (515±60 versus 
463±45; Fig 3.7 (b)) demonstrated no significant difference at endpoint on day 10.  
Differential counts were also performed.  TRAP+ osteoclasts reported as (mean±SEM) 
osteoclast number/mm2 (35±4 and 30±3; Fig 3.8 (a)) and as a percentage of total cells 
(8.2±1.4% and 7.8±1.1%; Fig 3.8 (b)) demonstrated no significant difference between the 
DR3wt and DR3ko OC cultures.  Finally osteoclast area (µm2, mean±SEM) was measured.  
Osteoclast area in DR3wt (925±116) and DR3ko (776±49) OC cultures were not significantly 
different (Fig 3.8 (c)). 
 
3.2.7 Assessing the Effect of TL1A on Osteoclast Differentiation (Ivory Discs) 
The results reported for glass coverslips (section 3.2.4) demonstrate that TL1A affects 
osteoclast differentiation.  The effect of TL1A on osteoclast differentiation on ivory discs 
was assessed. BMCs were isolated from the femora of age-matched female DBA/1 DR3wt 
and DR3ko mice (n=6) and cultured in osteoclastogenesis assays on ivory disc. The culture 
methodology is outlined in section 2.2.6.2.  At experiment end point on day 10 the total 
number of cells (macrophages and TRAP+ OC, reported as cells/mm2 (mean±SEM)) was 
significantly reduced in DR3wt OC cultures following addition of TL1A (-TL1A=515±60 
versus +TL1A=332±29, P=<0.05; Fig 3.7 (b)).   No significant difference in total cell number 
was observed in the control cultures (Fig 3.7(a)).  Differential counts were also performed.  
TL1A was found to significantly reduce osteoclast numbers (OC/mm2, mean±SEM) in 
DR3wt cultures (-TL1A=35±4 and +TL1A=20±4, P=<0.05; Fig3.8 (a)), though this did not 
translate into a significant reduction in % osteoclasts (-TL1A=8.2±1.4% versus 
+TL1A=5.2±0.7%; Fig 3.8 (b)).  The increase in osteoclast area (μm2 mean±SEM) induced 
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by TL1A was not significantly different (-TL1A=925.4±115.6 versus +TL1A=1275.7±170.2; 
Fig 3.8 (c)).  The addition of TL1A to DR3ko cultures had no effect on osteoclast numbers or 
size; however, it a significant increase in the total number of cells/mm2 was observed (-
TL1A=463±45/mm2 versus +TL1A=627±59/mm2 P=<0.05; Fig 3.7 (b)).  
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3.2.8 Impact of DR3 on Osteoclast Resorptive Function   
To assess whether DR3 affected OC resorptive function the area of the ivory disc resorbed 
was measured.  Data was expressed as the number of resorption pits/mm2 and % area 
resorbed (mean±SEM) for graphical presentation.  Comparison of DR3wt and DR3ko ivory 
discs showed that the absence of DR3 had a very significant effect on osteoclast 
resorptive function.  While resorption pits were present on discs from DR3wt OC cultures a 
very low number were observed on discs from DR3ko OC cultures (2.3±0.5/mm2 versus 
0.05±0.04/mm2, P=<0.001; Fig 3.9 (a)).  This translated into a very significant difference in 
% area resorbed between the two (8.5±4.8% versus 0.02±0.02%, P=<0.001; Fig 3.9 (b)); 
this result shows that DR3 plays an important role in osteoclast resorptive function. 
 
3.2.9 Impact of TL1A on Osteoclast Resorptive Function 
The impact of TL1A upon osteoclast resorptive function was assessed.  Data was reported 
as number of resorption pits/mm2 and % area resorbed (mean±SEM) for graphical 
presentation.  Addition of TL1A to DR3wt OC cultures was found to have no overall 
significant effect on osteoclast resorptive function.  An increase in the number of 
resorption pits/mm2 was observed following the addition of TL1A (2.3±0.5/mm2 versus 
4.0±2.1/mm2; Fig 3.9 (a)), however this was coupled with a decrease in the % area 
resorbed (8.5±4.8% versus 1.3±1.1%; Fig 3.9 (b)).  This result shows that % area resorbed 
is a better measurement of OC resorptive function than the number of pits.  Suggesting 
the decrease in resorption observed, following addition of TL1A, is due to the reduced 
number of OC present rather than a reduction in OC resorptive function. 
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3.2.10 Assessing the Effect of DR3 on Chemokine Production 
As an assessment of osteoclast activity chemokines involved in the formation of OC were 
measured in the supernatants of DR3wt and DR3ko control and OC cultures (section 
2.2.14.1). 
 3.2.10.1 CCL2 
In DR3wt and DR3ko control cultures (n=6, 3 reps per condition) levels of CCL2 peaked at 
day 7 with a maximum level of 835.5±129pg/ml (DR3wt) and 646.1±143pg/ml (DR3ko) 
detected (Fig 3.10 (a, i).  Levels of CCL2 in OC cultures (n=6, 3 reps per condition) 
increased across the time course with a maximum level of 94.8±19pg/ml in DR3wt cultures 
and 105.4±20pg/ml in DR3ko cultures detected at day 10 (Fig 3.10 (a, ii)).  There was no 
significant difference in CCL2 levels between the DR3wt and DR3ko in either the control or 
OC cultures. 
 3.2.10.2 CXCL1 
Levels of CXCL1, in DR3wt and DR3ko control cultures (n=6, 3 reps per condition) increased 
across the time course to a maximum level of 288.4±72pg/ml (DR3wt) and 240.7±72pg/ml 
(DR3ko) detected at day 10 (Fig 3.10 (b, i)).  In DR3wt and DR3ko OC cultures (n=6, 3 reps per 
condition) levels of CXCL1 peaked at a maximum level of 129.4±39pg/ml (DR3wt) and 
139.7±29pg/ml (DR3ko), detected on day 10 (Fig 3.10 (b, ii)).  No significant difference in 
CXCL1 levels was detected between the DR3wt and DR3ko in either the control or OC 
cultures. 
 3.2.10.3 CCL3 
CCL3 was detected across the time course in both DR3wt and DR3ko control cultures (n=3, 3 
reps per condition), with no significant difference in expression detected between the 
genotypes (Fig 3.10 (c, i)).  In OC culture supernatants, CCL3 (n=3, 3 reps per condition) 
was only detected at  day 3.  Levels were observed to be over three-fold higher in DR3wt 
cultures compared to DR3ko cultures (mean±SEM) (164.9±59.9pg/ml versus 
44.8±14.9pg/ml; Fig 3.10 (c, ii)) though this difference was not significant due to variation 
and the small sample size.  
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3.2.11 Assessing the Effect of TL1A on Chemokine Production 
Results from section 3.2.7 showed that TL1A has an effect on osteoclastogenesis; 
significantly reducing the number of osteoclasts formed.  Levels of CCL2, CXCL1 and CCL3 
were measured in control and OC culture supernatants to determine whether TL1A 
affects chemokine expression. 
 3.2.11.1 CCL2 
Addition of TL1A to DR3wt control cultures (n=6) had no significant effect on CCL2 levels 
(Fig 3.11 (a, i)).  In DR3wt OC cultures (n=6, 3 reps per condition) addition of TL1A caused a 
significant decrease in CCL2 levels (mean±SEM) across the time course (P=<0.0001).  
Levels of CCL2 were lower in DR3wt cultures containing TL1A at day 3 (-
TL1A=23.1±10pg/ml versus +TL1A=0pg/ml), day 7 (-TL1A=69.8±20pg/ml versus 
+TL1A=27.4±8pg/ml) and day 10 (-TL1A=94.8±19pg/ml versus +TL1A=59.2±13pg/ml; Fig 
3.11 (a, ii)).  
 3.2.11.2 CXCL1 
Levels of CXCL1 in DR3wt control cultures (n=6) increased across the time course with a 
maximum level of 288.4±72pg/ml (-TL1A) and 349.9±79pg/ml (+TL1A) detected at day 10 
(Fig 3.11 (b, i)).  Addition of TL1A to DR3wt OC cultures (n=6) had no significant affect on 
CXCL1 expression, with a maximum level of 129.4±39pg/ml (-TL1A) and 96.9±31pg/ml 
(+TL1A) detected on day 10 (Fig 3.11 (b, ii)). 
 3.2.11.3 CCL3 
Levels of CCL3 were comparable between DR3wt and DR3wt +TL1A control cultures (Fig 
3.11 (c, i)).  In DR3wt OC cultures (n=3, 3 reps per condition) addition of TL1A resulted in a 
greater than four-fold reduction in CCL3 at day 3 (-TL1A=164.9±60pg/ml versus 
+TL1A=37.1±14pg/ml; Fig 3.11 (c, ii)).  As with the DR3wt / DR3ko comparison this 
difference was not significant due to variation and small sample size. 
The data show, within statistical limitations, CCL2 to be a target of DR3/TL1A signalling.  
While CCL3 is a good candidate further testing and scientific rigour is required to prove 
that it is also a target.  This reduction in chemokine expression is RANKL dependent as no 
change in expression was observed in the control cultures.  
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3.2.12 Assessing the Effect of DR3 and TL1A on pro MMP-9 Release 
To explain the observed differences in OC function (section 3.2.8), levels of the inactive 
(pro) form of MMP-9, a gelatinase involved in the breakdown of the organic component of 
bone, were measured in both control and OC culture supernatants by ELISA (n=6, 3 reps 
per condition).  Levels of pro MMP-9 were found to be drastically reduced in control 
cultures, compared to OC cultures, with maximum levels of approx. 0.5ng/ml detected at 
day 3 (Fig 3.12 (a)).  No significant difference in pro MMP-9 was detected between the 
DR3wt and DR3ko control cultures.  In DR3wt and DR3ko OC cultures levels of pro MMP-9 
(mean ±SEM) were shown to increase over time (Fig 3.12 (a, ii)).  A significant decrease in 
pro MMP-9 was detected at day 10 in DR3wt compared to DR3ko OC cultures (8.9±9.1ng/ml 
versus 24.0±6.9ng/ml, P=<0.05).  Addition of TL1A to the DR3wt control and OC cultures 
had no significant effect on levels of pro MMP-9 (Fig 3.12 (b)).  These results show that 
while OC precursors can produce relatively low levels of pro MMP-9, stimulation of the 
cells by RANKL is required for up-regulation of its expression.  A limitation of this test 
however, is that it can only show levels of the inactive enzyme.  To overcome this 
limitation a gelatine zymogram was employed to look at both the pro and active forms of 
MMP-9.   
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3.2.13 Analysis of pro and Active MMP-9 in DR3wt and DR3ko Osteoclast Culture 
Supernatants by Zymography 
Analysis of culture supernatants in section 3.2.12 showed a significant difference in pro 
MMP-9 levels in DR3wt and DR3ko OC cultures.  The test however, was unable to determine 
whether the DR3ko cultures produce more inactive MMP-9; or whether the DR3wt and 
DR3ko cultures produce equal levels, with the DR3wt cultures converting more to the active 
form.  To determine whether DR3 had a role in MMP-9 activation a gelatine zymogram 
(section 2.2.14.4.1) was used to semi-quantitatively measure the levels of both pro and 
active MMP-9 in DR3wt and DR3ko OC culture supernatants (n=6; Fig 3.13).  Equal levels of 
pro MMP-9 (mean±SEM) were detected in both DR3wt and DR3ko supernatants at day 7 
(2.9±0.8ng/ml versus 2.7±0.3ng/ml) and day 10 (9.6±3.2ng/ml versus 7.7±2.5ng/ml, Fig 
3.14 (a)).  Levels of active MMP-9 were comparatively lower when compared to the pro 
form.  At day 7 low levels of active MMP-9 were detected in both DR3wt and DR3ko 
cultures.  At day 10 the amount of active MMP-9 in the DR3wt cultures was increased 
compared to the DR3ko (1.6±1.3ng/ml versus 0.4±0.3ng/ml), though this difference was 
not significant (Fig 3.14 (b)).  This result suggests that DR3 may have a role in the 
conversion of the inactive MMP-9 enzyme into its active form and that this partially 
explains some of the differences observed in osteoclast resorptive function. 
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3.2.14 Effect of DR3 on C57BL/6 Osteoclast Differentiation  
Results in this chapter have demonstrated for the first time functional data highlighting 
how DR3/TL1A signalling affects OC formation and function, with DR3 shown to be 
involved in OC function and the addition of exogenous TL1A reducing OC formation.  
However, these results are in contrast to those published by Bull, Williams et al (242), who 
showed that addition of TL1A enhanced OC formation.  To determine whether the strain 
of mouse used had a role in the contrasting results an osteoclast differentiation assay was 
performed using the C57BL/6 strain of DR3wt and DR3ko mice (n=1).  The culture 
methodology is outlined in section 2.2.6.2.  Comparison in total cell number 
(macrophages and TRAP+ OC, expressed as cells/mm2) between DR3wt and DR3ko OC 
cultures demonstrated no significant difference at endpoint on day 10 (397±103/mm2 and 
432±114/mm2; Fig 3.15 (a)).  Differential counts were also performed. TRAP+ osteoclasts 
reported as (mean±SEM) osteoclast number/mm2 (26±11/mm2 versus 20±2/mm2, Fig 3.15 
(b)) and as a percentage of total cells (6.1±2.0% versus 5.9±2.3%, Fig 3.15 (c)) 
demonstrated no significant difference between the DR3wt and DR3ko cultures. 
 
3.2.15 Assessing the Effect of TL1A on C57BL/6 Osteoclast Differentiation 
Results from section 3.2.7 showed that addition of TL1A to DBA/1 DR3wt OC cultures 
inhibited OC formation, in contrast to previously published work (242).  To determine 
whether this effect is due to the strain of the mouse TL1A was added to C57BL/6 OC 
cultures (n=1).   The culture methodology is outlined in section 2.2.6.2.  The total number 
of cells (macrophages and TRAP+ OC) per ivory disc are expressed as cells/mm2 
(mean±SEM) for graphical presentation (Fig 3.15 (a)).  Comparison between cultures ± 
TL1A demonstrated no significant difference at endpoint on day 10.    Differential counts 
were also performed.  A trend towards an increase in mean osteoclast number/mm2 
(26±11/mm2 versus 36±3/mm2; Fig 3.15 (b)) and mean % osteoclasts (6.1±2.0% versus 
8.8±1.8%; Fig 3.15 (c)) was detected in the DR3wt cultures following the addition of TL1A.  
No difference was detected in the DR3ko cultures.  These results support the report by 
Bull, Williams et al (242), confirming that the contrasting results were due to the 
difference in mouse strain used. 
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3.2.16 Effect of TL1A on CCL3 Release in C57BL/6 Osteoclast Cultures 
Levels of CCL3 were measured in supernatants from C57BL/6 DR3wt cultures ± TL1A, to 
determine whether an increase in this chemokine is partially responsible for the increase 
observed in OC formation.  CCL3 was detected across the time course in all cultures tested 
(Fig 3.16).  A 3-fold increase in CCL3 levels at day 3 (mean±SEM), was observed following 
the addition of TL1A (44.1±11pg/ml versus 159.2±125pg/ml).  This difference however 
was not significant due to low sample number. 
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3.2.17 Measurement of Cathepsin K in Culture Supernatant by Collagenase Bio-assay 
The results from the C57BL/6 experiment (section 3.2.14 and 3.2.15) agreed with the 
previously published data by Bull, Williams et al (242); that TL1A enhances OC formation.  
This established that the difference between the DBA/1 and C57BL/6 results, in response 
to TL1A, is not due to the reagents used but a difference between the two strains.  Having 
confirmed this further functional analysis was undertaken.  While MMP-9 has been shown 
to be involved in the degradation of the organic component of bone (106, 300, 301), it is 
not the most prominent bone degrading enzyme in osteoclasts; the principal bone 
degrading enzyme being the proteinase CatK (104, 105). At the time of writing, 
commercial reagents for the analysis of CatK in murine culture supernatants were limited, 
so a collagen bio-assay was developed to measure CatK activity.  The assay methodology 
is outlined in section 2.2.14.4.2.  Results are expressed as % binding of blank (mean±SEM) 
for graphical representation.  Comparison of the CatK control against the blank showed a 
reduction in binding of 24% (76±22% versus 100%) demonstrating that the assay can 
detect CatK activity.  However, when culture supernatants were tested at a 1:10 dilution 
(Fig 3.17 (a)) and a 1:100 dilution (Fig 3.17 (b)) an increase in % binding of >500% was 
detected for all samples.  The result suggests an unidentified substance in the sample, 
cross-reacting with the assay, masking any potential CatK activity.  To determine the cause 
of the cross-reactivity the effect of FCS on the assay was investigated.  
 
3.2.18 The Effect of Foetal Calf Serum on Detection of Cathepsin K Activity in the 
Collagen Bio-assay  
Results from section 3.2.17 suggested that a component of the osteoclast supernatants 
was cross-reacting with the collagen bio-assay, increasing the % collagen bound to over 
100%.  To determine whether the FCS present in the medium was the cause of the 
increased binding, FCS was titrated into the CatK control and blank.  The assay 
methodology is outlined in section 2.2.14.4.2.  Results are expressed as % binding 
(mean±SEM) for graphical representation.  In samples containing no FCS, comparison of % 
binding between the CatK control and blank were calculated to be 22±9.7 %.  Increasing 
the FCS levels, in the CatK control, up to 0.25% had no effect on the % binding (24±3.0%).  
When levels of FCS were increase to 0.5% a dramatic effect on the % binding was 
observed, with levels increasing to 138±5.2%.  Further increases in the level of FCS in the 
CatK control led to additional increases in % binding: 1% FCS – 245±10%, 2% FCS – 
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244±20%, 5% FCS – 275±8% and 10% FCS – 285±2% (Fig 3.18 (a)).  FCS was added to the 
blank control to determine whether this would negate the observed effect on % binding.  
When calculated against a blank control containing 10% FCS the % binding observed for 
the CatK control, for all FCS concentrations, was reduced > 2-fold.  Cat K with 0% FCS was 
observed to have an initial level of 9±5%.  Increasing the concentration of FCS to 0.25% 
had no effect on the level of binding (9.8±1%).  At a concentration of 0.5% FCS the % 
binding was observed to increase to 58±2%.  Subsequent increases in FCS concentration 
produced further increases in % binding, as observed previously; 1% FCS – 102±6%, 2% 
FCS – 102±11%, 5% FCS – 114±3% and 10% FCS – 118±0% (Fig 3.18 (b)).  
The results showed that, via this method, CatK cannot be measured in culture supernatant 
due to the presence of FCS.  All cultures were performed using 10% FCS in the medium 
which has been shown to cross-react with the assay, producing high levels of % binding 
and false negatives.   
 
3.2.19 Detection of Cathepsin K in Culture Supernatants by Zymogram 
Results from section 3.2.17 and 3.2.18 highlighted that CatK cannot be measured in 
culture supernatants using a collagen bio-assay, due to cross-reactivity with FCS present in 
the medium.  To determine whether CatK could be detected by zymogram, an assay was 
adapted from the work by Li et al (281) (section 2.2.14.4.2).  Initial optimisation was 
performed using a CatK control supplied by Biomedica.  Analysis of the zymogram showed 
that the Biomedica control failed to produce any clear bands, which are indicative of CatK 
activity (Fig3.19).  Non-specific dark bands were visible on the gel at a molecular weight 
(MW) of 54kDa.  These did not correspond to the MW of the pro and active forms of CatK 
(37kDa and 27kDa respectively).  Further optimisation of the CatK zymogram was 
performed using a second recombinant human CatK and tested at pH 4 and pH 5.  Use of 
the new control at lower pH values was able to produce some evidence of CatK activity.  
At pH 5 clear streaking was visible in the channels containing CatK at concentrations: 
4.6ng/ml, 0.92ng/ml, 184pg/ml and 36.8pg/ml (Fig 3.20 (a)).  At pH 4 an increase in 
streaking was observed with a lower level of detection of 7.36pg/ml.  Bands were also 
visible at a MW of approximately 36kDa corresponding to that of pro CatK, at 
concentrations of 184pg/ml, 36.8pg/ml and 7.36pg/ml (Fig 3.20 (b)).   
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3.3 Discussion 
The discovery in the 1990’s of the osteoclast differentiation factor, now commonly known 
as RANKL (15, 54, 56), has helped scientists gain an understanding of the role played by 
OC in bone remodelling and disease.  For the first time, pure populations of OC could be 
generated in vitro from the haematopoietic precursors present in bone marrow (302) 
without co-culture with other cell types.  The discovery has allowed scientist to study the 
direct effect of receptors, cytokines and chemokines on OC differentiation and function.  
Previously published work by Bull, Williams et al (242) showed a role for the TNFRSF 
member DR3 and its ligand TL1A in OC biology, though the mechanism through which 
they acted was not elucidated in this report.  The aim of this chapter was to determine the 
role of DR3/TL1A in OC differentiation and function. 
DR3 has been shown to play a role in T cell maintenance; through negative selection and 
anti-CD3-induced apoptosis during thymocyte development (280), though its role if any in 
bone marrow maintenance is unknown.  A review of the current literature also doesn’t 
yield any clues into the effects of the TNFSF cytokines and receptors on the bone marrow 
cell population.  With BM used as the source of haematopoietic precursors for all murine 
osteoclastogenesis assays, the effect of DR3 on the BM cell population was first 
determined.  No differences were observed between the DR3wt and DR3ko BM cell 
populations.  The data suggest that while DR3 may have a role in the maintenance of 
certain cell types at later stages of development; it does not affect the frequency of cell 
types in the BM, meaning any differences observed in future experiments can be 
attributed to a direct effect on OC differentiation and function.  Having confirmed that the 
starting populations of DR3wt and DR3ko assays were comparable the ability of the BM 
cells to differentiate into OC was investigated, using a standard system as a benchmark. 
Numerous studies have been conducted generating osteoclasts on glass coverslips in vitro 
using recombinant MCSF and RANKL.  The concentration of RANKL employed, ranges from 
1 to over 30ng/ml (303-305), depending on the source of the cytokine and the levels 
required to induce OC differentiation.  Concentrations of MCSF required for precursor 
proliferation were more consistent between groups.  Levels of 20 - 30ng/ml (37, 303-307) 
were routinely used ensuring that MCSF is a non-limiting factor in the assays.  For this 
study the concentrations of MCSF and RANKL used (25ng/ml and 2ng/ml) were pre-
determined from work previously carried out in the laboratory by Anja Bloom (308).   
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No difference was observed in total cell number or % osteoclasts in DR3wt and DR3ko glass 
coverslip cultures.  However, the differentiated osteoclasts were found to be very large, 
with some having a diameter >500µm (approximate surface area of >196,350µm2).   In 
vivo murine osteoclasts have been shown to have an area of approximately 300 - 400µm2 
(307).  Studies looking at OC surface area on glass coverslips are limited, though a study 
by Saltel et al (309) demonstrated OC cultured on glass grew to disproportionally large 
sizes (mean surface area of approximately 14000µm2) when compared to cells cultured on 
apatite (mean surface area approximately 3000µm2).  The reasons for the difference in 
size have not been extensively studied.  The work by Saltel et al (309) however, points to 
the inability of OC cultured on glass coverslips to polarise and generate an actin ring or 
sealing zone causing the OC to be thinner and more spread out.  Addition of TL1A to DR3wt 
cultures reduced total cell number while leading to a trend to increased OC size.  It is 
possible that in this system TL1A is enhancing osteoclastogenesis; increasing the number 
of precursor cells fusing together, lowering the total cell number and increasing osteoclast 
size.  To confirm this the number of nuclei / cell would have to be counted, to determine if 
following addition of TL1A there is an increase in cells fusing together to form the 
multinucleated OC.   
An alternative explanation for the decrease in cell number may be due to an apoptotic 
effect of DR3/TL1A signalling.  Work by Chinnaiyan et al (232) demonstrated that over-
expression of DR3 in MCF7 breast carcinoma cells and 293 cells induced rapid apoptosis.  
Additional work by Wen et al (246) and Borysenko et al (241) have shown that TL1A 
signalling can induce apoptosis in TF-1 cells and osteoblasts respectively.  However, these 
effects were only observed under certain regulated conditions.  The increased numbers of 
gaps (absence of cells) present in the DR3wt + TL1A cultures suggests an increase in cell 
death.  However, to determine whether this is due to TL1A signalling inducing cell death 
additional apoptosis assays would be required.  While enabling the easy visualisation of 
cells, the major limitation of using a glass substrate for osteoclastogenesis assays is that it 
does not allow the study of osteoclast resorptive function.  To determine whether DR3 
and TL1A had an effect on osteoclast differentiation and resorptive function, ivory 
(dentine) was chosen as a new substrate for culture.  Like bone, ivory is comprised of the 
mineral hydroxyapatite; a substrate osteoclasts can recognise and resorb and has been 
shown to be an affective substrate in osteoclast assays (41).   
Osteoclasts, when cultured on ivory, were observed to be greatly reduced in size when 
compared to the glass coverslip assays.  This result is in-line with the surface area of OC 
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reported by Redey et al (310) and Saltel et al (309), when cultured on a similar substrate 
(natural calcium carbonate = 1379±273μm2 and apatite = approximately 3000μm2 
respectively).  Analysis of the experimental outcomes showed that DR3 has no effect on 
osteoclastogenesis confirming what was observed in the glass coverslip assays.  Contrary 
to the work published by Bull, Williams et al (242) however, which showed in vitro TL1A 
enhanced osteoclastogenesis, TL1A reduced osteoclast differentiation in DR3wt cultures.  
The reasons for the difference in TL1A response between the two studies were not 
instantly obvious, but may be due to the difference in mouse strain used.  This will be 
discussed in further detail at a later point in this chapter.  TL1A was also found to 
significantly increase the total cell number in DR3ko cultures.  Reasons for this increase are 
currently not clear, as the only confirmed cellular receptor for murine TL1A is murine DR3.  
A 2008 study by Al-Lamki et al (272) however, suggested that TL1A may additionally signal 
through an as yet unidentified receptor.  In their study addition of TL1A to an organ 
culture of DR3-deficient mouse kidneys induced TNFR2 expression but did not activate NF-
κB and did not increase apoptosis of tubular epithelial cells.  Further experimentation is 
required to conclusively determine whether there is an alternative receptor for TL1A.  
Additionally, experimentation would be required using TL1A at different concentrations to 
determine whether the levels being used are having a blocking effect.   While signalling 
through RANK by its ligand RANKL is known to be crucial for OC differentiation (54) 
another member of the TNFSF, LIGHT (TNFSF14) has been suggested to be able to induce 
OC differentiation in its absence (182).  The study by Bull, Williams et al (242) showed that 
TL1A in the absence of RANKL and MCSF could not generate osteoclasts, however, it is 
unknown whether signalling by TL1A in the presence of MCSF is sufficient to induce 
osteoclast differentiation.  DR3 and TL1A were found to have no effect on cell number or 
on the induction of osteoclast formation, in control cultures.  The result confirms those 
reported by Bull, Williams et al that signalling by TL1A, in the absence of RANKL, is not 
sufficient for osteoclast differentiation.   
Having shown that TL1A has an effect on OC differentiation the effect of DR3/TL1A on 
osteoclast resorptive function was investigated.  The resorptive function of osteoclasts 
can be analysed through the number and area of the resorption pits they produce on the 
ivory surface.  DR3 was found to have a significant effect on osteoclast function.  In the 
absence of DR3, osteoclasts were found to be functionally inactive at the time point 
analysed with very low numbers of resorption pits produced, resulting in a mean of <0.5% 
of the ivory discs resorbed.  This data suggests that DR3 must play an important role in 
151 
 
osteoclast resorption; either through the process of osteoclast attachment, actin ring / 
sealing zone formation, acidification or enzyme release as there is no difference in 
osteoclast differentiation between the DR3wt and DR3ko cultures.  Failure in any of the 
aforementioned would result in the cellular phenotype observed, as demonstrated by a 
number of groups (103, 311-314).  Care must be taken when analysing the resorption pit 
data however, as levels were relatively low even in the DR3wt cultures.  This could make 
accurate interpretation of the role of DR3 in OC resorptive function difficult and raises the 
possibility that resorption by the DR3ko OC could be delayed rather than being functionally 
inactive. 
The role of TL1A in osteoclast resorptive function is less clear.  The increase in the number 
of resorption pits observed in the DR3wt cultures is off-set by the reduction in the mean % 
area resorbed.  The data suggests that TL1A does not play a role in OC function; the 
increase in resorption pit numbers and reduction in area resorbed could be attributed to 
the reduction in osteoclasts numbers.  Fewer osteoclasts would result in small individual 
resorption pits rather than the larger, merged resorption pits observed in the DR3wt –TL1A 
cultures.  This would then create the observed effect where there is an increase in 
resorption pit number but a decrease in the % area resorbed.  Analysis of OC numbers and 
resorption pits has demonstrated a role for DR3 in OC resorptive function and TL1A in OC 
differentiation.  To determine the mechanism through which the effects were being 
driven, culture supernatants were analysed for soluble mediators involved in OC 
formation and activity.  The migration, recruitment and fusion of mononuclear precursor 
cells into multinucleated OC, is controlled by a family of small cytokines known as 
chemokines; so called as they have the ability to induce chemotaxis in nearby responsive 
cells.  The effect of DR3/TL1A upon chemokine release from murine OC precursors 
(monocytes / macrophages) and osteoclasts is currently unknown.   
As discussed in the introduction the chemokines CXCL1 (1.3.5.2), CCL2 (1.3.5.3) and CCL3 
(1.3.5.4) are involved in osteoclastogenesis.  The results from the supernatant analysis of 
this study showed DR3 to have no effect on CCL2 or CXCL1 expression in control or OC 
cultures, however the trend towards a 3-fold decrease in CCL3 levels in DR3ko OC cultures 
highlights expression of this chemokine as a target of DR3.  Perhaps surprisingly the 
reduction in DR3ko CCL3 levels did not correspond to a reduction in OC numbers.  This 
suggests that there may be redundancy in the chemokine system.  Further experiments, 
blocking either the receptors for CCL3 (CCR1 and CCR5) or the chemokines CCL4 and CCL5 
(which signal through the same receptors) (315), would be required to prove this.  If there 
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is redundancy then blocking either the receptors or the chemokines should result in a 
reduction in OC numbers. 
The reduction observed in CCL2 and CCL3 levels, following addition of TL1A to DR3wt 
cultures, provides a possible mechanism for the reduction in OC differentiation observed.  
Studies in CCL2-deficient mice, which have been shown to have inhibited OC formation 
(84), highlight the importance of this chemokine in the migration and fusion of OC 
precursors.  Additional experiments are required however, to determine which of these 
chemokines has the more dominant role.  CCL2 and CCL3 add-back experiments, to 
restore the DR3wt phenotype, would identify which of the chemokines is responsible for 
the reduction in OC numbers.  The addition of TL1A to DR3wt cultures had no effect on 
CXCL1 levels. While in a human macrophage cell line TL1A induces CXCL8 secretion (240) 
the same is not true of the murine ortholog. 
Analysis of soluble mediators identified CCL2 and CCL3 as targets of TL1A signalling.  The 
mechanism through which DR3 affects osteoclast resorptive function was then 
investigated.  Two enzymes involved in the degradation of bone by osteoclasts are the 
gelatinase MMP-9 (106) and the proteinase Cathepsin K (104), though some debate exists 
about the exact role of MMP-9 in osteoclast function.  Evidence for a role of MMP-9 in 
bone resorption has been shown by a number of groups (106, 118, 119), though work by 
Chen et al (120) has shown that it is not rate limiting, as the resorptive activity of OC in 
MMP-9 null mice compares to that of wild type mice (121).  Emerging evidence also 
suggests an alternative role for MMP-9, in osteoclast migration.  Evidence that MMPs 
have a role in osteoclastic invasion was provided by Sato et al (123) who showed that OCs 
are able to migrate through collagen in the absence of other cells and that inhibitors of 
these MMPs inhibited osteoclast migration.  Comparison of DR3wt and DR3ko OC cultures 
showed a significant increase in the inactive form of MMP-9 (pro MMP-9) in the DR3ko 
cultures by ELISA, suggesting that DR3 possibly inhibits MMP-9 release. To determine the 
source of the MMP-9 the OC precursor’s cultures were tested.  Levels of MMP-9 were 
found to be greatly reduced in both the DR3wt and DR3ko cultures ± TL1A.  The result 
shows that while the OC precursors express background levels of MMP-9, the majority of 
the enzyme is produced by cells that have been activated by RANKL and are 
differentiating / differentiated into osteoclasts.   A limiting factor of the ELISA used for the 
analysis however, is that it did not measure the active form of the enzyme, which is the 
component involved in the degradation of bone.  This means that such data was unable to 
differentiate between DR3ko cultures producing more inactive MMP-9 or whether DR3wt 
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and DR3ko cultures produce the same level but the DR3wt cultures convert more to the 
active form.  To measure the active form of MMP-9 a gelatine zymogram was employed.  
The zymogram showed equal levels of pro MMP-9 between the two cultures, but levels of 
the active form were raised in the DR3wt cultures at day 10, suggesting that DR3 has a role 
in MMP-9 activation. 
Activation of MMP-9 is a stepwise process requiring the activation and activity of a 
number of other MMPs.  Studies by Toth et al (316) demonstrated that the activation of 
pro MMP-9 can be accomplished via a cascade of zymogen activation initiated by MT1-
MMP and mediated by MMP-2.  Activation of pro MMP-9 through an interacting protease 
cascade involving plasmin and MMP-3 has also been demonstrated in vitro and in human 
tumour cells (317).  In the study by Dreier et al (318) addition of plasmin, a partial 
activator of pro MMP-1 and pro MMP-3 was found to enhance the activation of pro MMP-
9.  Blockade of MMP-3 activity through an inhibitor was also observed to dose-
dependently prevent activation of pro MMP-9 (318).  The MMPs -7 (319), -13 (320) and -
26 (321) were also shown to activate pro MMP-9, albeit with different efficiencies.  A 
schematic representation of the mechanism involved in the activation of osteoclast pro 
MMP-9 is shown in Fig 3.22.  How DR3 influences the activation of MMP-9 is however, 
currently unknown.  The observed difference in levels of active MMP-9 between the DR3wt 
and DR3ko cultures would not fully account for the very significant difference observed in 
osteoclast resorptive function, therefore DR3 must have an effect on another aspect of 
osteoclast resorptive function. 
The main proteinase involved in osteoclastic resorption is Cathepsin K (104).  Commercial 
methods for the quantitative measurement of murine CatK levels in culture were not 
readily available and so methods were developed in-house.  Development of the collagen 
bio-assay initially showed some success when using a CatK control.  Reduction in collagen 
binding was detected compared to the blank suggesting that enzyme activity could be 
measured.  However, when samples were used, levels of binding increased >500%.  
Further analysis showed that this was due to the foetal calf serum present in the culture 
supernatant which was cross-reacting within the assay, rendering it unsuitable for the 
detection of CatK in supernatant.  Work on detecting CatK by zymogram was adapted 
from a method by Li et al (281), who developed a technique for the detection of 
fentomole quantities of mature CatK from osteoclasts.  Optimisation of the method 
produced promising results with a CatK standard being detected down to levels of 
7.36pg/ml, when the gel was incubated at pH 4.  Problems arose however, in sample 
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testing.  CatK is tightly controlled by the osteoclast and so is only released in to the 
resorption pit (322, 323) after the actin ring has formed the sealed zone.  To free the CatK 
into the culture supernatant the cells would require lysis.  Correspondence with Li also 
confirmed that, for their method to work successfully the culture medium must be serum 
free and the cells lysed to free the CatK, thus further work into the optimisation of the 
CatK zymogram was halted.   
Another component of osteoclast resorptive function is the rearrangement of the 
intracellular actin to form the actin ring, enabling the cell to create a tight seal with the 
bone surface.  An immunocytochemistry technique was developed for the staining of the 
actin and nuclei of multinucleated osteoclasts and their precursors, to determine whether 
DR3ko cells are able to successfully form a sealed zone (Appendix I).  The method was 
optimised successfully in DR3wt cultures, with the actin and nuclei being readily visualised 
under a fluorescent microscope.  Further work is required however, to determine whether 
DR3 has an effect on actin ring formation. 
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For the first time functional data has been shown highlighting how DR3/TL1A signalling 
affects OC formation and function; with DR3 involved in OC function and the addition of 
exogenous TL1A reducing OC formation.  However, the overall results were in contrast to 
that published by Bull, Williams et al (242), who showed that the addition of TL1A to 
murine BMM directly promotes osteoclastogenesis.  Comparison between the work 
performed in this study and the work by Bull, Williams et al highlighted the main 
difference in experimental procedure to be the strain of mouse used; DBA/1 versus 
C57BL/6.  The exact difference between the DBA/1 and C57BL/6 mouse strains that would 
cause the observed differences are unknown.  Work by Akhter et al (324) demonstrated 
breed related differences in bone histomorphometry between C57BL/6 and DBA/1 mice, 
with higher bone mineral content in the C57BL/6 mice, and a higher % osteoclast surface 
area at the distal femur in the DBA/1 mice.  This data suggests that there is a difference 
between the strains in the bone cells and also the factors that control them.  Variations in 
fracture healing (325), bone density (326), MSC growth kinetics, MSC differentiation 
potential and MSC surface epitope expression (134, 327) have also been reported 
between inbred strains.  Studies into expression levels of the TNFSF between mouse 
strains have not been carried out.  A study by Linkhart et al (328) however, comparing 
osteoclast formation between C57BL/6 and C3H/HeJ mice suggests that genes affecting 
the bone marrow osteoclast precursor population may contribute to the relative 
differences in bone density and OC formation.  Whether there is a difference in baseline 
TL1A expression between the DBA/1 and C57BL/6 mice is also currently unknown, as 
reagents for the detection of the cytokine were unavailable at the time of the study.  To 
determine whether the difference in the effect of TL1A was due to operator or mouse 
strain, osteoclast assays were performed using a C57BL/6 mouse under the same 
conditions as the DBA/1 work.  As with the DBA/1 study DR3 was shown to have no effect 
on osteoclastogenesis.  Addition of TL1A to the DR3wt cultures however, led to a trend 
towards an increase in osteoclast numbers/mm2 confirming what was reported by Bull, 
Williams et al (242).  Supernatant analysis highlighted that CCL3 levels were also 3-fold 
higher in DR3wt cultures following the addition of TL1A, demonstrating that CCL3 is still a 
target of TL1A signalling even though the effect on expression is different.  These results 
confirm that the observed differences between the DBA/1 and C57BL/6 cultures are due 
to some intrinsic difference between the strains. 
Further analysis into the mechanism of DR3 and TL1A signalling in murine osteoclasts, was 
terminated at this point.  The differing results between the DBA/1 and C57BL/6 strains 
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highlighted that while murine studies provide a valuable system for the study of cellular 
activity and disease they may not reflect the human system.  While some cell types and / 
or diseases can only be investigated in a murine model the isolation and culture of human 
osteoclasts is possible.  In the human system OC precursors can be found circulating in the 
peripheral blood and are easily obtained, allowing the study of human OC directly.  For 
these reasons the human model was used for further study into the mechanism of 
DR3/TL1A signalling on osteoclasts and their precursors.  
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3.4 Conclusion 
At the conclusion of this chapter the following objectives have been met: 
 The cellular phenotype of bone marrow isolated from DBA/1 DR3wt and DR3ko 
mice was charaterised. 
 In vitro osteoclast cultures from BMCs isolated from DBA/1 DR3wt and DR3ko mice 
were developed on glass coverslips and ivory discs 
 The impact of DR3 on OC formation and resorptive function, in vitro, was 
assessed. 
 TL1A’s effect on OC formation and resorptive function, in vitro, was determined. 
The results have shown that while DR3 is not involved in the homeostasis of bone 
marrow, or osteoclast differentiation it plays a role in osteoclast resorptive function.  
DR3ko osteoclasts have been shown to have reduced resorptive activity in 
osteoclastogenesis assays and while the mechanism for this is not conclusive, the data 
suggests that DR3 has a role in the activation of the bone resorbing enzyme MMP-9.  
Further work is required however, to determine what effect DR3 may have on actin ring 
formation and Cathepsin K expression.  DR3’s only confirmed TNFSF ligand TL1A has been 
shown to play a key role in osteoclast differentiation; though its effects are dependent on 
the mouse strain used.  In the DBA/1 model addition of TL1A significantly reduced 
osteoclast formation while in the C57BL/6 it had the opposite effect.  The reasons for the 
difference in cellular response to TL1A are unknown but could be due to an intrinsic 
genetic variation between the two strains.  TL1A has been shown to act mechanistically 
through either decreasing (DBA/1) or increasing (C57BL/6) levels of the chemokine CCL3.  
In the DBA/1 model TL1A has also been shown to exert an effect on CCL2, reducing the 
levels expressed in OC cultures, providing another possible mechanism of action.  While 
the murine model of osteoclastogenesis has provided insight into the mechanism of DR3 
and TL1A signalling the difference in DBA/1 and C57BL/6 response highlights the 
shortcomings.  Whether either of these two responses to TL1A is comparable to the 
human system is unknown and will be investigated in chapter 4. 
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Chapter 4 
 
Investigating the Regulation of Osteoclast 
Differentiation and Function by TL1A in 
Human Cells.  
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4.1 Introduction 
The study into the effect of DR3 and TL1A on murine osteoclast differentiation and 
resorptive function in chapter 3 provided valuable insight into the mechanisms through 
which they act.  The results demonstrated DR3 has an important role in osteoclast 
resorptive function; however the difference in response to TL1A between the two murine 
strains (DBA/1 and C57BL/6) highlighted the shortcomings in using mouse models.  To 
gain a better understanding of the effects of TL1A on OC and their precursors, the system 
was transferred into a human model. 
A number of studies have been carried out looking at the effect of TL1A on monocytes 
and macrophages, though the effect on OC is less understood.   In vitro, TL1A has been 
shown to be involved in the activation and differentiation of monocytes / macrophages.  
Work by Kim et al (239) in 2001, using the human monocytic cell line THP-1, 
demonstrated that cross linking of DR3 resulted in the induction of MMP-9.  This was 
further supported by Kang et al (278) who in 2005 showed that treatment of THP-1 cells 
with recombinant human TL1A dose-dependently induced MMP-9 expression.  Co-
stimulation of the THP-1 cells with IFN-γ was also observed to induce the expression of 
CXCL8 (Interleukin-8 (IL-8)), but failed to induce TNF or CCL2.  In 2006 Su et al (240) 
investigated the effect of TL1A on CXCL8 expression from primary monocytes and 
macrophages.  TL1A had no effect on CXCL8 secretion from monocytes though it was 
observed to stimulate CXCL8 expression by macrophages.  A role for TL1A in macrophage 
differentiation was put forward by McLaren et al (270).  In their study they demonstrated 
that TL1A signalling through DR3 promoted the differentiation of macrophages into foam 
cells through an increase in the uptake of acetylated low-density lipoprotein (LDL) and 
oxidized LDL.  While the effect of TL1A on monocytes and macrophages has been 
investigated there are currently no papers that extensively look at the effect of TL1A on 
OC differentiation and function in a human system.  In the Bull, Williams et al (242) study 
DR3-deficient mice were shown to be protected from bone erosions associated with AIA.  
In vitro, TL1A was shown to enhance osteoclastogenesis from bone marrow macrophages 
(BMM) in a DR3-dependent manner.  When they looked in a human system TL1A 
significantly promoted osteoclastogenesis in PBMC cultures.  However, the cell type that 
the TL1A was acting upon and the mechanism through which it was exerting its effect was 
not investigated.  This raises the question as to whether TL1A is acting upon monocytes / 
macrophages (OC precursors) directly or indirectly via T-cells, which express DR3 (230, 
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248) and affect OC differentiation (58).  To address this question the starting population 
of an OC assay would have to be comprised of just monocytes / macrophages, eliminating 
the effect of other cell types. 
In vivo OC are derived from haematopoietic precursors; the most abundant source of 
these cells is the bone marrow.  While it is acceptable to use BMM as a source of 
precursor cells in a murine model, ethical and practical difficulties mean that this is not a 
suitable method for an in vitro human system.  Haematopoietic precursors are present in 
peripheral blood as mononuclear cells, which serve as a readily accessible alternative 
source of OC precursors (12, 35, 36).  Until 15 years ago the subset of these cells that act 
as OC precursors was not entirely clear.  Initial work on identifying the subset was 
performed by Quinn et al (37) who showed that adherent PBMCs that differentiated into 
OC expressed macrophage associated antigens CD68, CD11b and CD14.  This suggested 
that osteoclasts can be derived from CD14-positive (CD14+) monocytes.  Further work by 
Massey and Flanagan (38) confirmed this by showing that selection of CD14+ cells from 
PBMCs enhanced osteoclastic bone resorption, providing an easy source for the study of 
human OC.  For this study, CD14+ cells were isolated from female volunteers, as females 
are at an increased risk of OC related disease such as osteoporosis and rheumatoid 
arthritis (189-191, 329).  
The aims of this chapter were to optimise culture of osteoclasts from human CD14+ cells 
isolated from PBMCs and determine the effect of TL1A on osteoclast formation and 
function.   Supernantants were collected across the culture period and analysed for 
specifc mediators that have a role in osteoclast differentiation and function. The data was 
used to determine the mechanism through which DR3/TL1A regulates osteoclastogenesis 
in humans.  The specific objectives of this chapter are listed below: 
 To define the purity of CD14+ cells isolated from human PBMCs. 
 To determine whether human osteoclast precursors cells express DR3. 
 To develop a reproducible in vitro culture system for the generation of osteoclasts 
from human CD14+ cells using ivory discs as the supporting matrix . 
 To measure the effect and identify the mechanism through which TL1A modulates 
osteoclast differentiation and function.  
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4.2 Results 
4.2.1 Defining Base-line Purity and Expression of CD14 and DR3 on Freshly Isolated 
CD14+ Cells  
Osteoclast precursors used in all osteoclastogenesis assays reported in this chapter were 
isolated from PBMCs using density gradient centrifugation and magnetic isolation (section 
2.2.7). Blood was obtained from pre-menopausal females and precursor cells were 
identified on the basis of positive expression of CD14, as determined by flow cytometry 
(section 2.2.8).   PBMC numbers obtained from 50ml of blood ranged from 1.74x107 to 
1.00x108.  Isolation, based on expression of CD14, resulted in the positive selection of 
approximately 10% of the starting cell number (1.08x106 to 8.25x106).  Initially using this 
method only 30% of the cells recovered were deemed to be CD14+ by flow cytometry (Fig 
4.1 (a, i)); this value was too low to perform the OC assays.  Over subsequent assays the % 
CD14+ cells isolated increased to > 90% (Fig 4.1 (a, ii)).  All assays in this chapter had a 
purity of >90% CD14+ monocytes. 
The morphology of the CD14+ cells was studied by differential staining (section 2.2.5).  
Cells were identified by their size, granularity and nucleus size and shape.  Cells in the 
CD14+ isolate were found to be between 10 - 20µm in diameter and predominantly had a 
kidney-shaped nucleus, which occupied approximately half of the cell (Fig 4.1 (b)).  The 
cytoplasm contained variable numbers of granules.  The morphology of the CD14+ cells, 
therefore, corresponded to that of monocytes (330). 
DR3 expression on the CD14+ cells was tested by flow cytometry and expression reported 
as a histogram for graphical presentation.  No shift in signal was detected between the 
isotype control and the anti-DR3 antibody on the isolated CD14+ cells (Fig 4.1 (c)) 
demonstrating that freshly isolated CD14+ cells did not express DR3. 
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4.2.2 Assessing the Impact of Substrate on DR3 Expression 
The environment in which cells are grown can determine whether they express DR3.  Su 
et al (240) and Kang et al (278) showed that CD14+ cells expressed DR3; however, the 
expression was linked to activation of the cells by the pro-inflammatory cytokine TNF, 
bacterial LPS (278) or differentiation in RPMI medium for 6 – 7 days (240, 270, 278).  OC 
can be grown on a variety of substratum; glass, plastic or bone (ivory).  Initial experiments 
were performed to look at whether these substrates effect DR3 expression.  CD14+ cells 
were isolated (day -7) and grown for 7 days in culture medium supplemented with MCSF 
(section 2.2.9 and Fig 2.6).   DR3 expression was gauged by flow cytometry and reported 
as fold-change in median fluorescent intensity (MFI) compared to the isotype control (day 
0; section 2.2.10).  No DR3 expression was detected on CD14+ cells cultured on a glass 
substrate for 7 days (Fig 4.2 (a)), demonstrating that glass is not suitable for the induction 
of DR3.  Culture of CD14+ cells on plastic (Fig 4.2 (b)) and ivory (Fig 4.2 (c)) resulted in a 
marked up-regulation of DR3 expression (6.7-fold increase and 1.4-fold increase).  The 
data shows that DR3 expression can be induced on CD14+ cells when cultured in MCSF for 
7 days on a plastic or ivory substrate. 
 
4.2.3 Maintenance of DR3 Expression over Time Course of Osteoclast Assay 
Osteoclast assays in this chapter were comprised of mixed cell populations; monocytes, 
macrophages, pre-OC and mature OC.  It is currently unknown whether the addition of 
RANKL, to induce OC differentiation, affects DR3 expression on CD14+ cells.  CD14+ cells 
were isolated (day -7) and cultured in MCSF for 7 days (n=1) on ivory discs.  DR3 
expression was confirmed (Fig 4.3 (a)) and RANKL added to cultures (day 0).  DR3 
expression was tested in the cultures on day 3, 7, 10 and 14 by flow cytometry (section 
2.2.8) and MFI reported relative to the isotype control.  DR3 was detected in cultures on 
day 3 with a 3.7-fold increase in fluorescence (Fig 4.3 (b)), day 7 (2.1-fold increase; Fig 4.3 
(c)), day 10 (2.3-fold increase; Fig 4.3 (d)) and day 14 (2.8-fold increase; Fig 4.3 (e)).  While 
levels of DR3 expression were variable due to only one rep being performed the data 
demonstrates that RANKL does not affect DR3 expression, and that TL1A can have a 
sustained effect on OC differentiation across the time course. 
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4.2.4 Assessing the Impact of TL1A upon Osteoclast Differentiation in Plastic Tissue 
Culture Plates 
Flow cytometry of CD14+ cells demonstrated induction of DR3 expression after culture in 
MCSF on a plastic substrate.   To determine what effect this would have on OC formation 
TL1A was added to OC cultures, as described in section 2.2.10.1 (Fig 4.4).  The total 
number of cells (TRAP+ and TRAP-) per well were counted and expressed as cells/mm2 
(mean±SEM) for graphical presentation (Fig 4.5 (a)).  There was no significant difference in 
the total number of cells counted in the presence or absence of TL1A at day 1 (-TL1A = 
498±54/mm2 versus +TL1A 540±70/mm2).  Total cell number did not vary significantly 
across the time course.  Differential cell counts were also performed on TRAP+ cells. TRAP+ 
cells were classified as mononuclear or multinucleated osteoclasts and were reported as 
TRAP+/mm2 (mean±SEM).  The number of TRAP+ cells increased from day 1 (-
TL1A=1.9±0.3/mm2 versus +TL1A=2.4±0.4/mm2) to day 5 (-TL1A=13.9±1.8/mm2 versus 
+TL1A=17.6±2.2/mm2).  TL1A significantly increased the number of TRAP+ mononuclear 
cells (P=<0.01; Fig 4.5 (b)) present across the time course of the experiment though no 
significant differences were detected at individual time points.  As with TRAP+ cells the 
number of OC present in the cultures increased across the differentiation time course 
(day 1: -TL1A=0.07.5±0.03 versus +TL1A=0.05±0.03 and day 5: -TL1A=10.27.5±1.87 versus 
+TL1A=13.61±2.31).  Addition of TL1A significantly increased osteoclast formation across 
the time course (P=<0.05; Fig 4.5 (c)), though no significant differences were detected at 
individual time points.  These results suggest that TL1A drives OC precursor differentiation 
and fusion into multinucleated OC. 
 
4.2.5 Assessing the Impact of TL1A upon Chemokine Release during 
Osteoclastogenesis in Plastic Tissue Culture Plates 
To determine the mechanism through which TL1A drives OC differentiation, supernatants 
were collected at every media change during the course of the experiments described in 
section 4.2.4. Soluble mediators known to be involved in OC fusion (CXCL8 and CCL2) were 
measured by ELISA.    CXCL8 levels (mean±SEM) on day 0 were measured at 3.1±0.2ng/ml.  
Levels of CXCL8 were found to peak at day 1 following a significant increase (-TL1A = 
11.9±2.2ng/ml; P<0.0001) before dropping significantly to background levels on day 2 (-
TL1A = 1.8±0.1ng/ml; P<0.0001) and staying constant for the remainder of the time 
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course.  CXCL8 levels were not altered by the addition of TL1A at any of the time points 
studied (Fig 4.6 (a)).  Next CCL2 levels (mean±SEM) were measured.  On day 0 CCL2 levels 
of 17.9±2.3ng/ml were detected.  Levels were observed to drop to 11.5±2.4ng/ml on day 
2.  A moderate increase in CCL2 was observed on day 3 (17.1±3.7ng/ml) before dropping 
back down on day 4 (10.7±1.7ng/ml).  CCL2 expression did not vary significantly between 
time points or following addition of TL1A (Fig 4.6 (b)). The results show that in this human 
system, TL1A does not affect osteoclastogenesis by targeting CXCL8 or CCL2.  
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4.2.6 Development of Osteoclast Cultures from CD14+ Cells on Ivory Discs 
Before human OC assays on ivory discs could be performed, optimisation of the method 
was carried out to determine a time point that would provide the optimal balance 
between cells counted and area resorbed.  OC were required to be established and 
functional, but numbers not to have reached a maximum level or plateaued.  Ivory was 
selected as the bone-substrate of choice as it is composed of hydroxyapatite and was 
successfully utilised in the murine OC assays described in chapter 3.  Osteoclasts 
(multinucleated TRAP+ cells that contained >3 nuclei) were successfully cultured from the 
CD14+ cells as described in section 2.2.10.2 and Fig 2.8.  Cells were evenly distributed over 
the entire area of the 6mm diameter ivory disc used in these assays (Fig 4.7 (a i-vi)).  The 
number of OC per mm2 (mean±SEM) for each disc is presented graphically in Fig 4.7 (b).  
OC numbers were first analysed on day 7 of culture.  A significant increase in OC numbers 
was detected between day 7 and 10 (0 versus 22±3; P=<0.01). OC numbers increased 
further between day 10 and 14 (22±3 versus 30±8), reaching a peak at day 18 (50±8) and 
plateauing at day 21 (48±6).  Osteoclast function was measured by quantifying the area of 
disc resorbed (%, mean±SEM; Fig 4.8). At day 7 no resorption pits were identified on any 
of the discs evaluated.  However, a significant increase in the area of the disc resorbed 
was detected by day 10 (7.5±1.3; P=<0.01). This increased further between day 14 and 18 
(9.5±2.4 versus 40.4±4.9; P=<0.01) and between day 18 and 21 (40.4±4.9 versus 69.5±4.4; 
P=<0.01) when substantial surface erosion was detected.  Day 14 was chosen as the time 
point for experiment termination for human OC assays based on the criteria for OC 
numbers.  
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4.2.7 Assessing the Impact of TL1A Dose upon the Development of Osteoclasts on 
Ivory 
In order to assess the impact of TL1A on OC formation and resorptive function, 
subsequent assays were performed on ivory and terminated on day 14.  As only modest 
effects of TL1A were observed at 10ng/ml an additional dose of 100ng/ml was 
investigated (methodology is described in section 2.2.10.2 and Fig 2.9).  OC were detected 
in all cultures containing RANKL at days 7, 10 and 14.  No OC were observed in control 
cultures (MCSF±TL1A; Fig 4.9).  The total number of cells per mm2 (mean±SEM) for each 
disc is presented graphically in Fig 4.10 (a) for control cultures and Fig 4.10 (b) for OC 
cultures.  At day 7 in control cultures, cells expanded in MCSF in the presence or absence 
of TL1A; cell numbers were 0ng/ml TL1A=534±70 versus 10ng/ml TL1A=736±84 versus 
100ng/ml TL1A=537±83.  These did not change significantly over time.  The total number 
of cells at day 7 in OC cultures was 518±33.  This was comparable to the OC cultures with 
10ng/ml TL1A (582±31) and 100ng/ml TL1A (569±26).  Over the remaining time points 
assessed no significant difference within or between groups were detected.  Differential 
counts were performed where TRAP+ OC reported as OC per mm2 (mean±SEM) showed 
TL1A to have a dose-dependent effect (Fig 4.10 (c)).   At day 7 no significant difference 
was detected between the cultures (0ng/ml TL1A=5±1 versus 10ng/ml TL1A=6±1 versus 
100ng/ml TL1A=7±1).  OC numbers were observed to be increased in the 10ng/ml TL1A 
cultures and significantly in the 100ng/ml TL1A cultures at day 10 (0ng/ml TL1A=8±1 
versus 10ng/ml TL1A=10±1 versus 100ng/ml TL1A=9±1, P=<0.05) and day 14 (0ng/ml 
TL1A=7±1 versus 10ng/ml TL1A=11±1 versus 100ng/ml TL1A=12±2, P=<0.05) when 
compared to cultures without TL1A.  This translated into a significant increase in OC 
numbers across the time course in both the 10ng/ml TL1A cultures (P=<0.01) and the 
100ng/ml TL1A cultures (P=<0.0001).  No significant difference in OC number was 
detected between the 10ng/ml and 100ng/ml TL1A cultures. 
 
4.2.8 Assessing the Impact of TL1A Dose upon Osteoclast Resorptive Function 
TL1A has been demonstrated to increase OC formation.  To assess whether TL1A affected 
OC resorptive function the area of the ivory disc resorbed was measured.  Data was 
expressed as the % area resorbed (mean±SEM) for graphical presentation (Fig 4.11).  Low 
levels of resorption were detected at day 7 in all cultures (0ng/ml TL1A=0.4±0.4%, 
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10ng/ml TL1A=0.6±0.2% and 100ng/ml TL1A=0.7±0.2%).  At day 10 levels of resorption 
were observed to increase in the cultures containing TL1A (0ng/ml TL1A=0.9±0.3%, 
10ng/ml TL1A=1.8±0.4% and 100ng/ml TL1A=1.6±0.4%).  At day 14 a dose-dependent 
effect was observed with significantly increased resorption observed in cultures 
containing 10ng/ml and 100ng/ml TL1A, compared to those without (0ng/ml 
TL1A=1.3±0.3%, 10ng/ml TL1A=2.8±0.4% and 100ng/ml TL1A=5.2±1.6%, P=<0.001).  This 
translated into a significant increase in % area resorbed across the time course in both the 
10ng/ml TL1A cultures (P=<0.0001) and the 100ng/ml TL1A cultures (P=<0.01).   
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4.2.9 Assessing the Impact of TL1A Dose upon Chemokine Production  
To explain the increase in OC formation observed in section 4.2.7, levels of the 
chemokines CXCL8, CCL2 and CCL3 were measured in control and OC culture supernatants 
(mean±SEM).    
4.2.9.1 CXCL8 
Stimulation of the macrophage cell line THP-1 with TL1A has been shown by Su et al (240) 
and Kang et al (278) to induce expression of CXCL8.  To determine whether the same 
effect is observed in primary macrophages and OC cultures, levels of CXCL8 were 
measured.  Levels of CXCL8 in control cultures (Fig 4.12 (a, i)) were found to be unaffected 
by the addition of TL1A.  Levels were observed to be highest at day 0 (8.6±1.8ng/ml) 
dropping across the time course to their lowest point at day 10 (0ng/ml 
TL1A=2.3±0.5ng/ml versus 10ng/ml TL1A=1.8±0.3ng/ml versus 100ng/ml 
TL1A=3.0±1.5ng/ml).  Levels of CXCL8 in OC cultures (Fig 4.12 (a, ii)) were highest at day 0 
(9.0±0.8ng/ml) and fell across the time course to day 10 (0ng/ml TL1A=1.6±0.3ng/ml 
versus 10ng/ml TL1A=1.8±0.3ng/ml versus 100ng/ml TL1A=1.9±0.6ng/ml).  No significant 
differences were detected in CXCL8 levels between the OC cultures. 
 4.2.9.2 CCL2 
Analysis of murine OC culture supernatants in chapter 3 demonstrated that TL1A acts 
upon CCL2 expression, significantly reducing levels across the time course.  In contrast to 
this result work by Su et al (240) and Kang et al (278) showed that stimulation of THP-1 
cells with TL1A had no effect on CCL2 levels.  TL1A was found to have no effect on CCL2 
levels in control cultures (Fig 4.12 (b, i)) across the time course.  Addition of TL1A had no 
effect on CCL2 expression in OC cultures (Fig 4.12 (b, ii)) with levels peaking at day 7 
(0ng/ml TL1A=25.7±3.7ng/ml versus 10ng/ml TL1A=28.8±4.0ng/ml versus 100ng/ml 
TL1A=26.6±5.0ng/ml) before dropping at day 10 (0ng/ml TL1A=13.5±3.2ng/ml versus 
10ng/ml TL1A=16.1±2.8ng/ml versus 100ng/ml TL1A=16.9±4.3ng/ml). 
4.2.9.3 CCL3 
Murine OC assay supernatant analysis in chapter 3 showed for the first time that CCL3 
expression is affected by TL1A; inducing expression in the C57BL/6 model and reducing 
expression in the DBA/1 model.  Levels of CCL3 in control cultures (Fig 4.12 (c, i)) showed 
no significant difference within or between groups across the time course.  Levels of CCL3 
in OC cultures (Fig 4.12 (c, ii)) were observed to increase across the time course, with TL1A 
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having a dose-dependent effect.  Levels of CCL3 at day 0 were measured at 
48.2±4.6pg/ml.  Levels increased on day 7 (0ng/ml TL1A=70.9±20.1pg/ml versus 10ng/ml 
TL1A=73.2±16.2pg/ml versus 100ng/ml TL1A=147.6±37.0pg/ml) and day 10 (0ng/ml 
TL1A=78.0±21.7pg/ml versus 10ng/ml TL1A=101.1±28.8pg/ml versus 100ng/ml 
TL1A=156.0±56.0pg/ml).  At day 14 levels of CCL3 in the 0ng/ml TL1A (79.5±22.4pg/ml) 
and 10ng/ml TL1A (118.0±35.9pg/ml) cultures continued to increase.  A slight decrease 
was observed in the 100ng/ml TL1A cultures (137.4±20.6pg/ml).  CCL3 levels in the 
100ng/ml TL1A cultures were found to be significantly increased (P=<0.001) across the 
time course when compared to cultures without TL1A. 
 4.2.9.4 Correlation of Chemokines with OC Numbers and Resorptive Function 
To determine whether OC numbers (Fig 4.13) or % area resorbed (Fig 4.14) are related to 
the chemokine levels found in the OC culture supernatants Spearman correlation analysis 
was performed.   A significant and positive correlation between CCL3 and OC numbers on 
day 7 (r=0.53, P=<0.01), day 10 (r=0.51, P=<0.01) and day 14 (r=0.46, P=<0.05) was 
detected.    No correlation was detected between CXCL8 or CCL2 and OC numbers at any 
of the time points tested.  Analysis of % area resorbed and chemokine levels also 
demonstrated a significant and positive correlation with CCL3 on day 7 (r=0.42, P=<0.05), 
day 10 (r=0.52, P=<0.01) and day 14 (r=0.67, P=<0.001).  No correlation was observed 
between % area resorbed and CXCL8 and CCL2.  The results suggest that CCL3 is driving 
the increased OC formation and resorptive function observed in the OC cultures 
containing TL1A. 
 
4.2.10 Production of Pro-Inflammatory Cytokines TNF and TL1A by Osteoclast Cultures 
Upon activation, OC precursors (macrophages) can endogenously produce the pro-
inflammatory cytokines TNF (173), a driver of OC formation and function, and TL1A (254).  
To ensure that the increase in OC formation and resorptive function observed in sections 
4.2.7 and 4.2.8 could be attributed to the exogenous TL1A and not due to TL1A inducing 
TNF expression (278), levels of the cytokines were measured in supernatant by ELISA.  
Induction of TNF by TL1A was not demonstrated in any of the cultures tested.  
Endogenous TL1A was only tested in the MCSF+RANKL cultures.  No endogenous TL1A 
was detected.  This result confirms that the observed effects of TL1A are independent of 
TNF and endogenous TL1A.   
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4.2.11 Assessing the Impact of TL1A Dose upon Total MMP-9 Expression 
To explain the increase in OC function levels of total MMP-9 were measured in OC culture 
supernatants by ELISA (mean±SEM, section 2.2.14.4.1).  Levels of total MMP-9 (Fig 4.15 
(a)) increased from day 0 (3.9±0.4µg/ml) to day 7 (0ng/ml TL1A=4.9±0.7µg/ml versus 
10ng/ml TL1A=6.2±0.9µg/ml versus 100ng/ml TL1A=6.0±0.5µg/ml).  A decrease was 
detected in all cultures at day 10 (0ng/ml TL1A=3.2±0.5µg/ml versus 10ng/ml 
TL1A=3.5±0.4µg/ml versus 100ng/ml TL1A=5.2±0.8µg/ml) followed by an increase in 
expression at day 14 (0ng/ml TL1A=4.8±1.1µg/ml versus 10ng/ml TL1A=5.2±0.5µg/ml 
versus 100ng/ml TL1A=7.5±1.0µg/ml).  TL1A was observed to have a dose-dependent 
effect on total MMP-9 levels.  A significant increase in total MMP-9 expression, across the 
time course, was detected in the 100ng/ml TL1A cultures compared to the 10ng/ml TL1A 
cultures (P=<0.05) and the cultures without TL1A (P=<0.001). 
Comparison of total MMP-9 levels at day 14 with % area resorbed showed a significant 
correlation (Spearman r = 0.5, P=<0.01; Fig 4.15 (b)), inferring that TL1A is driving total 
MMP-9 expression and thus OC function. 
 
4.2.12 Levels of Pro and Active MMP-9 in OC Cultures 
While TL1A was shown to increase levels of total MMP-9, the ELISA used was unable to 
distinguish between the pro and active forms.  To determine whether addition of TL1A 
increased levels of active MMP-9, a gelatine zymogram (section 2.2.14.4.1) was used to 
semi-quantitatively measure the levels of both pro and active MMP-9 in OC culture 
supernatants ±TL1A 100ng/ml (Fig 4.16).  Levels of pro MMP-9 (Fig 4.17 (a)) detected at 
day 0 in cultures with and without TL1A were measured as 0.7±0.2ng/ml.  These did not 
vary greatly over time with the exception of day 3; levels of pro MMP-9 in cultures 
without TL1A were observed to increase (1.2±0.4ng/ml) while levels of pro MMP-9 in the 
100ng/ml TL1A cultures decreased (0.5±0.1ng/ml).  A significant increase in active MMP-9 
was detected across the time course in the cultures containing 100ng/ml TL1A (P=<0.01; 
Fig 4.17 (b)).  This significant increase in active MMP-9 across the time course was due to 
levels being detected in the 100ng/ml TL1A cultures from day 3 onwards (0ng/ml 
TL1A=0.0±0.0ng/ml versus 100ng/ml TL1A=0.07±0.06ng/ml), compared to day 7 in 
cultures without TL1A (0ng/ml TL1A=0.05±0.02ng/ml versus 100ng/ml 
TL1A=0.07±0.03ng/ml).  From day 7 onwards levels of active MMP-9 did not differ 
significantly.  
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4.3  Discussion 
Comparison of DR3wt and DR3ko OC, and the effects of TL1A on OC differentiation and 
function in chapter 3 illustrated the possible roles that this receptor and ligand play in OC 
biology.  Use of a murine model demonstrated that DR3 has an important role in OC 
resorptive function as very little resorption was observed in DR3ko cultures.  Problems 
with the murine model however, were discovered when investigating the effect of TL1A.  
Using two different strains of mouse TL1A was found to produce opposing effects on OC 
differentiation; in a DBA/1 model TL1A reduced OC numbers while in a C57BL/6 model 
TL1A enhanced OC numbers.  These differences led to the question: which, if either, was 
representative of what would happen in a human system.  The study of TL1A and OC 
biology in a human system also provides a number of additional advantages over the 
murine model.  A limiting factor in the murine system was the lack of specific reagents; 
e.g. antibodies for the detection of TL1A, specific monoclonal antibodies for the detection 
of DR3 and non-destructive methods for the detection of Cathepsin K, all of which are 
available for a human system.  Current work into the effect of TL1A on human OC is very 
limited.  Bull, Williams et al (242) are the only group who have investigated the effects of 
exogenous TL1A on OC differentiation in vitro.  Their study showed that exogenous TL1A 
added to PBMC cultures significantly enhanced OC formation.  Analysis of these results 
requires care, as there were limitations affecting the study.  Firstly, only two repetitions of 
the experiment were carried out and so natural variation in response to TL1A between 
donors may have been missed.  Secondly, osteoclastogenesis assays were carried out 
using PBMCs rather than isolated monocytes / macrophages.  For this reason it is not clear 
whether the TL1A was acting upon the OC precursors directly or indirectly via T-cells.  
Thirdly, the mechanism through which DR3/TL1A signalling enhanced OC formation was 
not investigated.  The aim of this chapter was to investigate whether, in a human system, 
TL1A could act directly upon OC precursors, what effect TL1A would have upon OC 
differentiation and function and the mechanisms involved. 
The most abundant source of OC precursors can be found in the bone marrow however, 
ethical and practical difficulties mean that this is not a suitable source for a human 
system.  Work by Fujikawa et al (331) demonstrated that in vitro TRAP+ OC could be 
differentiated from circulating human monocytes  (CD14+, CD11b+ and HLA-DR+), though 
the exact subset was not clear.  Human peripheral blood consists of two major subsets of 
monocyte, CD16+ (CX3CR1hiCD14loCD16hiCD11b+CD11c+CCR2-CD62L-) and CD16- 
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(CX3CR1loCD14hiCD16-CD11bhiCCR2+CD62L+), comprising 5-10% and 90-95% of the 
monocytes respectively (32, 332).  Comparison of the CD16- and the CD16+ monocyte 
subsets by Komano et al (39) found that only the CD16- subset differentiated into OC 
while the CD16+ subset responded to RANKL by increasing expression of TNF and IL-6.  The 
data shows that the CD16- subset of peripheral blood monocytes can be used as a source 
of OC precursors, though to be isolated from the CD16+ monocytes a positive marker has 
to be chosen.  Isolation of monocytes by the marker CD14, which has high expression on 
CD16- monocytes, has been shown to enhance osteoclastic bone resorption 2-4 fold 
compared to un-fractionated PBMCs (38).  This demonstrates that CD14 can be used as a 
marker to isolate the subset of monocytes in the peripheral blood that are OC precursors.   
An alternative to primary cells for the study of OC differentiation and function is the use 
of cell lines.  Cell lines provide an almost unlimited supply of cells with similar genotypes 
and phenotypes.  Their use avoids variation between individuals and bypasses ethical 
issues associated with human assays (333).  A number of cell lines have been utilised for 
studying OC differentiation; these include the human pre-osteoclast cell line FLG 29.1 
(334, 335), the monoblastic cell line UG3 (336, 337) and the monocyte cell line THP-1 
(338, 339).  Care must be taken when using cell lines however, as there are a number of 
limitations.  As the cells have undergone a mutation to become immortal they may retain 
very little of the original in vivo characteristics of the cell that they are meant to 
represent, meaning that they have low biological relevance to the organism being studied.  
Low levels of variation between experiments, due to the homogeneity of the cells, also 
means that the data is not representative of the general population and could not be 
extrapolated out.  For these reasons investigation into the effect of TL1A on human OC 
differentiation and function used primary cells (CD14+ monocytes).  This enabled levels of 
variation between individuals to be established and ensured that the results were as 
relevant to what occurs in vivo as possible 
For the analysis of the effect of TL1A on human osteoclast differentiation and function a 
purified CD14+ population was chosen over a PBMC population.  Use of a purified CD14+ 
population allowed for the specific analysis into the effects of TL1A on OC precursors and 
determination of the mechanisms involved; eliminating any possible indirect effects of 
TL1A on osteoclastogenesis through T cells (58, 230, 248) and other PBMCs.  Flow 
cytometry, a powerful and accurate method for the analysis of cell types via the 
expression of cell surface markers, was used to determine the purity of the CD14+ cells 
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isolated from the PBMCs.  Initial attempts at isolation of CD14+ cells from PBMCs 
generated a population that was only 30% pure, with the remaining 70% being composed 
of other PBMCs.  Following improvement of the method the purity of the CD14+ 
population was increased to >90%, consistent with the purity obtained by other groups 
using the same method (340, 341).    Following culture in MCSF for 7 days the CD14+ purity 
of the cell population was observed to slightly increase, though a small percentage of 
CD14- cells (less than 10%) were still present in the cultures.  Histological analysis of the 
CD14+ isolated cells showed that they had a monocytic morphology; 10 - 20µm in 
diameter with a kidney shaped nucleus (330).  These results demonstrate that a highly 
pure mono-cellular population of monocytes can be obtained through positive selection 
of the marker CD14.  The expression of DR3 on these cells was then investigated. 
Expression of DR3 on primary human monocytes / macrophages and the macrophage cell 
line THP-1 has been shown by  Su et al (240),  Kang et al (278) and McLaren et al (270).  
However, the expression on primary human monocytes / macrophages was linked to 
activation of the cells by the pro-inflammatory cytokine TNF, bacterial LPS (278) or 
differentiation in RPMI medium for 6 – 7 days (240, 270, 278).  To analyse the effect of 
TL1A on OC differentiation and function confirmation of DR3 expression on the CD14+ 
cells isolated from the PBMCs was required.  Flow cytometry upon CD14+ cells obtained 
from the PBMC fraction revealed no DR3 expression. This data supports the observation 
made by Kang et al (278) that DR3 was not constitutively expressed on circulating 
monocytes. Whether expansion of monocytes in MCSF is sufficient to stimulate DR3 
expression in CD14+ cells has not been previously determined.  CD14+ cells were therefore 
cultured for a 7 day period in MCSF and 3 support matrices were tested (glass, plastic and 
ivory).  Expression of membrane bound DR3 was detected (by flow cytometry) on day 7 on 
cells cultured on both plastic and ivory; though which splice variant of DR3 the JD3 
antibody detects is unknown.  DR3 was not detected on cells cultured on glass.  Time 
points after day 7 were not investigated, so it cannot be ascertained as to whether there 
is a delay in DR3 expression on cells grown on glass or if they will never express DR3.  The 
lack of DR3 expression on cells cultured on glass provides an explanation for the glass 
assay results in chapter 3, where no difference was observed between the DR3wt and 
DR3ko cultures following addition of TL1A.  The failure of cells cultured on glass to induce 
DR3 expression meant that the DR3wt cells are effectively the same as the cells in the 
DR3ko cultures.  TL1A is therefore unable to act upon the cells and have any effect on OC 
formation.   The reasons for the differential substrate-dependent expression of DR3 are 
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not entirely clear.  Saltel et al (309) demonstrated that osteoclasts grown on a glass 
substrate spread more than OC grown on an apatite substrate (mean surface area of 
approx. 14000µm2 versus 3000µm2). The podosome belt formed during the process of OC 
spreading enabled them to adhere to the glass surface however, the OC were unable to 
form a sealing zone.  An explanation for the lack of sealing zone is provided by work by 
Nakamura et al (342) who suggests that actin ring formation is substrate-dependent.   
These data suggest that monocytes / macrophages will express DR3 when grown in MCSF 
and supported by an appropriate matrix. This may be particularly important when 
macrophages / monocytes are recruited to sites of bone resorption, informing them of 
their departure from the peripheral circulation and arrival at the bone surface.  Having 
confirmed CD14+ cells express membrane bound DR3 following culture in MCSF on a 
suitable substrate, the effect of TL1A on differentiation was investigated.  
Initial work into the effect of TL1A on OC differentiation was performed using a plastic 
substrate.  High levels of DR3 expression were observed on CD14+ cells cultured on this 
substrate, so if TL1A was to have an effect then a difference should be observed between 
cultures.  Studies generating OC from CD14+ cells on plastic and ivory (or similar 
substrates such as dentine and bone) have used widely ranging levels of the recombinant 
cytokines MCSF and RANKL.  Concentrations of RANKL used ranged from 3ng/ml to 
100ng/ml (37, 343-348); as with the mouse recombinant cytokines this was dependent on 
the source of the cytokine and the levels required to induce OC differentiation.  Levels of 
MCSF, required for cell proliferation and RANKL-induced osteoclastogenesis, ranged from 
10ng/ml to 50ng/ml (37, 343-348).  Again this was dependent on the supplier of the 
cytokine and ensuring that it was not a limiting factor in the experiment.  In this study the 
concentrations of MCSF and RANKL used (5ng/ml and 5ng/ml) were taken from the 
supplier ED50 (effective dose at which the protein exhibits 50% of its maximum effect) and 
work previously carried out in the laboratory.  No difference was observed in total cell 
number between cultures with and without TL1A across the time course.  This would 
suggest that in this system, TL1A is not involved in the expansion of cells.  However, as the 
experiment was only taken to 5 days, it cannot be ascertained whether this member of 
the TNFSF would increase the survival of the cells, as observed by Wen et al (246) in the 
TF-1 cell line.  TL1A was found to significantly increase the number of TRAP+ mononuclear 
cells and TRAP+ multinucleated OC across the time course, demonstrating that TL1A can 
act directly on monocytes / macrophages in a manner similar to TNF, synergistically 
enhancing RANKL induced OC formation (282, 283).  The results from this experiment 
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supported the work by Bull, Williams et al (242), that TL1A enhances OC formation, while 
showing for the first time that it does this via acting directly on the precursor cells.  To 
determine the mechanism through which TL1A was enhancing the formation of OC, 
culture supernatants were analysed. 
As discussed in section 1.3.5 chemokines are messengers that act upon OC precursors, 
inducing their migration from the blood stream to sites of bone resorption and 
subsequent formation of the multinucleated OC.  To date there are no studies that 
examine the effect of TL1A on CCL2 and CXCL8 production by OC, though some work has 
been performed with monocytes and macrophages.  Kang et al (278) and Su et al (240) 
demonstrated that TL1A induced CXCL8 expression in THP-1 cells and primary 
macrophages, though no effect was observed on CCL2 expression. 
In the present study TL1A was found to have no effect CCL2 or CXCL8 expression in OC 
cultures grown on a plastic substrate.  The lack of response observed in CCL2 levels is 
contrary to those observed in the murine cultures in chapter 3 where addition of TL1A 
significantly reduced CCL2 expression.  This may be caused by the difference in substrate 
(plastic versus ivory) used to perform the assays, or due to a difference in the 
osteoclastogenic mechanism employed between the two species.  However, the result 
does agree with the study by Su et al (240) who demonstrated that TL1A does not affect 
CCL2 expression in monocytes or macrophages.  The reason for the difference in CXCL8 
expression between this study and those by Kang et al (278) and Su et al (240) is unclear.  
Levels of TL1A used by Kang et al and Su et al (100 – 1µg/ml) were >10 times greater than 
those used in this study (10ng/ml), raising the possibility that the required signalling 
threshold to induce CXCL8 expression had not been reached.  To address the questions 
raised in chemokine expression and to study the effect of TL1A on OC resorptive function, 
subsequent assays were performed on ivory discs; a substrate osteoclasts can recognise 
and resorb (41).  Before any assays were carried out the method for the culture of human 
OC, on ivory discs, required optimisation. 
To study the effect of TL1A on OC differentiation and resorptive function the assay was 
set-up to obtain a balance between OC numbers and resorptive activity.  The time point 
selected for experiment termination required OC to have been established for at least one 
earlier time point and for numbers not to have peaked or plateaued.  The OC were also 
required to demonstrate resorptive function on at least one earlier time point.  A time 
point of day 14 was selected for experiment termination as all criteria were met.  All 
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subsequent OC assays on ivory discs were terminated on day 14 of culture with RANKL.  
To address the contrasting effects of TL1A on CXCL8 expression between this study and 
those by Kang et al (278) and Su et al (240) a second concentration of 100ng/ml TL1A was 
also used. 
Addition of TL1A to control cultures and OC cultures had no effect on total cell number 
across the time course.  This supports the result observed in the plastic tissue culture 
plates that, in this system, TL1A is not involved in the proliferation and expansion of OC 
precursors.  While TL1A did not affect total cell number it was observed to have a 
profound dose-dependent effect on OC number, in OC cultures.  This supports the 
observation by Bull, Williams et al (242) that in PBMC cultures TL1A can enhance 
osteoclastogenesis, showing for the first time that it does this by acting directly on the 
CD14+ OC precursors.  The effect of TL1A on OC formation is in-line with other members 
of the TNFSF.  Work by Lam et al (282) and Azuma et al (283) demonstrated that TNF 
(TNFSF2) can enhance OC formation in permissive levels of RANKL, acting directly on the 
precursor cells.  Edwards et al (182) showed that LIGHT (TNFSF14) dose-dependently 
enhanced RANKL-induced osteoclastogenesis.  A difference in the effect of TL1A 
compared to TNF and LIGHT in the above mentioned studies, however, is the effect on the 
control cultures.  Azuma et al (283), Kobayashi et al (349) and Edwards et al (182) 
demonstrated that TNF and LIGHT induce OC in the absence of RANKL; while in this study 
TL1A was unable to induce osteoclastogenesis on its own.  A possible explanation for this 
is that the other studies used PBMCs, so endogenous levels of RANKL would be present in 
the cultures.  Having shown TL1A to have an effect on OC differentiation the effect on 
osteoclast resorptive function was investigated.  TL1A had a dose-dependent effect on the 
% area resorbed, with a five-fold increase observed in the 100ng/ml cultures over those 
without.  It is not clear from this study whether this increase in resorptive function is a 
result of the increase in OC numbers or as a result of an increase in the resorptive 
function of the OC.   
To determine the mechanism through which TL1A was driving the increase in OC numbers 
and resorption, culture supernatants were analysed for soluble mediators.  MMP-9 is a 
gelatinase involved in the degradation of bone by OC (106, 300, 301), whose increase in 
expression can potentially lead to an increase in area resorbed.  This was shown by Grassi 
et al (350) who demonstrated when OC were grown in the presence of permanent CXCL12 
they displayed a two-fold increase in the ability to resorb bone-like material and secreted 
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increased amounts of MMP-9.  Studies by Kim et al (239) and Kang et al (278) have 
identified MMP-9 expression to be a target of TL1A signalling in the human macrophage 
THP-1 cell line, while  results from chapter 3 demonstrated a role for DR3 in MMP-9 
activation.  Currently however, it is unknown what affect DR3/TL1A have on MMP-9 
expression from human OC.  To investigate the effect of TL1A on MMP-9 expression, 
supernatants were analysed from OC cultures for total MMP-9.  TL1A was observed to 
have a dose-dependent effect on levels of total MMP-9.  This result demonstrates for the 
first time that TL1A effects MMP-9 expression in OC cultures, adding support to the Kang 
et al (278) study, and providing an important mechanism to explain the increased 
resorption observed.  Further support for the importance of the increase in total MMP-9 
as a mechanism for the increase in resorption came from correlation of the two variables.  
Levels of total MMP-9 were found to significantly correlate with % area resorbed, 
demonstrating a positive relationship between the two.  In chapter 3 DR3 was confirmed 
to have a role in the activation of murine MMP-9.  To verify whether TL1A resulted in an 
increase in the active form of MMP-9 a gelatine zymogram was employed to measure 
inactive and active levels across the time course.  Addition of TL1A (100ng/ml) to cultures 
was observed to activate MMP-9 at an earlier time point, leading to a significant increase 
in levels across the time course.  The data shows a novel mechanism for DR3/TL1A 
signalling in human OC; increasing levels of total MMP-9 and inducing earlier activation of 
the enzyme.   
While MMP-9 has a role in bone resorption, the key enzyme involved in the process is the 
proteinase Cathepsin K (104, 105).  As with the murine assays in chapter 3, commercial 
methods for the quantitative measurement of CatK levels in culture require the total lysis 
of cells, releasing the CatK into the supernatant.  Immunocytochemistry techniques were 
developed for staining the actin ring, nuclei and CatK in situ in OC cultures (Appendix II).  
An anti-CatK antibody was tested at a range of concentrations (1μg/ml - 4μg/ml) along 
with an equivalent isotype control, and binding visualised by counter staining with a FITC-
conjugated secondary antibody.  The anti-CatK antibody detected the presence of CatK at 
all concentrations; though levels of detection were observed to increase from 1μg/ml - 
3μg/ml.  Analysis of the isotype signal showed no non-specific binding at concentrations 
of 1μg/ml and 2μg/ml, with low levels being detected at 3μg/ml and 4μg/ml.  Taken 
together the results suggested that the optimal concentration of antibody for the 
visualisation of CatK in OC, in situ, was 2μg/ml.  The effect of TL1A on CatK expression is 
unknown and further experimentation would be required to potentially resolve this issue.  
195 
 
Having revealed a potential mechanism through which TL1A is driving the increase in OC 
resorptive function, the mechanism for the increase in OC formation was investigated. 
Levels of endogenously expressed TNF and TL1A were measured in the cultures to ensure 
that the observed effects could be directly attributed to the exogenously added TL1A.  In 
addition the chemokines CXCL8, CCL2 and CCL3 were measured to determine whether the 
change in substrate or TL1A concentration affected their expression.  The observed effects 
of TL1A on OC formation in this study were proved to be independent of endogenous TNF 
and TL1A.  Levels of CXCL8 were unaffected by the addition of TL1A in both control and 
OC cultures.  This result supports the earlier observation in the plastic tissue culture plate 
assays, though again is contrary to that observed by Kang et al (278) and Su et al (240).  
The reason for the difference in CXCL8 expression between the studies is not clear; but 
may be down to the concentration of TL1A used or co-stimulation of the cells with IFNγ.  
Kang et al (278) only observed an increase in CXCL8 expression when a concentration of 
250ng/ml TL1A was used in conjunction with IFNγ, while in the Su et al (240) study a level 
of 1µg/ml TL1A induced a change in CXCL8 expression.  This level of TL1A is significantly 
higher compared to in vivo levels, even in a disease state; in RF+ RA patients mean levels in 
serum were measured at 7.4±6.8ng/ml, over 100 times lower than that used in the Su et 
al study.   
TL1A was demonstrated to have no effect on CCL2 levels in both control cultures and OC 
cultures.  This result is different to that observed in the murine model in chapter 3, where 
TL1A led to a reduction in CCL2 levels, but is comparable to the Kang et al (278) and Su et 
al (240) studies.  The difference in the human and murine model suggests a difference in 
the mechanisms through which TL1A effects osteoclastogenesis.  This is not without 
precedent as there are a number of discrepancies between the immune system of mouse 
and man (351), highlighting again the caution that should be taken when extrapolating the 
data from one model to the other.   
In contrast to CXCL8 and CCL2, TL1A was observed to have a dose-dependent effect on 
CCL3 expression in OC cultures with a significant increase observed in the 100ng/ml TL1A 
cultures across the time course.  This supports the observation in chapter 3 that CCL3 
expression is a target of TL1A signalling.  This result, taken with the observations by Choi 
et al (87) and Han et al (88), suggests that the TL1A-induced increase in CCL3 is 
responsible for the increase in OC numbers observed.  To prove this hypothesis however, 
an anti-CCL3 add back experiment would be required to determine whether OC numbers 
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could be returned to base-line in the 100ng/ml TL1A cultures, thus proving that the 
increase in CCL3 is the responsible factor.  Levels of CCL3 in the control cultures were 
unaffected by TL1A, showing baseline expression.  This shows that the increase in CCL3 
expression by TL1A is a RANKL-mediated effect.  Correlation of chemokine levels and OC 
numbers provides further evidence for the role of TL1A-induced CCL3 expression in 
enhancing osteoclastogenesis.  Levels of CCL3 were found to significantly and positively 
correlate with OC numbers and % area resorbed on day 7, 10 and 14; no correlation was 
observed with levels of CXCL8 and CCL2.  While correlation does not directly identify 
cause and effect it does demonstrate that the effects observed between TL1A-induced 
CCL3 expression, the increase in OC numbers and the % area resorbed are related.   
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4.4 Conclusion 
At the conclusion of this chapter the following objectives were met: 
 CD14+ cells were isolated from human PBMCs and the purity defined. 
 DR3 expression on OC pre-cursors was determined. 
 An in vitro assay for the generation of OC from CD14+ cells on plastic and ivory 
was developed. 
 TL1A’s effect on OC formation and resorptive activity was determined and the 
mechanism identified. 
Results from the human osteoclast assays revealed a key role for TL1A in osteoclast 
biology.  While its receptor DR3 was found not to be constitutively expressed on 
circulating CD14+ monocytes / macrophages (OC pre-cursors), it could be induced in vitro 
by culture in the presence of MCSF on a plastic or ivory substrate.  TL1A was proved to 
have a significant role in osteoclast differentiation and resorptive function, significantly 
increasing osteoclastogenesis and osteoclast resorptive function in a dose-dependent 
manner.  For the first time in a human system TL1A was found to dose-dependently affect 
levels of the chemokine CCL3, total MMP-9 and active MMP-9 in OC cultures, providing a 
potential mechanism through which it drives increased OC formation and resorptive 
activity. The data has also shown that these effects on OC differentiation and resorptive 
function are independent of the cytokine TNF or endogenous TL1A.  These results 
highlight the DR3/TL1A pathways as regulators of OC differentiation and activity.  
However, whether DR3/TL1A have a role in the pathogenesis of diseases characterised by 
hyper OC activity is currently unknown and will be investigated in chapter 5. 
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Chapter 5 
Investigating the Role of DR3/TL1A in 
Human Bone-Related Disease 
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5.1 Introduction 
In Chapter 4 the effect of TL1A upon OC differentiation from human precursor cells was 
analysed and its impact upon in vitro OC function quantified. TL1A increased OC numbers 
and promoted resorptive function in a DR3- and dose- dependent manner. Biological 
responses attributed to DR3 and TL1A were discovered through in vivo studies into the 
pathogenesis of a number of inflammatory conditions for instance: inflammatory bowel 
disease (254, 263) and psoriasis (269).  Whether DR3 and TL1A are implicated in the 
pathology of diseases associated with OC hyper-activity, such as the inflammatory 
arthritides and post-menopausal osteoporosis (OP), has not been established. In this 
chapter the potential impact of DR3 and TL1A upon the adverse bone pathology 
associated with human diseases such as rheumatoid arthritis (RA) and osteoporosis are 
explored. 
A number of diseases are characterised by phenotypic OC hyper-activity that leads to 
focal bone erosions, generalised reduction in bone mineral density and systemic 
osteoporosis.  These diseases included both inflammatory arthritides such as RA (352, 
353), the spondyloartritides (ankylosing spondylitis (AS) (354) and psoriatic arthritis (PsA) 
(355)), as well as non-inflammatory conditions such as OP (52, 197) and Paget’s disease of 
bone (356).  The exact aetiology of these diseases are unknown and very likely different.  
However, evidence from recent studies implies that the DR3/TL1A pathway is implicated 
in disease pathogenesis.  In the last year Konsta et al (267) demonstrated that TL1A levels 
in ankylosing spondylitis were 2.6-fold higher in anti-TNF treatment-naïve patients 
(581±175.5pg/ml) compared to healthy controls (226.7±48.24pg/ml). The association 
between DR3/TL1A and RA is stronger and has been reported several times in the 
literature (264-266). Finally, work by Bamias et al (3) demonstrated an increase in DR3 
levels in psoriatic skin lesions compared with healthy controls; and that TL1A expression 
was primarily localised to keratinocytes and macrophages.  Whilst these studies were not 
linked to the pathology of psoriatic arthritis, TL1A could well contribute to the 
development of skin lesions and/or joint pathology associated with PsA. Well designed, 
clinical studies are required to prove this conclusively.  In this proof-of-concept study, 
archived serum samples were used to identify inflammatory arthritides potentially 
modulated by TL1A. 
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The greatest number of samples available had been collected from cohorts of RA patients. 
RA is a disease characterised by persistent inflammation of multiple joints and infiltration 
by immune cells (171). The uncontrolled inflammatory response leads to structural 
changes within the joint: hyperplasia of the synovial lining and damage to cartilage and 
bone.  While the factors that trigger the onset of RA are unknown, members of the TNFSF 
certainly play critical roles in its pathogenesis (180-182, 357, 358).  Levels of RANKL 
(TNFSF11) (180), TNF (TNFSF2) (181) and LIGHT ( TNFSF14) (182, 183) have all been shown 
to be up-regulated in the serum and synovial tissue of RA patients, compared to healthy 
controls.  The importance of RANKL in osteoclast formation and resorptive activity is well 
established (15, 16, 60).  Studies by Thomson et al (184), Kudo et al (185) and Edwards et 
al (182) demonstrated that TNF and LIGHT were also able to act either independently or 
synergistically with RANKL to increase OC formation and function.  This data highlights the 
importance of the TNFSF in RA pathogenesis. The association between DR3/TL1A and RA 
was first established in 2004 by Osawa et al (265). He revealed that duplication of the DR3 
gene was more prevalent in RA patients than healthy individuals.  Bamias et al (264) and 
Zhang et al (266) subsequently showed that TL1A levels were elevated five-fold 
(4.55±5.96ng/ml versus 0.89+0.86ng/ml) in RA patient serum (264) and increased (up to 
600pg/ml versus 0pg/ml) in RA synovial fluid (266).  The functional significance of raised 
TL1A levels in RA was not studied, although Bamias et al (264) suggested that TL1A could 
constitute a measure of disease activity.  Currently there is a body of published data that 
supports a pathogenic role for TL1A in RA (264-267, 269), however there is no such 
foundation for OP. For this reason, in the second part this chapter, osteoclastogenesis by 
the TL1A pathway was evaluated in precursor cells isolated from OP patient blood 
samples.  TL1A expression was also quantified in serum specimens. 
OP is a disease defined by a generalised low bone mineral density (BMD), which leads to 
an increased risk of fracture (187).  The decrease in BMD can be unproblematic.  However, 
osteoporotic fracture can lead to a loss of mobility, increased morbidity and eventual 
mortality (192).  The aetiology and pathogenesis of osteoporotic fractures are not fully 
defined.  A major contributing factor is an imbalance in the bone remodelling process, 
where bone resorption exceeds bone formation.   How this relates to the in vivo 
pathogenesis of the disease, the mechanisms which drive it and the potential implications 
for fracture formation and repair have barely been considered.  However, given the post-
menopausal status of the majority of OP patients with fractures; oestrogen deficiency is 
considered a primary cause (359, 360).  Studies by D’Amelio et al (200, 201) also 
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demonstrated an up-regulation of the TNFSF members RANKL (0.32 – 2.0pg/ml versus 
0.036 – 0.14pg/ml) and TNF (53 - 178.25pg/ml versus 32.9 - 53.7pg/ml) in osteoporotic 
PBMC cultures compared to post-menopausal controls.  This suggests that changes in 
expression of the TNFSF may contribute to the imbalance in bone remodelling and 
increased risk of fracture associated with OP.  The role of DR3/TL1A in fracture and OP has 
not been previously studied.   The proof-of-concept study in this chapter will provide the 
first evidence assessing whether changes in expression of DR3 and / or TL1A are 
associated with fracture and / or OP.  Evidence will be provided via recruitment and 
comparison of three post-menopausal patient cohorts: non-osteoporotic with / without 
fracture and osteoporotic with fracture.    
The aims of this chapter were two-fold.  Firstly, to analyse levels of TL1A in serum of 
patients with different forms of arthritis.  Secondly, to determine whether expression of 
DR3 and / or TL1A are altered in the pathogenesis of fracture and / or OP.  The specific 
objectives are listed below: 
 To measure TL1A levels in serum from patients with rheumatoid arthritis, 
psoriatic arthritis, osteoarthritis (OA) and healthy controls. 
 To analyse TL1A levels in seropositive and seronegative RA patient serum. 
 To determine the effect of anti-TNF treatment on serum TL1A levels in RA 
patients. 
 To investigate whether serum TL1A levels are linked to erosive RA. 
 To obtain ethical approval for the collection and analysis of blood samples 
from 3 cohorts of treatment-naïve, post-menopausal patients 
 To recruit sufficient patients from 3 defined cohorts (up to a maximum of 15 
patients per group) for this proof-of-concept study. These were defined as:-: 
1. Patients without osteoporosis or fracture (OP-Frac-) 
2. Patients without osteoporosis but with fracture (OP-Frac+) 
3. Patients with osteoporosis and fracture (OP+Frac+) 
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 To measure TL1A and TNF levels in serum samples collected from the three 
patient groups. 
 To isolate and culture sufficient CD14+cells (osteoclast precursor cells) from 45 
ml of patient blood samples and define DR3 expression. 
 To design and conduct osteoclast differentiation assays with adequate 
replicates and controls for statistical evaluation to fulfil the aim of the 
chapter. 
 To measure the effect of TL1A upon CD14+ precursor cells isolated from the 
three groups of post-menopausal patient (above) in osteoclast differentiation 
assays.  
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5.2 Results 
5.2.1 Assessing Serum TL1A Levels in Patients with Arthritis 
Levels of TL1A were measured in the serum of patients with the following arthritides: RA 
(n=75), PsA (n=11) and OA (n=5).  Serum obtained from healthy volunteers was used as 
normal controls (n=12).  Results (reported as mean±SEM) are presented graphically in Fig 
5.1 (a)).  TL1A was detected in serum from all four patient cohorts, though levels were 
observed to vary within and between groups.  Levels were significantly elevated in the RA 
cohort (1.99±0.3ng/ml, min=0ng/ml and max=14.2ng/ml; P=<0.05). A small, but non-
significant, increase was observed in the PsA cohort (0.43±0.2ng/ml, min=0ng/ml and 
max=1.67ng/ml). TL1A levels in normal controls was consistently low (0.23±0.02ng/ml, 
min=0.16ng/ml and max=0.34ng/ml).  Serum concentration of TL1A in the OA cohort 
(0.23±0.2ng/ml. min=0ng/ml and max=0.85ng/ml) was not significantly different from 
controls. 
 
5.2.2 Analysing Levels of TL1A in Rheumatoid Arthritis Rheumatoid Factor Subgroups 
Rheumatoid factor (RF) was measured in RA patient serum by ELISA (section 2.2.15.2).  RA 
patient samples were sub-divided into two groups according to their rheumatoid factor 
status (i.e. positive (RF+; > 20units/ml) or negative (RF-; < 20units/ml)). TL1A levels 
measured in section 5.2.1 were analysed to determine whether the presence of RF 
affected serum concentration.  Results are reported as mean±SEM in Figure 5.1 (b).  
Levels of TL1A were significantly elevated in the RF+ group (2.83±0.5ng/ml) compared to 
the RF- group (0.42±0.1ng/ml; P=<0.01) and normal controls (0.23±0.02ng/ml; P=<0.01).  
There was no difference between the RF- subgroup and normal controls.  A significant 
correlation between TL1A and RF was detected (r =0.70, P=<0.0001).  
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5.2.3 Determining the Effect of Anti-TNF Treatment on Serum TL1A Levels in 
Rheumatoid Arthritis 
To determine whether anti-TNF treatment affects serum TL1A levels, RA patient samples 
from section 5.2.2 (RF+ and RF-) were divided into two groups: patients treated with TNF 
antagonists versus standard disease-modifying anti-rheumatic drugs (DMARDs).   A small, 
but non-significant reduction in TL1A was observed in the RF+ anti-TNF patient cohort 
(anti-TNF=2.33±0.6 versus DMARDs=3.40±0.7ng/ml).  TL1A levels in the RF- patients 
treated with TNF antagonists also demonstrated a slight, non-significant, reduction 
compared to those treated with DMARDs (anti-TNF=0.36±0.1 versus 
DMARDs=0.49±0.2ng/ml; Fig 5.2 (a)).  Serum TL1A levels were significantly lower in the RF- 
anti-TNF cohort compared to the RF+ anti-TNF cohort (P=<0.05). 
 
5.2.4 Assessing TL1A Levels in Erosive and Non-Erosive Rheumatoid Arthritis 
To determine whether TL1A levels were linked to erosive status, RA samples from section 
5.2.2 were grouped depending on the radiological presence of erosive disease at the time 
of sampling.  TL1A levels were significantly elevated in RF+ samples displaying erosive 
disease (4.34±1.0ng/ml; P=<0.01) compared to non-erosive disease (2.00±0.6ng/ml).  No 
significant difference was observed in the RF- subgroup (erosive=0.39±0.1ng/ml versus 
non-erosive=0.1±0.1ng/ml; Fig 5.2 (b)). 
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5.2.5 Assessing TL1A and TNF Levels in Serum from Three Cohorts of Post-Menopausal 
Patients 
TL1A and TNF concentration were measured by ELISA in serum harvested from blood 
samples obtained in clinic. Three groups of post-menopausal women who presented in 
fracture clinic were studied; those with osteoporosis and recent fracture (OP+Frac+, n=3), 
those without osteoporosis but with recent fracture (OP-Frac+, n=6) and those without 
osteoporosis and fracture (OP-Frac-, n=6).  Patients were recruited to the study based on 
the following inclusion / exclusion criteria: 
Inclusion criteria 
 Attending for first bone density scan; Adult; Female; Post-Menopausal 
Exclusion criteria 
 Recent fracture (in the past 3 months); History of corticosteroid use (except 
inhaled or topical) or anti-TNF therapy; Patients with known seropositive 
rheumatoid arthritis, inflammatory bowel disease; Recent history of continuous 
treatment with bisphosphonate, calcitonin, Strontium ranelate or parathyroid 
hormone (i.e. for more than 3 months); Patients with known primary 
hyperparathyroidism; Currently taking part in another study. 
Levels of TL1A (mean±SEM; Fig 5.3) were elevated in patients with fracture (OP-Frac-
=47.2±29.0pg/ml versus OP-Frac+=90.8±4.5pg/ml and OP+Frac+=103.1±2.3pg/ml), though 
this difference was not significant.  The presence of OP had no significant effect on serum 
TL1A levels.  TNF was not detected in the OP-Frac-, OP-Frac+ and OP+Frac+ serum samples 
as levels were below the limit of detection for the ELISA (8pg/ml).    
208 
 
 
 
 
 
 
 
  
209 
 
5.2.6 Defining Baseline Expression of CD14 and DR3 on Freshly Isolated Patient-
Derived CD14+ Cells 
Expression of CD14 and DR3 on freshly isolated CD14+ cells from three cohorts of post-
menopausal patients was assessed by flow cytometry (section 2.2.8); OP-Frac-, OP-Frac+ 
and OP+Frac+.  Expression is represented graphically as fold increase in MFI relative to the 
isotype control (mean±SEM; Fig 5.4).  High levels of variation in CD14 expression was 
detected within the OP+Frac+ cohort.  The presence of fracture had no significant effect on 
CD14 expression: OP-Frac-=7.7±1.9 versus OP-Frac+=4.1±1.0.  Comparison between the 
fracture cohorts demonstrated no significant effect of osteoporosis on CD14 expression: 
OP-Frac+=4.1±1.0 versus OP+Frac+=16.4±8.1.  DR3 was not expressed on freshly isolated 
CD14+ cells from the post-menopausal patient cohorts (Fig 5.4 (b)). 
 
5.2.7 Assessing Expression of CD14 and DR3 on Patient-Derived CD14+ Cells after 7 
Days Culture in MCSF 
Patient-derived CD14+ cells were isolated (day -7) and cultured on ivory for 7 days in 
medium supplemented with MCSF.  Expression of CD14 (Fig 5.5 (a)) varied greatly within 
each group.  Comparison of CD14 expression (fold increase relative to isotype; 
mean±SEM) between the cohorts without osteoporosis demonstrated no significant effect 
of fracture (OP-Frac-=11.1±4.2, OP-Frac+=11.3±3.1).  Osteoporosis also had no significant 
effect on CD14 expression (OP-Frac+=11.3±3.1 and OP+Frac+=11.8±8.2).  Expression of DR3 
(Fig 5.5 (b)) was only detected on one patient sample (OP-Frac+, 1.8-fold increase).  No 
significant difference in DR3 expression was detected between the patient cohorts. 
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5.2.8 Assessing the Ability of Patient-Derived CD14+ Cells to Differentiate into 
Osteoclasts 
Osteoporosis is a disease characterised by  increased osteoclast activity leading to a 
reduction in bone mineral density (200).  For this reason, the ability of the patient-derived 
CD14+ cells to differentiate into osteoclasts (Fig 5.6) was investigated under our pre-
defined culture conditions (section 2.2.12).  Total cell and specific osteoclast counts were 
determined for each experimental disc at each time point investigated.  
The total number of cells per mm2 (mean±SEM) for each disc is presented graphically in 
Fig 5.7 (a, i) for control cultures (MCSF) and Fig 5.7 (a, ii) for OC cultures (MCSF+RANKL).  
In the control cultures fracture had no significant effect on total cell number.  OP 
however, was demonstrated to have a significant effect on total cell number across the 
time course (P=<0.0001).  Comparison of total cell number in the fracture cohorts showed 
elevated cell numbers at day 3 in OP cultures (OP-Frac+=174±39/mm2 versus 
OP+Frac+=399±75/mm2); these did not change significantly over time.  In the OC cultures 
fracture was demonstrated to have no significant effect on total cell number.  OP resulted 
in significantly increased cell numbers across the time course (P=<0.0001).  Total cell 
number at day 3 was measured as OP-Frac+=244±46/mm2 versus OP+Frac+=446±68/mm2 
and did not vary significantly over time. 
Differential counts were performed and TRAP+ OC, reported as OC / mm2 (Fig 5.7 (b)) and 
% OC (Fig 5.7 (c)).  Very low levels of spontaneous OC formation were detected in control 
(MCSF) cultures across the time course.  The presence of fracture or osteoporosis did not 
affect spontaneous OC formation.  In OC cultures (MCSF+RANKL), OC were first detected 3 
days after addition of RANKL.  Numbers increased between day 3 and day 7 and remained 
constant at day 14.  Fracture had no significant effect on OC number or % OCs.  
Comparison between fracture cohorts showed no significant effect of OP on OC number 
and % OCs across the time course. 
5.2.9 Assessing the Resorptive Function of the Patient-Derived Osteoclasts 
To determine whether fracture or osteoporosis is associated with an increase in OC 
resorptive activity the area resorbed by patient-derived OC was measured.  OC resorptive 
activity was expressed as % area resorbed (mean±SEM) for graphical presentation (Fig 5.7 
(d)).  Osteoclastogenic resorptive function was observed in cultures from the three patient 
cohorts.  Levels of resorption in cultures derived from patients without OP at day 10 and 
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day 14 were: OP-Frac-=0.13±0.06% and 0.66±0.52% versus OP-Frac+=0.33±0.22% and 
0.39±0.30%.  No significant difference was detected demonstrating that OC resorptive 
activity is not affected by fracture.  The presence of OP was determined not to affect OC 
activity, with no significant difference in resorption at day 10 and day 14 between the 
fracture cohorts: OP-Frac+=0.33±0.22% and 0.39±0.30% versus OP+Frac+=0.09±0.06% and 
0.18±0.09%.   
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5.2.10 Assessing CCL3 Expression in Patient-Derived Osteoclast Cultures 
As an assessment of osteoclast formation the chemokine CCL3 (361) was measured in the 
supernatants of the patient-derived OC cultures (Fig 5.8 (a)).  The presence of fracture had 
no significant effect on CCL3 expression across the time course.  At day 0 levels of CCL3, in 
the non-OP cohorts, were measured at OP-Frac-=89.8±23.7pg/ml versus OP-
Frac+=76.0±18.0pg/ml.  These remained constant at day 7.  At day 10 levels in the OP-Frac- 
cultures dropped significantly compared to the OP-Frac+ cultures (23.1±9.9pg/ml versus 
98.5±24.6, P=<0.05).  At day 14, levels of CCL3 were observed to increase in the OP-Frac- 
cultures (36.7±10.0pg/ml) and decrease in the OP-Frac+ cultures (86.9±6.5pg/ml).  Analysis 
of CCL3 levels in the fracture cohorts demonstrated no effect of OP on CCL3 levels.  CCL3 
expression in the OP+Frac+ at day 0 were measured as 78.4±21.6pg/ml and remained 
relatively constant across the time course.   
 
5.2.11 Assessing Total MMP-9 Expression in Patient-Derived Osteoclast Cultures 
As an assessment of OC resorptive function expression of total MMP-9 was measured in 
supernatants from patient-derived OC cultures by ELISA (Fig 5.8 (b)).  Levels of total MMP-
9 (mean±SEM) were significantly elevated (P=<0.0001) in the fracture cohort cultures (OP-
Frac+) across the time course, compared to the non-fracture cohort cultures (OP-Frac-).  At 
day 0 levels of total MMP-9 were measured at; OP-Frac-=0.89±0.2µg/ml versus OP-
Frac+=1.66±0.6µg/ml.  Levels were observed to increase at day 7, with significantly 
elevated total MMP-9 detected in the fracture cohort (OP-Frac-=1.58±0.4µg/ml versus OP-
Frac+ 3.23±0.7µg/ml; P=<0.05).  Total MMP-9 levels in the OP-Frac- dropped at day 10 
(1.15±0.4µg/ml) and remained low at day 14 (0.53±0.2µg/ml).  In the fracture cohort, OP-
Frac+, levels at day 10 were observed to decrease (1.89±0.4µg/ml) but were significantly 
higher at day 14 (2.68±0.6µg/ml; P=<0.01). 
Comparison of the fracture cohorts demonstrated no effect of OP on total MMP-9 
expression.  Levels of total MMP-9 were comparable between the fracture cohorts at each 
time point tested.    
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5.2.12 Assessing the Impact of TL1A on the Ability of Patient-Derived CD14+ Cells to 
Differentiate into Osteoclasts 
In Chapter 4, TL1A (100ng/ml) enhanced OC formation (over control levels) when added 
to precursor cells isolated from the blood of normal (pre-menopausal) human volunteers.  
In this chapter, precursor cells were harvested from post-menopausal patients with / 
without fracture and osteoporosis. The effect of fracture and OP on OC formation and 
resorptive function in response to TL1A (100ng/ml) was measured.  Serious unidentified 
microbial infection was noted in 48% of cultures 3 – 5 days after the addition of TL1A.  All 
reagents used in the assay were tested (MCSF, RANKL, TL1A, polyHistidine and human OC 
medium) separately in human OC medium (no cells) to determine the source of the 
infection. After 1 week in culture (37°C, 5% CO2), no infection was detected in any of the 
samples tested. This confirmed that the reagents were not the source of the infection.  
The likely source of the infection was the patient cells; although this was not tested.  
In the remaining (52%) of viable cell cultures containing TL1A, there was no effect on cell 
expansion or survival. Total cell number (mean±SEM) in control and OC cultures (±TL1A) 
were comparable (Fig 5.9).  In control cultures (MCSF±TL1A) fracture had no effect on OC 
precursor response to TL1A.  Total cell numbers at day 3 in the non-OP cultures (OP-Frac-: 
-TL1A=132.4±34 versus +TL1A=131.1±38 and OP-Frac+: -TL1A=174.0±39 versus 
+TL1A=235.5±42) were not significantly different following the addition of TL1A, and 
showed minimal variation across the time course.  Total cell numbers in the fracture 
cohort cultures were also unaffected by the addition of TL1A.  Numbers at day 3 (OP-Frac+: 
-TL1A=174.0±39 versus +TL1A=235.5±42 and OP+Frac+: -TL1A=398.7±75 versus 
+TL1A=412.8±66) were consistent across the time course.  The data demonstrated that OP 
does not change precursor proliferation or survival in response to TL1A.  In OC cultures 
(MCSF+RANKL±TL1A) fracture and OP were again shown to have no significant effect on 
cell survival and proliferation in response to TL1A.  Total cell numbers in the non-OP 
cultures were constant from day 3 onwards (OP-Frac-: -TL1A=211.2±36 versus 
+TL1A=159.6±35 and OP-Frac+: -TL1A=243.7±46 versus +TL1A=241.6±39).  This trend was 
also observed when comparing the fracture cohorts: total cell numbers at day 3 were OP-
Frac+: -TL1A=243.7±46 versus +TL1A=241.6±39 and OP+Frac+: -TL1A=446.4±68 versus 
+TL1A=482.6±103. 
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Differential counts of TRAP+ OC (OC / mm2 and % OC; mean±SEM) demonstrated that 
TL1A does not affect spontaneous or RANKL-induced OC formation in fracture or OP 
patient-derived cultures (Fig 5.10 and Fig 5.11). 
Across the time course low levels of spontaneous OC formation were detected in the 
control cultures (MCSF±TL1A).  The presence of fracture or OP had no significant effect on 
spontaneous OC precursor differentiation in response to TL1A.  The presence of fracture 
had no significant effect on RANKL-induced osteoclastogenesis following addition of TL1A.  
OP was also demonstrated to have no significant effect on RANKL-induced OC 
differentiation in response to TL1A.  OC were detected in the fracture cohort cultures 
from day 3 onwards however, no significant difference was detected between the cohorts 
at any of the time points tested or across the time course.  
 
5.2.13 Assessing the Impact of TL1A on Patient-Derived Osteoclast Resorptive Function 
To determine whether fracture or osteoporosis affects OC resorptive function in response 
to TL1A, the area resorbed by patient-derived OC was analysed.  OC resorptive activity is 
presented graphically as % area resorbed (mean±SEM; Fig 5.12).  Addition of TL1A had no 
effect on OC resorptive function in fracture and OP patient-derived cultures. 
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5.3 Discussion 
OC over-activity is associated with focal bone erosions and the generalised bone loss that 
is observed in  a number of diseases including RA (352, 353), AS (354) , PsA (355) and post-
menopausal OP (52, 197).  While the exact aetiology of these diseases remains unknown, 
cytokines belonging to the TNFSF such as RANKL (TNFSF11), TNF (TNFSF2) and LIGHT 
(TNFSF14) are up-regulated. Furthermore, published literature has identified key roles for 
the TNFSF cytokines in promoting OC activity (180-183, 200, 201).  It is therefore entirely 
feasible that excess production of TNFSF cytokines drive osteoclast-dependent pathology 
in diseases like RA and OP. In the last 10 years a role for the TNFRSF / TNFSF members 
DR3 (TNFRSF25) and TL1A (TNFSF15) was proposed.  Elevated levels of TL1A were 
detected in serum samples obtained from AS (267) and RA (264) patients.  TL1A was not 
linked with bone pathology in these papers; furthermore TL1A has not been previously 
studied in the context of OP. The aim of this chapter was two-fold: 
1. To analyseTL1A levels in the serum of patients with different forms of arthritis.  
2. To determine whether DR3 and TL1A were implicated in the pathogenesis of 
osteoporosis and/or fractures in patients without osteoporosis. 
Serum TL1A levels were increased 8.7-fold in RA patients (1.99±0.3ng/ml) compared to 
healthy controls (0.23±0.02ng/ml).  This result adds support to the work published by 
Bamias et al (264). His study demonstrated that TL1A levels in serum were increased 5-
fold in RA patients (4.55±5.96ng/ml) over age- and sex-matched controls 
(0.89±0.86ng/ml).  In the present study, TL1A was also increased 1.9-fold in PsA patient 
serum (0.43±0.2ng/ml).  Although TL1A was raised in the serum from PsA patients the 
level was not significantly different to the controls.  In a study by Bamias et al (269) DR3 
and TL1A expression were shown to be significantly induced in psoriatic skin lesions.  TL1A 
expression was demonstrated to primarily localise to keratinocytes and macrophages 
within the psoriatic lesions.  Bamias also identified in several cases of psoriasis nuclear 
localisation of TL1A in inflammatory and fibroblast-like cells, which did not occur under 
steady state conditions.  Nuclearisation of TL1A was also detected in the synovial 
membrane of RA patients suggesting a potential common pathway between skin and 
synovial inflammation (269).  Taken with the results from this current study the increase 
in serum TL1A and subsequent nuclear localisation may provide a possible explanation 
why a subgroup of patients with psoriasis develop arthritis.  Additional studies are 
required to determine whether the up-regulation of DR3/TL1A is linked to the 
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development and bone pathology associated with psoriatic arthritis: osteolysis, 
ankylosing, formation of spurs, paramarginal erosions and calcification within the area of 
enthesitis (362).  A detailed study examining serum TL1A in psoriasis patients and 
following disease progression would provide a number of important observations.  Cell 
studies looking at OC and OB response to any increase in TL1A would also provide a 
mechanism through which the bone pathology associated with PsA progresses.  RA and 
PsA are inflammatory arthritides characterised by bone pathology.  To determine whether 
serum TL1A levels were also elevated in an arthritides not primarily associated with bone 
pathology, samples obtained from OA patients were studied. 
OA is a chronic joint disease characterised by focal and progressive hyaline articular 
cartilage loss.  Concomitant changes in the bone underneath the cartilage also occur 
including marginal outgrowths and osteophytes.  Modest inflammation may also be 
present in and around the soft tissue of the joint (363, 364).  In this study levels of serum 
TL1A measured in OA patients (0.23±0.2ng/ml) were not significantly different to that of 
the controls (0.23±0.02ng/ml).  This suggests that persistent inflammation, as observed in 
RA and PsA, is a driving factor in the elevation of serum TL1A expression.   This elevation 
in serum TL1A is subsequently linked to the bone pathology associated with the 
inflammatory arthritides.  If persistent inflammation were the only contributing factor to 
the increased TL1A expression then levels between the RA and PsA cohorts should be 
consistent.  However, TL1A levels in the RA cohort (1.99±0.3ng/ml) were 4.7-fold higher 
than their PsA counterparts (0.43±0.2ng/ml).  This suggests that additional factors in RA, 
such as the presence of rheumatoid factor (RF), may be driving the increase in TL1A 
expression. 
An explanation for the difference in TL1A levels between the RA and PsA samples was 
gained from work by Moll, Wright (365), Cassatella et al (366) and Prehn et al (253).  In 
1973 Moll, Wright (365) recognised that PsA patients were seronegative for rheumatoid 
factor (RF), whereas patients with RA were typically seropositive.  The importance of this 
in relation to TL1A expression was demonstrated by Cassatella et al (366) and Prehn et al 
(253).  In their studies, stimulation of monocytes with immunocomplexes such as RF, 
significantly induced the expression of TL1A by the cells.  The data suggests that RF 
present in RA patients stimulates expression of TL1A by monocytes, increasing serum 
levels over that of PsA patients.  To determine whether the presence of RF is a significant 
factor in serum TL1A levels, the RA patient cohort was split into seropositive and 
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seronegative sub-groups.  Patients were deemed to be seropositve if RF was > 20units/ml.    
Levels of TL1A were found to be significantly increased in the RF+ sub-group over the RF- 
sub-group (6.7-fold) and the normal controls (12.3-fold).  The study by Bamias et al (264) 
also demonstrated an increase in TL1A levels in the RF+ sub-group, when compared to the 
controls (6.9-fold), adding support to the results in this study.  In this study and the 
Bamias et al study (264) a strong significant correlation between TL1A and RF was 
discovered, demonstrating an important link between RF and TL1A in vivo.  Treatment of 
RA is routinely through DMARDS though those with severe arthritis can be treated with an 
anti-TNF biological.  Whether anti-TNF treatment affects serum TL1A levels is currently 
unknown.   
RA patients (RF+ and RF-) were grouped depending on their treatment; DMARDs versus 
anti-TNF treatment.  Anti-TNF treatment led to a slight reduction in serum TL1A levels 
compared to the DMARDs in both the RF+ and RF- cohorts.  However, these reductions 
were not significant, demonstrating that anti-TNF treatment does not affect serum TL1A.  
This result is in contrast to that observed in the Bamias et al (264) study.  In the Bamias et 
al study TL1A levels were measured in patients before treatment with a TNF inhibitor, 
adalimumab, (6.77ng/ml) and 3 months post-treatment (2.8ng/ml).  A significant 
reduction in serum TL1A was observed suggesting that anti-TNF treatment did have an 
effect on TL1A expression.  There were a number of differences between the Bamias et al 
study and the study performed in this thesis however.  The Bamias et al study measured 
TL1A in a group of patients both pre- and post- treatment while in this study levels in the 
patients pre-treatment were unknown; meaning that the Bamias et al study has greater 
statistical power.  The duration that the patients were on anti-TNF treatment in this study 
before being sampled were also unknown; meaning that some if not all of the patients in 
the anti-TNF treatment group could have started treatment well over three months 
before being tested.  This does raise an interesting possibility however, that following 
anti-TNF treatment serum TL1A levels could initially drop but rise again over time.  It 
should be noted that in the Bamias et al study levels of TL1A in the anti-TNF treated group 
were still 3.1-fold higher than those observed in the normal controls, suggesting that TL1A 
could still exert a significant effect on the pathogenesis of the disease.  While TL1A levels 
have been shown to be affected by the presence of RF and the effect of anti-TNF 
treatment debatable its link to erosive disease remains unknown.   
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To determine whether serum TL1A levels were linked to erosive disease the RA patient 
samples (RF+ and RF-) were grouped depending on whether they displayed erosions at the 
time of sampling.  TL1A levels were significantly elevated (2.2-fold) in the RF+ group 
displaying erosive disease over the non-erosive RF+ group.  Levels of TL1A were also 3.9-
fold higher in RF- patients with erosive disease over non-erosive disease, though this was 
not significant.  This data adds support to the work by Bamias et al (264) which revealed 
that TL1A was significantly elevated in the RF+ patients with active disease over those in 
remission (8.2±8.7ng/ml versus 4.1±4.1ng/ml).  In the Bamias et al study however, no 
difference was observed in the RF- patients (active=1.93±1.08ng/ml versus 
remission=1.96±1.58ng/ml).  The data from this study and the Bamias et al (264) study 
provides evidence for a role of TL1A in the pathogenesis of erosive disease.  This is further 
supported with the results from chapter 4, where addition of TL1A to in vitro OC cultures 
significantly enhanced OC formation and resorptive activity.  Additional support for the 
role of TL1A in erosive pathology came from studies by Zhang et al (266) and Bull, 
Williams et al (242) in murine models of CIA and AIA.  Administration of TL1A to a CIA 
model significantly aggravated CIA induction (266).  Clinical score in CIA-TL1A treated mice 
were significantly elevated compared to the CIA-PBS control group.  Histopathologically 
CIA-TL1A treated mice displayed increased cartilage loss, severe pannus formation and 
bone destruction and deformation (266).  In the AIA model co-administration of TL1A 
resulted in significant dose-dependent exacerbation of disease (242), increasing the size 
of bone erosions and severity of bone destruction.  The data, taken as a whole, suggests a 
significant role for TL1A in the pathogenesis of RA, with increased levels responsible for 
increased bone destruction.  The link between TL1A and RA raises a number of interesting 
possibilities: could TL1A levels be used as a prognostic marker for erosive disease and is 
increased TL1A responsible for the non-responders to anti-TNF treatment? 
Currently there are no reliable prognostic markers for RA at disease onset.  RF and anti –
CCP have been shown to be associated with more severe joint damage.  However, an 
increase in RF and anti-CCP is typical of a relatively advanced stage of disease; therefore 
they are of limited use in the very early stages (367, 368).  Whether TL1A serum levels 
could be used as a prognostic marker for erosive RA remains to be tested.  The RA 
patients used in this study all had established disease, so it is not known whether TL1A 
levels are up-regulated before the onset of RA or after disease progression has started.  
To answer this question a long term study would be required with patients who display at 
clinic with signs of early arthritis.  Serum TL1A levels would then have to be measured and 
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monitored over time to determine whether there is any direct link between TL1A, 
pathogenesis of RA and erosive disease.  Possibly of even more importance is the effect of 
anti-TNF treatment on TL1A.  While anti-TNF treatment has made it possible for many RA 
patients to have a better quality of life, there are those who do not respond to the 
treatment.  The reasons behind the lack of response to treatment are unknown; however 
it is plausible that in these individuals the erosive damage is being driven by increased 
TL1A and not TNF.  Through studying the cells of these patients and measuring their TL1A 
and DR3 expression it should be possible to obtain a better understanding of the 
complexities of RA and, in the long term, develop better treatments for the management 
of the disease.  While this study and those by Osawa et al (265), Bamias et al (264) and 
Zhang et al (266), have revealed a role for DR3 and TL1A in the pathogenesis of RA 
nothing is currently known about their involvement in fracture  or post-menopausal OP.  
This was investigated in the second half of this chapter. 
To determine whether DR3/TL1A have a role in the development of post-menopausal 
osteoporosis and / or fracture, patients were recruited to one of three cohorts, depending 
if they met the criteria set out in section 2.2.15.  The three patient cohorts were defined 
as: 
 Patients without osteoporosis or fracture (OP-Frac-) 
 Patients without osteoporosis but with fracture (OP-Frac+) 
 Patients with osteoporosis and fracture (OP+Frac+) 
The role of DR3/TL1A in the pathogenesis of fracture could be identified through 
comparison of the non-OP cohorts (OP-Frac- and OP-Frac+).  The role of DR3/TL1A in the 
pathogenesis of OP could then be determined through comparison of the fracture cohorts 
(OP-Frac+ and OP+Frac+).  The number of patients recruited to each group for this proof-of-
concept study was lower than hoped, with 6 recruited to both the OP-Frac- and OP-Frac+ 
cohorts and only 4 recruited to the OP+Frac+ cohort.  The reason for the lower than 
expected recruitment can be attributed to a low number of patients presenting at clinic in 
the time frame of the study, who conformed to the inclusion and exclusion criteria.  The 
study also presented a number of limitations, meaning a certain degree of care must be 
taken with interpretation of the results.  The low patient numbers in each group mean 
that any differences may be masked by the inherent variation between individuals.  The 
lack of a with osteoporosis without fracture cohort also means that it is difficult to fully 
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identify the effect of fracture and the effect of OP in the OP+Frac+ cohort results.  While all 
post-menopausal, the exact age of the patients recruited to the study are unknown; due 
to causes outside of the operators control resulting in the patient data being lost.  This 
raises the possibility that the mean age in the cohorts could be significantly different and 
any observed effects could be due to this rather than fracture or OP.  Having recruited 
patients to the study, levels of TL1A and TNF, a member of the TNFSF associated with 
increased OC activity (184), were measured in the serum. 
The role of the TNFSF following the menopause in fracture and post-menopausal 
osteoporotic fracture has not been fully elucidated.  Oestrogen deficiency associated with 
the menopause has been linked to a subtle increase in expression of the TNFSF members 
RANKL and TNF in ex vivo cultures of PBMCs (200, 201), circulating monocytes (202) and 
bone marrow macrophages (203, 204).  Whether expression of TL1A and TNF is altered in 
vivo in post-menopausal women following fracture or OP is unknown and was 
investigated.  TL1A was detected in serum from 10 out of 13 patients.  Comparison of the 
non-OP cohorts demonstrated an up-regulation of TL1A following recent fracture (1.9-
fold); while no difference was observed between the fracture cohorts.  This result 
suggests that TL1A is up-regulated following fracture but not as a consequence of OP.  
Support for fracture leading to an increase in TNFSF members is provided by a study by 
Kon et al (369).  They showed that TNFSF members RANKL, OPG and TNF are temporally 
up-regulated during fracture healing, with levels related to the stage of repair.  While still 
unknown, up-regulation of TL1A expression in response to fracture could be part of the 
complex array of signalling molecules and pro-inflammatory cytokines involved in skeletal 
repair.  In contrast serum TNF was not detected in any of the patient samples.  This 
suggests three possibilities: i) the up-regulation of TNF is localised to the site of skeletal 
repair and is not systemic, ii) TNF was not required at the stage of skeletal repair when the 
samples were obtained and iii) elevated serum TNF is not a contributing factor in the 
pathogenesis of fracture and / or OP.  Further studies with increased numbers are 
required to conclusively say either way.  Characterisation of CD14 and DR3 expression on 
cells from the post-menopausal cohorts was then carried out to determine whether 
fracture or OP change the cellular phenotype of the OC precursor. 
Analysis of the freshly isolated patient-derived cells demonstrated a high level of variation 
in CD14 expression in the OP+Frac+ cohort.  Comparison of the non-OP cohorts and the 
fracture cohorts demonstrated fracture and OP had no significant effect on CD14 
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expression, with approx. 60% of the isolated cells showing moderate to high expression.  
After 7 days culture in MCSF the variation in CD14 expression on the cells increased 
greatly, though no significant difference between the cohorts was observed.  The reason 
behind the high variation in CD14 expression between and within the patient cohorts is 
not clear but may be due to age.  Work by Sadeghi et al (370) demonstrated that 
monocytic CD14 expression alters during aging, with cells changing from a 
CD14bright/CD16dim phenotype to a CD14dim/CD16bright phenotype.  This change in CD14 
expression during aging is further supported by work from Kósa et al (371).  In their study 
they showed that there is a significant down-regulation in transcriptional activity of the 
CD14 gene in post-menopausal bone when compared to pre-menopausal bone.  DR3 
expression was found to be non-existent on the freshly isolated cells.  This supports the 
observation by Kang et al (278) and the work in chapter 4: that DR3 is not constitutively 
expressed on circulating monocytes.  In contrast to the results in chapter 4, DR3 
expression was not detected on the cells after 7 days culture in MCSF on ivory; with the 
exception of one patient in the OP-Frac+ cohort.  As with CD14 expression the absence of 
DR3 may also be due to changes in the immune system as a person ages.  While currently 
there are no papers looking at the effects of aging on monocyte / macrophage DR3 
expression, it has been documented that some functions of these cells are impaired in 
aged animal models (372) and elderly individuals (373).  However, the menopause has 
been linked to an increase in the expression of some receptors, such as soluble IL-6 
receptor (374).  Further work is required to determine the effects of aging and the 
menopause on DR3 expression.  Though the patient-derived cells exhibited no DR3 
expression and variable CD14 expression osteoclastogenesis assays were continued, to 
determine what effect this may have on the ability of the cells to undergo OC 
differentiation.   
Comparison of the total cell number in both the control (MCSF) and OC cultures 
(MCSF+RANKL) demonstrated a significant effect of OP.  Total cell numbers were 
significantly increased in the OP+Frac+ cohort compared to the non-OP cohorts, suggesting 
a change in cell viability.  Studies into cell viability in patients with osteoporosis are 
limited.  In a study by D’Amelio et al (200) PBMC viability between post-menopausal 
controls and osteoporotic patients were analysed by the 3-(4,5-dimethylthiazol-2-yl)-
2,5,diphenyltetrazolium bromide (MTT) assay.  Viability of PBMC’s obtained from 
osteoporotic patients were found to be slightly increased over the post-menopausal 
controls, when cultured in MCSF and MCSF+RANKL; however, this increase in viability was 
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not significant.  This data, taken in conjunction with the results from this study, suggest 
that a fundamental change in cell viability is part of the pathogenesis of osteoporosis.  The 
mechanism behind this change in cell viability is currently is unknown.  Survival of 
monocytes / macrophages is dependent on signalling from the cytokine MCSF through its 
receptor c-FMS (375, 376).  Levels of MCSF added to the cultures of the patient-derived 
cells were constant.  This means that the ability of the cells to survive and proliferate in 
culture should be equal.  The differences in total cell number observed suggested that the 
non-osteoporotic monocytes / macrophages received reduced survival signals compared 
to their osteoporotic counterparts.  This could be due to altered levels of c-FMS 
expression on the cohort cells, though further work would be required to confirm this.  
Differential cell counts were then performed on the cultures to determine if there was a 
difference in the ability of the cells to undergo spontaneous OC formation or RANKL-
induced OC formation.  
Fracture and OP had no effect on spontaneous OC formation.  This result is in contrast to 
work published by D’Amelio et al (200).  In their study they demonstrated significantly 
higher levels of ‘spontaneous’ osteoclast formation from osteoporotic patient PBMC 
cultures (45.5±13.4 OC/105 cells) compared to pre-menopausal controls (15.1±10.5 
OC/105 cells).  Differences in experimental procedure between this study and that by 
D’Amelio et al (200) could explain the observed differences in osteoporotic spontaneous 
OC formation.  In the D’Amelio et al study PBMC cultures were used, compared to CD14 
cultures used in this study. The set of experiments in the D’Amelio study were also 
performed without the addition of MCSF and RANKL to the cultures.  However, the 
presence of other PBMCs in the cultures would produce the cytokines required for cell 
survival and OC differentiation (377-379).  Increases in RANKL and MCSF production by 
PBMCs post-menopause has also been demonstrated by a number of groups (380-382), 
providing an explanation for the high levels of spontaneous OC formation observed in the 
D’Amelio et al study.  Comparison of the OC cultures from non-OP and fracture cohorts 
also demonstrated no effect of the two conditions on RANKL-induced osteoclastogenesis.  
This suggested that a fundamental change in the ability of CD14+ cells to undergo 
osteoclast formation is not responsible for the increased OC activity associated with OP.  
This is supported by an additional set of experiments in the D’Amelio et al (200) study and 
a study by Jevon et al (383).  In these studies PBMCs cultured from osteoporotic patients 
demonstrated no increase in osteoclastogenic potential, compared to post-menopausal 
controls, when cultured in the presence of exogenous MCSF and RANKL.  The results 
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demonstrated that a change in the ability of CD14+ cells to undergo spontaneous or 
RANKL-induced OC formation is not related to fracture or the pathogenesis of OP.  The 
resorptive activity of the OC was then investigated to determine whether fracture or OP 
increased the ability of the OC to resorb bone. 
In the 2003 study by Jevon et al (383) OC derived from PBMCs from osteoporotic patients 
demonstrated increased OC resorptive activity, with respect to pre-menopausal controls.  
Interestingly this was not due to an increase in OC numbers, suggesting a fundamental 
change in OC resorptive activity.  In this present study a low level of resorption was 
detected in the patient OC cultures.  However, fracture and OP had no effect on OC 
resorptive function.   As with OC formation in the D’Amelio et al (200) study, the key 
factor in the increased resorption observed in the Jevon et al (383) study seems to be the 
presence of PBMCs in the cultures.  Factors released by the PBMCs can exert a direct 
effect on the formation and function of the OC.  This would lead to the difference in 
results observed between the present study and those by D’Amelio et al (200) and Jevon 
et al (383).  Fracture and OP have been demonstrated to have no effect on the ability of 
post-menopausal-derived CD14+ OC precursors to undergo osteoclastogenesis.  To 
determine whether they have any effect on mediators of OC formation and function, 
levels of CCL3 and total MMP-9 were evaluated in the culture supernatants. 
Published studies have demonstrated CCL3 (87, 88) and total MMP-9 (350) to be 
mediators of OC formation and resorptive activity; with CCL3 expression involved in OC 
formation (87, 88) and MMP-9 involved in OC resorption (350).  Levels of CCL3 were 
comparable between the three cohorts across the time course: consistent with the 
comparable levels of OC formation observed between the cultures.  In contrast to CCL3, 
fracture was found to have a significant effect on expression of total MMP-9.  The 
increase in total MMP-9 observed in the fracture cultures is supported by studies from 
Colnot et al (384) and Uusitalo et al (385).  In the study by Colnot et al (384) MMP-9 was 
demonstrated to regulate crucial events in fracture repair.  MMP-9-deficient mice were 
found to have non-union and delayed union of fractures due to dysregulation of cartliage 
remodelling and impaired ossification.  In the work published by Uusitalo et al (385) MMP-
9 production was demonstrated to be significantly up-regulated following fracture.  
Immunohistochemistry identified MMP-9 to be predominantly localised in osteoclasts and 
chondroclasts at the osteochondral junction.  Taken with the data from the current study 
the results demonstrate that the presence of fracture has a significant effect on total 
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MMP-9 release from OC and their precursors.  The results reported in this chapter have 
demonstrated that fracture and OP have no direct effect on osteoclast formation or OC 
resorptive activity.  While DR3 expression was not identified on the CD14+ cells, the effect 
of fracture and OP on cellular response to TL1A was investigated.  
When TL1A was added to the cultures expression of DR3 was not detected on the surface 
of the cells.  It cannot be conclusively ascertained however, whether induction of DR3 
expression was delayed, appearing on the surface of the cells after the TL1A had been 
added to the cultures.  Addition of TL1A to the non-OP and fracture cultures had no effect 
on total cell number, osteoclast number, % osteoclasts or resorptive function.  This 
suggested that DR3 expression on the CD14+ cells was not delayed and induced at a later 
time point 
The investigation into the role of DR3/TL1A into the pathogenesis of fracture and OP has 
revealed some surprising results.  However, care must be taken with their interpretation 
as the study was limited in both patient numbers and cohorts recruited.  TL1A was 
elevated in the fracture cohorts; however, increased sample numbers are required to 
conclusively prove whether this difference is significant. A post-study power calculation 
indicated that a sample size of 18 patients per cohort is required to obtain a conclusive 
result.  Comparison between the fracture cohorts also demonstrated no difference in 
serum TL1A, suggesting that OP has no effect on TL1A expression.  Without a ‘with 
osteoporosis without fracture’ cohort however, this conclusion cannot be confidently 
made.  Cellular studies also revealed that DR3 is not expressed on OC precursors isolated 
from post-menopausal women.  While OP led to an increase in OC precursor cell viability 
there was no difference in their ability to undergo osteoclastogenesis or increased 
resorptive function.  This data was in contrast to that by D’Amelio et al (200) and Jevon et 
al (383); highlighting the importance of all cell types in the pathogenesis of osteoporosis.  
While an increase in OC activity has been highlighted as a key factor in the progression of 
OP, decreased bone formation by the OB also plays a significant role (198, 199).  The 
presence of DR3 on osteoblasts has been shown by Borysenko et al (241) and Bu et al 
(261).  The role that DR3 plays in OB differentiation and activation has not been fully 
investigated, though it was shown by Borysenko et al (241) to have a potential role in 
normal OB function.  The effect of DR3 on OB differentiation and function will be 
investigated in chapter 6. 
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5.4 Conclusion 
At the conclusion of this chapter the following objectives were met: 
 Serum TL1A was identified as being significantly elevated in RF+ RA patients. 
 Anti-TNF treatment was determined to have no significant effect on RA patient 
serum TL1A levels. 
 Serum TL1A levels were demonstrated to be linked to erosive pathology in RA. 
 Ethical approval for the collection and analysis of blood samples, from 3 cohorts 
of post-menopausal treatment-naïve patients was acquired and patients were 
recruited to the cohorts. 
 Serum TL1A was identified as being raised in post-menopausal fracture patients. 
 DR3 expression was revealed to be absent from post-menopausal OC precursors. 
 Fracture and OP were identified as not having a direct effect on OC formation and 
resorptive activity, or altering cellular response to TL1A. 
The aim of this chapter was to examine the role of DR3/TL1A in the pathogenesis of 
diseases characterised by OC hyper-activity.  The results have demonstrated that TL1A is 
elevated in arthritides associated with persistent inflammation; significantly so in patients 
with RA over healthy controls.  Further breakdown of the RA patients into sub-groups 
according to their RF status (RF+ and RF-) revealed that the presence of RF had a significant 
effect on TL1A levels, causing increased expression of the cytokine by stimulated 
macrophages (253, 366).  The effect of anti-TNF treatment on serum TL1A is debatable 
and requires further work.  Results from this study fail to demonstrate anti-TNF treatment 
having a significant effect on TL1A levels.  A study by Bamias et al (264), however, showed 
a significant reduction in TL1A following anti-TNF treatment.  It is interesting to note that 
TL1A levels in the anti-TNF treatment patients in the Bamias et al (264) study were still 
considerably higher than healthy controls; suggesting that TL1A still exerts a significant 
effect on the pathogenesis of the disease.  This would provide a possible explanation for 
why some people do not respond to anti-TNF treatment.  Comparison of TL1A levels in RA 
patients with non-erosive and erosive disease also pointed to a role of the cytokine in 
driving erosive pathology.  Further work into whether serum TL1A could be used as an 
early prognostic marker for RA disease severity, however, remains to be seen.  For the 
first time this study has also examined the role of DR3 and TL1A in the pathogenesis of 
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fracture and OP through a proof-of-concept analysis of three post-menopausal patient 
cohorts: 
 -osteoporosis –fracture 
 -osteoporosis +fracture 
 +osteoporosis +fracture 
Fracture patients were demonstrated to have increased levels of serum TL1A; however, 
this increase was not statistically significant.  Whether serum TL1A is therefore up-
regulated following fracture and the significance of this requires further testing with much 
larger patient numbers.  Culture of the patient-derived CD14+ cells demonstrated OP to 
have a significant effect on cell viability.  Interestingly, however, this increase in cell 
viability did not translate into increased OC formation or resorptive activity.  These results 
were in contrast to work published by D’Amelio et al (200) and Jevon et al (383) who 
showed an increase in osteoclast differentiation and activity, respectively, in cultures from 
osteoporotic patients.  These studies however, used PBMCs as a source of cells and 
highlight the important role of other cell types in the pathogenesis of osteoporosis.  
Fracture and OP were also deemed to have no effect on OC precursor response to TL1A.   
TL1A had no effect on cell survival, OC formation or resorptive activity in any of the 
cultures tested.  The most intriguing aspect of this study was the demonstration that 
patient-derived CD14+ cells, cultured for 7 days in MCSF, showed no expression of DR3.  
The reasons for the lack of expression, when compared to the results from chapter 4, 
suggests a fundamental change in the cells with aging. However, there are currently no 
studies looking at the expression of death receptors on the surface of immune cells and 
how these change with age.  This finding could have important implications not only in the 
pathogenesis of adverse bone pathology but also with the impaired immune response 
associated with aging.  Further research is required to elucidate the importance of DR3 
expression on normal monocyte / macrophage / T cell immune function.  In addition to 
OC precursor’s expression of DR3 has also been demonstrated on the surface of OB.  
However, whether it has a role in OB differentiation and bone formation is unknown and 
will be investigated in the next chapter. 
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Chapter 6 
The Role of Death Receptor 3 in Murine 
Osteoblast Function 
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6.1 Introduction 
Investigations in chapter 5, which studied the potential role of the DR3/TL1A pathway in 
the pathogenesis of RA and OP, produced a number of intriguing findings.   Serum TL1A 
levels were frequently higher in seropositive RA patients with erosive bone disease than in 
RA patients without bone changes detectable by X-ray.  However, there was no link 
between DR3/TL1A and increased fracture risk or OP. This was a surprising finding as each 
condition is characterised by OC-over activity, and both TL1A and DR3 were found to 
promote OC differentiation and increase bone-matrix resorption (Chapter 4).  Increased 
OC activity is a causal factor in reducing BMD and bone quality associated with OP.  
However, reduced OB activity and increased differentiation of mesenchymal stem cells 
into adipocytes rather than OB also plays a significant role (198, 199, 386).   As discussed 
in the introduction OB activity is regulated by a number of factors within its 
microenvironment, including members of the TNFSF and their receptors.  Recent studies 
by Bu et al (261) and Borysenko et al (241) identified expression of DR3 on the surface of 
human OB and the MG63 OB cell line, revealing it as a potential regulator of bone 
formation.  This chapter will therefore investigate whether DR3 and TL1A are expressed 
by murine OB, and assess the functional role they play in OB differentiation and bone 
formation in vitro. 
The function of the death receptor group of the TNFRSF in OB differentiation, function 
and survival has not been fully defined, with studies demonstrating opposing effects of 
signalling on OB differentiation and survival.  Osteoblasts express the death receptors Fas 
(CD95, TNFRSF6) (261, 387), DR4 (TNFRSF10A), DR5 (TNFRSF10B) (261, 388), TNFR1 
(TNFRSF1A) (261) and DR3 (TNFRSF25) (241, 261) at varying levels throughout their 
differentiation.  Studies into the effects of these receptors and their ligands on OB biology 
have demonstrated roles in inhibition of OB differentiation (261, 387, 389-392), induction 
of apoptosis (261, 388, 393, 394) and stimulation of early OB proliferation (389, 395).  
These data highlight the complex role that death receptors play in OB homeostasis, 
simultaneously affecting survival and differentiation.  Expression of full-length DR3 on 
primary human OB and the MG63 cell line was initially shown by Bu et al (261).  This 
finding was supported by Borysenko et al (241), who additionally investigated the role of 
DR3 and TL1A in OB survival. 
In the Borysenko et al (241) study cross-linking of DR3 with an anti-DR3 monoclonal 
antibody (mAb) on the osteoblastic MG63 cell line was demonstrated to result in the 
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apoptosis of a large proportion of cells. This effect however, was only observed at low cell 
densities (1x103 cells/cm2).  At higher cell densities (3x103 cells/cm2 and 9x103 cells/cm2) 
the effects of DR3 cross-linking on survival were lost in a graded manner; with % viable 
cells comparable between the naïve and anti-DR3 treated cultures.  Intriguingly, addition 
of TL1A to primary OB cultures had no effect on apoptosis, suggesting that the primary 
role of DR3/TL1A in OB biology is not cell survival.  This is supported by the results from 
long-term antibody cross-linking of DR3 on MG63 cells.  These experiments showed that 
antibody cross-linking resulted in altered growth pattern of the cells to a monotonous 
monolayer and reduced matrix synthesis, suggesting that activation of DR3 inhibits OB 
differentiation.  This role of DR3 in inhibition of OB differentiation was not conclusive, the 
effects were not reproducible with TL1A or in primary human OB (241).  Therefore, 
activation of DR3 expressed on OB can result in a number of effects: inducing apoptosis, 
or inhibiting differentiation of MG63 cells.  The study by Borysenko et al only investigated 
activation of DR3 by cross-linking or with non-physiological levels of TL1A (0.1μg/ml) on 
an OB cell line.  The potential role of DR3 in the regulation of normal primary OB 
differentiation and function was not investigated.  To address this question the role of 
DR3 in OB differentiation and function was analysed in this chapter using primary OB 
isolated from male DR3wt and DR3ko mice.   
Analysis of OB alkaline phosphatase (ALP) activity and mineral deposition can provide 
valuable insight into their differentiation and function (396-402).  ALP is an early marker 
of OB differentiation and is highly synthesised by the cells.  It is initially expressed in the 
cytoplasm of the OB, though it is soon observed on the cell surface and in matrix vesicles 
that interact with the mineralised matrix (403, 404).  Deletion of the tissue non-specific 
form of ALP in mice results in abnormal calcification, indicating the importance of the 
enzyme in the formation of the osteoid and in mineral deposition (405).  As part of the 
mineralisation process the OB is required to break down organic components of the bone 
matrix; either removing old collagen fragments from the surface of the resorption pit or as 
part of matrix maturation (18-20, 166).  This process has been demonstrated to be 
mediated by members of the MMP family (19).  Work by Parikka et al (19) demonstrated 
that the osteoprogenitor population express MMP-2, -8, -13 and -14.  Further work by Ben 
David et al (402) revealed the presence of the gelatinase MMP-9 in mesenchymal stem 
cell-derived cultures.  Investigations in chapter 3 and chapter 4, which studied the effect 
of DR3 in OC differentiation and function, demonstrated that DR3/TL1A affects MMP-9 
activation.  The effect of DR3 on OB-derived MMP activation has never been investigated. 
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The aim of this chapter was to explore the role of DR3 in regulating OB differentiation and 
mineral deposition using precursor cells derived from the bone marrow of DR3wt and 
DR3ko mice.  The effect of DR3 on OB differentiation was investigated by monitoring ALP 
levels over the time course of the experiments.  Supernatants were collected across the 
culture period.  MMP-2 and -9 were measured to determine DR3’s effect on OB MMP 
expression.  DR3’s role in regulating the function of mature OB was examined by 
quantifying levels of mineral deposition.  The specific objectives of this chapter are: 
 To isolate and culture osteoprogenitor cells from DBA/1 mice. 
 To characterise DR3 and TL1A expression by osteoprogenitors and mineralising 
osteoblasts. 
 To assess the impact of DR3 on alkaline phosphatase, mineralisation and pro 
MMP-9 expression by osteoblasts grown from two mouse strains (DBA/1 and 
C57BL/6). 
 To determine the effect of DR3 on osteoblast-derived MMP-2 and MMP-9 levels. 
 To characterise the in vivo bone phenotype of DR3wt and DR3ko mice, bred on a 
DBA/1 background.  Male and female mice were evaluated aged 8 weeks and 20 
weeks. 
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6.2 Results 
6.2.1 Isolation and Culture of Osteoprogenitors from DBA/1 Mice 
For in vitro functional analyses, OB are frequently derived from mesenchymal stem cells 
that are isolated from BM and bone explants (398, 406, 407).  OB assays from DBA/1 mice 
had not been established previously in the laboratory.  In the first instance the best source 
of progenitor cells was identified, BM cells (from femora) and homogenised 
epiphysis/metaphysis explants from one mouse were tested (section 2.2.16).  Bone 
marrow cultures produced significantly increased numbers of OPCs compared to the 
explant cultures across the time course (P=<0.0001; Fig 6.1 (a)).  Significant differences 
were noted in confluence at every time point from day 26 to day 36 (58±3% versus 
43±3%, P=<0.01).  Cells isolated from the BM and explant cultures never reached 100% 
confluence.   
Since BM cells produced the more efficient culture system, they were adopted as the cell 
source of choice for all subsequent assays.  Next BM were isolated from the femora of 3 
animals (DR3wt and DR3ko; Fig 6.1 (b)) to determine whether increased numbers of starting 
mesenchymal stem cells would give rise to sufficient healthy OPCs for functional 
assessments.  After only 3 days in culture, OPC confluence was calculated as 63±3% in 
DR3wt and 58±3% in DR3ko cultures, and reached near 100% confluence at day 10 
(DR3wt=95±5% versus DR3ko=98±3%). 
All subsequent OB assays using DBA/1 mouse cells used BM isolated from the femora of 
three 3 animals as the initial source of MSCs.  
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6.2.2 Expression of DR3 on Osteoprogenitors and Mineralising Osteoblasts 
Borysenko et al (241) demonstrated expression of DR3 on the MG63 osteoblast cell line 
and human osteoblasts cultured from mesenchymal stem cells by flow cytometry and 
western analysis.   However, expression of DR3 on murine OPCs and mature mineralising 
OB has not been demonstrated previously.  CD44 and RANKL are expressed at all stages of 
OB differentiation (408-413); they were tested alongside DR3 as surrogate markers of OB 
differentiation.  Expression levels of DR3, CD44 and RANKL were measured by flow 
cytometry (section 2.2.17) and reported as fold increase in median fluorescent intensity 
(MFI) of the isotype control (mean±SEM).  
DR3 expression was detected on the surface of DR3wt OPCs (1.8±0.2).  A small sub-
population of DR3wt cells demonstrated increased levels of DR3 expression, visualised by 
the shoulder present on the flow cytometry histogram.  Levels of DR3 expression were 
reduced on DR3wt mineralising OB (1.4±0.8; Fig 6.2 (a)) compared to the OPCs.   Negligible 
levels of DR3 were detected on the surface of DR3ko OPCs and mineralising OB.  The 
diminutive expression detected was attributed to non-specific binding of the polyclonal 
antibody used for analysis.   
Comparable levels of CD44 (DR3wt=14.7±1.6, DR3ko=13.3±2.4) and RANKL (DR3wt=3.0±0.8, 
DR3ko=2.6±0.8) expression were detected on the surface of OPCs from DR3wt and DR3ko 
mice.  Analysis of the DR3wt and DR3ko mineralising OB demonstrated no significant 
difference in CD44 (DR3wt=12.4±3.8, DR3ko=13.0±5.3) or RANKL (DR3wt=5.6±2.3%, 
DR3ko=5.5±2.4) expression between the genotypes (Fig 6.2 (b) and Fig 6.2 (c)) 
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6.2.3 Development of Primers for the Detection of TL1A 
TL1A expression by OPCs and mineralising OB has not been determined previously.  At the 
time this study was conducted, commercial antibodies for the detection of murine TL1A 
were unavailable.  For this reason, four primers for the detection of murine TL1A mRNA 
(by PCR) were designed and tested in-house.  As a positive control TL1A expression was 
induced by stimulation with immune complexes (IC) in RAW cells.  mRNA was isolated and 
converted to cDNA (section 2.2.18.1).  TL1A gradient PCR was performed according to 
section 2.2.18.2.  Estimated TL1A product sizes for each of the four primers were 
calculated as follows: primer 1 – 75bp, primer 2 – 149bp, primer 3 – 166bp, and primer 4 
– 91bp.  No bands were detected at any temperatures for primer 1.  At 53°C and 60°C no 
product was detected for primer 2 and 3, while multiple bands were detected at 55.6°C 
(primer 2 = 200bp, 250bp and ~300bp; primer 3 = 150bp and 300bp), 58°C (primer 2 = 
200bp, 250bp and ~300bp; primer 3 = 150bp and 100bp) and 59°C (primer 2 = 100bp, 
200bp and 300bp; primer 3 = 150bp and 100bp), suggesting a level of non-specific 
amplification (Fig 6.3 (a)).  A band at ~96bp was detected at all temperatures for primer 4, 
corresponding to the estimated TL1A product size (Fig 6.3 (b)).  All subsequent murine 
TL1A PCR reactions were performed with primer 4 and an annealing temperature of 59°C. 
 
6.2.4 Assessing the Specificity of Primer 4 for the Amplification of TL1A mRNA  
To assess the specificity of primer 4 for TL1A, amplified product from section 6.2.3 was 
excised from the electrophoresis gel (Fig 6.4 (a)) and sent to Eurofins MWG Operon 
(Ebersberg, Germany) for sequencing.  Results from the sequencing and subsequent 
BLAST analysis revealed the product to be a 94% match to murine TL1A (Fig 6.4 (b)), with 
the remaining 6% error possibly due to mis-reading by the sequencer.  The results confirm 
the specificity of primer 4 for TL1A. 
 
6.2.5 Determining Expression of TL1A by Osteoprogenitors and Differentiating 
Osteoblasts 
Investigation into the effect of DR3/TL1A in OC formation and resorptive function in 
chapter 3 revealed contrasting effects of TL1A in the DBA/1 and C57BL/6 strains.   
Subsequent assays in this chapter were performed using cells derived from DBA/1 and 
C57BL/6 mice, to determine whether there were strain-specific differences in OB biology.  
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DBA/1 OPCs were isolated and cultured according to section 6.2.1.  C57BL/6 OPCs were 
isolated and cultured according to work previously carried out in the laboratory by Anja 
Bloom (308).  To assess whether OPC or differentiating OB express TL1A, mRNA was 
isolated from C57BL/6 and DBA/1 DR3wt and DR3ko cells.  mRNA was tested by RT-PCR 
using primer 4 (section 2.2.24.3).  A band at ~96bp was detected for OPCs (day 0) and 
differentiating OB (days 5, 10 and 15) corresponding to the size of TL1A (Fig 6.5).  The 
result demonstrates that OPCs and differentiating osteoblasts produce TL1A mRNA. 
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6.2.6 Assessing the Impact of DR3 on Osteoblast Alkaline Phosphatase Activity 
To assess the effect of DR3 on OB differentiation, mineralisation assays were performed 
using DBA/1 and C57BL/6-derived cells and levels of the early OB differentiation marker 
ALP were analysed (section 2.2.16.1).  ALP activity was expressed as % staining 
(mean±SEM) for graphical presentation (Fig 6.6).   
Levels of ALP staining were significantly elevated in DBA/1 DR3wt cultures across the time 
course compared to the DR3ko cultures (P=<0.05; Fig 6.7 (a)).  At the earliest time point 
assessed (day 17) levels were raised in the DR3wt cultures (43±8%) over the DR3ko cultures 
(32±7%), however this difference was not significant.  These levels did not vary 
significantly over the remaining time points assessed: day 20, day 23 and day 26.  
In C57BL/6 cultures (Fig 6.7 (b)) levels of ALP staining at day 17 were significantly elevated 
in the DR3wt (66±2%) versus DR3ko (34±3%; P=<0.0001) cultures.  These levels remained 
relatively constant to day 23.  At day 26 a significant increase in ALP staining was observed 
in the DR3wt (76±3%; P=<0.001) compared to DR3ko (44±4%; P= <0.01) cultures.  
Significantly elevated ALP staining was detected in the in DR3wt cultures (P=<0.0001) 
across the time course. 
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6.2.7 Determining the Effect of DR3 on Osteoblast Cell Number 
The increase in ALP staining observed in section 6.2.6 could be due to increased cell 
number in the DR3wt cultures.  To identify whether DR3 affected cell proliferation, cells 
were stained with DAPI and cell number calculated (section 2.2.14.5; Fig 6.8(a)).  
Comparison of cell number (cell / mm2, mean±SEM) demonstrated no significant 
difference between DR3wt (34.5±3.2) and DR3ko (35.8±3.6) cultures (Fig 6.8 (b)).  The data 
indicates that DR3 does not affect OPC / OB proliferation or cell survival.   
 
6.2.8 Determining the Effect of DR3 on the Expression of Pro MMP-9 
Degradation of the ECM and matrix maturation by OB-lineage cells during bone 
remodelling is regulated by members of the matrix metalloproteinase family, which 
include MMP-9 (121, 414).  As a primary functional measure, the effect of DR3 upon pro 
MMP-9 expression by OB was determined.  Levels were measured (by ELISA) across the 
differentiation time course in supernatants harvested from both DBA/1 and C57BL/6 
cultures (section 2.2.14.4.1). 
In DBA/1 cultures, levels of pro MMP-9 (Fig 6.9 (a)); mean±SEM) were significantly 
elevated at day 3 when DR3wt and DR3ko were compared (3.45±0.67ng/ml versus 
1.47±0.19ng/ml; P=<0.0001).  At day 7 pro MMP-9 levels in both DR3wt and DR3ko cultures 
dropped (0.80±0.16ng/ml versus 0.68±0.23ng/ml) and continued to decline to day 26 
(0.21±0.18ng/ml versus 0.16±0.16ng/ml), when levels were comparable.  Nevertheless, 
levels of pro MMP-9 were significantly elevated in the DR3wt versus DR3ko cultures across 
the time course (P=<0.05). 
In C57BL/6 cultures (Fig 6.9 (b)) levels of pro MMP-9 at day 3 were 0.31±0.10ng/ml and 
0.03±0.02ng/ml for DR3wt and DR3ko respectively.  These levels were lower than those 
observed in the DBA/1 cultures.  Pro MMP-9 levels remained low and relatively consistent 
until day 14, when they increased significantly to 0.51±0.17ng/ml for DR3wt and 
4.09±1.00ng/ml for DR3ko (P=<0.05).  Maximum pro MMP-9 levels were observed in DR3wt 
on day 23 (2.49±0.72ng/ml) and DR3ko on day 20 (7.44±1.24ng/ml).  This translated into 
significantly elevated pro MMP-9 in DR3ko over DR3wt cultures across the time course 
(P=<0.0001). 
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6.2.9 Identifying the Effect of DR3 on Activation of Osteoblast-Derived MMPs in 
C57BL/6 Cultures 
Analysis of DR3wt and DR3ko cultures in section 6.2.8 showed a significant increase in pro 
MMP-9 in the DR3ko cultures.  To ascertain whether DR3 was involved in the activation of 
OB-derived MMPs, a gelatine zymogram (section 2.2.14.4.1) was used to semi-
quantitatively measure levels of pro and active MMP-2 and MMP-9 in C57BL/6 DR3wt and 
DR3ko OB cultures (n=1; Fig 6.10).  Results are reported graphically as band intensity 
relative to a pro MMP-9 standard at a known concentration (10ng/ml).  Further testing of 
C57BL/6 assays and DBA/1 assays was not performed due to time constraints of the 
project and ending of the AR UK studentship that funded this study.  
Levels of pro MMP-2 detected at day 3 were low in both DR3wt (0.002) and DR3ko (0.002) 
cultures (Fig 6.11 (a, i)).  At day 7 the relative levels of pro MMP-2 in both DR3wt and DR3ko 
cultures increased (0.10 versus 0.08) and showed minor variation across the 
differentiation time course.  In contrast to pro MMP-2, at day 3 levels of active MMP-2 
(Fig 6.11 (a, ii)) were 5.8-fold higher in the DR3wt (0.64) cultures compared to the DR3ko 
(0.11) cultures.   Levels of active MMP-2 increased in the DR3ko cultures up to day 14 
(0.53), where they were comparable to the DR3wt (0.56).  Expression of active MMP-2 
followed a similar pattern in DR3wt and DR3ko cultures for the remainder of the time 
course. 
Relative band intensity of pro MMP-9 at day 3 was calculated at 0.06 and 0.05 in DR3wt 
and DR3ko cultures respectively (Fig 6.11 (b, i)).  Levels of pro MMP-9 remained 
comparable and relatively low across the time course, peaking at day 23 in the DR3wt 
(0.10) and day 17 in the DR3ko (0.09) cultures.  This result differs to the result in section 
6.2.8 as DR3 had no effect on pro MMP-9 expression.  DR3 was demonstrated to have an 
important role in the activation of OB-derived MMP-9.  Stark differences in levels of active 
MMP-9 were observed between the DR3wt and DR3ko cultures across the time course (Fig 
6.11 (b, ii)). Levels of active MMP-9 were highest at day 3 in the DR3wt cultures (0.19) and 
declined to day 20 (0.03).  In contrast, active MMP-9 was not detected in the DR3ko 
cultures until day 20 (0.05), where levels were similar to the DR3wt. 
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6.2.10 Assessing the Effect of DR3 on Osteoblast Mineralisation  
The results from sections 6.2.6 and 6.2.9 showed that the presence of DR3 was linked to 
increased levels of OB differentiation and MMP activation.  To determine what affect this 
had on OB mineral deposition, levels of mineralisation in DBA/1 and C57BL/6 cultures 
were analysed (Fig 6.12).   
Levels of mineralisation (%; mean±SEM) in DBA/1 cultures (Fig 6.13 (a)) at day 17 were 
calculated at 2.6±0.4% (DR3wt) and 1.8±0.3% (DR3ko).  Mineralisation increased at day 20 
in the DR3wt cultures (4.5±0.7%), while levels remained constant in the DR3ko (1.8±0.3%).  
Significantly elevated levels of mineralisation were detected in DR3wt cultures at day 23 
(DR3wt=8.8±2.3% versus DR3ko=3.0±0.6%; P=<0.0001).  This resulted in significantly 
increased levels of mineralisation across the time course in the DR3wt cultures 
(P=<0.0001). 
In C57BL/6 cultures levels of mineralisation were observed to be elevated compared to 
the DBA/1 cultures (Fig 6.13 (b)).  At day 17 mineralisation in the DR3wt and DR3ko cultures 
were 19.1±4.0% and 2.5±0.9% respectively.  Levels of mineralisation significantly 
increased in DR3wt (29.1±6.5%) cultures at day 20 compared to the DR3ko (3.5±1.1%; 
P=<0.01).  Both DR3wt and DR3ko cultures displayed increased mineralisation over the 
remaining time points tested, resulting in significantly elevated  mineralisation in the 
DR3wt over the DR3ko cultures (P=<0.0001).  
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6.2.11 Comparison of DBA/1 and C57BL/6 Osteoblast Phenotype 
Differences in in vivo fracture healing and adult bone density have been demonstrated 
between inbred stains of mice (325, 326).  The causes of these differences are unknown 
but variations in vitro MSC growth kinetics have been reported, suggesting dissimilarities 
in OB behaviour between strains (134, 327).  To assess whether there was any 
fundamental variation in differentiation and function between DBA/1 and C57BL/6-
derived OB, ALP staining (section 6.2.6), pro MMP-9 expression (section 6.2.8) and 
mineralisation (section 6.2.10) were compared in DR3wt cultures.   
ALP activity was presented graphically as % of well displaying positive staining 
(mean±SEM).  At day 17 levels of ALP staining (section 6.2.6) were significantly elevated in 
the C57BL/6 DR3wt cultures compared to the DBA/1 DR3wt cultures (66±2% versus 43±8%; 
P=<0.01). Levels of ALP staining remained relatively constant in the DBA/1 DR3wt cultures 
across the time course.  In the C57BL/6 cultures ALP staining remained constant up to day 
23, a significant increase in staining was observed at day 26 (76±3%; P=<0.001).  
Significantly elevated levels of ALP were detected across the time course in the C57BL/6 
DR3wt compared to the DBA/1 DR3wt cultures (P=<0.0001; Fig 6.14 (a)).     
The expression profile of pro MMP-9 (section 6.2.8) was observed to differ between the 
DBA/1 and C57BL/6 DR3wt cultures across the time course (Fig 6.14 (b)), with levels 
peaking early in the DBA/1 (day 3) and late in the C57BL/6 (day 23) cultures.  At day 3 
levels of pro MMP-9 were 10 times higher in the DBA/1 cultures over the C57BL/6 
(3.45±0.67ng/ml versus 0.31±0.10ng/ml; P=<0.0001).  Levels were comparable between 
the two strains from day 10 to day 17.  At day 20 the expression of pro MMP-9 reversed 
with increased levels detected in the C57BL/6 cultures compared to the DBA/1 
(1.08±0.36ng/ml versus 0.17±0.12ng/ml).  Expression of pro MMP-9 peaked in the 
C57BL/6 cultures at day 23 with levels displaying a significant 17-fold increase compared 
to the DBA/1 cultures (2.49±0.72ng/ml versus 0.14±0.09ng/ml; P=<0.0001). Across the 
time course no significant difference in pro MMP-9 expression was detected between the 
DBA/1 and C57BL/6 cultures. 
Mineral deposition was expressed as a % of the well surface with positive staining for 
alizarin red (mean±SEM).  Levels of mineralisation (section 6.2.10) in the C57BL/6 DR3wt 
cultures were significantly elevated across the time course compared to the DBA/1 DR3wt 
(P=<0.0001; Fig 6.14 (c)).  Mineralisation at day 17 was calculated at 19±4% (C57BL/6) and 
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3±0.4% (DBA/1).  Levels of mineralisation increased in both the C57BL/6 and DBA/1 
cultures across the differentiation time course.  Mineralisation peaked at day 26, where 
significantly elevated levels were detected in the C57BL/6 compared to the DBA/1 
cultures (55±8% versus 8±1%; P=<0.0001). 
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6.2.12 Phenotypic Analysis of Weight, Femur Length and Bone Density in DBA/1 DR3wt 
and DR3ko Mice 
The results from the in vitro OB mineralisation assays demonstrated differences in 
differentiation (section 6.2.6) and mineral deposition (section 6.2.10) between DBA/1 and 
C57BL/6 DR3wt- and DR3ko-derived OB.  To determine whether these differences had an 
effect on the in vivo bone phenotype, mouse weight, femur length, femur bone density 
and vertebra bone density were measured.  Male and female DBA/1 mice were used for 
the study to correspond with the OC assays (chapter 3) and OB assays (section 2.2.20; Fig 
6.15).  Measurements were taken in mice aged 8 and 20 weeks to identify any changes 
that occur during aging. 
 6.2.12.1 Mouse Weight 
Mouse weights are reported as grams (mean±SEM) for graphical presentation.  At 8 weeks 
(Fig 6.16 (a)) DR3wt male mice were significantly heavier than their DR3ko counterparts 
(21.3±0.6g versus 18.5±0.6g; P=<0.01).  In the female cohort no difference was detected 
between the DR3wt and DR3ko mice (15.3±0.3g versus 16.5±0.2g).  Male DR3wt (P=<0.0001) 
and DR3ko (P=<0.05) mice were significantly heavier than their female counterparts.  At 20 
weeks of age (Fig 6.17 (a)) no significant difference in weight was detected between male 
DR3wt and DR3ko mice (30.7±1.6g versus 29.3±0.7g).  In the female cohort DR3wt mice 
weighed significantly more than the DR3ko mice (25.5±0.8g versus 20.3±1.1g; P=<0.05).  
Male DR3wt (P=<0.05) and DR3ko (P=<0.0001) mice were significantly heavier than their 
female counterparts at 20 weeks. 
 6.2.12.2 Femur Length 
X-rays of disassociated murine femora were taken using the Carestream In Vivo FX Pro 
(section 2.2.20).  Femur lengths were calculated using Carestream Molecular Imaging 
Software and presented graphically in mm (mean±SEM).   At 8 weeks of age (Fig 6.16 (b)) 
no significant differences were observed in femora length between the DR3wt and the 
DR3ko male (12.4±0.2mm versus 11.8±0.4mm) and female (11.7±0.3mm versus 
11.8±0.2mm) cohorts.  At 20 weeks (Fig 6.17 (b)) no significant difference in femur length 
was detected in the male cohort (11.4±0.3mm versus 10.7±0.2mm) or the female cohort 
(9.5±0.4mm versus 10.5±0.1mm; P=<0.05).  Male DR3wt femora were significantly longer 
than the female DR3wt femora (P=<0.0001) at 20 weeks. 
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 6.2.12.3 Femur and Vertebra Bone Density 
Femur and spine bone density (g/cm3, mean±SEM) were calculated from X-rays according 
to section 2.2.26.  At 8 weeks of age male femur bone densities were 1.63±0.15 (DR3wt) 
and 1.50±0.09 (DR3ko).  Female femora bone densities were calculated as 1.52±0.09 and 
1.61±0.03 in DR3wt and DR3ko mice respectively.  Comparison of the data revealed no 
significant difference in femora bone density between the DR3wt and DR3ko mice.  As with 
the femora, no significant difference was detected in vertebra bone density at 8 weeks in 
male and female mice.  Vertebra bone densities in male mice were 2.56±0.39 (DR3wt) and 
2.83±0.30 (DR3ko).  Female vertebra bone density at 8 weeks was 2.57±0.11 in the DR3wt 
and 2.77±0.16 in the DR3ko (Fig 6.16 (c, ii)). 
Femora bone density at 20 weeks (Fig 6.17 (c, i)) in male DBA/1 mice were 1.71±0.06 and 
1.73±0.04 (DR3wt and DR3ko).  In females, femora bone density in the DR3wt was 1.70±0.02 
and 1.72±0.03 in the DR3ko.  Differences in femora bone density in the males and females 
at 20 weeks were not significant.  Comparison of vertebra bone density at 20 weeks (Fig 
6.17 (c, ii)) revealed no significant difference between the DR3wt and DR3ko in both male 
(2.72±0.27 versus 3.39±0.32) and female (3.29±0.15 versus 3.05±0.49) DBA/1 mice. 
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6.3 Discussion 
Formation of new bone is the principal function of the OB (130).  OB bone formation is 
coupled to OC resorptive activity, resulting in a balanced cycle of bone remodelling.  
Aberrant OB activity has been linked to the pathogenesis of a number of diseases: 
decreased bone formation in OP (198, 199); and increased bone formation in the 
spondyloartritides, such as ankylosing spondylitis (AS) (288, 354, 415, 416).  The effects of 
the TNFRSF death receptors on OB activity are poorly understood, with much debate on 
their exact role.  Members have been demonstrated to induce apoptosis, inhibit 
differentiation or have no effect at all (261, 387-390, 417, 418).  Work published by Bu et 
al (261) and Borysenko et al (241) showed positive expression of DR3 on the surface of the 
human OB MG63 cell line and primary human OB.  Whether DR3 is expressed by murine 
primary OB and the role that it plays in normal OB function has never been investigated.  
TL1A, the TNFSF ligand for DR3, is known to be expressed by endothelial cells as well as 
activated monocytes, dendritic cells and T cells (237, 252, 253).  No studies have been 
performed however, investigating whether TL1A is produced by OPCs or mineralising OB.  
The aims of this chapter were to firstly assess whether murine OPCs and OB express DR3 
and TL1A.  Secondly, to investigate the role of DR3 in OB differentiation, matrix 
maturation and mineral deposition. 
Osteoblasts originate from mesenchymal stem cells (MSCs).  The MSC differentiates into 
the mature mineralising OB through a number of intermediary stages; the progenitor cell, 
the osteoprogenitor, the immature OB and finally the mature OB.  In studies where 
murine OBs are required BM is commonly used as the source of MSCs (398, 399, 401, 419, 
420).  However, other MSC sources have been employed, including epiphysis explants 
(421), compact bone and adipose tissue (422).  In the present study DBA/1 BM and 
epiphysis / metaphysis explants were investigated to determine which MSC source 
produced the higher number of OPCs for use in subsequent mineralisation assays.  
Increased numbers of OPCs were observed in the BM cultures.  This result was in contrast 
to that by Cheng et al (421) who revealed epiphysis-derived MSCs had increased cell 
proliferation and differentiation potential over BM-derived MSCs.  The difference in 
results between the two studies can be explained by the method in which the BM was 
isolated.  In the Cheng et al (421) study BM was isolated exclusively from the diaphysis, as 
the epiphyses were completely removed.  In the present study the epiphyses were still 
present when the BM was isolated from the femora, meaning that MSCs present in the 
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epiphysis, as well as the BM, were obtained.  This ‘dual’ source of MSCs in the BM cultures 
also provides an explanation for the difference in OPC numbers generated in the BM and 
epiphysis cultures in the current study; with a higher starting MSC number in the BM 
cultures compared to the epiphysis cultures. BM was chosen as the MSC source for all 
subsequent experiments.  BM isolated from the femora of one mouse, however, 
produced inadequate numbers of OPCs for the mineralisation assays (between 4x105 and 
7x105 cells required; confluent T75 tissue culture flask).  The effect of increasing the 
starting MSC population on OPC generation was investigated by increasing the number of 
mice and femora from which BM was isolated.   
In the BM versus epiphysis explant experiment OPCs reached ~60% confluence after 34 
days culture.  This suggested that the starting population of MSC was too low to 
sufficiently proliferate to the required number of cells.  In a study by DiGirolamo et al 
(423) human MSCs were demonstrated to lose some of their proliferative capacity and 
differentiation potential over time.  This raised the possibility that this may also occur in 
the murine system.  The effect of increasing the MSC starting concentration on OPC 
confluence was investigated.  Increasing the starting population of MSCs, using BM 
isolated from the femora of 3 DBA/1 mice, resulted in the generation of OPC confluence 
after 10 days culture.  The number of mice used for the isolation of BM and time taken for 
the generation of confluent OPCs is not generally reported.  The time taken for the OPCs 
to reach confluence in the present study was comparable to that reported by Baddoo et al 
(5-7 days; (398)).  However, in the Baddoo et al (398) study the number of mice used to 
generate the OPCs was not stated.  In previous work from our laboratory the femora from 
one C57BL/6 mouse had been shown to produce comparable numbers of OPCs in the 
same timeframe (308) as the current study.  A number of possible reasons exist for the 
difference between the inbred strains of mice.  C57BL/6 mice are generally larger than 
DBA/1 mice and as such have more BM: this equates to increased MSC numbers obtained 
per femur.  Work published by Phinney et al (327) and Peister et al  (134) has also 
described differences in MSC growth kinetics between C57BL/6 and DBA/1 mice.  There is 
still some debate regarding whether MSC proliferation potential is greater in the DBA/1 or 
C57BL/6 strains: with Phinney et al (327) showing DBA/1-derived MSCs, and Peister et al 
(134) showing C57BL/6-derived MSCs to expand more rapidly.  Having determined the 
conditions required for MSC culture, DR3 expression on OPCs and mineralising OB was 
explored. 
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Expression of DR3 on MG63 cells and primary human OB has been demonstrated by Bu et 
al (261) and Borysenko et al (241).  However, there are currently no papers examining DR3 
expression on murine OPCs or OB.  This gap in knowledge of murine DR3 expression is 
most likely due to the limited availability of quality reagents for its detection.  In the 
present study DR3 expression was demonstrated for the first time on the surface of 
murine OPCs.  The majority of cells exhibited a 2-fold MFI signal over the isotype; 
however, a small sub-population of OPCs exhibited an increased level of DR3 expression.  
This supports the observation by Borysenko et al (241) who showed that while the 
majority of MG63 cells displayed a two-fold increase in signal compared to the isotype 
control, there was a small population that expressed DR3 eight times above the isotype.  
Why DR3 expression is increased in a small subpopulation of OPCs is not clear.  The 
differing levels of expression may be due to the cells being at different stages of 
differentiation.  Studies by Colter et al (424) and Sekiya et al (425) identified a 
subpopulation of cells in MSC cultures that were smaller, displayed increased proliferation 
and were precursors for the more mature larger cells, demonstrating the heterogeneity of 
the cultures.  Additional, more detailed flow cytometric analyses of the murine OPC 
cultures are required to identify the population of stem cells that express DR3.  DR3 
expression in mineralising OB was observed to be reduced when compared to the OPCs; 
mineralising OB only exhibited a 1.4-fold increase in expression over the isotype.  Changes 
in DR3 expression may be due to the temporal regulation of receptor expression during 
OB differentiation.  This is supported by work by Bonnelye et al (426) and Deckers et al 
(427).  In their respective studies differential expression of the oestrogen receptors α and 
β (426) and the VEGF receptors (427) were revealed during OB differentiation with levels 
changing depending on the maturation stage of the OB.  
In addition to DR3, expression of CD44 and RANKL on the surface of the OB was 
investigated.  CD44, a receptor for hyaluronan involved in cell-cell and cell-matrix 
adhesion, and RANKL, are expressed by OB at all stages of differentiation: MSC, OPC and 
mature OBs (408-413, 428, 429).  Levels of osteoblast RANKL expression are variable and 
dependent upon which receptors on the cell surface are activated.  For example, OBs 
derived from mice lacking CD44 and the PGE2 receptors, EP2 and EP4, have been shown to 
have reduced expression of RANKL (430, 431).  The effect on OB differentiation and 
function was not investigated in these studies, though in vivo fewer OB and subtle 
increases in cortical thickness were observed in CD44-/- mice compared to wild-type (431).  
In contrast, signalling through TNFR1 by TNF up-regulated RANKL expression on the OB 
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(432).  To examine whether ablation of DR3 affected levels of CD44 and RANKL, cell-
surface expression was analysed on OPCs and mineralising OB.  Comparable expression of 
CD44 and RANKL were detected on the surface of DR3wt and DR3ko OPCs and mineralising 
OB.  This result demonstrated that absence of DR3 does not affect homeostatic 
expression of RANKL and CD44.  After demonstrating the expression of CD44, RANKL and 
DR3, the expression of TL1A by OB was investigated. 
TL1A mRNA has been detected in murine total tissue RNA extracts (255), mouse joints 
(266) and murine myeloid and T cells (433).  Detection of TL1A mRNA in the OB however, 
has never been previously demonstrated in human or murine OB.  The result from this 
study revealed for the first time the production of TL1A mRNA by OB.  Some caution must 
be taken with the data, however, as many regulatory mechanisms occur after the 
manufacture of mRNA affecting the translation of the message into protein (434).  
Addition of a poly(A) tail to mRNA extends its half-life by protecting it from degradation.  
In contrast, transcriptional regulation of mRNA can lead to the termination of protein 
synthesis.  Examples of these can be seen in the control of OB pro-collagen mRNA by 
cortisol.  In the study by Delany et al (435) cortisol was shown to decrease the stability of 
alpha 1 (I) pro-collagen mRNA, resulting in decreased production of type I collagen.  
Additional investigation by qPCR is required to determine whether TL1A mRNA is 
temporally regulated providing insight into the stage of OB differentiation in which TL1A 
acts.  The results thus far in this chapter have established constitutive expression of TL1A 
and expression of DR3 on OPCs, and to a lesser extent, mineralising OB.  What effect, if 
any, this exerted on OB differentiation and function was then explored in OB 
mineralisation assays using MSCs derived from both DBA/1 and C57BL/6 mice. 
ALP is highly expressed by OB and is an early marker of OB differentiation.  In both DBA/1 
and C57BL/6 mineralisation assays DR3 significantly increased levels of ALP staining.    This 
result showed similar parallels to those reported by Frost et al (389) with TNF.  In the 
Frost et al study addition of low doses of TNF (<10pmol) to OB cultures increased ALP 
activity by stimulating early OB proliferation (389) and implied that the increased ALP 
expression in the DR3wt over the DR3ko cultures could be explained by more efficient cell 
expansion in DR3wt assays.  Comparison of cell number between the DR3wt and DR3ko 
cultures however, did not reveal any significant difference.   Thus the data suggests that 
DR3 has an autocrine role in regulating early OB differentiation, which is being driven by 
the constitutive expression of TL1A.  To prove that DR3/TL1A are driving this autocrine 
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effect add back experiments, using either anti-TL1A or soluble DR3 (sDR3), are required to 
neutralise this outcome.  If DR3/TL1A are responsible, then following addition of anti-TL1A 
or sDR3 to DR3wt and DR3ko cultures, levels of ALP staining in the DR3wt cultures should be 
comparable to the DR3ko cultures.  The differences observed in the rate of differentiation 
between the DR3wt and DR3ko cultures had the potential to affect levels of mineral 
apposition in the cultures.  For mineralisation to occur maturation of the matrix is 
required; this process is performed in part by OB-derived MMPs.    
While the OB is the cell responsible for the formation of new bone it does display some 
collagen degradation characteristics. In 1986 Takahashi et al (20) described osteoblastic 
phagocytosis of collagen fibrils and mineralised bone matrix in vitro. The mechanism of 
how the OB degraded these components was not investigated in this study.  Further 
support for the bone degradation ability of OB was provided by Everts et al (18) and 
Mulari et al (436).  In these studies OC-independent organic bone degradation and 
cleaning of resorption pits was observed by ALP-, osteopontin-, and osteocalcin-positive 
cells of mesenchymal origin.  These observations were  further built upon by Parikka et al 
(19), who confirmed that human MSC-derived OB thoroughly removed exposed collagen 
fibres from the bottom of resorption lacunae.  This was shown to be by MMPs rather than 
cysteine proteases; use of an MMP inhibitor inhibited degradation of the organic bone 
matrix while a cysteine protease inhibitor had no effect.  Which MMPs are the most 
crucial in OB bone degradation, however, remains unknown.  Parikka et al (19) 
demonstrated by western blot and gelatine zymography the presence of MMP-2, -8, -13 
and -14 in OB cultures.  MMP-9 has also been shown by zymogram and PCR to be 
produced by OB (402), though the functional significance of this in OB bone degradation 
has not been investigated.  A suggested role for OB-derived MMPs in matrix maturation 
was put forward by Filanti et al (166).  In their study levels of MMP-2, -9 and -14 were 
revealed to increase in cultures up to the time of nodule formation.  These observations 
lead to the proposal that the MMPs are involved in the process of maturing the matrix 
ready for mineral deposition.  The results from chapter 3 and chapter 4 have identified 
osteoclastic MMP-9 expression and activation to be a target of DR3 signalling.  The effect 
of DR3 on OB-derived MMP-2 and MMP-9 was therefore assessed.   
Analysis of DBA/1 and C57BL/6 OB culture supernatants produced contrasting results in 
pro MMP-9 expression.  Pro MMP-9 was significantly elevated in DBA/1 DR3wt cultures, 
while levels were highest in the C57BL/6 DR3ko cultures.  The data suggested an intrinsic 
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difference between the inbred strains in their mechanistic approach to bone formation.  
While the ELISA provided detail on the levels of the inactive form of MMP-9 it had a 
number of limitations.  The ELISA was not able to distinguish whether the DBA/1 DR3wt 
and C57BL/6 DR3ko cultures produced more pro MMP-9, or if activation of MMP-9 was 
increased in the DBA/1 DR3ko and C57BL/6 DR3wt cultures; active MMP-9 being 
responsible for the cleavage of collagen.  To determine whether DR3 affected the 
activation of OB-derived MMP-9, a gelatine zymogram was used to discern levels of the 
inactive and active forms.  Levels of pro and active MMP-2 were also analysed in the 
zymogram to determine whether DR3 affected the activation of additional MMPs.  
Limitations on time, due to the end of the AR UK studentship that funded this project, 
meant that culture supernatants from only one C57BL/6 assay were analysed. 
Levels of pro MMP-2 were found to be comparable between DR3wt and DR3ko cultures and 
showed minimal variation across the time course of the experiment when measured by 
zymography.  This was also true for pro MMP-9.  Comparison of pro MMP-9 expression by 
ELISA and zymogram revealed a discrepancy in results; with the ELISA revealing a 
significant difference in DR3wt and DR3ko pro MMP-9 expression, while only a slight 
difference was observed in the zymogram.  The discrepancy in pro MMP-9 expression is 
potentially due to the semi-quantitative nature of zymogram analysis.  For accurate 
quantification of enzyme levels enzyme titrations and standard curves are required (437).  
The analysis performed in this study compared the samples to just one pro MMP-9 
control, and so only an approximation of enzyme levels could be calculated.  
Analysis of active MMP-2 and MMP-9 showed elevated levels in the DR3wt cultures 
compared to the DR3ko cultures.  The active forms of MMP-2 and MMP-9 were detected 
across the full duration of the time course.  In the current study supernatant from only 
one C57BL/6 experiment was tested by zymography, meaning that it was insufficiently 
powered to draw firm conclusions on the effect of DR3 on MMP activation.  Comparison 
of active MMP-2 and MMP-9 in the DBA/1 and C57BL/6 cultures would provide important 
information as to whether the expression profiles differ between the strains, as with pro 
MMP-9.  The increased levels of active MMP-2 and MMP-9 detected in the C57BL/6 
cultures led to the hypothesis that DR3 has an important, novel role in activation of OPC 
and OB-derived MMP-2 and MMP-9.  The mechanism through which DR3 signalling results 
in the activation of MMP2 and MMP-9 is unknown.  A possible mechanism for how DR3 
leads to the activation of MMP-2 and MMP-9 can be gained from looking at the molecules 
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known to be involved in this process.  Activation of MMP-2 is a two-step process resulting 
in an intermediate 64kDa form generated by MMP-14 (MT1-MMP) / TIMP-2 activity, and a 
mature form generated by the action of the plasmin system (438).  Activation of MMP-9 is 
performed by a number of factors including: MMP-2, -3, -14 and plasmin (316-320).  This 
raises the possibility that DR3 acts upon either MMP-14 or plasmin expression controlling 
the activation of MMP-2 and subsequently MMP-9.  Addition to OB cultures of a plasmin 
inhibitor or selective inhibition of MMP-14 and MMP-2 with specific inhibitory antibodies 
would demonstrate which of the molecules DR3 signalling targets.  A review of the current 
literature does not yield any examples of a homeostatic role of death receptors in MMP 
activation.  However, in the study by Ben David et al  (402), addition of TNF to OB cultures 
resulted in increased release of active MMP-9 and -2 into the supernatants, as 
determined by gelatine zymography.  This study demonstrated that signalling through 
death receptors by their ligands induced the expression and activation of MMPs.  To 
conclusively prove the significant role of DR3 in MMP activation add-back experiments 
using sDR3 or anti-TL1A to neutralise DR3 signalling are required.  If DR3 signalling is 
critical for MMP activation then following addition of sDR3 or anti-TL1A, levels of active 
MMP-2 and MMP-9 in DR3wt cultures should be comparable to that of the DR3ko cultures.  
Measurement of the degradation products (c-telopeptide fragments) of type I, type II and 
type V collagen in the DR3wt and DR3ko cultures with / without sDR3 or anti-TL1A would 
also provide evidence of DR3’s role in MMP-2 and MMP-9 activity (19).  The relationship 
between MMPs and mineralisation could also be deduced by the use of MMP inhibitors in 
DR3wt OB assays.  If MMP-2 and MMP-9 are crucial for mineralisation then inhibition of 
these MMPs should result in a reduction in levels of mineral deposition.  Through 
comparison of the effects of the MMP inhibitors on mineralisation it may be possible to 
deduce which MMP has the more significant role in matrix maturation and mineral 
deposition.  Having shown that DR3 enhanced OB differentiation and MMP activation, 
DR3’s effect on mineral deposition was examined. 
Levels of mineralisation were significantly decreased in both DBA/1 and C57BL/6-derived 
DR3ko cultures compared to the respective DR3wt cultures.  This difference between the 
DR3wt and DR3ko cultures in mineralisation highlights an important role of DR3 in the 
process of normal OB mineralisation.  There are currently no reported studies that 
examine the effects of death receptor ablation on osteoblast mineral apposition.  A 
number of studies however, have demonstrated similar effects on in vitro mineral 
apposition in extracellular Ca2+-sensing receptor knockout mice (CaR-/-) (439) and type 2 
276 
 
cannabinoid receptor-deficient mice (CB2-/-) (440).  In these studies reduced nodule 
formation and mineral deposition were shown in the respective knockouts compared to 
their wild-type counterparts.  The levels of mineralisation reported were also comparable 
to the DR3ko cultures in this study.  The mechanism through which CaR and CB2 receptors 
regulated mineralisation was not fully defined, though Sophocleous et al (440) 
demonstrated CB2 signalling controlled OB function through activation of the MAPK-ERK 
signalling pathway.  DR3 has also been identified to be able to activate the MAPK 
signalling pathway in TF-1 cells (246), whether DR3 signalling regulates OB function in the 
same manner remains to be explored.   
In the only other study exploring the effect of DR3 signalling on OB function, Borysenko et 
al (241) demonstrated that cross-linking of DR3 with an anti-DR3 mAb inhibited 
differentiation and function of the MG63 OB cell line.  Cross-linking of receptors, however, 
may cause activation that is significantly different to that of the natural ligand.  This was 
highlighted in the Borysenko et al study as they were not able to reproduce the result 
with TL1A or in primary human OB.  Signalling through DR3 by TL1A was also 
demonstrated to induce apoptosis.  This was only observed in the MG63 cell line using 
high levels of TL1A (0.1μg/ml) and was not reproducible with primary human OB.  Taken 
together the data from the current study and that by Borysenko et al (241) suggests a 
possible dual function of DR3/TL1A in OB biology, similar to that of TNFR1 and TNF (389-
392), where low levels of stimulation drive OB differentiation but higher levels inhibit 
differentiation or induce apoptosis.  Comparison of OB derived from TL1A-deficient mice 
and wild-types would produce valuable evidence for the role of TL1A signalling in OB 
differentiation.  Addition of anti-TL1A to DR3wt cultures would also demonstrate the 
specific activation effect of TL1A in OB differentiation, if OB differentiation and 
mineralisation levels are reduced to that of the DR3ko.  This finding could have important 
implications in the bone pathology of a number of diseases, such as AS and RA, where 
changes in DR3/TL1A expression potentially lead to aberrant OB function; this is discussed 
in more detail in chapter 7.   
Comparison between the DBA/1 and C57BL/6 cultures demonstrated a comparable role of 
DR3 in OB differentiation, matrix maturation and mineralisation.  Levels of ALP staining 
and mineral deposition, however, were significantly elevated in the C57BL/6 cultures.  The 
potential reasons for the differences between the two inbred strains are discussed in 
chapter 7.  Having demonstrated a difference in OB differentiation and function between 
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DR3wt and DR3ko mice in vitro, the in vivo consequences on weight, size and bone density 
were investigated. 
In vitro DR3 was demonstrated to play an important role in normal OB differentiation and 
mineral deposition.  Whether this had any effect on the in vivo bone phenotype was 
unknown and was investigated in male and female DBA/1 mice.  At 8 and 20 weeks male 
mice were observed to be significantly heavier than their female counterparts.  This was 
consistent with weight-sex characteristics observed by a number of groups (441, 442).  
Differences in weight between the DR3wt and DR3ko mice were observed in males at 8 
weeks and females at 20 weeks.  Whether these differences in weight were caused by 
reduced bone formation, however, was not certain as no difference in femur or vertebra 
bone density were detected at any of the time points tested.  While bone density 
between the DR3wt and DR3ko mice were comparable, differences in other factors such as 
fat or muscle could produce the observed disparity in weight.  OB, adipocytes (fat cells) 
and myocytes (muscle cells) are all derived from mesenchymal stem cells.  While DR3 has 
been demonstrated to affect OB differentiation nothing is currently known about its role 
in adipocyte and myocyte proliferation, differentiation and function.  To address this gap 
in the literature, culture of DR3wt and DR3ko MSCs in medium specific for adipocyte 
differentiation (serum free, insulin, high density lipoprotein and Dex; (443)) or myocyte 
differentiation (5% FCS, VEGF, bFGF, and IGF-1; (444)) is required.  By comparing the 
ability of the DR3wt and DR3ko cells to differentiate into these cells and analysing the 
activation of the adipocyte specific transcription factor, peroxisome proliferator-activated 
receptor-γ (PPAR-γ) and myocyte specific transcription factor, MyoD the role of DR3 can 
be deduced. 
The in vitro studies performed in this chapter demonstrated increased bone 
mineralisation by male DR3wt-derived OB.  However, this did not translate into an increase 
in in vivo bone density in the DR3wt mice compared to the DR3ko mice.  A possible 
explanation for this discrepancy is that while OB activity is reduced in the DR3ko animals a 
balance in bone remodelling is still retained due to reduced OC activity.  Analysis of OB-
derived soluble RANKL and OPG, in DR3wt and DR3ko OB assay supernatants, would 
provide evidence as to whether the absence of DR3 alters levels of mediators involved in 
OC differentiation.  Co-culture assays would also demonstrate whether OB induced OC 
differentiation is reduced in the DR3ko mice compared to the DR3wt.  Comparison of 
relative levels of in vivo bone formation using fluorescent calcium-chelating compounds 
278 
 
and in vivo bone resorption using urinary excretion of [3H]tetracycline (445) would also 
highlight whether there are any significant differences in the balance of bone remodelling 
between the DR3wt and DR3ko mice.  A second possible explanation for the observed 
discrepancy is that while the amount of mineral between the DR3wt and DR3ko mice is the 
same, other related factors such as bone quality (BQ), bone volume to total volume 
(BV/TV), trabecular thickness (Tb Th) and bone surface density (BS/TV) may be different.  
Additional work is required before it can be confidently said that there are no differences 
in bone phenotype between the DR3wt and DR3ko mice.  Analysis of the bones with micro 
CT would allow very accurate 3D recreation and calculation of BV/TV, TB Th, BS/TV and 
BQ (446).  Analysis of the bones by histomorphometry would also reveal what cells are 
present at sites of bone remodelling, what stage of differentiation they are at, and where 
they are in conjunction to one another.  Bone histomorphometry has the additional 
advantage of providing detailed information about bone turnover (measured by 
tetracycline labelling) and mineralisation (measured by osteoid seam width and 
mineralisation lag time) (447). 
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6.4 Conclusion 
At the conclusion of this chapter the following objectives were met: 
 Expression of DR3 was demonstrated on the surface of primary murine 
osteoprogenitors and mineralising osteoblasts. 
 TL1A mRNA was constitutively expressed by DBA/1 and C57BL/6 osteoprogenitors 
and differentiating osteoblasts. 
 DR3 was revealed to be involved in homeostatic osteoblast differentiation and 
mineral deposition. 
 DR3 was confirmed to be involved in the activation of osteoblast-derived MMP-2 
and MMP-9. 
 Initial analysis on the in vivo bone phenotype of male and female DBA/1 DR3wt 
and DR3ko mice was performed. 
The results from this study have revealed a novel homeostatic role for DR3 in OB function.  
Expression of DR3 by murine OPC and mineralising OB was demonstrated, with higher 
levels detected in OPCs compared to mineralising OB.  For the first time this study has also 
shown constitutive expression of TL1A by OPCs and differentiating OB.  Levels of ALP were 
significantly elevated in DR3wt cultures compared to DR3ko cultures, identifying a role of 
DR3 in OB differentiation.  The lower levels of OB differentiation observed in the DR3ko 
cultures had the knock-on effect of reducing matrix maturation and mineral deposition.  
Expression of pro MMP-9 was affected by DR3, though intrinsic differences were observed 
between the two mouse strains: levels of pro MMP-9 were higher in DBA/1 DR3wt cultures 
and C57BL/6 DR3ko cultures.  Analysis of inactive and active MMP-2 and -9 in C57BL/6 
cultures showed a potential novel role for DR3 in the activation of osteoblast-derived 
MMPs; providing a possible mechanism for the increased mineralisation observed in the 
DR3wt cultures.  These results highlight, for the first time, DR3 as an important autocrine 
regulator of OB differentiation and function.  These findings could have important 
implications in the elucidation of the mechanisms involved in diseases characterised by 
aberrant OB activity, such as osteoporosis and ankylosing spondylitis. 
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7 General Discussion 
Bone remodelling is a balanced process that is carried out by the OC and the OB.  An 
imbalance in the activity of either of these two cells can result in a number of bone 
pathologies that are detrimental to a person’s quality of life.  Increased OC activity leads 
to excessive bone resorption giving rise to diseases that are characterised by generalised 
bone loss and focal erosions, such as osteoporosis and RA.  Increased bone formation by 
the OB can have equally devastating effects, as seen in ankylosing spondylitis, where the 
spinal vertebra can become fused.  The aetiology of these diseases and what causes the 
change in OC, OB behaviour is complex and multifactorial.  Members of the TNFSF and 
their receptors have been shown to have a pivotal role in control of bone remodelling.  
The TNFSF member RANKL (TNFSF11), its receptor RANK (TNFRSF11A) and soluble decoy 
receptor OPG (TNFRSF11B) are critical for regulating OC differentiation (54).  TNF (TNFSF2) 
and LIGHT (TNFSF14) have also been demonstrated to act synergistically with RANKL in 
vitro, enhancing OC formation (182, 282, 283).  In vivo changes in expression of the TNFSF 
and TNFRSF members have been linked to the pathogenesis of a number of diseases 
characterised by adverse bone pathology.  An up-regulation of RANKL, TNF and LIGHT 
have been identified in the serum and synovial fluid of RA patients (180-183), while in 
post-menopausal OP increases in TNF expression have been identified (448).  The exact 
function of all TNFSF and TNFRSF members in bone however, is unknown.  Recent in vitro 
studies have demonstrated that signalling through DR3 (TNFRSF25) by its ligand TL1A 
(TNFSF15) can increase OC formation (242) and induce OB apoptosis (241).  Changes in 
DR3/TL1A expression have also been linked to diseases characterised by adverse bone 
pathology such as RA (264, 265) and AS (267).  The mechanisms through which DR3/TL1A 
affected OC, OB biology and contributed to the pathology of adverse bone disease, 
however, remained undetermined.  This thesis set out to explore three main aims:   
1. To determine the effect of DR3/TL1A on OC formation and resorptive function 
and identify the mechanisms involved. 
2. To assess the role of DR3/TL1A in RA and OP; diseases characterised by increased 
OC activity. 
3. To identify the role of DR3 in OB differentiation and function.  
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7.1 Effect of DR3/TL1A on Murine and Human Osteoclast Differentiation and 
Resorptive Function 
The study by Bull, Williams et al (242) in 2008 was the first to demonstrate an effect of 
DR3/TL1A on OC formation and function.  In their study murine BM and human PBMC 
cultures were used as the primary cell sources for OC assays.  This meant that it could not 
be determined whether DR3/TL1A were enhancing OC formation directly via the OC 
precursor or indirectly by altering the production of RANKL and TNF by T cells, which also 
express DR3 (236, 237).  This study set out to determine whether DR3/TL1A affected OC 
differentiation directly and to identify the mechanisms involved, in both murine and 
human models.   
Isolation of OC precursors from the BM of DR3wt and DR3ko mice demonstrated DR3 to 
have an important role in OC resorptive function; with very low levels of resorption 
detected in the DR3ko cultures.  This difference in resorption suggested a number of 
possibilities including; delayed maturation of the OC resulting in a delay in resorptive 
activity or a fundamental difference in OC attachment, cytoskeleton rearrangement or 
bone degrading enzyme release.  Analysis into the mechanism through which DR3 
regulated bone resorption demonstrated an increase in levels of active MMP-9 in DR3wt 
compared to DR3ko culture supernatants.  This increase corresponded with the increase in 
bone resorption and revealed for the first time a role of DR3 in MMP-9 activation.  
Whether the link between active MMP-9 and resorption observed in the murine assays 
was due to a causal relationship was not clear from this study.   Determining the answer 
to this question may not be straight forward, as specific MMP-9 inhibitors are not readily 
available.   The thiirane MMP inhibitor SB-3CT has been demonstrated by Gu et al (449) to 
be a selective inhibitor of MMP-2 and MMP-9.  In their studies SB-3CT was found to 
reduce MMP-9 degradation of the ECM protein laminin, providing significant protection 
against brain damage in an experimental model of focal cerebral ischaemia.  Addition of 
SB-3CT to DR3wt OC cultures and analysis of resorptive function by quantification of the 
area of the ivory disc resorbed and measurement of collagen degradation products (c-
telopeptide fragments) in the supernatants would provide important information on the 
role of MMP-9 in OC resorption.  In addition to regulation of MMP-9 activation DR3 may 
also regulate additional aspects of OC resorptive function, such as cytoskeleton 
rearrangement, CatK expression or c-Src kinase activity. 
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Initiation of OC resorption requires the OC to rearrange its cytoskeleton, forming an actin 
ring (101).  Disruption to the formation of the actin ring results in the inhibition of bone 
resorption, as a sealed zone around the ruffled membrane is unable to form (450).  In the 
current study an immunocytochemical method for the visualisation of actin ring formation 
was developed in DR3wt cells (appendix I), though the study into actin ring formation in 
DR3ko OC was not performed.  Comparison of actin ring formation in DR3wt and DR3ko-
derived OC would identify whether this process is regulated by DR3.  If differences are 
observed then the mechanism for how DR3 regulates actin ring formation would require 
elucidation.   
The investigation in this thesis into the effect of DR3 on murine CatK production by an in-
house developed bioassay and zymography were inconclusive.  Using the developed 
methods the protease was not detected in the culture supernatants due to cross-
reactivity with FCS.  Additional follow up experimentation analysing CatK mRNA levels in 
DR3wt and DR3ko OC by qPCR and protein levels by SDS-PAGE and Western blot (451) 
should be performed to demonstrate involvement of DR3 in CatK regulation.  C-Src is the 
dominant src family kinase expressed in OC and acts as an adaptor protein through its 
enzymatic activity (452, 453).  In a study by Miyazaki et al (99) c-Src activity was identified 
as being essential for OC function, with disruption of c-Src by adenovirus induced Src 
mutants resulting in significantly decreased OC resorption.  Targeted disruption of the c-
Src proto-oncogene in mice was also demonstrated to lead to the development of an 
osteopetrotic phenotype due to defects in OC resorptive function (100).  These data 
present variations in c-Src activity as a potential cause for the stark difference in OC 
resorptive function observed between the DR3wt and DR3ko OC.  Immunoprecipitation of 
c-Src from DR3wt and DR3ko cultures and visualisation by SDS-PAGE and Western blot 
would identify whether levels are comparable between the two genotypes.  Analysis of 
the immunoprecipitated c-Src activity (454) in vitro would also reveal if c-Src activity is 
potentially regulated by DR3. 
In the course of this study TL1A was demonstrated to have opposing effects on OC 
formation in DBA/1 and C57BL/6 OC cultures.  Addition of TL1A to DBA/1 cultures 
significantly inhibited OC formation in a DR3-dependent manner, while addition of TL1A 
to the C57BL/6 cultures enhanced OC formation.  The result from the C57BL/6 OC assay 
supported the published results by Bull, Williams et al (242); who demonstrated addition 
of TL1A significantly enhanced C57BL/6 OC development from DR3wt but not DR3ko BMC.  
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To explain the mechanism through which TL1A was regulating OC formation, culture 
supernatants were analysed for soluble mediators known to be involved in OC migration. 
Formation of the multinucleated OC is dependent on the action of chemokines inducing 
the migration of OC precursors.  The investigation into the mechanism through which 
DR3/TL1A affected OC formation revealed a contemporary role for murine TL1A in 
regulating the expression of the chemokines CCL2 and CCL3.  In the DBA/1 model TL1A 
significantly reduced expression of CCL2 and lowered expression of CCL3 in a DR3-
dependent manner.  In contrast, CCL3 expression in the C57BL/6 cultures was elevated.  
Whether CCL2 and CCL3 were the only two factors regulated by TL1A and were fully 
responsible for the changes in osteoclastogenesis observed remains to be tested.  Work 
by Lean et al (361) and Okamatsu et al (455) identified CCL9 as the main chemokine 
expressed by murine OC and that it promoted RANKL induced OC formation.  Regulation 
of CCL9 expression by TL1A could therefore have a significant effect on 
osteoclastogenesis.  Likewise changes in the expression of CCL5, also known to stimulate 
the migration of OC precursors (85), would affect OC formation.  Analysis of chemokine 
receptor expression (CCR1, CCR2, CCR4 and CCR5) by flow cytometry would provide 
evidence of an additional possible mechanism by which TL1A could regulate OC 
formation.  While chemokines are essential for OC precursor migration, to form the 
multinucleated OC the mononuclear cells must undergo a process of fusion.  The process 
of OC fusion is not fully understood, though a number of molecules have been identified 
to mediate this process.  E-cadherin (456) and macrophage fusion receptor (MFR; (457) 
have been shown through the use of neutralising antibodies to be involved in monocyte / 
macrophage fusion.  In a study by Yagi et al (458) ablation of dendritic cell-specific 
transmembrane protein (DC-STAMP) resulted in the complete abrogation of OC cell 
fusion.  Overexpression of DC-STAMP in RAW-D cells however, significantly enhanced 
RANKL-induced OC formation (459).  Analysis of the expression of these fusion proteins by 
immunological staining and qPCR (459) could reveal additional targets of DR3/TL1A 
regulation of OC formation.   
The investigation into the effect of TL1A on OC formation and the mechanism of action 
revealed contrasting results between the DBA/1 and C57BL/6 strains (table 7.1).  The 
cause of this inherent difference in cellular response to TL1A is unknown.  Intrinsic 
differences between inbred strains of mice have been shown by a number of groups and 
are discussed in chapter 3.  Variations in DR3 and TL1A expression between DBA/1 and 
C57BL/6 OC precursors could also provide a possible explanation for the opposing effect 
285 
 
of TL1A on OC differentiation.  Flow cytometric analysis of DR3 expression on the surface 
of the OC precursors and analysis of TL1A levels in OC culture supernatants would 
determine whether there is a difference in DR3/TL1A expression between the strains.  
Currently however, specific monoclonal antibodies for the detection of murine DR3 on 
monocytes / macrophages and soluble TL1A are not commercially available 
The murine models of osteoclastogenesis used in this thesis provided important insights 
into the role of DR3/TL1A in OC formation and function.  The opposing effects of TL1A in 
the DBA/1 and C57BL/6 strains however raised a problem; which, if either, of the two 
mouse models was representative of the human system.  Additionally, the lack of specific 
murine reagents meant that levels of DR3 and TL1A expressed by OC and their precursors 
could not be measured.  To address these limitations in the murine assays the study was 
transferred into a human model; as the direct effect of TL1A on OC precursors (CD14+ 
monocytes) could be examined and reagents for the detection of DR3 by flow cytometry 
and TL1A by ELISA were readily available. 
In the current study expression of DR3 was demonstrated to be induced on CD14+ 
monocytes following culture in MCSF for 7 days (chapter 4).  Addition of TL1A to the DR3+ 
CD14+ cultures identified for the first time a direct and dose-dependent effect on human 
OC formation and resorptive function.  The increase in OC formation correlated with a 
significant increase in levels of the chemokine CCL3 and suggested that this was the main 
target of DR3/TL1A signalling in the human system.  Further experimentation is required 
as outlined above for the murine system to determine whether TL1A signalling also 
regulates expression of chemokine receptors, RANK or the fusion proteins involved in OC 
formation.  The increase in OC resorptive function observed in the human assays 
correlated with an increase in total MMP-9 release.  This supported the results published 
by Kim et al (239) and Kang et al (278) who identified MMP-9 expression to be a target of 
TL1A signalling in the human macrophage THP-1 cell line.  TL1A was further identified to 
have a role in the activation of human osteoclastic MMP-9.  How DR3/TL1A signalling 
regulated MMP-9 activation was not investigated in this study and should be investigated 
as previously discussed for the murine assays.  While MMP-9 is known to have a role in 
bone resorption the principal enzyme involved is CatK (104, 127).  An in situ 
immunocytochemistry method was developed for the detection of CatK in OC cultures, 
however due to time constraints brought about by the end of the AR UK funding the 
effect of TL1A on CatK expression was not fully investigated (Appendix II).  To fully explore 
whether DR3/TL1A signalling regulates CatK expression analysis of CatK mRNA levels by 
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qPCR and detection of protein levels by Western blot and immunocytochemistry should 
be performed.   
In the human (chapter 4) and murine (chapter 3) in vitro assays performed in this thesis 
DR3/TL1A were shown to have an effect on OC resorptive function, by increasing the area 
of the ivory disc resorbed.  The analysis of resorption pits throughout the course of this 
thesis (chapters 3, 4 and 5) employed a standard method; discs were stained with 
toluidine blue and the area resorbed analysed by light microscopy (460).  A limitation of 
this method was that it did not provide any detail on pit depth or pit volume.  Alternative 
methods for the analysis of resorption pits have been described in the literature including 
confocal microscopy (129) and scanning electron microscopy (461).  At the end of this 
study a portion of time was spent on the development of a method for the analysis of 
resorption pits by confocal microscopy (Appendix V).   
Comparison of the human and murine studies, used to determine the mechanism of 
DR3/TL1A in regulating OC differentiation and function, demonstrated a number of 
similarities and differences between the two systems (table 7.1).  In both the murine and 
human models DR3 was identified as having a significant role in OC resorptive function 
and MMP-9 activation.  The effect of TL1A on chemokine expression however, varied 
between species.  In the human system CCL3 was identified as being a key target of TL1A 
signalling with expression of CCL2 unaffected.  This was in contrast to the murine system 
where CCL2 was identified as a key target of TL1A.  Differences in chemokine and 
chemokine receptor expression between mouse and human systems are not uncommon; 
e.g. CXCR1, CXCL8, CXCL7 and CCL13 are expressed in humans but not mice, while CCL9 
and CCL12 have been identified in mice but not humans (351).  The significance of these 
differences cannot be conclusively determined as there is considerable redundancy built 
into the system.  This result further highlighted the care that must be taken when 
extrapolating results from a murine system into a human system, as subtle differences in 
mechanisms may be present. 
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Outcome DBA/1 (DR3wt) C57BL/6 (DR3wt) Human 
Total Cell Number ↓ ↔ ↔ 
OC Formation ↓ ↑ ↑ 
OC Resorption ↓ Not tested ↑ 
CCL2 ↓ Not tested ↔ 
CCL3 ↓ ↑ ↑ 
CXCL8 - Not tested ↔ 
CXCL1 ↔ Not tested - 
Active MMP-9 ↑ (DR3 only) Not tested ↑ 
Table 7.1.  The Effect of TL1A on OC Function in murine and human in vitro OC Assays 
 
7.2 Role of DR3/TL1A in Inflammatory Arthritis 
As discussed in the introduction aberrant expression of DR3 and TL1A have been linked to 
the pathogenesis of a number of inflammatory conditions including inflammatory 
arthritides such as RA (264-266) and AS (267, 268).  The consequence of the aberrant 
expression of TL1A in the pathogenesis of these diseases was not investigated in any of 
the above mentioned studies.  The present study set out to clarify the significance of 
increased TL1A expression in RA and to determine whether TL1A levels were also elevated 
in patients with psoriatic arthritis. 
In the current study TL1A levels in RA patients were elevated 8.6-fold over normal 
controls, significantly correlated to levels of RF, and revealed for the first time to be linked 
to the presence of erosive disease (chapter 5).  Taken in conjunction with the results 
reported by Bamias et al (264), Zhang et al (266) and the in vitro data from chapter 4 the 
result suggested that TL1A is a significant driving factor in the increased bone resorption 
associated with RA.  Further support for this theory is provided by work performed in 
murine models of AIA (242) and CIA (266).  In these experiments administration of TL1A 
significantly exacerbated disease, increasing the size of bone erosions and the severity of 
bone destruction.  The RA patients used in this study all had established disease, so it was 
unknown whether TL1A levels were elevated before the onset of RA or after the disease 
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was established.  A long-term study measuring serum TL1A in patients who present at 
clinic with signs of early arthritis would determine whether there is a direct link between 
TL1A levels and the pathogenesis of erosive disease.  The outcome of this study would 
thus predict whether TL1A could be used as a prognostic marker of disease severity. 
Treatment of RA is routinely through the prescription of DMARDs, though patients with 
severe arthritis can be treated with anti-TNF biological such as adalimumab, etanercept 
and infliximab.  Clinical investigations into anti-TNF therapy in RA have provided evidence 
that TNF regulates the expression of other pro-inflammatory cytokines such as IL-6 and IL-
8 (462).  Migone et al (248) reported that TL1A mRNA was up-regulated in HUVEC cells 
following TNF stimulation suggesting that TL1A is also under TNF regulation.  However, 
there is still some debate over this as Cassatella et al (366) revealed that production of 
TL1A by immune complex stimulate monocytes was unaffected following treatment with 
TNF neutralising antibodies.  In the present study RA patients on anti-TNF therapy were 
shown to have comparable levels of serum TL1A when compared to patients on DMARDs, 
suggesting that control of TL1A expression is independent of TNF.  This result was in 
contrast to that reported by Bamias et al (264), who demonstrated that anti-TNF 
treatment significantly reduced serum TL1A levels.  However, in the Bamias et al (264) 
study TL1A levels in the anti-TNF treatment cohort were still significantly higher than the 
normal controls.  These data provide a possible explanation why some RA patients do not 
respond to anti-TNF therapy.  Studies examining expression of TL1A levels in anti-TNF 
responders and non-responders would help determine whether TL1A levels could predict 
the likelihood of successful treatment.  If TL1A levels are significantly elevated in the non-
responder cohort over the responder cohort then it could be reasonably assumed that the 
erosive pathology in the non-responder patients is primarily being driven by TL1A. 
The relationship between TL1A and bone degradation reported in this thesis and in the 
studies mentioned above (242, 264, 266) present TL1A as an attractive target for therapy.  
In the Bull, Williams et al (242) study administration of TL1A neutralising antibodies to the 
CIA model of RA, the industry standard for assessing potential therapies, resulted in 
reduced disease activity.  While this result was very promising further testing is required 
to characterise the efficacy and safety of anti-TL1A treatment.  The current biological 
treatment of RA, anti-TNF, is associated with a significant 80% increase in the risk of 
serious infection in the first 6 months which reduces to a significant 20% increase over 
subsequent years (463).  The numbers of studies looking at the role of DR3/TL1A in 
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infections however are limited.  In a 2008 study, Meylan et al (256) showed that control of 
Toxoplasma gondii parasitic infection was not dependent on DR3, as DR3-deficient mice 
displayed an immune response comparable to the wild-type.  However, in recent studies 
by Buchan et al (464) and Twohig et al (243) DR3/TL1A were shown to have important 
roles in the development of optimal T cell immunity against Salmonella (464) and efficient 
development of antiviral T cell immunity (243).  In the Buchan et al (464) study, infected 
DR3-deficient mice had reduced numbers of antigen-experienced and proliferating CD4+ T 
cells compared to wild-type littermates, resulting in impaired bacterial clearance.  The 
impaired immunity to viral infection reported by Twohig et al (243) in the DR3-deficient 
mice, was associated with a reduction of up to 90% in T cell response and impaired anti-
MCMV NK response during acute infection, which became lethal.  Further investigation is 
required into the role of DR3/TL1A in infection and the effects of DR3/TL1A blockade on 
infection occurrence before anti-TL1A can be considered as a therapeutic treatment for 
RA and moved into clinical trials.   
While there is a growing body of evidence linking DR3/TL1A to RA a number of studies 
have suggested that TL1A may also be linked to the pathogenesis of the SpAs.  In the 
current study the potential role of TL1A in PsA was investigated.  Analysis of PsA patient 
serum in the current study revealed for the first time an increase in levels of TL1A.  This 
increase was of a much smaller magnitude than observed in the RA patients (1.9-fold 
versus 8.6-fold).  The data in conjunction with the study by Konsta et al (267), who 
showed increased levels of serum TL1A in AS patients, points to a potentially important 
role of DR3/TL1A in the pathogenesis of the SpAs.  These studies are limited in that they 
do not look at the consequences of the increased TL1A expression on the bone pathology.  
A number of animal models of spondylitis exist and should be utilised to further 
understand the role of DR3/TL1A in the progression of the disease.  Spontaneous 
ankylosing enthesopathy has been described in DBA/1 group-housed male mice, with 
onset occurring as early as 2-3 months of age and prevalence ranging from 50% to 100% 
(465).  Histological analysis of grouped male DBA/1 DR3wt and DR3ko mice would provide 
information on incidence and severity of the disease and show whether DR3ko mice are 
protected against spontaneous SpA.  Visualisation of DR3 and TL1A in the joints by 
immunohistochemistry would identify the cells through which DR3/TL1A exert an effect.  
In addition to the experimental mouse models of disease more detailed clinical studies are 
required to elucidate the role of TL1A in the SpAs.  The current study into TL1A levels in 
PsA patients was inadequately powered due to the low number of patients recruited.  To 
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conclusively demonstrate that TL1A levels are elevated in PsA a larger cohort of patients 
are required.  PsA is also related to the skin condition psoriasis, with studies reporting that 
between 5% and 42% of psoriasis sufferers develop PsA (362).  Elevated expression of DR3 
and TL1A have been reported by Bamias et al (269) in skin lesions of patients with 
psoriasis, raising the possibility that DR3/TL1A may have a role in the development of PsA 
from psoriasis.  Studies into serum TL1A and DR3 expression in psoriasis patients and 
follow up to see whether they develop PsA would provide proof-of-concept of DR3/TL1A’s 
involvement in the onset of PsA.   
The data presented in this thesis adds to a growing body of evidence (264-267) identifying 
a role for DR3/TL1A in the pathogenesis of the inflammatory arthritides (table 7.2) 
however, no such groundwork has been established for OP.  OP is a disease characterised 
by a generalised bone loss due to OC over activity.  This thesis provided the first proof-of-
concept study investigating the role of DR3/TL1A in the pathogenesis of OP. 
Arthritis Serum TL1A 
Ankylosing Spondylitis ↑ 
Psoriatic Arthritis ↑ 
Osteoarthritis (control) ↔ 
Rheumatoid Arthritis (Seropositive - erosive) ↑↑↑ 
Rheumatoid Arthritis (Seropositive – non-erosive) ↑↑ 
Rheumatoid Arthritis (Seronegative - erosive) ↑ 
Rheumatoid Arthritis (Seronegative – non-erosive) ↔ 
Table 7.2.  Relative Changes in Serum TL1A Levels in Inflammatory Arthritides Compared 
to Normal Controls 
 
7.3 Role of DR3/TL1A in Post-Menopausal Osteoporosis and Fracture 
As discussed in the introduction OP is characterised by low BMD and an increased risk of 
fracture.   This thesis provided the first proof-of-concept study investigating the role of 
DR3/TL1A in fracture and / or post-menopausal OP; by comparing serum TL1A levels, DR3 
expression on OC precursors and osteoclastogenesis in pre-menopausal controls and 
three post-menopausal patient cohorts: non-osteoporotic with / without fracture and 
osteoporotic with fracture.   
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TL1A levels were reduced in the post-menopausal OP-Frac- cohort compared to the pre-
menopausal controls.  However, levels of TL1A in the post-menopausal fracture cohorts 
(with/without OP) were comparable to the pre-menopausal controls (Appendix III).  This 
suggested that like the TNFSF members RANKL, OPG and TNF (369), TL1A is temporally up-
regulated during fracture healing.  This is the first time that changes in TL1A expression 
have been linked to fracture repair.  Further testing is required to demonstrate this link 
conclusively.  Recruitment of additional patients to each cohort and the recruitment of a 
pre-menopausal fracture cohort would add power to the current study and also reveal 
whether changes in TL1A expression following fracture are observed across all ages.  To 
demonstrate the importance of TL1A in in vivo fracture healing murine fracture models 
can be utilised.  Induction of fracture in wild-type and TL1A-deficient mice and analysis of 
healing by dorsal-ventral radiographs and histological analysis of total fracture area, 
cartilage area and mineralised tissue area (325) would demonstrate if TL1A is an integral 
part of fracture repair.   
Probably the most intriguing aspect of this study was the discovery that OC precursors 
derived from post-menopausal patients expressed negligible levels of DR3 compared to 
pre-menopausal–derived OC precursors (Appendix III).  The reasons for the difference in 
DR3 expression between the pre- and post-menopausal cohorts were not clear from this 
study.  The effect of aging, fracture and OP on OC precursor expression of death receptors 
is unknown, as no studies have been performed looking at this specific aspect.  A detailed 
flow cytometric study looking at the expression of the death receptors on OC precursors 
isolated from pre- and post- menopausal patients with / without fracture and OP patient 
cohorts would identify changes in the expression profiles associated with age, fracture 
and disease.  Another possibility for the variation in DR3 expression between the pre-and 
post-menopausal cohorts is that the expressed isoform of DR3 changes following the 
menopause.   In humans there are at least 13 DR3 splice variants (230, 244), while in mice 
there are 3 (280).  Studies by Twohig et al (466) and Bamias et al (467) have demonstrated 
differential expression of the murine DR3 splice variants between naïve and activated T 
cells.  This raises the possibility that the post-menopausal-derived cells may be expressing 
an alternative isoform of DR3 that is not detected by the JD3 monoclonal antibody used 
for flow cytometry in this study.  Analysis of the DR3 transcripts by RT-PCR cloning and 
sequencing would provide additional evidence on the effects of the menopause on DR3 
expression.  What effect the absence of DR3 on post-menopausal human OC precursors 
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had on osteoclastogenesis has never been previously investigated and was subsequently 
explored.   
Analysis of the pre- and post-menopausal OC cultures revealed significantly reduced cell 
viability and OC formation in the post-menopausal cultures compared to the pre-
menopausal cultures (appendix IV).  This suggested that DR3 may have a role in the 
regulation of OC precursor cell viability and optimal OC differentiation.  To explore the 
role of DR3 in maintaining OC precursor cell viability and differentiation further 
investigation is required.  The reduced cell number observed in the post-menopausal 
cultures suggests that DR3 is required to either sustain proliferative potential or inhibit 
apoptosis in the OC precursors.  Measurement of cell proliferation through the 
incorporation of 5-bromo-2’-deoxyuridine (Brdu) or 3H-Thymidine; flow cytometric 
analysis of early and late apoptosis using Annexin V and propidium iodide (468); and 
measurement of caspase-3 activity in cell culture lysates would determine whether the 
difference in cell viability is due to changes in proliferative potential or apoptosis.  The 
mechanism of how DR3 regulates OC precursor cell viability also remains to be explored.   
Levels of MCSF used in the human assays in this study were identical.  This raises the 
possibility that DR3 may indirectly regulate c-FMS expression or c-FMS affinity for MCSF.  
Comparison of c-FMS expression in pre- and post-menopausal OC precursors by flow 
cytometry would reveal whether expression is indirectly regulated by DR3.  To determine 
how the absence of DR3 on post-menopausal OC precursors may affect OC formation a 
number of studies should be performed; testing of RANK and chemokine receptor 
expression by flow cytometry; testing of fusion protein expression by qPCR and 
immunostaining; and testing for expression of the master transcription regulator of 
osteoclasts, NFATc1 (64), by qPCR and immunofluorescence.  A reduction in expression of 
any of the aforementioned would result in the decreased OC formation observed in the 
post-menopausal cultures.   
Comparison of the pre- and post-menopausal OC cultures performed in this thesis 
presented some intriguing findings and indicated that DR3/TL1A are not directly 
responsible for the increased OC activity associated with post-menopausal OP (table 7.3). 
Increased OC activity however, is just one key factor in the pathogenesis of OP.  
Histomorphometric analysis of iliac and cancellous bone from osteoporotic patients 
demonstrated decreased OB activity and bone formation (198, 199, 469).  The presence of 
DR3 on the surface of human OB has been shown by Bu et al (261) and Borysenko et al 
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(241) though the role of DR3 in OB biology is uncertain.  Whether DR3 was also expressed 
on the surface of murine OB and its homeostatic function were unknown and therefore 
investigated. 
Outcome OP-Frac- OP-Frac+ OP+Frac+ 
Serum TL1A ↓* ↔ ↔ 
CD14+ DR3 
Expression 
↓↓ ↓↓ ↓↓ 
Total Cell Number ↓↓ ↓↓ ↓ 
OC Number ↓↓ ↓↓ ↓ 
% OC ↓* ↓ ↓ 
% Resorption ↓* ↓* ↓* 
Table 7.3.  Comparison of the Post-Menopausal OC Assay Outcomes to Pre-Menopausal 
Assays (*=Change not significant) 
 
 
7.4 Role of DR3 in Osteoblast Differentiation and Function 
In the only previous study into the effect of DR3 on OB biology Borysenko et al (241) 
demonstrated that activation of DR3 on the MG63 cell line by cross-linking could induce 
apoptosis or inhibit MG63 OB differentiation.   In their study however, the effect of DR3 
on normal OB differentiation and mineral deposition was not investigated. This was 
addressed in the current study through analysis of primary OB cultured from the BM of 
DR3wt and DR3ko mice. 
Cell surface expression of DR3 on primary murine OPCs and mineralising OB was 
demonstrated for the first time (chapter 6). DR3 expression on murine OPCs was 
demonstrated to be equivalent to that shown by Borysenko et al (241) on human OB, with 
an approximately 2-fold increase of signal over the isotype control.  DR3 expression on 
mineralising OB was reduced compared to the OPCs. This raised the question as to 
whether the reduction in DR3 expression was due to a loss of receptor or whether the 
DR3 isoform expressed had changed as discussed in section 7.3. 
This study was the first to identify production of TL1A mRNA by OPCs and differentiating 
OB.  While constitutive expression of TL1A mRNA was detected in OPCs and mineralising 
OB it is not known whether levels were temporally regulated during differentiation.  
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Analysis of OPC and OB TL1A mRNA levels by qPCR at varying stages of differentiation 
would identify if transcriptional activity of TL1A increases or decreases depending on the 
stage of OB maturity.  A limitation of the study into OB TL1A expression however, was 
that actual protein levels could not be measured as specific commercial antibodies for the 
detection of soluble TL1A or membrane-bound TL1A were not available at the time of 
study.  Generation of these reagents would allow the measurement of TL1A in the culture 
supernatants by ELISA or membrane-bound TL1A by flow cytometry.  The expression 
profile of TL1A and DR3 on OPCs and OB also suggested a potential autocrine role for DR3 
in OB differentiation; this was supported by the results obtained from the mineralisation 
assays.   
Analysis of the mineralisation assays performed in this study demonstrated DR3 to have a 
significant role in DBA/1 and C57BL/6 OB differentiation, MMP-2 and -9 activation and 
mineral deposition.  Levels of ALP, an early marker of OB differentiation, were significantly 
elevated in the DR3wt cultures over the DR3ko cultures.  A number of possibilities exist by 
which DR3 may regulate OB differentiation.  Early stages of OB differentiation are driven 
by the autocrine action of Wnt proteins signalling through LRP5 and the serpentine 
frizzled receptors.  In a study by Rawadi et al (396) signalling through the Wnt autocrine 
loop was demonstrated to mediate the induction of ALP.  Blockade of Wnt signalling by 
overexpression of DKK1 or LRP5∆C inhibited induction of ALP, demonstrating the 
importance of this signalling pathway in OB differentiation.  Loss of function of LRP5 was 
also found to lead to the development of OP due to decreased bone formation (147).  
Analysis of Wnt and LRP5 expression by qPCR would demonstrate any changes induced by 
the ablation of DR3, identifying a possible mechanism through which the receptor may 
regulate OB differentiation.  Differentiation of the MSC into the early immature OB is also 
dependent on the induction of the transcription factors Runx2 (137) and Osx (138).  
Variations in expression of these transcription factors caused by the ablation of DR3 
would result in the differences in ALP activity observed.   
In addition to enhancing ALP levels, DR3 was shown to have a role in the regulation of OB-
derived MMP activation; with levels of active MMP-2 and MMP-9 elevated in the DR3wt 
C57BL/6 cultures compared to the DR3ko.  Taken together with the results from the OC 
assays this identified MMP activation as a key target of DR3 signalling.  The processes of 
MMP-2 and MMP-9 activation are discussed in chapters 6 and 3 respectively.  Selective 
inhibition of the molecules involved in MMP activation with specific inhibitory antibodies 
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or shRNA and measurement of MMP-2 and MMP-9 activation by quantitative zymography 
would reveal important insights into the regulatory mechanisms of osteoblastic MMP-2 
and MMP-9 activation by DR3.   
Analysis of mineral deposition in the DBA/1 and C57BL/6 DR3wt and DR3ko cultures 
demonstrated DR3 to have an important role in the regulation of OB mineralisation; with 
levels in the DR3ko cultures significantly reduced compared to the DR3wt.  Whether the 
variation in mineralisation was due to the difference in OB differentiation and matrix 
maturation or due to a specific effect of DR3 on mineral deposition is still unclear.  In a 
study by Sophocleous et al (440) activation of the MAPK-ERK signalling pathway by the 
type 2 cannabinoid receptor was demonstrated to control OB function.  DR3 has also been 
shown to activate MAPK in TF-1 cells (246) suggesting a possible mechanism through 
which DR3 regulates bone formation.  In a study by Albers et al (399) the frizzled receptor 
FZD9 was also revealed to have an important role in bone formation, as FZD9-deficient 
mice displayed a low bone mass caused by impaired bone formation.  Analysis of FZD9 
transcription in DR3wt and DR3ko OB would identify whether DR3 indirectly regulates OB 
mineralisation through FZD9 expression.  The final stages of OB differentiation and 
mineralisation are dependent on the induction of the transcription factors Osx and ATF4 
(139), leading to the generation of the mature bone forming OB.  Analysis of these 
transcription factors by qPCR in DR3wt and DR3ko OB would identify whether they are 
under the influence of DR3 regulation and provide important mechanistic insights into OB 
differentiation and function.   
In the current study DR3 has been demonstrated to regulate OB differentiation and 
function in both the DBA/1 and C57BL/6 cultures; however levels of ALP and mineral 
deposition were significantly elevated in the C57BL/6 cultures compared to the DBA/1 
cultures (table 7.4).  As discussed in chapter 3 fundamental differences in bone biology 
between inbred strains of mice have been reported (134, 325-327), though the exact 
reasons for these differences are unknown.  In the last 10 years 5-HT (serotonin) has been 
reported as being a key regulator of bone homeostasis (470, 471).  Expression of the 5-HT 
receptors and transporters (5-HTT) has been demonstrated on the surface of OPCs and 
mineralising OB (471, 472).  In 5-HT2B receptor knockout mice Collet et al (471) 
demonstrated reduced OB differentiation as measured by ALP activity.  This subsequently 
resulted in fewer mineralisation nodules.  This was built upon by Baudry et al  (470) who 
demonstrated that tissue nonspecific alkaline phosphatase is a target of 5-HT2B signalling.  
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Differences in 5-HT receptor expression have been demonstrated in the brains of inbred 
mice (473).  It is currently not known whether OB 5-HT2B expression also differs between 
strains but this does present a possible explanation for the differences observed between 
the DBA/1 and C57BL/6 mice in normal OB function.  The data presented in this thesis and 
published studies (264, 266, 267) demonstrates a complex role of DR3/TL1A in OC and OB 
biology and in the pathogenesis of various adverse bone pathologies; these are discussed 
below in section 7.5. 
Outcome DBA/1 C57BL/6 
ALP Activity ↑ ↑↑ 
Mineral Deposition ↑ ↑↑ 
Cell Proliferation ↔ - 
Pro MMP-9 ↑ ↓ 
Active MMP-9 - ↑↑ 
Active MMP-2 - ↑↑ 
RANKL ↔ ↔ 
CD44 ↔ ↔ 
Table 7.4.  Effect of Autocrine DR3/TL1A Signalling on DBA/1 and C57BL/6 DR3wt OB 
Differentiation and Function 
 
7.5 DR3/TL1A in Adverse Bone Pathology 
The in vitro and ex vivo studies performed in this thesis suggest three models of how 
changes to DR3/TL1A expression can lead to an imbalance in the bone remodelling cycle, 
resulting in diseases characterised by adverse bone pathology. 
1. Rheumatoid Arthritis 
In vitro assays have shown that high levels of TL1A significantly enhance OC formation and 
resorptive function (chapter 4).  This is supported by the work in chapter 5, and the study 
by Bamias et al (264), that demonstrated high levels of serum TL1A was linked to the 
presence of erosive disease in RA.  In the Borysenko et al (241) study long–term 
stimulation of DR3 on MG63 cells inhibited OB differentiation or induced OB apoptosis, 
suggesting that high levels of TL1A may also produce the same effect in vivo.  In vivo this 
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dual action of DR3/TL1A would shift the bone remodelling balance towards excessive 
bone erosion, resulting in the joint destruction and generalised osteopenia observed in 
diseases such as RA (Fig 7.1). 
2. Spondyloarthritis 
AS and PsA are diseases characterised by increased bone formation.  TL1A levels were 
revealed to be elevated in both PsA patient (chapter 5) and AS patient serum (267).  In 
chapter 6, DR3 was demonstrated to have a role in the regulation of OB differentiation 
and mineral deposition.  The data raises the possibility that small increases in TL1A, as 
observed in AS and PsA, could stimulate bone formation leading to the formation of 
syndesmophytes and fusion of spinal vertebra (Fig 7.1).  TL1A titration studies are 
required however, to conclusively determine what effect increasing levels of TL1A have on 
OB differentiation and mineral deposition.  
3. Osteoporosis 
DR3 expression has been shown to be lost on the surface of post-menopausal-derived OC 
precursors, suggesting that expression of the receptor disappears with aging (chapter 5).  
In the investigation into the role of DR3 in OB function (chapter 6) decreased OB 
differentiation and mineral deposition were observed in DR3ko mice.  This raises the 
possibility that loss of DR3 on the OB post-menopause may be responsible for the reduced 
bone formation seen in OP.  This would shift the balance of bone remodelling away from 
bone formation towards increased resorption (Fig 7.2).  To prove this hypothesis further 
human work and animal models should be utilised.  Characterisation of DR3 on pre- and 
post-menopausal OPCs and mineralising OB would determine whether DR3 expression is 
lost post-menopause.  Generation of an inducible OPC / OB DR3 conditional knockout 
rodent (474) would also allow for the in vivo effects of OB DR3 ablation on the 
pathogenesis of OP to be studied. 
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7.6 Future Work 
The work performed in this thesis has revealed many novel aspects of the role of 
DR3/TL1A in the regulation of bone biology.  A number of important questions still remain 
to be answered and require further investigation. 
 The exact mechanism through which DR3/TL1A regulates OC resorption still 
remains unknown.  The effect of DR3/TL1A on actin ring formation, CatK expression 
and c-Src activity requires elucidating to identify what aspects of OC resorptive 
function DR3/TL1A may regulate. 
 DR3 has been demonstrated to increase activation of OC and OB MMPs.  The 
mechanism how DR3 regulates the activation of these MMPs remains elusive and 
requires investigation. 
 Serum TL1A is increased in RA patients with erosive disease, whether TL1A can be 
used as a prognostic marker for disease severity however is unknown.  Assessment 
of serum TL1A levels in patients who display at clinic with early signs of arthritis and 
follow up throughout the course of the disease would provide valuable information.  
An in-depth study into the effects of anti-TNF treatment on serum TL1A levels could 
also provide answers as to why some patients do not respond to treatment. 
 DR3/TL1A were revealed to have no direct effect on the increased OC activity 
associated with OP.  Analysis of post-menopausal OC assays using PBMCs as a 
starting population would determine whether DR3/TL1A have an indirect effect on 
increased OC activity in post-menopausal OP. 
 DR3 has been shown to potentially regulate OB differentiation and function in an 
autocrine manner.  Investigation into its effect on the OB specific transcription 
factors Runx2, OSX and ATF4, would provide valuable insight into the mechanism 
and time frame of its action.  Titration of TL1A into OB cultures would also reveal 
the effect of raised cytokine levels on OB function, producing a possible mechanism 
for the adverse bone pathology observed in AS and PsA. 
 In vivo OC differentiation is controlled by OB expression of RANKL and OPG.  To 
determine whether DR3/TL1A signalling on the OB can indirectly regulate OC 
formation expression of soluble RANKL and OPG should be analysed in DR3wt and 
DR3ko OB cultures.  Co-culture assays using OC and OB derived from DR3wt and 
DR3ko mice would further reveal whether DR3/TL1A signalling on the OB is required 
for optimal OC differentiation and function.  
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7.7 Concluding Remarks 
At the outset of this thesis the role of DR3/TL1A in OC and OB biology and disease 
characterised by adverse bone pathology were unknown.  This study has identified a 
potentially important role of DR3/TL1A in OC and OB differentiation and function.  DR3 
has been shown to be involved in OC resorptive function through the activation of MMP-
9, while TL1A has been demonstrated to effect OC formation through regulation of 
osteoclastogenic chemokine expression.  In vitro DR3 has been revealed to have a role in 
normal OB differentiation and bone formation affecting levels of ALP expression, 
activation of MMP-2, -9 and mineral deposition.  In vivo TL1A has been linked to the 
pathogenesis of erosive RA, with levels unaffected by anti-TNF treatment.  Intriguingly 
DR3/TL1A were shown to have no direct effect on the increased OC activity associated 
with OP, with DR3 expression not induced on CD14+ cells isolated from post-menopausal 
females.  Further research is required to fully elucidate the mechanisms through which 
DR3/TL1A act however, the data presented in thesis demonstrates for the first time 
DR3/TL1A to be potentially important regulators of bone remodelling.  
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Appendix I Visualisation of Actin Ring Formation by Immunocytochemistry 
When resorbing bone, OC undergo rearrangement of their actin.  This forms a ring, which 
surrounds the ruffled border and is involved in the creation of the sealed zone (17, 475).  
A possible mechanism for the observed difference in DR3wt and DR3ko resorptive function 
(section 3.2.8) could be an inability of the DR3ko mice to rearrange their actin.  
Optimisation of actin ring and nucleus immunocytochemistry (ICC) was performed to 
enable the visualisation of the actin and nucleus in OC cultures (section 2.2.6).   Analysis of 
stained osteoclasts under the fluorescent microscope showed that a 1:100 dilution 
(0.5units/ml) of the Alexa Fluor® 594 phalloidin stain was sufficient to visualise the cellular 
actin.  Actin (red) was observed as diffuse staining in mononuclear precursors cells and 
non-bound multinucleated osteoclasts.  In fully differentiated OC the actin was visualised 
as a highly organised ring around the outer edge of the cell.   Staining with DAPI (blue) at 
300nM was found to be suitable for the visualisation of the nuclei in both precursor cells 
and multinucleated osteoclasts. 
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Appendix II Visualisation of Cathepsin K by Immunocytochemistry 
While the gelatinase MMP-9 has been shown to be involved in osteoclastic bone 
resorption (300, 301) it is not the main factor; the proteinase Cathepsin K has been shown 
to be the key enzyme involved in this process (104, 105).  Detection of Cathepsin K by 
ELISA was not possible without lysis of the cells, as Cathepsin K release is restricted to the 
sealed zone under the OC.  To enable detection of Cathepsin K, within the OC and the 
sealed zone, a method was established for the immunocytochemical staining of the 
enzyme. The immunocytochemistry methodology is outlined in section 2.2.19.  An anti-
Cathepsin K antibody was tested at concentrations of 1µg/ml, 2µg/ml, 3µg/ml and 
4µg/ml, along with an isotype control at equivalent concentrations.  For visualisation an 
anti-rabbit FITC conjugated antibody was employed.  A signal, representing the presence 
of Cathepsin K, was visible at all concentrations.  The % of luminosity of the green signal 
image was calculated per image.  The luminosity of the Cathepsin K signal was observed to 
increase from 1μg/ml to 3μg/ml (9.8% versus 12.5% versus 15.1%).  At 4μg/ml the level of 
luminosity decreased to 7.8%. No non-specific signal from the isotype control was 
detected at concentrations of 1μg/ml and 2μg/ml.  A non-specific signal was detected 
when the isotype control was used at 3μg/ml (2.7%), increasing slightly when used at 
4μg/ml (3.1%).  The results suggest that the optimum concentration for the visualisation 
of Cathepsin K is 2μg/ml. 
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Appendix III Comparison of Serum TL1A and DR3 and CD14 Expression on CD14+ Cells 
Isolated from Pre-Menopausal Controls and Post-Menopausal Patients 
Serum and CD14+ cells were isolated from the peripheral blood of pre-menopausal 
controls (chapter 4) and post-menopausal patient cohorts (chapter 5).  Serum TL1A levels 
were measured by ELISA and reported graphically as pg/ml (mean±SEM).  Isolated CD14+ 
cells (day -7) were cultured on ivory for 7 days in medium supplemented with MCSF to 
determine whether there is a fundamental difference in expression following the 
menopause.  Expression is presented as fold increase in MFI relative to the isotype control 
(mean±SEM).  Levels of serum TL1A in the pre-menopausal controls were measured at 
(117.3±29.3pg/ml).  These were comparable to the post-menopausal fracture cohorts (OP-
Frac+=90.8±4.5pg/ml and OP+Frac+=103.1±2.3pg/ml).  Serum TL1A levels in the non-OP 
non-fracture cohort were reduced (OP-Frac-=47.2±29.0pg/ml), however, this difference 
was not significant (Fig Appendix III (a)). 
Pre-menopausal CD14+ cells demonstrated a 10.0±2.3-fold increase in CD14 expression 
over the isotype (Fig Appendix III (b)).  No significant difference in CD14 expression was 
observed compared to the post-menopausal OP-Frac- (11.1±4.2), OP-Frac+ (11.3±3.1) and 
OP+Frac+ (11.8±8.2) patient cohorts.  DR3 expression increased 5.1±1.6-fold on the pre-
menopausal control-derived cells.  This was significantly elevated compared to the OP-
Frac- (0.9±0.1; P<0.01), OP-Frac+ (1.1±0.2; P=<0.01) and OP+Frac+ (1.1±0.0; P=<0.05) 
patient-derived cells (Fig Appendix III (c)). 
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Appendix IV Comparing the Differentiation and Resorptive Function of Pre-
Menopausal and Post-Menopausal Patient–Derived Osteoclasts  
Following culture in MCSF for 7 days DR3 expression was not induced on the surface of 
post-menopausal patient-derived CD14+ cells, this was in stark contrast to the pre-
menopausal control cells (Appendix III).   To determine whether there was a fundamental 
difference in the ability of patient-derived CD14+ cells and pre-menopausal-derived CD14+ 
cells to differentiate into osteoclasts, results from chapter 4 (pre-menopausal) and 
chapter 5 (post-menopausal) were compared.   
The total number of cells per mm2 (mean±SEM) for each disc is presented graphically in 
Fig Appendix IV (a).  Total cell number in the pre-menopausal cultures were observed to 
be significantly increased across the time course compared to the post-menopausal OP-
Frac-, OP-Frac+ (P=<0.0001) and OP+Frac+ (P=<0.01) cultures.  At day 7 total cell numbers 
in the cultures were calculated as; pre-menopausal=534±70, OP-Frac-=211±36, OP-
Frac+=244±46 and OP+Frac+=446±68.  These did not change significantly over time. 
Differential counts were performed and TRAP+ OC reported as OC / mm2 (Fig Appendix IV 
(b)).  OC numbers in the pre-menopausal cultures increased across the time course from 
5±1 at day 7 to 7±1 at day 14. OC numbers in the post-menopausal cultures at day 7 were; 
OP-Frac-=2±1, OP-Frac+=2±1 and OP+Frac+=1±1, these did not vary significantly across the 
time course.  A significant increase in OC numbers was detected in the pre-menopausal 
cultures across the time course compared to the OP-Frac-, OP-Frac+ (P=<0.01) and OP+Frac+ 
(P=<0.05) cultures. 
OC resorptive activity was expressed as % area resorbed (mean±SEM) for graphical 
presentation (Fig Appendix IV (c)).  Levels of resorption in cultures at day 10 were; pre-
menopausal=0.9±0.3%, OP-Frac-=0.1±0.1%, OP-Frac+=0.3±0.2% and OP+Frac+=0.1±0.1%.  
Levels in the pre-menopausal cultures increased at day 14 (1.3±0.3%) while remaining 
relatively constant in the post-menopausal cultures (OP-Frac-=0.7±0.5%, OP-
Frac+=0.4±0.3% and OP+Frac+=0.2±0.1%).  Across the time course no significant difference 
was detected in OC resorptive function.   
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Appendix V Improving the Methodology of Analysing Resorption Pits on Ivory Discs - 
Results 
The current method employed for the functional assessment of counting resorption pits 
(toluidine blue staining, photographing, highlighting resorption pits and calculation of the 
% area resorbed) is time consuming, taking 6 hours to fully analyse an experiment (12 
discs).  While this method provides the surface area of the disc that is resorbed it does not 
provide any indication of the depth of the resorption pit.  At the end of this project a 
portion of time was spent on developing a more sensitive method for the analysis of pit 
area and depth in 3D.  Use of confocal microscopy was optimised for the accurate analysis 
of resorption pit depth; the methodology is described in section 2.2.18. 
Discs were initially placed onto a glass slide and scanned using reflective light (Appendix V 
a (a)).  Images produced were of a higher quality and resolution than those produced 
using a standard light microscope.  However, the reflectance of the discs was relatively 
low, so resolution of the pits was not at the highest level that can be produced with the 
equipment.  Discs were also prone to distortion under the lens of the microscope due to 
drying out.  This had the knock-on effect of changing the focus, meaning that the accuracy 
of pit depth measurement could not be relied upon.  To address the reflectance and 
distortion problems, discs were stained with the fluorescent dye calcein and mounted 
onto glass slides using DPX.  Discs were scanned using a laser of wavelength 495nm.  
Images produced had a higher resolution than those scanned with reflective light 
(Appendix V a (b)).  The high resolution of the scan allowed for accurate 3D reconstruction 
of the pits (Appendix V b (a)) as well as analysis of pit area and depth (Appendix V B (b)).  
In the samples tested resorption pits were found to have a depth ranging from 3µm to 
20µm.  These results are within the range observed by other groups using laser scanning 
confocal microscopy and scanning surface profiling (476-478) for pit measurement.   
Optimisation of the confocal microscope for the analysis of resorption pits showed that 
accurate high resolution pictures, in 2D and 3D, could be obtained, allowing the accurate 
calculation of pit area and pit volume. 
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Appendix V Improving the Methodology of Analysing Resorption Pits on Ivory Discs - 
Discussion 
A standard method for the analysis of resorption pits was employed throughout this 
thesis;  sonication of discs, staining with toluidine blue and analysis of resorption pit area 
by light microscopy (460).  However, a number of alternative methods have been used by 
other groups including confocal microscopy (129) and scanning electron microscopy (461).  
Use of a confocal microscope for the analysis of resorption pits was selected and a 
method developed (comparison between the standard method and confocal is found in 
Table 8.1).  Initial work on the confocal microscope using reflective light produced higher 
resolution images than those seen with just a light microscope.  However, the images 
were not as ‘sharp’ or detailed as is possible to obtain with a confocal microscope, due to 
the low reflectance of ivory (Appendix V).  To overcome this, discs were stained with the 
fluorescent dye calcein, which binds to calcium.  To visualise the discs a laser of 
wavelength of 495nm was required to excite the calcein.  When excited calcein emitted 
light at a wavelength of 515nm (green), this was then used to visualise the disc surface.  
The images produced via this method were of a higher resolution and more detailed than 
those generated using reflective light and light microscopy.  Pits were clearly visible on the 
surface of the discs with the edges clearly defined.  Creating a ‘z-series’ stack (multiple 
images through a section) allowed for the 3D recreation of the resorption pit.  Further 
analysis could then be performed using the images, such as depth measurements and 
cross-sectional analysis.  Using this method of 3D recreation, pit depth was found to range 
between 3µm and 20µm (Appendix V).  These pit depths were found to be within the 
range observed by other groups, validating the method; Inui et al (477) (approx. 6μm 
using a scanning surface profiler), and Parikka et al (476) and Jeon et al (478) (approx. 
10μm and 5μm - 25μm respectively, using scanning confocal microscopy).  However, a 
number of issues were identified that required further development before the method 
could be used for high throughput analysis of resorption pits.   
Ivory discs were found to dry out under the confocal; this created distortion in the disc 
and had the knock-on effect of altering the focus.  Occurrence of this during the 
generation of a ‘z-series’ would lead to inaccurate measurements.  Some work was done 
on mounting the ivory discs onto glass slides using DPX and covering with a coverslip.  
While this did help with the drying out and distortion it was not without its own problems.  
The thickness (0.3-0.7mm) and inherent roughness of the ivory discs meant that mounting 
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was not straight forward, as a large percentage of the glass coverslip was not supported 
and could crack if put under too much pressure.  While this wouldn’t affect the disc, the 
cracked glass was a risk to the lens of the confocal microscope so broken slides could not 
be analysed.  Development of a method to mount the ivory discs safely would allow the 
use of the confocal microscope for analysis. 
 
Standard Method 
Confocal 
Microscopy 
Reflective Light 
Confocal 
Microscopy 
495nm Laser 
Time Taken to 
Analyse 1 
Experiment 
(12 Discs) 
Approx. 6 hours Approx. 4 hours Approx. 4 hours 
    
Relative Picture 
Resolution 
Low Medium High 
    
Calculation of Pit 
Area 
Yes Yes Yes 
    
Calculation of Pit 
Depth 
No Yes – Low Accuracy Yes – High Accuracy 
Table 8.1. Comparison of methods for the analysis of osteoclast resorption pits on ivory 
discs. 
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